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This section provides a medium through which Canadian surgeons can declare themselves, briefly
and informally, on the day-to-day affairs of surgery.

What’s the Question?
*

*
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Recently two seemingly unconnected
happenings prompted me to review an
old worry which I have had for some
years. The first was the arrival of
the November 1980 issue of the
Canadian Journal of Surgery and the
second was a long consultation with a
patient who had fresh, untreated
achalasia of the esophagus.
The meeting was cordial enough
but long because of the unusual per
sistence and perspicacity of the pa
tient. He not only knew what ques
tions to ask but it was clear from the
beginning that he would not be satis
fied with mere professional opinion—
he wanted the facts! Being of scien
tific bent he knew well the signif
icance of clinical trials, whether single
blind, double blind or crossover. He
showed himself to be one of the
cognoscenti when he stated he had
heard that most surgical trials were
actually half blind. A few years ago
he would have been labelled a “dif
ficult patient”, a “troublemaker” or
“neurotic”, but I hope we are more
enlightened today. He was in fact
exercising his right as a consumer to
know everything there is to know
about the product. After all, caveat
emptor still reigns supreme. It was an
engaging conversation, but imagine
my embarrassment when, somewhat in
advance of my patient, I realized that
when he popped the crucial question
I would not be able to answer it.
Fortunately, my mind had already
been prepared by happening number
one. I had read in this Journal a paper
on achalasia1 just the day before. One
might criticize some gaps in the pre
sented data, for example: Of those
who had reflux was it acid or alkaline
(and if alkaline, would a Roux-en-y
diversion have been easier and better)?
VOLUME 24, NO. 3, M AY 1981 /

Were the follow-up visits done by sur
geons or “blindly” by other physi
cians? Were there not even a small
number of complications from these
major procedures? But I must report
that what sprang to mind was a longdiscontinued Alka Seltzer television
advertisement. This playlet lasted only
a few weeks, 4 or so years ago. It
was not a “hard sell”. It featured a
conservatively dressed, bespectacled
man at a desk holding “the goods”.
The background was of a film studio
with microphone booms, lights, came
ras, and so on. The salesman gave
an earnest “pitch” that ended with
the strongest possible admonition
that “Alka Seltzer is the answer!”.
After a brief pause, a lone voice
broke the silence—“okay, but what’s
the question?” The group broke up
in laughter and it was over.
As I shifted in my seat, I realized
that in this recent paper and others
on achalasia we surgeons are ad
dressing ourselves to lace trimmings
without knowing the shape of the
clothes. The simple question I was
about to be asked (and clearly could
not answer) was: what is the proven
best treatment for achalasia? It would
be useless to quote this or that series
on surgery or two others for com
parison on pneumatic dilatation,
finishing with my esteemed opinion.
For my patient this just would not do.
“No,” he replied—he did ask of
course as I knew he would—“hasn’t
anyone randomly compared the two
main treatments and made blind fol
low-up assessments?” “No,” I said,
“but in my opinion . . .” Well, what
else?
So to my worry. It troubles me that
here is a question that is much more
amenable to an answer than some,
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and yet in 1981 we still pass opinions
or support philosophies.1 Surely a
well planned study of the two main
treatments used in this disease is long
overdue. Let it not be by a depart
ment of surgery or a division of gas
troenterology, but by a joint team who
will draw up an initially acceptable
protocol and rule out observer bias
on both sides. Certainly this would not
be easy and the answer might not be
a simple yes or no, but we had better
make an attempt soon—the con
sumers are getting smarter every day.
But even more disturbing is the
frightening array of similar simple
surgical questions that pop up after
only a few minutes' reflection. Many
of these problems are unfashionably
simple and may not require the fund
ing of a specialized laboratory, but
this surely should make the search
for their solution attractive to prac
tising physicians and surgeons. The
layman soon will not be satisfied with
mere opinions and philosophies when
to his mind, unfettered as it is by
professional training, we should by
now have scientifically proven that
treatment A is better than B except in
his or her case, where C is best. It
will do no good to explain tactfully
that the two parties holding com
pletely opposite views cannot get to
gether to study this or that.
I do not imply that such work has
not been or is not being done in many
centres. One need only peruse the
same issue of our Journal to see a
model project2 with a valuable answer
proved beyond any reasonable doubt.
Surgeons have made frequent contri
butions such as this over the years,
but far too much of our literature is
anecdotal. No one could deny the
educational value of clinical reports,
215
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adequate respiration; the patient should be kept under continued
surveillance. Instructions in the package insert provided by the manufac
turer should be carefully followed. Do not administer an antagonist in the
absence of clinically significant respiratory or cardiovascular depression.
Employ oxygen, intravenous fluids, vasopressors and other supportive
measures as indicated. Gastric emptying by emesis or lavage may be
helpful. Hemodialysis carried out within ten hours of ingestion may be of
some value. Plasma levels of acetaminophen should be determined.

DOSAGE A N D A D M IN IS TR A TIO N
Percocet Tablets: Usual adult dose is one tablet every six hours, as needed
for pain.
Percocet-Demi Tablets: Usual adult dose is one or two tablets every six
hours. Children twelve years and older: half a tablet every six hours.
Children six to twelve years: a quarter of a tablet every six hours. Not in
dicated for children under six years of age.
Dosage should be adjusted according to the severity of the pain and the
patient’s response.

DOSAGE FORM S

Percocet Tablets: Bottles of 40,100 and 500 white, scored tablets, each
containing oxycodone hydrochloride 4.5 mg, oxycodone terephthalate 0.38
mg, acetaminophen 325 mg, caffeine 32 mg.
Percocet-Demi Tablets: Bottles of 40,100 and 500 blue quadrisected
tablets, each containing oxycodone hydrochloride 2.25 mg, oxycodone
terephthalate 0.19 mg, acetaminophen 325 mg, caffeine 32 mg.
Complete prescribing information available on request.
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but where divergent therapies are
hotly defended we badly need to apply
scientific standards in learning what
truth we can. Only then, when faced
with the question as to what is scien
tifically proven to be the best treat
ment for achalasia, will I surely and
with pleasure be able to tender an
opinion; but in honesty, at present, I
must answer that I do not know.
Oh yes, my patient has gone off to
“think about it” for a week or two.

J . L . S t o l l e r , m b , f r c s , f r c s [c ]

CORRESPONDENCE

Division of general surgery,
Vancouver General Hospital,
Vancouver, BC
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Carotid Endarterectomy
Twenty-five years after the first
reports1,2 of carotid endarterectomy,
this procedure has become one of the
most frequently performed vascular
operations.3 Although carotid lesions
account for only about 15% of strokes
they make up 65% of those that
follow a previous transient ischemic
attack.4 Operation is indicated in
symptomatic patients with stenotic or
ulcerative lesions and can be carried
out with a mortality of less than 2%.
The procedure is associated with in
traoperative stroke in about 2% of
patients, and only 1% will be left with
permanent neurologic deficit.5
Some aspects of carotid endarterec
tomy are still controversial. Despite
Thompson’s report5 advocating endar
terectomy for asymptomatic patients
who undergo other operations, Heyman and associates6 in a prospective
study found that while 13.9% of
asymptomatic men and women with
bruits had strokes during a 6-year
follow-up compared with 3.4% who
had no bruit, in those who had strokes
there was poor correlation with the
bruit. The implication was that caro
tid endarterectomy would not have
prevented the stroke.
Despite the increasing number of
noninvasive techniques available to
study the carotid arteries it is gen
erally agreed that angiography re
mains a prerequisite to surgery.
During the operation moderate
hypertension should be maintained
and the patient heparinized. Hyper
cardia is no longer used and the use
of shunts is controversial, with about
a 50% division of opinion. Stump
pressure has proved an unreliable in
dication as to which patient requires
a shunt. In this issue (page 304)
Hansebout and his colleagues report
on the use of electroencephalographic
(EEG) monitoring intraoperatively to
indicate which patient needs a shunt.
VOLUME 24, NO. 3, MAY 1981 /

However, they report a 7% incidence
of neurologic complications postoperatively which is higher than that
usually reported and their method
ology is uncontrolled. Significant re
sults would require a larger series
with lower mortality and morbidity.
Their approach is interesting but the
case for EEG monitoring remains un
proven and is considered unreliable
and cumbersome by most vascular
surgeons.
Finally it is encouraging to note
from the reports of Garraway and
associates7 and Levy8 that the inci
dence of stroke is declining.
H.J.

S c o t t , m d , f a c s , f r c s [c ]
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Primary Vaginal Incision during
Cesarean Section
To the coeditors.—The assumption of
Drs. Bryan and Strickler (Can J Surg
1980; 23: 581-3) that primary entry
into the vagina in the course of low
transverse cesarean section had not
been reported in the medical literature
in recent decades is erroneous. This
complication is a well recognized con
sequence of undiagnosed sacculation
of the pregnant uterus and has been
reported in association with this
anomaly on several occasions.1'2 The
distorted anatomic relations of the
vagina, bladder and sacculated gravid
uterus have been illustrated clearly
by Spearing.3
Regrettably, the anomaly is rarely
diagnosed before operation.1 In a
patient recently admitted to our serv
ice, gross elevation of the uterine
cervix almost beyond the reach of
the examining finger facilitated a
positive diagnosis at 32 weeks’ gesta
tion. Anticipating the high vaginal
position, the surgeon avoided incising
it by opening the uterus above the
level of the umbilicus. As a result
both the operation and the postoper
ative course were uncomplicated.
Although only a high degree of
suspicion permits preoperative diag
nosis of uterine sacculation, inadver
tent vaginal incision during cesarean
section makes this diagnosis highly
probable. It is very likely, therefore
that most (if not all) of the four cases
reported by Drs. Bryan and Strickler
were instances of undiagnosed uterine
sacculation.
L e s l i e I f f y , m d , f r c s [ c ], f a c o g

Division of maternal—fetal medicine,
College Hospital,
CMDNJ—New Jersey Medical School,
Newark, NJ
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REVIEW ARTICLE

Acute Renal Failure as a Consequence of Sudden
Renal Artery Occlusion
A l b e r t o G. de la R ocha , m d , fr c s [c ],* M arietta Z o r n , m d | and A llan R. D o w n s , m d , fr c s [c ], fa cs :|:

Acute renal failure secondary to renal
artery occlusion is rare but can be
reversed and is therefore important to
recognize. The authors report two such
cases to draw attention to the
diagnosis and management of the
condition. In one case, occlusion
of the artery to a single functioning
kidney was responsible for the
clinical presentation; in the other,
bilateral renal artery emboli were
responsible. The authors present a
detailed review of the English
literature to determine the prognostic
value of the duration of anuria
preceding operation in patients
with renal artery occlusion to a
solitary kidney. This factor showed
no correlation with viability of renal
tissue, functional recovery or patient
survival. Surgical management offers
the best prospect of success in
these patients.

inversee et, de ce fait, il est important
qu’elle soit reconnue. Les auteurs
decrivent deux cas afin d'attirer
I'attention sur le diagnostic et le
traitement de cette affection. Dans
un cas, I'occlusion de I'artere menant
au seul rein fonctionnel du patient
fut responsable du tableau clinique;
dans I'autre cas, des embolies des
deux arteres renales en furent la
cause. Les auteurs presentent une
revue fouillee de la litterature de
langue anglaise afin de determiner la
valeur previsionnelle de la duree
d'anurie precedant I'operation chez
les malades ayant une occlusion de
I'artere renale d'un seul rein. Ce
facteur n’a montre aucune correlation
avec la viabilite du tissu renal, la
recuperation de la fonction renale ou
la survie du patient. La chirurgie offre
les meilleurs chances de succes
chez ces patients.

Case Reports

Case 1
An 80-year-old woman with a history
of hypertension, arteriosclerotic heart
disease, aortic stenosis and peripheral
vascular occlusive disease was admitted
to the Health Sciences Centre in Win
nipeg with a 2-day history of left flank
pain, nausea and a declining urine out
put. At the time of admission she was
taking digoxin. propranolol, nitroglycerin,
furosemide and cimetidine.
On physical examination she was
afebrile. She had a blood pressure of
205/100 mm Hg and a regular pulse rate
of 65 beats/min. The chest was clear.
There was a grade 3/6 systolic ejection
murmur at the base of the heart. The
abdomen was soft and the left flank
and costovertebral angle were tender.
On bladder catheterization no urine
could be obtained. Laboratory findings
were as follows: hemoglobin value 12
mg/dl, leukocyte count 11.6 X 109/1,
serum sodium value 116 mmol/l, serum
potassium 4.7 mmol/l, serum creatinine
4.3 mg/dl (380 iimoi/1) and blood urea
nitrogen value 38 mg/dl (urea, 13.57
mmol/l). A retrograde pyelogram ruled
out an obstructive lesion.
Abdominal aortography by the retro
grade Seldinger technique revealed bi
lateral renal artery occlusion (Fig. 1).
The right kidney, which was atrophic,
was supplied by collateral circulation.
Although the left renal artery was not
seen at its origin there was opacification
of the intrarenal branches by way of
collateral vessels shown on delayed films.
Selective catheterization of the left renal
artery showed severe ostial stenosis and
a filling defect occupying almost the
entire length of the vessel (Fig. 2).
At operation, the left renal artery was
opened longitudinally and a well or
ganized thrombus removed. After a no.
3 Fogarty catheter had been passed to
remove distal clot, good back bleeding
was noted from three major branches of
the artery. Aortorenal bypass grafting

Acute renal failure secondary to sud
den renal artery occlusion is not a
common entity. Nevertheless it is im
portant to recognize the condition be
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cause of its potentially reversible
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t Resident in surgery, Health Sciences
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sider renal artery revascularization,
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because
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we hope to dispel this no
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L’insuffisance renale aigue secondaire
a I’occlusion d'une artere renale est
une affection rare, mais elle peut etre

with expanded polytetrafiuoroethylene
(GORE-TEX; W.L. Gore & Associates,
Flagstaff, Ariz.) was performed. A peri
toneal dialysis catheter was inserted
before closure. The total duration of
renal ischemia was 18 hours, estimated
from the onset of symptoms.
The patient required peritoneal dialy
sis for the first 5 days after operation;
this facilitated control of incipient pul
monary edema.
Urinary flow began 3 days after oper
ation at a rate of 10 rnl/h increasing to
1500 ml/d at 13 days.
Seven days after operation a renal
flow study was carried out using radio
active hippuran. It demonstrated a nor
mal-sized left kidney with decreased
flow and uptake and a prolonged intrarenal transit time. The right kidney was
not visualized. Another abdominal aortogram obtained on the 13th postoper
ative day showed a patent aortorenal
graft with good filling of the intrarenal
branches (Fig. 3).
The patient was discharged 34 days
after operation at which time her blood
pressure was 135/70 mm Hg (while
taking her preoperative medications). The
BUN value was 27 mg/dl (urea, 9.64
mmol/1) and her serum creatinine value
1.5 mg/dl (132.6 u,mol/l).

FIG. 1—Case I. Preoperative aor
togram. Atrophic right kidney is sup
plied by collateral circulation (arrows).
Left renal artery is completely occluded
(single arrow).

FIG. 2— Case 1. Preoperative selective
left renal angiogram showing severe
ostial stenosis (single arrow) and arterial
thrombus (arrows).
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A 70-year-old woman with a history
of atrial fibrillation and congestive heart
failure, which was being treated With
digoxin and furosemide, was admitted to
a rural hospital with a 2-day history of
lower abdominal pain, nausea and
vomiting.
Physical examination showed that she
was afebrile, in atrial fibrillation with a
ventricular rate of 140 beats/min and
a blood pressure of 130/80 mm Fig. The

whole abdomen was diffusely tender but
particularly so in the left lower quadrant.
Acute diverticulitis was suspected. Over
the following 48 hours the patient
became febrile and complained of in
creasing right lower quadrant pain. A
diagnosis of acute appendicitis was made
and the patient was referred to our in
stitution.
On admission to the Flealth Sciences
Centre the patient complained of dif
fuse abdominal pain. On physical
examination bilateral flank tenderness

Fig. 3a

Fig. 3b

Case 2

FIG. 3— Case 1. (a) Postoperative aortograin. Early films show patent aorto
renal bypass graft (arrow), (b) Postoperative aortogram. Delayed films demonstrate
filling of intrarenal artery branches (arrows).

FIG. 4— Case 2. Preoperative selective renal angiogram showing bilateral renal
artery embolism.

FIG. 5— Case 2. Postoperative renal angiogram shows patent renal arteries and
poor nephrographic phase.
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monstrated patency of both renal arteries
and a poor nephrographic phase (Fig. 5).
Renal blood flow, measured by radio
active xenon washout scanning, was
greater than 90 ml/min for 100 g tissue.
The patient was discharged 51 days
after operation and although her renal
function remained depressed (BUN 57
mg/dl [urea, 20.35 mmol/1], serum
creatinine 7.5 mg/dl [663 p.mol/1]), dialy
sis was no longer required.

and diminished bowel sounds were
present. The hemoglobin level was 13
mg/dl, leukocyte count 27 X 109/1,
serum concentration of sodium was 126
mmol/1 and of potassium 3.7 mmol/1,
the BUN value was 30 mg/dl (urea,
10.7 mmol/1) and serum creatinine value
was 3.8 mg/dl (336.2 p.mol/1). On urin
alysis turbid urine was noted with 100
erythrocytes per high power field, many
pus cells, granular hyalin and white-cell
casts and an abundance of bacteria.
The patient became anuric on the day
after arrival and the serum creatinine
level rose to 5.0 mg/dl (422 y.mol/1).
Systemic sepsis was not evident. Angio
graphy demonstrated bilateral renal
thromboembolism (Fig. 4). Transcatheter
thromboembolectomy was attempted but
failed. Twenty-four hours later a bi
lateral renal artery embolectomy was
carried out. A dialysis catheter was left
in the peritoneal cavity.

Role of Anuria in Prognosis
To evaluate the duration of anuria
as a prognostic sign in patients who
undergo emergency renal artery oper
ation, we collated and analysed the
data for cases of acute arterial occlu
sion to a single functioning kidney
recorded in the English literature.
Since the report of Baird and col
leagues1 in 1965 we found 23 cases
(Table I1'19). Including our case 1,
there have been 15 women and 9 men
with a median age of 62 years.
There were three causes of acute
arterial occlusion in these patients:

Anuria requiring peritoneal dialysis
continued for 5 days after operation but
at 17 days the urine output had increased
to 1150 ml/d. Peritoneal dialysis was
continued intermittently for 36 days after
operation. Another renal angiogram de

thromboembolism
(14
patients),
thrombosis (8 patients) and critical
ostial stenosis behaving hemodynamically as a complete obstruction (2 pa
tients). Pre-existing cardiac disease
was documented in 10 patients with
thromboembolism, while hypertension
was predominant in those with throm
bosis.
Preoperative BUN and serum crea
tinine levels, recorded in 12 patients,
were 122 ± 80 m g/dl (urea, 43.55 ±
28.6 mmol/1) and 9.4 ± 3.8 m g/dl
(811 ± 336 u.mol/1) respectively
(mean ± standard deviation) and the
duration of anuria for the whole group
ranged from 10 hours to 43 days with
a mean of 48 hours.
Operation was undertaken in all 24
cases. Embolectomy of the renal artery
was performed in 14 instances anu
thrombectomy with bypass grafting in
8. One patient each underwent throm 
bectomy and thromboendarterectomy.
Six patients (25%) died, but in 83%
of the entire group recovery of renal
function was documented.
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A u th o rs

Sex

Age,
y

F

59

F
M
M

62
75
65

F

63

Love and
Bush-’
G o ld sm ith and
c o lle a g u e s '
T o w n e and
B e rn h a rd 4
T h om as and
P ta tf•

BUN,
m g/dl

P a th o lo g ic fe a tu re s
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throm bosis
Em bolism
Em bolism
Em bolism
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—

10

Th rom boendarterectom y

17

— '
—
—

—
—

12
12
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R en al em bolectom y
Renal em bolectom y
R en al em bolectom y

__
_

18

A o rto re n al saphenous
bypass

Schram ek and

F
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P re se n t report
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F
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Th om as and
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Wl

51

M

84
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S m ith w ick and
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A th e ro s c le ro s is , c ritic a l
ste n o sis
A th e ro s c le ro s is , th rom b osis

—

—

43

F

63

H y p e rte n sio n , em bolism

147

—

48

M

45
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17.4

48

Renal em bolectom y and
p a rtia l nephrectom y
Renal em bolectom y

F

57

112

—

48

M

52

—

—

F

57

170

—

F

57

37

—

F
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H y p e rte n sio n , a th e ro sc le ro sis,
th ro m b o sis
H y p e rte n s io n , a th e ro sc le ro sis,
throm b osis
A o rtic th rom b osis, renal
em bolism ?
L e ft em bolus, a tro p h ic rig ht
kid n e y
Em bolism

—

—

Schonw ald and F
c o lle a g u e s ''
M
B re s t and

45

—
126

Lacom be"
S u lliv a n and
B a rry and
H o d g es1'
P e te rso n and
M c D o n a ld '"

220

73

H y p e rte n s io n , a th e ro sc le ro sis,
th ro m b o sis postop.
Em bolism

F
M
F

66
62
70

Em bolism
Em bolism
Em bolism

F

67

F

57

H yp ertension , a th e ro sc le ro sis,
throm b osis
E m b olism

BUN.
m g/dl

—

A th e ro s c le ro s is , c ritic a l
ste n o sis le a d in g to
o cc lu sio n , throm b osis
Em bolism

>

P o sto p e ra tiv e
D uratio n
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a n u ria , h

C re a tin in e ,
m g/dl

_
_
__

_

r
O u tco m e /fo iio w -u p
N o rm o te n siv e , 2 mo
Died
Died
Good renal fu n ctio n ,

1.3

18

Renal em bolectom y

-

-

F u n c tio n a l recovery

38

4.3

18

Throm bectom y, a orto re n al
bypass

27

1.5

N o rm otensive, 2 mo

81

6.5

24

_

1.3

4 yr

—

36

A o rto re n a l saphenous
bypass
A o rto re n a l saphenous
bypass
Throm bectom y

—

«r

—

2.3

12 mo

43

2.4

5 mo

—

—

N orm al

Norm al

T eflon ilio re n a l g ra ft

38

2.1

48

A o rto re n al bypass

__

1.3

N o rm o te nsive , fun ctio n a l reco very
N orm otensive, fu n ctio n a l recovery
H yp ertensive but
asym ptom atic, 12 mo
Norm otensive, 3 mo

48

Throm boem bolectom y

28

_

F u n ctio n a l re co ve ry, 8 mo

48

Renal em bolectom y

—

__

72

Renal em bolectom y

—

_

8.1

75

11.2

4‘/$ d

Left sp lenorenal
a rte ria l a na stom o sis
Renal em bolectom y

_
345
96

8.6

100

9.5

5d
9d
9d
10 d
43 d

Renal em bolectom y
Ren al em bolectom y
Renal em bolectom y
L e ft ilio re n a l saphenous
vein graft
Renal em bolectom y

VOLUME 24, NO. 3, M A Y 1981

/

8

1.2

30

2.1

Co ng estive h e a rt fa ilu re ,
died
Good renal scan uptake
15 d, died in ho sp ita l
of ce re b ral em bolism
Good control of
h y p e rte nsion , 9 yr
Fu n ction a l reco very

105
57

4.1
6.7

Died
Fu nction a l reco v e ry
Fu nction a l reco very

10
—

2.4

N o rm o te n siv e , 6 wk
Fu n ction a l re co ve ry
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At follow-up (range 6 weeks to 9
years, mean 5 months), in 87.5% of
hypertensive patients the condition
was better controlled; BUN and
serum creatinine levels decreased to
a mean of 36.3 ± 26.9 mg/dl (urea,
12.96 ± 9.6 mmol/1) and 2.6 ± 1.5
mg/bl (229.8 ± 132.6 u.mol/1) re
spectively.
The duration of anuria before oper
ation had no clear prognostic value
for either recovery of renal function
or survival. Patients who were anuric
for 48 hours or less had a mean serum
creatinine value of 1.95 ± 0.8 mg/dl
(172.4 ± 70.7 u.mol/1) postoperatively
and those with preoperative anuric
periods over 48 hours had a serum
creatinine of 3.30 ± 2.7 mg/dl (291.7
± 238.7 u.mol/1) (P = 0.05, Student's
/-test). The duration of anuria preoperatively did not differ between sur
vivors and nonsurvivors (median, 48
hours and 33 hours respectively).

holism should be considered in any
patient with abdominal or flank pain
known to have cardiac disease.
Acute renal ischemia may be sus
pected from the clinical findings or
from an excretory pyelogram that
fails to opacify one or both of the
kidneys. While renal scintiscanning
may be useful to substantiate the
diagnosis, arteriography is the d e 
finitive procedure that demonstrates
the site of obstruction and the degree
of collateral circulation. The quality
of the nephrographic phase may also
be of prognostic value regarding
viability of the renal tissue.
Laboratory investigations, including
enzyme determination24 and urinalysis
are of limited value. Peterson and

D iscussion

Acute renal artery occlusion may
be due to thromboembolism,9'12,16,17,19-25
thrombosis5,7'18'26 or extension of
aortic dissection27 (Table II). Renal
artery thrombosis following blunt ab
dominal trauma, although infrequent,
is well recognized.28 Critical stenosis
of the renal artery can behave hemodynamically as a total occlusion as
demonstrated by Heaney and associ
ates29 and Thomas and Pfaff.5
The clinical presentation of acute
renal artery occlusion may mimic
other acute abdominal conditions such
as nephrolithiasis with ureteral colic
or gastrointestinal disease, so that
diagnosis and institution of treatment
are frequently delayed by approxi
mately 5V4 days.30
The presence of renal artery em-

Table 11-Causes of Acute Renal Artery
Occlusion
Embolic
Cardiac: mitral thrombus
atrial fibrillation
prosthetic valve
primary cardiac tumours
subacute bacterial endocarditis
Noncardiac: paradoxical emboli
atheroembolic
clot formed during a n gio
graphy
Thrombotic
Traumatic: surgery
violence
angiography
Atraumatic: critical stenosis
retrograde propagation of an
aortic thrombus
Extension of aortic dissection
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F IG . 6— E xtrarenal collateral system,
(a) Pericapsular netw ork, (b) Peripelvic
netw ork, (c) Periureteric network.
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McDonald19 demonstrated that hema
turia and proteinuria are present in
only 25% and 50%, respectively, of
cases of renal artery occlusion.
It may be easier to recognize acute
arterial occlusion in a solitary func
tioning kidney since anuria or severe
oliguria is constant. Recrudescence or
worsening of previously well con
trolled arterial hypertension, as in our
case 1, may also indicate the presence
of a single functioning kidney with
pre-existent occlusive renal artery dis
ease. An accurate medical history
should tell about previous nephrec
tomy, blunt abdominal trauma or pye
lonephritis, conditions that may have
caused the loss of renal parenchyma.
The kidney is resistant to acute
ischemia because of the relation of
renal blood flow to oxygen consump
tion11,32 and the presence of an ex
tensive and effective renal collateral
circulation.2,33,34
Reduced blood flow influences renal
function differently from other tissues.
For most organs, such as cardiac or
skeletal muscle, oxygen consumption
is the major determinant of blood
flow. In the kidney, the reverse is
true, blood flow serves as a deter
minant of oxygen use.31
The kidney has a high perfusion
rate, approximately 300 g of renal
tissue receives over 20% of the car
diac output, resulting in an average
flow of 4 ml/rnin for each gram of
tissue.3' This level is almost four times
greater than that of the heart or brain
and greatly exceeds the requirements
of basal renal cell metabolism.
This high perfusion rate generates
a force that promotes blood filtration.
The glomerular filtrate is subjected to
the active tubular reabsorptive pro
cesses (Na+ handling) and it is at this
level, tubular cell function, that the
major renal metabolic expenditure
resides. Hence, with decreased blood
flow, there is a reduction in filtrate
production and a concomitant reduc
tion in tubular work and oxygen
needs. Anuria, in this instance, reflects
the inability to generate appreciable
filtrate production rather than irrever
sible damage to the renal paren
chyma.31
The kidney has an extensive net
work of collateral vessels, capable of
meeting basal renal metabolic require
ments (1 ml of oxygen per minute petgram of tissue). The quality of the
collateral circulation depends not only
on the severity of the pre-existent
occlusive disease but also on the loca
tion of the occlusion. Collateral flow
is greater in proximal occlusions
because there is a critical point of
221

communication between the collateral
vessels and the distal portion of the
main renal artery.35 The time required
to develop an adequate collateral net
work varies; Love and Bush2 have
shown that collateral vessels appear as
early as 8 hours after the onset of
ischemia.
There are two major collateral sys
tems, the extrarenal and intrarenal.31
Collectively, the peripelvic, pericapsular and periureteric networks con
stitute the extrarenal system (Fig. 6)
The extrarenal system as a whole
stems from the lower intercostal ar
teries and the aortoiliac system. The
perforating capsular arteries, arising
from the intralobar arteries, form the
intrarenal collateral system and these
terminate by communicating with the
capsular network.34 An angiogram of
a normal-sized kidney, a nephrographic phase, visualization of colla
teral circulation and opacification of
the renal artery distal to the point of
occlusion indicates a favourable out
come.14,36
It has been suggested that renal
viability can be assessed only at the
time of operation.16 The presence of
back-bleeding signifying good colla
teral flow and the recovery of normal
colour in the renal parenchyma fol
lowing restoration of flow both in
dicate a good prognosis.6,14
Lessman and associates24 stated re
cently that angiography and operation
may not be indicated in patients with
renal artery embolism, that anticoagu
lation gives better results, especially in
high-risk patients. While this approach
may be acceptable for a patient with
distal, intrarenal embolism, occlusion
of the renal artery or its major
branches should be managed more
aggressively. The angiographer, if well
versed in percutaneous transcathete;
thromboembolectomy may try, after
locating the thrombus or embolus, to
extract the occluding material from
the renal artery as described by Deterling in his discussion of Magilligan’s
communication28 and by others;37 how
ever, operation should follow prompt
ly if this procedure fails.
Summary
Acute renal failure secondary to
sudden renal artery occlusion is un
common but should be recognized as
an entity that responds favourably to
operation. Patients with a solitary
kidney are at a high risk of death or
dialysis-dependence if the condition is
not recognized promptly and treated
effectively.
Anuria does not indicate an irrever
222

sibly damaged kidney because of ex
tensive and effective renal collateral
circulation, and the relation of renal
blood flow to oxygen consumption.
The duration of anuria preceding re
vascularization is not a prognostic in
dicator of renal viability, functional
recovery or survival.38
Operation offers the best means to
achieve recovery of renal function and
patient survival,39 predominantly in
patients with a single functioning kid
ney rendered acutely ischemic by
complete arterial occlusion.
We thank Dr. R.G. MacDonald, divi
sion of urologic surgery, Health Sciences
Centre, Winnipeg, for allowing us to
include his patient (case I).
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A Major Advance
in
Analgesia

zomax

zomax

HIGHLY EFFECTIVE IN
ACUTE PAIN

HIGHLY EFFECTIVE
ANALGESIC
As clinically demonstrated in
controlled comparative studies
vs single-entity and
combination analgesicsinvolving over 4400 patients on
ZOMAX with acute or chronic
pain-and employing the
classical reference models for
assaying the relative efficacy
of analgesics

zomax
HIGHLY EFFECTIVE IN
CHRONIC PAIN

Sprains, strains, fractures. . .
“The results indicate that from
the standpoint of both
effectiveness and tolerability
zomepirac represents a useful
alternative to existing analgesic
agents for the management of
acute orthopedic pain.” 2

zomax
A SINGLE ZOMAX TABLET...
90% OF PATIENTS REPORTED
PAIN RELIEF
4
%

‘A LOT”

"MODERATE"

"A LITTLE”

29%

37%

20%
"NONE'

*— "COMPLETE''

10%
J

Total number of patients: 73
Mean duration of therapy: 4.8 days
FINAL GLOBAL EVALUATIONS...
96% RESPONSE TO THERAPY
M ARKED

M O D E R A TE

30%

44%

FINAL GLOBAL EVALUATIONS
OF TWO STUDIES ON CHRONIC
ORTHOPEDIC PAIN

C h ro n ic d e g e n e ra tive jo in t p a in: 111 p a tie n ts

104 (9 3 % )

N u m b er and p e rc e nt
re s p o n d in g to Z O M A X th era p y
(m in im a l to co m p le te )

EFFECTIVE FROM THE
FIRST TABLET
.. the most exciting recent
development in analgesic
drugs is the emergence of
peripherally acting agents that
are clearly superior to the usual
dose of aspirin and compare
favorably with the analgesic
combination products...
Zomepirac is a prototype of this
therapeutic class,.. .” 1

ZOMAX.. .“ will provide a
significant contribution to the
multifaceted therapeutic
approach required for optimum
management of patients with
chronic orthopedic pain.” 4

M IN IM A L
22%

C h ro n ic o rth o p e d ic pain: 244 p a tie n ts 180 (7 4 % )

> THE FIRST COMPREHENSIVE NON-ADDICTING
AN ALGESIC.. .comprehensive because of its
: * broad use in the many dimensions of pain

zomax
SUPERIOR OR AT LEAST
EQUIVALENT TO APCt
CODEINE COMBINATIONS

zomax

Structurally and
pharmacologically, ZO M AX
zomepirac sodium is a non
narcotic analgesic and has not
demonstrated addiction or
dependency potential.3'9

zomax

SIGNIFICANTLY SUPERIOR
TO ASA
A Lot

zomax
NON-NARCOTIC
NON-ADDICTING
ANALGESIC

NO DEVELOPMENT OF
TOLERANCE

POST ORAL SURGICAL PAIN
C ONSTANT MEAN D AILY DOSES OVER A 12-MONTH PERIOD
Adapted from Honig
Zom epirac 100

+APC contains: ASA 227 mg, phenacetin 162 mg &
caffeine 32 mg. This specific combination not
available in Canada.
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/

Aspirin 6 5 0 ^ ^ w

A Little^ ^ ^ ^ ^ ^ ^ ^ ’ lacebo

~

Adapted from Cooper5

Va

1

2
3
TIM E (Hours)

4

“Results.. .were quite
surprising to us, since we
have not previously shown a
single-entity drug which is
not a narcotic or narcotic
antagonist to be superior to
650 mg aspirin.”5

“It is noteworthy that
zomepirac, a single-entity
analgesic, has been shown to
provide analgesia at least
equivalent to that afforded by a
narcotic combination without
unusual side effects.”6

zomax
SIGNIFICANTLY FEWER
SIDE EFFECTS THAN ASA
In Ruoffs study3, ZOM AX
.. had significantly fewer
adverse reactions and fewer
limiting adverse reactions than
did patients treated with
aspirin.”

6
295
No. of patients

“... no evidence of
development of tolerance
during extended therapy with
zomepirac.” 10

zomax
NO EVIDENCE OF
WITHDRAWAL SYMPTOMS
“... abrupt change from oral
zomepirac to aspirin
demonstrated no evidence of
withdrawal symptoms.” 11

zom ax
“. .. is unlikely to be abused.” 11

NEW...
FOR THE MANY
DIMENSIONS OF PAIN...
PRESCRIBING INFORMATION

TABLETS 100 mg

zomax

zom epirac sodium

The first comprehensive
non-addicting
analgesic

Prompt and prolonged action
Significantly effective analgesia
No development of tolerance
Non-narcotic, non-addicting
Well tolerated in both
acute and chronic pain

ACTION: ZOMAX zomepirac sodium is a pyrrole-acetic acid salt with
analgesic and anti-inflammatory properties qualitatively similar to
other non-steroidal anti-inflammatory drugs. In clinical trials it has
been found to be useful as an analgesic agent.
Zomepirac hasan analgesic effect within one hourof administration,
and a duration of action usually of at least four hours. Peak plasma
concentrations are achieved within one hour and the plasma half-life
is approximately four hours.
INDICATIONS AND CLINICAL USE: ZOMAX zomepirac sodium has
been found useful for the relief of pain.
It has been found to be of value for the relief of moderately severe
pain in post-operative patients in cases where oral analgesics can
be used.
CONTRAINDICATIONS: Contraindicated in patients with peptic ulcer
or any other active inflammatory disease of the G.l. tract, patients
having demonstrated hypersensitivity to it and in patients in whom
ASA and other non-steroidal anti-inflammatory drugs induce bronchospasm, rhinitis or urticaria.
WARNINGS: Safe conditions for use in patients with marked im 
pairment of renal or hepatic function have not been established.
Patients with less severe renal impairment may require lower doses,
and kidney function tests should be performed periodically.
Give under close supervision to patients with a history of G. I. disor
ders as peptic ulceration and gastrointestinal bleeding have been
reported. Safety in pregnancy, lactation and in children under 12
have not been established.
PRECAUTIONS: Elevations of BUN and serum creatinine, and an in
crease of urinary tract infections have also been reported in clinical
trials with zomepirac. Consider risk-benefit and maintain clinical sur
veillance when using zomepirac for prolonged periods. Perform
periodic kidney function tests, particularly in patients who may take
the drug for three months or more.
Since zomepirac sodium inhibits platelet function and prolongs
bleeding time, patients with coagulation disorders should be care
fully monitored. Since mild peripheral edema has been reported in
some patients on long-term zomepirac sodium therapy, use with
caution in patients with edema, hypertension and compromised
cardiac function.
DRUG INTERACTIONS: Concomitant administration of high doses of
salicylates and zomepirac are not recommended. Ophthalmologic
examination should be carried out at periodic intervals.
ADVERSE REACTIONS: Gastrointestinal: Side effects in order of
decreasing frequency: nausea, diarrhea, G.l. distress, flatulence,
abdominal pain, constipation, dyspepsia, vomiting, anorexia and
gastritis. Ulceration (1%) and G.l. bleeding (0.7%) have been noted.
Urogenital: As with other drugs which inhibit prostaglandin syn
thetase, urinary tract infection, cystitis, urinary frequency, elevated
BUN/serum creatinine and nocturia have been reported at a total
incidence of 3% to 7%.
Dermatological: Rash, pruritus, skin irritation, sweating and urti
caria have been observed.
Central Nervous System: Dizziness, drowsiness, headache and
insomnia have been reported.
Cardiovascular: Mild edema and hypertension have been observed.
OVERDOSAGE: The stomach should be emptied by induction of
emesis or by gastric lavage. Follow by administration of activated
charcoal.
DOSAGE AND ADMINISTRATION: One 100 mg tablet every four to
six hours as required. For milder pain 50 mg (1/2 tablet) every four
to six hours may be adequate. Doses larger than 400 mg. daily have
not been extensively studied. The long-term safety and efficacy
have not been established. Zomepirac sodium is not recommended
for use in children.
DOSAGE FORM: ZOMAX zomepirac sodium is available as scored,
pale yellow, hexagonal 100mg tablets, imprinted “ McNEIL" and
“ ZOMAX", each containing zomepirac sodium dihydrate equivalent
to 100 mg of zomepirac (free acid).
Product monograph available on request.
REFERENCES
1. Beaver, W. T : J Clin Pharmacol 20 (4, Part2): 213-15, April, 1980
2. Mayer, J. G., Ruoff, G. E.: J Clin Pharmacol 20 (4, Part 2):
285-91, April, 19803. Ruoff, G. E. e ta l.: J Clin Pharmacol 20 (5-6,
Part 2): 377-84, May-June, 1980 4. McMillen, J. I. et al.: J Clin
Pharmacol 20 (5-6, Part 2): 385-91, May-June, 1980 5. Cooper,
S. A ..J Clin Pharmacol 20 (5-6, Part2): 230-42, April, 19806. Baird,
W. M ., Turek, D.: J Clin Pharmacol 20 (4, Part 2): 243-49, April,
1980 7. Cooper, S. A .: CurrTherRes; Vol 28 (5) Nov., 1980 8. Data
on file, McNeil Laboratories (Canada) Limited 9. Pruss.T. P. etal. J
Clin Pharmacol 20 (4, Part 2): 216-22, April, 198010. Honig, S :. J
Clin Pharmacol 20 (5-6, Part 2): 392-96, May-June, 1980
11. O'Brien, C. P., Minn, F. l . \ J Clin Pharmacol 20 (5-6, Part 2):
397-400, May-June, 1980

* Trademark

ZMX-JA2-12/80E

CANADIAN CARDIOVASCULAR SOCIETY

Effects of Hydrogen Peroxide on Isolated Myocardium
G eorge V. F orester,

ph d,*

In a preliminary series of experiments,
the mechanical responses of myo
cardium to dilute solutions of hydrogen
peroxide were examined in 19 isolated
rat papillary and 25 human atrial
muscles under normoxic and hypoxic
conditions.
When a single dose (0.5 to 1.0 ml)
of 3% hydrogen peroxide (final
concentration 0.01% to 0.02%) was
added to normoxic muscle, developed
force rose significantly (P < 0.05)
followed by a gradual increase in
resting force resulting in contracture.
A similar result was obtained in
normoxic hypodynamic human atrial
muscle. Under hypoxic conditions a
single dose of hydrogen peroxide
caused a significant (P < 0.05)
improvement in mechanical properties
of both preparations: developed
force increased while resting
force decreased. However, these
changes were followed by a
progressive irreversible contracture.
In contrast, when a 0.06% solution
of hydrogen peroxide was slowly
infused at a constant rate (2 ml/min),
human atrial muscle showed a
significant (P < 0.05) increase in
developed force and a significant
(P < 0.05) decrease in resting
force from the hypoxic state
while the rat papillary muscle
only showed a significant (P < 0.05)
increase in resting force. Contracture
did not occur in either preparation.
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The authors conclude that controlled
contact between cardiac muscle and
dilute solutions of hydrogen peroxide
can alter the mechanical characteristics
of myocardial tissue.
Dans une serie d’experiences
preliminaires, la reponse mecanique
du myocarde a des solutions diluees
de peroxyde d’hydrogene a ete
etudiee sur 19 muscles papillaires
isoles de rats et sur 25 muscles
auriculaires humains dans des
conditions d'oxygenation normale ou
d’hypoxie.
Quand une seule dose (0.5 a 1.0 ml)
de peroxyde d’hydrogene a 3%
(concentration finale de 0.01% a 0.02%)
fut ajoutee a du muscle normalement
oxygene, la force developpee
augmenta significativement (P < 0.05),
puis fut suivie d’une augmentation
graduelle de la force au repos
entrainant une contracture. Un resultat
similaire fut obtenu sur du muscle
auriculaire humain en condition
d’hypodynamie et d'oxygenation
normale. Sous hypoxie, une seule
dose de peroxyde d’hydrogene entraina
une amelioration significative
(P < 0.05) des proprietes mecaniques
des deux preparations: la force
developpee augmenta alors que la
force au repos diminua. Toutefois, ces
changements furent suivis d'une
contracture progressive irreversible.
En comparaison, quand une solution
de peroxide d'hydrogene a 0.06%
fut administree en perfusion lente
a vitesse de 2 ml/min, le muscle
auriculaire humain sous hypoxie
montra une augmentation significative
(P < 0.05) de la force developpee
et une diminution significative
(P < 0.05) de la force au repos alors
que le muscle papillaire du rat ne
montrait qu'une augmentation
significative (P < 0.05) de la force
au repos. On n'observa pas de
contracture avec aucune des prepara
tions. Les auteurs concluent qu’un
contact controle entre le muscle
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cardiaque et des solutions diluees
de peroxyde d’hydrogene peut modifier
les caracteristiques mecaniques du
tissue myocardique.

The use of hydrogen peroxide to help
minimize the hemodynamic conse
quences of myocardial ischemia has
been proposed for a number of
years.1,2 Although the oxygen-liberat
ing potential of hydrogen peroxide has
been examined for possible therapeutic
use in various clinical situations,3’7 its
action on cardiac tissue, under nor
moxic or hypoxic conditions, has not
been well documented. Various studies
have shown that dilute solutions of
hydrogen peroxide applied directly to
the epicardial surface or infused into
the coronary circulation increase the
survival time of the ischemic myocar
dium.1’7"'0 Previously,
myocardial
mechanical responses to hydrogen
peroxide were observed in situ and
extramyocardial changes were diffi
cult to control. Therefore we exam
ined the direct mechanical effects of
dilute solutions of hydrogen peroxide
in vitro on isolated strips of cardiac
tissue.
M aterial and M ethods

Nineteen left ventricular papillary
muscles were obtained from the hearts
of male Wistar albino rats, sacrificed
by stunning and cervical dislocation.
With the informed consent of 25
patients, isolated strips of endocardial
trabeculae were obtained from the
right atrial appendage of each patient
at the time of open-heart surgery.
After the myocardial specimens
were isolated, they were mounted on
an isometric force recording system11
in a 150-ml open muscle bath. The
bathing solution for both preparations
was a modified Tyrode solution of the
following composition (mmol/1): so
dium chloride 117, potassium phos
phate 102, potassium chloride 3.5,
magnesium sulfate 3.1, sodium bicar
bonate 28 and glucose 5.6. Calcium
227

chloride concentration was 2.5 mmol/
1 in the solution for rat muscle and
3.0 in that for human muscle. The pH
was maintained at 7.4 when the solu
tion was supplied with a mixture of
95% oxygen and 5% carbon dioxide
(normoxic). Muscles were stimulated
by a Grass model S-88 stimulator
(Grass
Instrument Co., Quincy.
Mass.) set at 50% above threshold
voltage through platinum electrodes
placed on each side of the preparation.
Initially the rate was set at 6 stimuli/
min and was raised progressively to
120/min for the remainder of the
study. Rat papillary muscles were
maintained at 27°C while the tempera
ture for human atrial muscle was kept
at 37 °C. Isometric responses were
measured by a UC-2 isometric force
transducer (Statham. Instruments,
Oxnard, Calif.) and recorded on a
Grass model 7 polygraph (Grass In
strument C o.); the mechanical data
consisted of maximum developed force
and resting force (expressed in mg).
During 90 minutes of equilibration,
muscles were progressively extended
so that all studies were performed at
the peak of the length-tension curve.
Episodes of hypoxia were imposed by
shutting off the oxygen supply to the
muscle bath. Previous studies12 have
shown that hypoxia is associated with
a decrease in developed force and an
increase in resting force. In some ex
periments, hypoxia was accelerated by
replacing the oxygen supply with ni
trogen. Hydrogen peroxide (Wampole,
USP) was added either as a single 0.5
to 1.0-ml bolus of 3% hydrogen
peroxide (final concentration 0.01%

to 0.02%) or by slowly infusing a
0.06% solution of hydrogen peroxide
in the modified Tyrode solution with
a Harvard infusion pump at a rate of
2 ml/min so that the bath concentra
tion rose 0.0008% every minute. The
bath volume was kept constant
through an overflow device.
Data were analysed by a paired ttest. A change was considered signifi
cant at the 95% level (P < 0.05).
R esu lts

Table I summarizes the results ob
tained from these studies. When hy

drogen peroxide was added as a bolus
under normoxic conditions, there was
a significant increase in developed
force while resting force remained un
changed. Following this, irreversible
contracture developed in that resting
force progressively increased while
developed force decreased. Fig. 1 illu
strates the effects of a single dose of
hydrogen peroxide on the mechanical
activity of human atrial muscle under
normoxic conditions. Within 12 min
utes (upper panel), developed force
underwent a ninefold increase while
resting force remained stable. Beyond

1 m in u te
i

l

F IG . 1__Effects of hydrogen peroxide on mechanical activity of isolated
hum an atrial muscle under norm oxic conditions. Arrow indicates point at which
hydrogen peroxide was added, resulting in bath concentration of 0.01% . In lower
tracing, sensitivity has been reduced by 0.5.

Table I—Effect of Hydrogen Peroxide on Mechanical Properties of Isolated Cardiac Muscle
---------- 1-------------- ------------------Human atrial muscle

------------— -----------------

Hypodynamic/
bolus
(n = 6)

Normoxic/
Condition
Developed force, mg
Control
Hypoxia
Hydrogen peroxide
Resting force, mg
Control
Hypoxia
Hydrogen peroxide)
Contracture
Time, min

(n = 5)

42 ± 38"

392 ± 138"
—

*

_

Rat papillary muscle

Hypoxic/
bolus
(n = 8)

Hypoxic/
infusion
(n = 6)

Normoxic/
bolus
(n = 3)

581 ± 262

j" 500 ± 234"

663 ± 180'

* 11423 ± 224

“ 1296 ± 194

*

_

888 ± 188.

156 ± 73.

L.052 ± 724

[_389 ± 244 _

783 ± 189J

71 ± 23

112 ± 35

I" 73 ± 36

r 63 ± 27

123 ± 32

—

-

*"1108 ± 32

“1 94 ± 16

—

110 ± 23

110 ± 33

Present
13 ± 3

Present
16 ± 3

L 73

± 33

Present
11 ± 8

*L

74 ± 2 1

123 ± 32

Absent

Present
16 ± 2

Hypoxic/
bolus
(n = 8)

Hypoxic/
infusion
(n = 8)

P 770 ± 164

J 694 ± 224

* “1422 ± 152

.389 ± 154

1.861 ± 242

1054 ± 537

jm

* 30

186 ± 60
*r
1.131 ± 33
Present
16 ± 2

^'110

± 36'

1177 ± 83 *
.116 ± 33J
Absent

*P <0.05.
-

(Measurements taken at time of maximum inotropic effect of hydrogen peroxide.
Figures are mean ± standard deviation.
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this period (Fig. 1, lower panel), con
tracture developed.
In six human preparations we found
that developed force at control levels
was less than 50 mg, therefore these
muscles were termed hypodynamic

12

and placed in a separate category.
Hydrogen peroxide given as a single
bolus resulted in a significant increase
in developed force while resting force
did not change (Table I). In all hypodynamic preparations a contracture

i

Min
(i

G

^w**"**"*

H

FIG. 2— Effects of bolus of hydrogen peroxide on mechanical activity of hypodynamic isolated human atrial muscle. Time marker (upper tracing) indicates I second
while lower tracing shows isometric force recording. Marker in panel B represents
50 mg of force. In panels D, E and F baseline has been electronically altered to
preserve tracings. Panel H is continuation of panel G.

A SENSITIVITYx 2.0

FIG. 3— Effects of bolus of hydrogen peroxide on mechanical activity of hy
poxic human atrial muscle. In upper tracing, hydrogen peroxide was added to
hypoxic tissue. In middle, sensitivity was reduced by 0.5. In lower tracing, sensitivity
was restored to same level as in upper tracing.
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developed within 16 minutes of adding
hydrogen peroxide (Fig. 2). Within
1 minute of adding the hydrogen
peroxide a rapid increase in developed
force was observed (Fig. 2B). By 2
minutes, developed force had in
creased 10-fold over the control level
while resting force had not changed
(Fig. 2C). Between 2 and 9 minutes,
resting force steadily increased while
developed force remained stable (Figs.
2D, E and F). Contracture became
apparent after 9 minutes (Figs. 2, G
and H) as developed force rapidly
diminished and resting force con
tinued to increase. This contracture
was found to be irreversible since re
peated washout with fresh Tyrode
solution produced no change.
In both human atrial and rat papil
lary muscles, hypoxia created a signifi
cant decrease in developed force and
an increase in resting force over con
trol values (Table I). A bolus of
hydrogen peroxide added to these hy
poxic preparations caused a signifi
cant increase in developed force and a
decrease in resting force which re
established control levels. However,
these changes were superseded by a
contracture that developed within 16
minutes in the rat and within 11 min
utes in the human preparation. Fig. 3
is an example of the effect of adding
a bolus of hydrogen peroxide to a
hypoxic preparation of human atrial
muscle. When the oxygen supply to
the muscle bath was shut off, there
was a progressive increase in resting
force and a-decrease in developed
force. Hydrogen peroxide added to a
net concentration of 0.01% caused an
initial marked increase in resting force
which decreased progressively over the
next 5 minutes to prehypoxic levels.
Over the same period there was a four
fold increase in developed force com
pared with prehypoxic values. The
middle tracing in Fig. 3 shows that
these changes were sustained for a
further 6 minutes and were followed
by a contracture (lower tracing).
Fig. 4A shows the control situation
for human atrial muscle. When hypoxic
conditions were imposed for 5 min
utes, developed force fell significantly
(Fig. 4B) and after 10 minutes rest
ing force increased (Fig. 4C) (Table
I). In an effort to avoid contracture
while maintaining the beneficial effect
of hydrogen peroxide, we infused
dilute hydrogen peroxide (0.06%)
directly into the muscle bath at a fixed
rate (2 ml/min). This resulted in
a significant increase in developed
force after 5 minutes (Fig. 4D) and
after 8 minutes (Fig. 4E) a decrease
in resting force that continued to the
229

end of the infusion (Fig. 4F). When
the infusion pump was turned off
developed force decreased and only
resting force returned to prehypoxic
levels (Fig. 4G ). It should be noted
that contracture did not occur in these
preparations, even after procedure was
repeated several times.
Similarly, rat papillary muscle
showed a significant reduction in de
veloped force and an increase in rest
ing force when hypoxic conditions
were imposed (Table I). In these
preparations, no significant change in
developed force over either hypoxic
or control values occurred with hy
drogen peroxide infusion while resting
force changes were significant in both
instances. As in the human muscle,
an infusion of hydrogen peroxide did
not result in contracture. The average
time required to produce the maxi
mum change in developed force dur
ing hydrogen peroxide infusion was 9
minutes with human atrial prepara
tions and 7 minutes with the rat pre
parations.
Discussion

Attempts to oxygenate ischemic
myocardium by using hydrogen perox
ide have been reported since the early
1960s. In a series of articles by
Urschel and colleagues7'9 the thera
peutic use of dilute solutions of hy
drogen peroxide resulted in a number
of favourable responses. In their
experiments with animals, arterial
oxygen tension (P0 2 ) was reduced,
either systemically (occluding the
trachea) or locally (cross-clamping the
aorta and ligating the coronary artery)
while hydrogen peroxide was admin
istered intravascularly or superficially
to the myocardial surface. They
found that the use of hydrogen per
oxide increased survival, reversed
arrhythmias and maintained arterial
pressure, presumably by increasing
P 0 2 . These results were confirmed by
Takahashi and associates10 who re
ported that epicardial superfusion
with a dilute solution of hydrogen
peroxide prevented the onset of fibril
lation, normalized blood pressure and
restored myocardial Po2 in hearts with
ligated coronary arteries. Olson and
Boerth1 recently evaluated the site of
infusion in rabbits with occluded
coronary arteries. They noted that
survival time and mean arterial pres
sure were enhanced by aortic infusion
of hydrogen peroxide at the level of
the coronary ostia. In their inter
pretation of the results, increases in
P0 2 alone could not account for these
changes. They suggested that hydro
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gen peroxide might have a direct
pharmacologic action on the myocar
dium. However, Goodlett and asso
ciates2 were unable to demonstrate
any positive inotropic effects when
they used hydrogen peroxide in dogs
with regional myocardial ischemia, al
though the low concentration of catal
ase in the dog may have been re
sponsible for this finding.7
Clinical effects of hydrogen perox
ide on the heart have been reported
in two articles. Sellers and associates3
in 1962 noted that a high concentra
tion applied topically provoked epi
sodes of cardiac arrest. In contrast,
Urschel and colleagues8 when admini
stering a lower concentration into the
root of the aorta to a patient in vas
cular collapse found that sinus rhythm
was restored and arterial pressure in
creased; however, these effects were
temporary and were obtained only
during periods of infusion.
Although a therapeutic effect of hy
drogen peroxide infusion was reported
in the above studies, the investigators
conclusions were based upon uncon
trolled experiments in which extramyocardial influences on the heart
were not considered. Accordingly, we
examined the direct mechanical effects
of hydrogen peroxide on the myocar
dium under carefully controlled con
ditions.
We found that the action of hy
drogen peroxide on the mechanics of
isolated tissue could be defined in
terms of the changes in both devel
oped and resting forces. In normoxic,
hypoxic and hypodynamic states, the

administration of hydrogen peroxide
always resulted in increased devel
oped force, which quickly rose to,
or exceeded, control levels. During
the period of this increase in de
veloped force, a reduction in resting
force from previous high levels was
noted in hypoxic specimens while no
substantial changes were observed in
hypodynamic or normoxic tissues. A
contracture, characterized by a pro
gressive increase in resting force with
diminishing developed force subse
quently occurred in myocardial tissue
exposed to high concentrations of
hydrogen peroxide. This contracture,
once provoked, was irreversible. We
were able to eliminate this effect in
our preparations by slow infusion of
hydrogen peroxide, thus limiting the
concentration in contact with the
cardiac muscle.
The initial increase in developed
force and decrease in hypoxic resting
force may be accounted for by the
liberation of oxygen from hydrogen
peroxide or as the result of a positive
inotropic action. The experimental re
sults of Urschel9 and Olson and
Boerth1 suggest that both may
be responsible. While the liberation
of oxygen can be substantiated
by direct measurement of Po2, the
inotropic action is suggested by our
results in normoxic tissue. Previous
studies have shown that an increase in
oxygen of up to one atmosphere does
not significantly change developed
force1 while hyperbaric conditions
produce a depression.13 In contrast,
Frezza and Bing14 suggested that all

INFUSION

5 Min

CONTROL

INFUSION

8

Pump off

Min

2 Min

FIG. 4__Effects of infusion of hydrogen peroxide on mechanical activity of
hypoxic isolated human atrial muscle. Time marker in upper tracing indicates seconds
while lower tracing shows isometric force recording. Infusion was begun midway
through panel C. Infusion rate is 2 m l/m in of 0.06% hydrogen peroxide into 150-ml
constant-volume bath.
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isolated strips of cardiac tissue anal
ysed in vitro may have hypoxic cores,
contributing to the changes we noted.
Contracture is a feature of ischemic
and hypoxic tissue. 12,15' 16 Its cause is
not completely understood although
calcium overload has been impli
cated . 16 In our experiments, irrever
sible contracture was present only in
muscles exposed to high concentra
tions of hydrogen peroxide and al
though this contracture appears sim
ilar to that seen in hypoxic tissue,
the underlying mechanisms may
differ. In the case of the contracture
due to hydrogen peroxide, a defi
ciency in oxygen was not responsible
since normoxic tissue exposed to hy
drogen peroxide also developed con
tracture. Therefore, it may be related
either to the toxicity of high levels of
oxygen or the oxidizing features of
hydrogen peroxide, both of which
could alter the contractile proteins.
In summary, these preliminary ex
periments indicate that controlled
contact between hydrogen peroxide
and myocardial tissue can produce
variable responses depending on dose
and condition of tissue. Low concen
trations appear to be therapeutic;

however, it remains to be determined
whether the benefits we noted are due
to the release of chemically bound
oxygen or to the pharmacologic action
of hydrogen peroxide. A carefully
designed protocol should clarify this.
We thank Mrs. Elizabeth Masson for
her help in preparing the manuscript and
Mrs. Joan Freda for her secretarial as
sistance.
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To study its hemodynamics the
authors describe two cases of
coronary artery fistula. They discuss
the use of radionuclide angiography
in this setting. The surgical technique
is outlined and the use of intraopera
tive electrocardiographic monitoring
is emphasized.
Chez I'adulte, une fistule arterioveineuse coronaire peut etre associee
a de I'angine de poitrine. II a ete
suggere qu'un detournement du sang
de I'artere coronaire a la fistule soit
la cause de I'angine, mais ceci n'a
pas ete demontre.
Les auteurs decrivent deux patients
ayant une fistule coronarienne et
chez qui ils ont etudie I'hemodynamique
de ces fistules. Ils discutent de

T H E C A N A D IA N JO U R N A L O F S U R G E R Y

(’utilisation de I'angiographie
isotopique dans cette situation. La
technique chirurgicale est soulignee
et on insiste sur ('importance d’une
surveillance electrocardiographique
durant I'intervention.

Coronary arteriovenous fistula is the
commonest form of coronary artery
anomaly to cause angina pectoris in
adults. 1' 2 It has been postulated that a
steal of blood from the native coro
nary circulation into the fistula is the
mechanism . 3"6 To our knowledge, this
hypothesis has not yet been proven . 7,8
We report two patients with a coro
nary artery fistula. The first patient
gave us the opportunity to study the
hemodynamics of a fistula in the
setting of an otherwise normal coro231

nary circulation. In the second patient
who had a coronary fistula and athe
rosclerotic coronary artery disease we
used radionuclide angiography to as
sess the shunt through the fistula.
Case R eports

Case 1
A 38-year-old man had a heart mur
mur and a 6-month history of typical
angina pectoris. He had participated in
athletics for most of his life but now
found the anginal symptoms disabling.
The heart murmur had been disco
vered recently by his family doctor, and
it was this finding associated with the
angina that prompted his referral.
The patient had no history of serious
illness.
On physical examination we found a
continuous murmur in the midsternum at
the fifth rib interspace. The cardiac
rhythm was normal, as was the blood
pressure. No other abnormalities were
found.
A plain chest film revealed no ab
normality (Fig. 1).
A resting electrocardiogram appeared
normal, but an exercise electrocardio
gram revealed a 3-mm depression of the
ST segments in leads V4_Band the patient
noted angina during the test.
Cardiac catheterization was performed.
The intracardiac pressures were all nor
mal and results of oximetry showed no
left-to-right shunt.
Coronary arteriography demonstrated
a coronary artery fistula between the
circumflex coronary artery and the coro
nary sinus (Fig. 2). The coronary ar
teries were otherwise completely normal.
Surgical ligation of the fistula was
recommended. At operation the external
cardiac anatomy was normal aside from
an extremely dilated circumflex coronary
artery which had an easily felt thrill.
Throughout the operation cardiac output
was assessed at regular intervals by the
thermodilution thermistor method.
The junction between the fistulous cir

FIG. 1—Case 1. Anteroposterior chest
roentgenogram shows no abnormality.
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cumflex coronary artery and the coro
nary sinus was difficult to dissect without
manipulating the heart which interfered
with cardiac function. Therefore cardio
pulmonary bypass was required during
the operative procedure on the fistula
itself.
To establish proper baseline hemo
dynamic data electromagnetic flow probes
were placed on the fistulous circumflex
coronary artery and on the normal left
anterior descending (LAD) coronary
artery before initiating cardiopulmonary
bypass. The mean blood flows through
both the fistula and the normal LAD
coronary artery were recorded as well as
cardiac output.
Partial cardiopulmonary bypass was
then established and the heart was kept
beating at normothermia. The V5 and
the inferior-wall leads of the electro
cardiogram were monitored throughout
the operative procedure.
The distal end of the fistula was care
fully dissected, then temporarily occluded
with a Silastic loop. The electrocardio
gram showed elevation of the ST seg
ment in the inferior-wall leads, indicating
exclusion of part of the normal distal
circumflex coronary artery. Upon release
of the Silastic loop the electrocardiogram
returned to normal. The right atrium
was opened and a steel dilator was
placed into the coronary sinus. The distal
end of the fistula was then reassessed
from both inside and outside the heart.
A more distal Silastic ligature was ap
plied to the fistula. This action produced
no electrocardiographic changes, so the
fistula was ligated at this site.
Following closure of the fistula, the
patient was weaned from bypass and
cardiac output and blood flow values
were again measured. Ligation of the
fistula resulted in a doubling of the
blood flow in the LAD coronary artery,
along with the expected reduction in
flow through the circumflex coronary
artery (Fig. 3). The pre- and postligation
cardiac output values were unchanged at
5.5 1/min.
The patient made a smooth recovery
from surgery and at 1 year after opera
tion was athletically active with no an

gina pectoris. The postoperative exercise
electrocardiogram was normal and a post
operative selective coronary arteriogram
demonstrated closure of the fistula as
well as enhanced visualization of the
normal coronary arteries (Fig. 4).
Case 2
A 54-year-old man was seen in May
1980 with class III stable angina pectoris
(New York Heart Association classifica
tion). He had had angina since 1974
and had suffered myocardial infarctions
in 1974 and in 1977. Since his symptoms
were progressive and poorly controlled
with medication, he was admitted to hos
pital for further assessment.
Physical examination revealed no car
diac murmur and only mild chronic
bronchitis. No other abnormality was
detected.
The intracardiac pressures were all
normal. Oximetry revealed no evidence
of a shunt. Coronary arteriograms de
monstrated three-vessel atherosclerosis
and a fistulous communication between
the circumflex coronary artery and the
right lower lobe pulmonary artery (Fig.
5).
Scanning of the myocardium with
thallium-201 demonstrated patchy uptake
of the radionuclide compatible with dif
fuse coronary artery disease.
The injection of macroaggregated al
bumin (MAA) labelled with iodine-131
into the left coronary ostium allowed us
to estimate that 25% of blood flow to
the left coronary artery was being di-

KIG. 3—Case 1. Pre- and postligation
blood flows are compared in fistula
(right) and in LAD (left) at constant car
diac output.

FIG. 2__Case 1. Selective left coronary arteriogram (right anterior oblique
projection) and sketch demonstrating fistula. LAD = left anterior descending coro
nary artery.
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verted to the pulmonary artery via the
fistula (Fig. 6).
Subsequently the patient underwent
triple-vessel coronary artery bypass graft
ing and ligation of the fistula. Intraoper
ative measurements of blood flow were
not made because diffuse, severe coro
nary atherosclerosis was present.
This patient made a smooth recovery
and is asymptomatic.
Discussion

When we first saw our second pa
tient, nuclear medicine facilities were
available to study the fistula. Myocar
dial imaging with 201T1 is useful for
detecting myocardial ischemia. In the
patient with coronary artery disease
and a coronary arteriovenous fistula,
thallium scanning is of limited value.
However, such a study is of particular
interest in the patient with a coronary
artery fistula who has angina and nor
mal coronary arteries.11'12 It is in this
instance that scanning with 201T1 may
demonstrate the area of myocardial
ischemia responsible for the angina.
The intracoronary injection of 131IMAA is helpful in calculating the
amount of blood being shunted from
the coronary circulation into the fis
tula,13 as demonstrated in our second
case.
In summary, we believe that we
have added credence to the hypo
thesis that a coronary artery fistula
produces angina by “stealing” blood

Many authors have postulated that
coronary artery fistulas cause angina
pectoris by “stealing” blood from the
normal coronary circulation,2'7 but
have not actually demonstrated this
phenomenon.
Our first patient allowed us to study
the means whereby a coronary artery
fistula causes angina pectoris in an
adult with otherwise normal coronary
arteries. Although our assessment was
not very sophisticated, we were able
to demonstrate increased blood flow
in the normal neighbouring coronary
arteries following ligation of the fis
tula, which lends credence to the coro
nary steal mechanism for producing
angina pectoris in patients with coro
nary fistulas.1'9
Ligation of a coronary arteriovenous
fistula is one type of cardiac surgical
procedure in which electrocardiogra
phic monitoring is essential through
out.3'5,10 In our first case, a small distal
branch of the circumflex coronary
artery was unknowingly excluded
from the coronary circulation by the
initial ligature, and the electrocardio
graphic changes indicated this. When
a more distal ligature was placed on
FIG. 5— Case 2. Selective left coronary
the fistula there were no electrocardio
arteriogram (right anterior oblique view).
graphic changes, and thus the fistula Coronary artery fistula is seen projected
could confidently be tied at that point. behind coronary catheter.

FIG. 4—Case 1. Postoperative selective left coronary arteriogram (right an
terior oblique view) and diagrammatic sketch following ligation of fistula. CCA =
circumflex coronary artery.
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from the native coronary circulation.
We suggest that radionuclide studies
are valuable in assessing patients with
a coronary artery fistula. Finally, we
wish to emphasize the importance of
electrocardiographic monitoring dur
ing ligation of the fistula to avoid
inadvertent myocardial ischemia.
We thank Dr. A. Mattar, division of
nuclear medicine, Memorial University
of Newfoundland, for his assistance in
preparing this manuscript, and we are
grateful to Mrs. B. MacKeil for her se
cretarial skills.
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Is It Important to Preserve the Chordae Tendinae and
Papillary Muscles during Mitral Valve Replacement?
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To evaluate the importance of
preserving chordae tendinae and
papillary muscles to left ventricular
function after mitral valve replacement,
12 dogs had Carpentier-Edwards or
Bjdrk-Shiley mitral valves inserted.
Cardiopulmonary bypass, systemic
hypothermia at 25°C and cold
cardioplegia were used. The period
of anoxic arrest was 30 minutes.
In six dogs, mitral valve replacement
was performed after complete excision
of the mitral valve. In the other
six dogs the anterior leaflet was
partially excised but all chordae
tendinae and papillary muscles were
left intact. Hemodynamic measure
ments, including left ventricular
function following volume loading,
w ere made preoperatively and
postoperatively. Left ventricular
angiograms were obtained post-
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operatively in all dogs.
Preoperatively there was no
significant difference in the left
ventricular function curves in the two
groups, but postoperatively the curves
showed significant differences.
In the group with preserved chordae
tendinae, left ventricular function
improved with volume loading to a left
ventricular end-diastolic pressure
of 20 mm Hg while in the group with
divided chordae tendinae, function
improved more slowly and ceased
to improve after loading to an
end-diastolic pressure of 15 mm Hg.
The mean left ventricular ejection
fraction following mitral valve
replacement with preserved papillary
muscles was 0.62 ± 0.01 and with
divided papillary muscles was
0.45 ± 0.05 (P < 0.05).
The authors conclude that it is
important to preserve chordae tendinae
and papillary muscles when carrying
out mitral valve replacement.
Afin d’evaluer I'importance, pour la
fonction ventriculaire gauche apres
un remplacement de valvule mitrale,
de preserver les cordages tendineux
et les muscles papillaires, 12 chiens
ont recu des valvules prosthetiques
Carpentier-Edwards ou Bjdrk-Shiley.
La circulation extra-corporelle, I'hypothermie generale a 25°C et la cardioplegie a froid ont ete utilisees.
La periode d'arret anoxique fut de
30 minutes. Chez six chiens, le
remplacement de valvule mitrale fut
fait apres excision complete de la
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valvule mitrale. Chez les six autres
chiens, le feuillet anterieur fut
excise partiellement mais les cordages
tendineux et les muscles papillaires
furent gardes intacts. Des mesures
hemodynamiques comprenant la
fonction ventriculaire gauche apres
remplissage ont ete realisees avant et
apres I'operation. Des angiogrammes
ventriculaires gauches ont ete obtenus
en post-operatoires chez tous les
chiens.
Avant I'operation, on n’a constate
aucune difference entre les deux
groupes dans les courbes de fonction
ventriculaire gauche; cependant, des
differences significatives ont ete mises
en evidence apres I’operation. Dans le
groupe chez qui on a conserve les
cordages tendineux, la fonction
ventriculaire s’est amelioree au
remplissage jusqu'a une pression
telediastolique ventriculaire gauche
de 20 mm de Hg; dans le groupe
dont les cordages tendineux furent
divises, cette fonction s'est amelioree
plus lentement et a cesse de s'ameliorer apres une charge entrainant
une pression telediastolique de 15 mm
de Hg. La fraction d’ejection ventri
culaire gauche apres remplacement
d’une valvule mitrale avec consertion des muscles papillaires fut de
0.62 ± 0.01 comparativement a 0.45
± 0.05 (P < 0.05) dans le groupe
avec muscles papillaires divises.
Les auteurs concluent a I'importance
de preserver les cordages tendineux
et les muscles papillaires lors de
la pose d’une prothese mitrale.
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thoracic aorta and the right atrium.
Hemodilution and systemic hypother
mia at 25°C were used in all animals.
Cold cardioplegia was used to lower
the myocardial septal temperature to
15°C and the period of anoxic arrest
was 30 minutes in all cases.
All leaflet tissue and chordae ten
dinae were completely excised in six
dogs and a 25-mm Carpentier-Edwards or Bjork-Shiley prosthesis was
inserted (group 1). In the remaining
six dogs, the anterior leaflet was par
tially excised in a triangle with its base
towards the left ventricular outflow
tract, but all its chordae tendinae and
the posterior leaflet with its chordae
tendinae were left intact. A 25-mm
Carpentier-Edwards or Bjork-Shiley
prosthesis was sutured to the mitral
anulus (group 2).
After removal of the clamp from
the aorta, all hearts were reperfused
for 15 minutes. A left atrial line was
inserted and cardiopulmonary bypass
discontinued without assistance of ino
tropic agents or vasodilators. All dogs
were in sinus rhythm. The thoraco
tomy was closed and the animals were
taken to the cardiac catheterization
laboratory 2 to 3 hours after the oper
ation. They were maintained under
anesthesia and with assisted ventila
tion. Arterial blood gases and serum
potassium values were monitored reg
ularly. Blood losses were replaced by
transfusion to maintain a systemic

Physiologic studies have suggested that
the continuity of the mitral anulus
and left ventricular wall through leaf
lets, chordae tendinae and papillary
muscles may play a role in left ventri
cular function.13 During mitral valve
replacement the leaflets and the chor
dae tendinae are usually excised and
a prosthesis is sutured to the mitral
anulus, disrupting the mitral anulus
attachments to the left ventricular
wall. This disruption may explain the
poor left ventricular function some
times seen following mitral valve re
placement. To evaluate the importance
of continuity of the mitral anulus with
the left ventricular wall during mitral
valve replacement, the following ex
perimental study was undertaken.
Methods

Mitral valve replacement was car
ried out in 12 mongrel dogs (weight
25 to 30 kg). Each dog was premedi
cated with diazepam and morphine.
General endotracheal anesthesia was
induced and maintained with sodium
pentothal and pancuronium bromide.
A femoral arterial catheter and a
Swan-Ganz catheter were inserted to
monitor systemic and pulmonary
artery pressures and cardiac output.
A left thoracotomy was performed
through the fourth intercostal space
and cardiopulmonary bypass estab
lished by cannulating the descending

Table 1 - Preoperative Hemodynamic Findings
Group
Hemodynamic m easurement

1-excised chordae

2-preserved chordae

P value

80 ± 9.8

82 ± 6.1

NS

12 ± 3.6

12 ± 4.3

NS

3.0 ± 0.2

3.0 ± 0.1

NS

Mean arterial
pressure, mm Hg
Mean pulmonary artery
pressure, mm Hg
Cardiac output,
l/m in
NS = not significant.

Table I I - Postoperative Hemodynamic Findings
Group
1

Hemodynamic measurement
Mean arterial pressure, mm Hg
Left ventricular
end-diastolic pressure, mm Hg
Left ventricular
end-diastolic volume, ml
Left ventricular
end-systolic volume, ml
Left ventricular
ejection fraction
Cardiac output, l/m in

2

P value

80 ± 4.6

82 ± 6.0

NS

6.6 ± 1.3

4.4 ± 1.1

0.05

76.4 ± 13.4

76.3 ± 7.6

NS

41.8 ± 11.6

29.5 ± 4.2

NS

0.45 ± 0.05
2.7 ± 0.02

0.62 ± 0.01
3.0 ± 0.2

0.001
NS

NS = not significant, P > 0.05.
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pressure of 100 to 120 mm Hg. Se
quential biplane ventriculography was
performed with 25 to 40 ml of Renografin-76 in the 70° right anterior
oblique (RAO) and the 30° left an
terior oblique projections.4 Left ventri
cular volumes were calculated using
standard area to length methods.5 A
longitudinal axis chord was measured
from the mid-point of the aortic valve
in the RAO projection to the apex,
in the end-diastolic and end-systolic
frames. The shortening of the longaxis chords was analysed in each
study. Volumes and chordal shorten
ing were calculated using a tablet
digitizer and dedicated microcomputer
(Digisonics Inc., Houston, Tex.). Car
diac output values were obtained at
various filling pressures. The animals
were then sacrificed and the hearts
removed for gross pathological exami
nation.
All data are expressed as mean ±
standard error of the mean. Statistical
significance was determined by the
paired Mest.
R esults

Preoperative hemodynamic meas
urements (mean arterial pressure,
mean pulmonary wedge pressure and
cardiac output) were similar in both
groups (Table I).
The postoperative measurements
are summarized in Table II. There
was no difference between the two
groups in terms of mean arterial pres
sure or cardiac output, but left ventri
cular end-diastolic pressure was signif
icantly lower (P < 0.05) in group 2
dogs. Moreover, there was no differ
ence in left ventricular end-diastolic
volume, but the left ventricular endsystolic volume tended to be smaller
in group 2 dogs although this dif
ference did not quite reach statistical
significance. However, group 2 dogs
had a significantly higher (P <
0.001) left ventricular ejection frac
tion postoperatively.
There was no measurable gradient
across the prosthesis in any animal
of either group at resting cardiac
output. The left ventricular func
tion curve obtained during volume
loading in dogs with intact chordae
tendinae was significantly better than
that in dogs with divided chordae
tendinae (Fig. 1).
Biplane
ventriculography
done
postoperatively (Figs. 2 and 3) and
measurement of shortening of the
longitudinal axis chords of the left
ventricle demonstrated a substantial
improvement in group 2 dogs.
Autopsy examination of all hearts
237

revealed no periprosthetic dehiscence
and no gross evidence of myocardial
infarction.
Subendocardial hemorrhage on
the left atrial wall was a common
finding and probably related to the
traction used to expose the mitral
valve during the operation.
Discussion

In earlier physiologic studies Wiggers and Katz1 and later Rushmer2"3
suggested that the continuity of the
mitral anulus with the left venricular
wall through the leaflets, chordae tendinae and papillary muscles may play
a decisive role in left ventricular func-

F IG . 1— P ostoperative left v e n tricu la r
lo ad in g curves. C O = c ard iac outp u t,
I.V E D P = left v e n tricu la r end-diastolic
p ressu re.

tion. Rushmer noted that during the
cardiac cycle, in the period of isovolumetric contraction, the long axis of
the left ventricle was reduced in
length while the circumference of the
left ventricle actually increased in size.
This reduction along the longitudinal
axis of the heart was attributed mainly
to the continuity of the left ventricular
wall with the mitral anulus. As the
mitral anulus descends in response to
papillary muscle contraction, left
ventricular circumference increases.
This allows the group of muscle fibres
in the central layers to stretch further
resulting in more tension in late
systole, more contraction and, there
fore, an increase in stroke volume.
During mitral valve replacement,
leaflets, chordae tendinae and papil
lary muscle heads are usually excised
and a prosthesis is secured in the
mitral anulus, disrupting the con
tinuity of the mitral anulus and left
ventricular wall. In the early 1960s
Lillehei and colleagues3 applied clini
cally the concept of maintaining the
continuity of the mitral anulus and
and left ventricular wall during mitral
valve replacement and found a de
creased operative mortality and in
cidence of postoperative low cardiac
output. Recently, Miller and asso
ciates7 showed that the operative mor
tality for mitral valve replacement is
decreased by preserving the posterior
leaflet and its chordae; their reasoning

F IG . 2— K nd-diastolic (A) and end-systolic (B) fram es of
po sto p erativ e le ft v en tricu lo g ra m a fte r m itra l valve replace
m en t w ith excision o f ch o rd ae ten d in a e a n d p apillary m uscles.
P o sto p e ra tiv e ejection fra c tio n in this dog w as 0.52 and longi
tu d in a l axis sh ortening w as 3 % . M ean ( ± SE M ) ejection fra c 
tio n a n d longitudinal axis sh o rte n in g fo r g ro u p w ere 0.45 ±
0.05 a n d 2% ± 3.6%, respectively.
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was that posterior wall rupture of the
left ventricle is less likely.
Other investigators disagree and do
not believe that preservation of the
mitral anulus to left ventricular at
tachments during mitral valve replace
ment alters operative mortality or
prevents deterioration of left ventri
cular function.8,9 Rastelli and asso
ciates" carried out short- and long
term experiments with the mitral valve
in dogs. They replaced the mitral
valve with a l-M Starr-Edwards ballvalve prosthesis with and without
preservation of the chordae tendinae.
A sham operation was also performed
on two dogs. Their results indicated
that preservation or excision of the
chordae tendinae does not affect car
diac performance when the mitral
valve is replaced with the Starr-Ed
wards ball-valve prosthesis. Interest
ingly, dogs with prosthetic mitral val
ves performed as well as dogs with
normal mitral valves (sham opera
tion ).
Our experiments, as originally sug
gested by Rushmer,2,3 indicate that
division of the mitral anulus attach
ment to left ventricle produces an
impairment of left ventricular func
tion as shown by a decreased resting
cardiac output (corrected for preload)
increased left ventricular end-diastolic
pressure, a worsening of the left ven
tricular ejection fraction and decreased
shortening of the longitudinal axis

F IG . 3— E n d-diastolic (A) and end-systolic (B) fram es of
posto p erativ e left v entriculogram a fte r m itral valve rep lace
m ent w ith preserv atio n o f chordae ten d in ae and papillary m u s
cles. P o sto p erativ e ejection fractio n in this dog was 0.65 and
lo n g itu d in al axis sh o rten in g was 1 9 % . M ean ( ± SE M ) ejection
frac tio n and longitudinal axis sh ortening fo r g roup were 0.61 ±
0.02 and 18% ± 7 % , respectively.
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chord. All our experiments were of
short term and our findings reflect
only changes in cardiac performance
within the first 24 hours after mitral
valve replacement.
We have applied this concept to
patients with chronic mitral regurgi
tation and have noted improved left
ventricular pressure-volume relations
compared with those who underwent
standard mitral valve replacement.
Unfortunately, preservation of chor
dae tendinae in patients with mitral
stenosis who require mitral valve re
placement is not feasible with cur
rently available prostheses. However,
mitral valve replacement in these pa
tients, when compared with those
who had mitral regurgitation, does
not seem to produce significant
change in left ventricular pressurevolume relations.10,1
We conclude that mitral anulus to

left ventricular wall integrity benefits
left ventricular function following
mitral valve replacement in dogs.
However, further short- and long-term
studies will be necessary before this
approach to mitral valve replace
ment can be recommended in humans.
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j r : Mitral valve replacement with preser
vation of papillary muscles and chordae
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The Big Toe in the Recovery Room:
Peripheral Warm-up Patterns in Children
after Open-Heart Surgery
R. W illiam K night ,

ba, m d * and J ohn

To evaluate the usefulness of toe
temperature warm-up patterns in
predicting survival in a group of
pediatric patients after cardiac
surgery, the condition of 70 children
Cage 3.9 yr ± 3.8 yr) was evaluated
for 24 hours postoperatively by
direct and indirect cardiac monitoring,
including toe temperature, while
in a heat controlled environment.
Two groups were identified—
60 survivors and 10 nonsurvivors.
The volume balance, pH and urine
output of all patients were maintained
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within acceptable values, but
nonsurvivors had a persistently lower
blood pressure. Systemic vascular
resistance separated survivors from
nonsurvivors but cardiac index did not.
A toe temperature that did not reach
32 °C within 4 hours of operation
was associated with increased
mortality.
With the peripheral warm-up patterns
a nomogram was constructed, its
predictive accuracy was identified
(99% valid} and the toe temperature
trends were correlated with
traditional monitoring techniques.
The authors conclude that
measurement of toe temperature
is a useful, inexpensive and noninvasive
addition to established methods of
monitoring after open-heart operations.
Afin d’evaluer comment 1'evolution
caracteristique du rechauffement de
I'orteil pouvait contribuer a predire
la survie apres chirurgie cardiaque
chez un groupe pediatrique, I'etat de
70 enfants (ages de 3.9 ± 3.8 ans)
a ete suivi pendant 24 heures apres
I’operation par une surveillance directe
et indirecte de la fonction cardiaque,
y compris la temperature de I'orteil,
alors qu'ils etaient dans un environ-
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nement a temperature controlee.
Deux groupes comprenant 60
survivants et 10 non-survivants ont ete
identifies. L'equilibre volumetrique,
le pH et le debit urinaire de tous les
patients se sont maintenus a I'interieur
de limites acceptables; cependant la
tension arterielle des non-survivants
etait constamment plus basse. La
resistance vasculaire generate a
distingue les survivants des nonsurvivants mais il n'en fut pas de
meme pour I’index cardiaque. Une
temperature de I’orteil qui n'avait pas
atteint 32°C dans les 4 heures qui
ont suivi I’operation etait associee
a une mortality accrue.
Un nomogramme a ete construit avec
revolution caracteristique de rechauf
fement peripherique. Sa precision
previsionnelle a ete identifiee
(valide a 99%) et une correlation a ete
etablie entre les tendances de
la temperature de I’orteil et les
techniques de surveillance conventionnelles.
Les auteurs concluent que la mesure
de la temperature de I’orteil
constitue une addition utile, peu
couteuse et non sanglante aux
methodes de surveillance etablies,
apres la chirurgie a coeur ouvert.
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Hippocrates, an astute clinical phy
sician, was the first to observe that
“it is a bad symptom when the head,
hands, and feet are cold, but it is a
very good symptom when the whole
body is equally hot”. In 1939 two
papers reported on the measurement
of peripheral skin temperature as an
index of peripheral circulation.1,2 Fur
ther work in this area refined the rela
tion between the skin surface tempera
ture of the big toe and volume of
blood flow per unit of time.3 Only in
the last decade has the potential of
this early work been realized and its
application to clinical medicine in
vestigated. Several centres currently
monitor toe temperature routinely in
their assessment of a patient’s cir
culation in shock or following major
surgery.4'10
To date, however, there have been
no reported studies of the use of peri
pheral temperature measurements as
an index of circulation in children.
The purpose of this paper is to com
pare the peripheral warm-up patterns
of survivors versus nonsurvivors in a
group of 70 children who underwent
cardiac surgery, to devise a nomogram
based on this comparison and to assess
the accuracy of peripheral tempera
ture measurement and to compare
this with several existing parameters
of circulation.
Study Group and Methods

Seventy infants and children (24
girls and 46 boys), who were operated
on at Vancouver General Hospital be
tween Jan. 1, 1978 and Feb. 29, 1980
for congenital heart disease, formed
the study group. Their mean age was
3.9 ± 3.8 (SEM) years (range 1
to 15 years) and the mean weight 15.1
± 11.9 kg. The indications for oper
ation are shown in Table I. Only
patients for whom complete clinical

and hemodynamic data had been
obtained were included in the study.
Ten (14%) patients died of cardiac
causes between 6 hours and 19 days
after operation. All required conti
nuous ventilation from the time of
operation until death.
Of the 60 remaining children, 50
required assisted ventilation postoperatively for 2 or more hours and 10
were breathing spontaneously within 2
hours of arrival in the recovery room.
The decision to ventilate was based on
the presence of high-risk disease, re
quiring an extensive procedure, long
perfusion times and marginal post
operative cardiopulmonary perfor
mance.
Postoperative Monitoring
All measurements were recorded
hourly. Toe temperatures were meas
ured by a thermistor probe (Aquamatic K. Thermia, model PT103;
Gorman-Rupp, Bellville, Ohio) taped
to the ventral surface of the big toe.
Rectal temperatures were measured
with a standard centigrade rectal ther
mometer. During the postoperative
period all patients were kept in a heat
controlled environment that main
tained ambient temperature at 23° ±
1°C.
An indwelling Foley catheter was
used to obtain urine. Arterial blood
pH analyses were performed on a
Corning Eel blood gas analyser (Corn
ing Medical, Medfield, Mass.).
The position of cardiac and intra
arterial lines inserted in the operating
room was confirmed by roentgeno
graphy or by transducing the pressure
waves via Statham P231D transducers
(Gould Statham Instrument Co., Hato
Rey, Puerto Rico) to a pressure/
electrocardiographic module (Elec
tronics for Medicine, White Plains,
NY), or both.

Table 1— In d ic a tio n s fo r O peration

In d ic a to r
A tr ia l septal defect
V e n tric u la r septal d e fe c t*
P u lm o n a ry valve stenosis
P u lm o n a ry valve stenosis +
a tr ia l septal d efect
T e tra lo g y of Fallot
W a te rs to n , Blalock shunt
T ra nspos i tion of g re a t
a rte rie s
A trio v e n tric u la r canal
A o rtic stenosis
Coa rctation
M iscellaneous

No. of
children

Survivors

N onsurvivors

S u rvival, %

19
12
4

19
12
4

0
0
0

100
100
100

6
7
7

4
4
7

2
3
0

67
57
100

5
3
2
2
3

3
2
2
2
1

2
1
0
0
2

60
67
100
100
33

"In c lu d e s 1 patient who also had pulm onary v a lv e stenosis.
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Cardiac output was determined at
1, 3, 6 and 18 hours postoperatively
on an Edwards thermal dilution car
diac output computer (model 9520A;
Edwards Laboratories, Santa Ana,
Calif.), in combination with a thermal
dilution probe (model 94-030-2.5F;
Edwards Laboratories). The injectate
catheter was packaged with the probe
(Edwards Laboratories). It measured
30 cm in length and 3.5 French in
diameter. All thermodilution curves
were recorded on an Edwards strip
chart recorder (model 9810).
Statistical Analysis
Statistical analysis was conducted
using Student’s paired and unpaired
f-tests and standard correlation regres
sion techniques.
Sensitivity, specificity and pre
dictive value are defined as follows:
sensitivity— true positives divided by
true positives plus false negatives,
specificity— true negatives divided by
true negatives plus false positives, and
predictive value—true positives di
vided by true positives plus false
positives.
Results

The ratio of blood volume trans
fused to volume lost for those who
died exceeded that of the survivors
as attempts were made to maintain
adequate arterial pressures in the
former group by volume loading.
However, no significant difference
was seen between the two groups
when right and left atrial preload
pressures were compared. Consistent
with the volume balance findings, non
survivors had generally higher preload
pressures.
A significant difference (P < 0.05)
between the mean arterial pressure or
afterload of survivors and nonsur
vivors was present immediately post
operatively and persisted throughout
the 24-hour observation period.
Urine output was maintained above
a minimally acceptable value (1 ml/kg
hourly) for both survivors and non
survivors, except during the first post
operative hour in the latter group,
but the difference was not significant.
It was possible to maintain pH
values within the normal range in
both groups postoperatively. Although
therapeutic intervention was required
by the third hour to prevent the
arterial blood from becoming increas
ingly acidotic in nonsurvivors, this had
no effect on improving the abnormal
trend of their toe temperatures.
Measurement of cardiac index
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FIG. 1— Average cardiac index in 1/
min .m 2 at indicated study times. White
circles represent survivors (r = + 0.88,
y = 0.06 x + 3.6), black circles repre
sent nonsurvivors (r = —0.33, y = 0.16
X + 3 .1 ). * = P > 0.05, ** = P <
0.05.

indicated
significant
differences
(P < 0.05) between the two groups
at 3 and 6 hours which were not
apparent immediately postoperatively
or 18 hours later (Fig. 1).' Cardiac
index values for the survivors were
consistently similar throughout the
postoperative period while those of
nonsurvivors varied considerably and
showed a slow progressive downward
trend.
Calculated systemic vascular re
sistance (blood pressure minus right
atrial pressure divided by cardiac
index) measured in resistance units/m 2
(Fig. 2) showed a significant dif
ference (P < 0.001) between 3 and
6 hours after operation. This was
associated with a profound vascular
collapse that could not be reversed
in those who died.
When the cardiac index and toe
temperature values of the two groups
were compared, it was apparent that

FIG. 2— Average systemic vascular re
sistance measured at 1, 3, 6 and 18 hours
postoperatively and plotted against mean
recorded toe temperatures. Solid line =
survivors, dotted line = nonsurvivors.
P < 0.001.

FIG. 4— Toe temperatures (bottom) of
ventilated nonsurvivors (squares) and
ventilated survivors (circles) showing
significant differences (*P < 0.05) oc
curring 4 hours after operation. Rectal
temperatures are given above.

FIG. 3— Toe temperatures (bottom)
of nonventilated (white circles) and ven
tilated (black circles) survivors indicating
insignificantly (P > 0.05) lower tem
perature in ventilated patients. Rectal
temperatures are shown at top.

FIG. 5— Toe temperatures (bottom) of
ventilated nonsurvivors (squares) and
nonventilated survivors (circles) show 
ing significant differences (*P < 0.05)
occurring 3 hours after operation. R ec
tal temperatures are shown above.
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while both groups were able to main
tain cardiac index values above the
acceptable minimum (2.2 l/m in«m 2),
this alone did not guarantee adequate
peripheral blood flow to warm the
extremities of the nonsurvivors.
Figs. 3 to 5 compare postoperative
warming trends for rectal tempera
tures and for toe temperatures under
conditions of spontaneous and assisted
ventilation. Similar toe temperatures
were observed in survivors with and
without ventilation assistance (P >
0.05), although warm-up was more
rapid in the latter group (Fig. 3). Fig.
4 demonstrates significant differences
(P < 0.05) in toe temperatures by 4
hours between ventilated survivors
and ventilated non-survivors. When
the ventilated survivors are compared
with the nonventilated survivors (Fig.
5), significant differences (P < 0.05)
in toe temperature were demonstrated
within 3 hours, in keeping with the
more rapid warm-up in the nonven
tilated survivors. At no time did core
temperatures discriminate amongst
the two groups.
Thermal correlation coefficients
drawn from these data showed a sus
tained, high, positive correlation (r =
+0.99) during warm-up for the sur
vivors. The nonsurvivors correlated
less well during warm-up (r =
+0.89), reached a lower peak and
then began a steady fall (r = —0.57).
A nomogram (Fig. 6) was therefore
constructed for both ventilated and
nonventilated survivors incorporating
the slopes derived from the mean
value trends. The nomogram demon
strated a consistent difference between
the two groups. The warm-up started
immediately in both groups and con
tinued until normal peripheral tempe
ratures were achieved. There was no
latent period preceding peripheral
warming as has been demonstrated in
adults.9,10 Children requiring ventila
tion had lower peripheral tempera
tures initially and, although warming
proceeded at similar rates, achieved

FIG. 6— Warm-up nomogram for ven
tilated and nonventilated survivors.
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lower plateau temperatures during
the initial 24-hour period after opera
tion.
The accuracy of the nomogram
was assessed by comparing the raw
data for the 60 patients requiring
assisted ventilation with the nomo
gram values (Fig. 7). The results of
this comparison indicated that as post
operative time increased all indices
of accuracy improved in parallel
fashion. Confidence limits for the
three indices were 99% valid.
Discussion

Peripheral vasoconstriction, evi
denced by cool extremities, is a fre
quent response to many forms of sur
gery.7'11 This association between vaso
constriction and peripheral cooling
has also been investigated in hypo
volemic, bacteremic and cardiogenic
shock.4,5’12 Low peripheral tempera
tures directly reflect poor peripheral
blood flow3 and inadequate systemic
vascular resistance (Fig. 2). The level
of circulating catecholamines follow
ing operative procedures does not
cause this postoperative vasocontriction.13
Although the cause of this pheno
menon has yet to be determined, the
change in peripheral temperature as
peripheral blood flow increases is a
very useful index of circulation. It was
demonstrated in 1974 that the peri
pheral warm-up pattern of the great
toe n adults following open-heart
operations was predictable and devia
tions from it were indications for pa
tient reassessment and treatment.10
Analysis of the warm-up patterns of
infants and children following cardiac
surgery also followed a predictable
pattern although it differed from that
seen in adults in that no latent period
was observed. Deviations from this
pattern v ere associated with a sub
stantial if,umber of deaths.

F IG . 7— Accuracy of toe tem perature
as screening test for survival after openh e a rt surgery in children. W hite squares
represent predictive value (r = 0.77),
w hite circles represent sensitivity (r =
0.67), black circles represent specificity
(r = 0.68).
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Data obtained from monitoring toe
temperatures postoperatively com
pared well with all the standard para
meters used to assess circulation.
Urine output is an indirect index of
blood flow but is subject to inac
curacies due to pre-existing renal
disease or the use of diuretics.
Theoretically body pH reflects
tissue metabolism and blood flow but
peripheral shunting, presence of drugs
and assisted ventilation all alter values
and therefore limit the usefulness of
this measurement.
Central venous pressure measure
ments provide information on func
tion of the right heart and act as a
guide to the adequacy of volume load
ing; however, they cannot provide
an index of how effective a given
circulating volume is.
The cardiac index provides precise
data on volume shift at a given time
but does not indicate the adequacy of
peripheral circulation at that instant
or over a period of time. This fact was
well demonstrated by those children
whose cardiac index remained above
minimal accepted normal values yet
whose peripheral temperature re
mained cool and who died.
In contrast, normal systemic vas
cular resistance was associated with
warm extremities and a healthy pa
tient, while vascular collapse was
associated with cool extremities and
a high mortality.
The mean arterial blood pressure
was the only routine parameter of
circulation that compared well with
peripheral temperature measurement
and systemic vascular resistance in
the early differentiation of patients
whose circulation was inadequate for
their needs and who would eventually
die.
Measuring toe temperatures post
operatively was simple to implement
in a standard nursing routine and the
equipment required was inexpensive.
In the absence of sophisticated equip
ment, measurement of toe tempera
ture is an accurate method for moni
toring the circulation in children and
adults in the postoperative period and
in the intensive care setting. It is not
intended to replace any existing
modalities but as an adjunct to de
vices already in use.
Since the construction of the pedi
atric nomogram we now carefully
reassess the child’s condition if the
toe is cold 4 hours postoperatively.
Most commonly simple volume deficit
is the cause and an appropriate re
sponse follows a volume challenge.
Occasionally a-blocking agents must
be given but they often must be com
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bined with volume, otherwise only a
transient effect is produced. When the
toe fails to warm up after these man
euvers a more careful search for other
causes is necessary. However, in their
absence and with adequate volume
replacement it is quite uncommon for
the toe to be cold unless the cardiovas
cular system is unstable. Measurement
of the blood pressure and toe tempera
ture is therefore a very useful exten
sion of existing methods and increases
our interpretative skills exponentially
rather than purely additively.
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W hat would constitute
a significant advance in
aminoglycoside antibiotic therapy?

Increased activity.
1X.vreased risk.

Rapidly bactericidal against sensitive organisms
□

Usually more active against Klebsiella sp. and
Enterobacter sp.
,

Particularly active against aminoglycosideresistant strains
□

Active against the majority of strains resistant to
tobramycin and gentamicin

□

Active against some amikacin resistant strains

Excellent clinical results in a therapeutically
challenging patient population
□

37 studies show 90% clinical cure/improvement,
including some compromised host conditions1

□

unusually high rate of pathogen elimination or marked
reduction

□

favorable response even in gentamicin failures

□

excellent results in children, including infants and
neonates

-
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Increased activity.
In creased risk.
...a significant advance inatniiK ^ yeoside therapy

netilmicin sulfate

3.

Rigorous clinical trials bear out safety expectations
□

demonstrated in 890 courses of therapy1

□

ototoxic reactions rare, mild and transient

□

nephrotoxic reactions usually mild always reversible with sufficient
follow-up

□

adverse reactions in children notably absent

□

local reactions infrequent

MINIMAL ADVERSE REACTIONS IN CHILDREN Clinical studies with pediatric patients also underscore the
absence of drug related side effects, In a special analysis of 360 courses of therapy in children, infants
and neonates, only one patient experienced a reaction considered probably related to NETROMYCIN,
which was reversed when the dose was lowered to recommended levels.

Simplified dosage
Twice daily dosage for most infections.
SYSTEMIC OR URINARY TRACT INFECTIONS The recommended dosage
of NETROMYCIN injectable for patients with urinary tract or systemic
infections with normal renal function is 4.0 to 6,0 m g/kg/day given in
three equal doses every eight hours or two equal doses every twelve
hours. In general, within this dosage range, lower dosage will be used
fa urinary infections and higher dosage for systemic infections. For
both uses, dosageshould be adjusted depending on severity of
infection and patient condition.
Fa the average adult (50-80 kg], depending on the severity of
infection the usual dose is 100 mg to 150 mg administered every 8
hours or 150 mg to 200 mg every 12 hours for 7 to 14 days.

ADVERSE REACTIONS

NETROMYCIN* INJECTABLE

in addition f f ^ o f e ^ i c i t y a te nephrotoxicity discussed A
PRECAUTIONS and WARNINGS, other adverse reactions, usually
m i^ 'iin d infrteutet which
observed and may te a s s ^ d d lw it h NfTROMYCiN therapy include
Serum Enzymes: tervases m se'dm transaminases iSGOT and SGPTj and alkaline phosphatase

tNafera JMIatcI
ANTIBIOTIC
Description: Mei!tm»cm syifaie is a semi synthetic. am jcychtQf. aminoglycoside antibiotic prepared U ,m a dehydrogenated analog of
gentamicin I , . ' It « a white to butt powder which i eadiiy soM te m water

Hypersensitivity Reactions: eosmoptea rash and drug fever
Hematology decrease m temwjtobm. leukocytes and platelets

..QlQijiiep to pale yellow sotette $ | pH 4 5 to a Is and is available

Composition METROWYON ineulawcm sulfare' is supplied as
in the following concentrations

C.N.S.. headache. malase. blurred vision and paresthesias

Netilmicin base'
:
.Stetum-mejabtiillte
Sodium sufete
Steium sulfate
Oisodiam edetate
Methylparaten
Propylparaber.
Samylteohol
Ware; lur mjection to

:
• ■

Other: f fu ite tte te h c4 lower te b s, vomiting, te rrte a

K'Di.iO
; 2.4 -4 .

00

e

-

1

:; in me event af dvefdos? or toxic feateon, h e f t f c t e ^ w ill aid'in the removal of n e u te r-m l/te t dtfiibiodd. Appropriate slipjwrhve'r
therapy should be instituted to maintain respiratory and kidney function
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SYMPTOMS AND TREATMENT OF OVEROOSAGE

;
. /

*

lo c a l, erythema, pam ,n a t r o n and hematoma:,

CONCENTRATION img/mU

DOSAGE AND ADMINISTRATION

- t e v - t e 0.2

00
10 0
t 9 m l.,

:

*

NETROMYCIN may be given by deep intramuscular injection % intravenously, according to the dffitcal situation Dosage should te
calculated on the basis of body weight but m obese patients a/ emaciated patents w nh low volumes of distribution, dosage should be A
based on an estimate of Tete body.mass
:.

9.0

10 m

; * Charged as tetilm cm soHate :

DOSAGE
The recomrtended dose fonptrrifntiscular and mtfffl/emms a dm m istlfofs is t d t e lp i

NAME OF DRUG

THERAPEUTIC CLASSIFICATION

n e t r o m y c in

an tito x ic

/ t e - - - '''

;

The usual d tg # o o o f treatment is. / to 54 days In dbmphcaieo nfecuons, a lo ng * course ef ifw apy may be necessary Panetrte
treated beyond the usual period should be carefully monitored for changes in renal, auditory arid vesnbukif function

iNeTiif/ueim Sulfate;

PATIENTS WITH NORMAL RENAL fUNCTION
ACTION. N t 1R0MYCIN is a baeierodal amibtcw. which acts by rr.febitmg normal proton synthesis m suseepttbfetectete It is thought ta
-p rr*^ m amino acid pQlymewatsan by tending to the
sobirnii
.;

;
;

INDICATIONS AND CLINICAL USES: NETROMYCIN may be indicated for the treatment of infections caused by susceptible strains of
yfsctemhtd ca!>. Proteus species W o le negative and some indole positive!, Klebsiella, tmgrobaoer. Gmbacier and Staphylococcus ■
.
species
Clmical studies have shown NETROMYCIN fo be effective « some serious infections caused by Pseudomonas aeruginosa and
S erratk species
:

Appropriate seftsttety studies should be performed to determine the susceptibility cf the causative organism to N£TROMYCfN. On
the basis uf clinical judgement and am opated bacteriologies* findings, therapy may be instituted before results of these tests are obtained
If susceptibility tests show that the causative organism is resistant to NETROMYCIN. NETROMYCIN freatmem should be iep!aced by other
.appropriate therapy
Although NETROMYCIN may be indicated for the treatment of serious staphylococcal infections, ns use should be reserved for those
staphylococcal infections also involving susceptible strains of Gram negative b a rte r* and then only when penicillin or other potentially less
P ^ h l p i ^ r ; d r ip Bfe inappropriate, fe g patients allergic’ to p e m c fe l
CONTRAINDICATIONS. NETROMYCIN is contraindicated m patients w ith a history of hypersensitivity to aminoglycosides.
WARNINGS
O totoxicity NETROMYCIN has the potential to cause disturbances m balance and a hearing loss Partculariy those patterns w ith com
promised renal function, those who have been treated previously w ith ototoxic drugs, or those who are receiving higher doses of
NETROMYCIN than those recommended are at greater risk. Reversal of developing ototoxicity is contingent on early recognition of the
signs and symptoms such as bnmtas. dimness or hearing less.
; in patients w ith impaired renal funeiion, the dose andiOr tregaency. of administration ei NETROMYCIN must be reduced {See AO
M INIS! RAT ION AND DOSAGE! and renal, vestibular and auditory function, as well as serum levels of NETROMYCIN should be monitored
ifepuem ly
:
NETROMYCIN should not be administered concomitantly w ifh potent loop diuretics such as ftitosem«te and ethacryntc acid as the
potential lor ototoxicity rs enhanced by the combination Diuretics may enhance aminoglycoside toxicity either by altering the antibiotic
concentration m serum and tissues or by a direct action on the auditory apparatus
Nephrotoxicity: The administration of-other potentially nephrotoxic drugs prior to ot m conjunction w ith NETROMYCIN is likely to m
ciease the risk of nephroKunoty
Nephrotoxicity manifested by an increase m the level of blood urea nitrogen, or serum creatinine, a decrease » creatinine clearance,
or the presence of easts, cells, or protein m the unite. has: beehyobserved in patients administered NETROMYCIN These have been
observed more frequently rn patients w ith a history of decreased renal function and m patients treated w ith larger doses of NETROMYCIN
than those recommended In most eases, these changes have teen mild and were reversible on discontinuing the administration of
NETROMYCIN Other risk factors include duration of therapy and concomitant admimstration of anticoagulants or turosemide Patients
with diabetes melutus appeared to have a slightly higher incidence of tenal reactions
Pregnancy: The safety of NETROMYCIN for use during pregnancy has not teen establishes Ammal and human studies have
demonstrated that there is a maternal fetal transfer of some aminoglycoside antibiotics Although this has not yet been demonstrated with
NETROMYCIN, the possibility should be considered
PRECAUTIONS
Treatment w ith NETROMYCIN may result m the overgrowth o ft e n susceptible organisms If Siipermfecbon occurs, appropriate
therapeutic measures should be instituted
NETROMYCIN, at doses considerably above those chwcaNy recommended b e greater than TO times!, has been shown to cause
neuromuscular blockade and respiratory attest m rats and mice. The injection of catoum chloride chested a complete and rapid antagonists
effect whereas neostigmine was ineffective
The possibility of neuromuscular blockade and respiratory arrest occurring m man should be considered, particularly if NETROMYCIN
is administered to patients receiving anesthetics, neuromuscular Blocking agents fe.g. succmyichoime or tubocuranne! or massive transfu
sions of citrate anticoagulated blood. Thiazide diuretics have been reported to aggravate tubocuranne induced neuromuscular block
Patients w ith neuromuscular disorders, such as myasthenia gravis or Parkinson's disease, are at particular risk, since NETROMYCIN
could aggravate muscular weakness
NETROMYCIN should be used with caution m premature and neonatal infants because of renal immaturity and the resulting pro
ionga iron of serum half Me of the drug
In patients w ith renal or pre existing 8th nerve dysfunction, pre treatment audiograms should te performed, and repeated during
the course of therapy If tinnitus or subjective hearing loss should occur, the administration or NETROMYCIN should be discontinued
It is recommended that peak serum concentrations o f NETROMYCIN be monitored where feasible Peak concentrations in excess of
16 mcg/ml for prolonged periods as well as trough concentrations greater than 4 mcg/ml should be avoided
The p o s s ib ly of development of resistance during prolonged therapy with NETROMYCIN should be kept in mmd

* j

For patients w ith systemic' infections, the usual dose is 4.0 to 6 0 mg/kg/day divided into two or three equal doses te d
administered every eight or rwelve hours, rgspectntey?'
'

fo r patients with serious systemic infections dsfe threatening), intravenous dosages up to 5 mg&g/day divided irtc three eqt ? ,
doses may be administered. This dosage should be reduced to 6 0 mg/kg/day as soon as etecaify indicated, usually w r ite 48 hours
Concomitant admimstration of a pencillm type anteiDhc wdh NETROMYCIN shoutt be considered 3S inmaf theiapy in certain teses
of sepsis, parhcalariy m tmmuwsuppressed patients, while awaiting culture and susceptibility results Treatment should be adjusted when

; :

lim ned cbmcal studies have shown NETROMYCIN may also be effective in the treatment of seriousbone and soft tissue infections

for patrems w ith uncomplicated urinary tract infectem, the recommended dose is 4 0 mg/kg/day div-ted mto two equal Joses ana
administered every IJ im m s fe r 1 to 10 days, for theavemge adult 1.50-80 kg! ISO mg maybe given every 12 hours.

Fonhe average
?b8 80 kgl, depending an tte severity o f infection, thp usual dose is TOG mg to 150 mg admimsteted eve y8 hoots or ISO mg to 209 mg every 12 hours for 1 to 14 days

NETROMYCIN may be indicated m the. treatment of the W m n n g when caused by susceptible organisms as listed above **“ ”
septicemia
lower respiratory n3Ci infections
urmarv tract mfechohs
peritonitis
endometrms

AOUITS:

!

f .

CHILDREN: The recommended dose is 6.0 to / 5 mgdcg/day divided into three equal doses and administered every eight hours Thts
should be reduced to 6.0 mgikg/day as soon as Umcaiiy rndcated
INFANTS AND NEONATES: tGreater than one week of agei The recommended dose -s 1 b to !< 0 mg/kg/day dividf.;
doses ami admuvsiered every 8 hours

to three equal1

PREMATURE AND FULL TERM NEONATES: U.sss than one week of agei - The recommended dose is 6 mg/kg/day divided mto tw o "
equal doses and admimstereo every twelve hours (See PRECAUTIONS!
PATIENTS WITH IMPAIRED RENAL FUNCTION

h

- ADULTS:
The mitial dose rs tbe same as that recommended far patients w ith normal renal function Dosage must be adjusted m patients w ith
impaired tenal function and when possible, serum concentrations of netilmicin should be monitored H serum concentrations cannot te
monitored, serum aeatmtoe and creatinine clearance values can be used as a guide lor dosage adjustments Adjustments m dosage can „
made by either lengthening the interval between doses or by a reduction in dose administered a t eight hour intervals as follows
Normal dosage - Adjusted Intervals 1 the patient's serum creatinine •$ known, -he interval between the usual single dose given y
eight hourly intervals can be calculated by multiplying the patient's serum creatinine by 3 factor of eight. Thus, a patient w ith a serum
creatinme of 3 mg/100 m l would be given 7 my/kg every 24 hours, »e. 3 x 8 - 24, raster than the usual dose of 2 mg/kg every
8 hours
Adjusted Dosage - Fixed Interval: The following table (Table Hi can be used as a rough guide for determining the appropriate reduced
dosage at 8 hour intervals The dosage can also be calculated using the (allowing formula.
y
Reduced maintenance dose -

observed creatinine clearance x usual dose

CHILDREN:
At present there is insufficient data to rktwtteend a specific dosage for children w ifh impaired renal function
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Protection of the Myocardial Homograft
1. The Cooling Bag
C la u d e C h a r t r a n d , m d , f r c s [ c ],* B r u n o L a r o c h e , m d ,
R o b e r t P a r e n t , b sc and P aul S t a n l e y , m d

Because severe cardiac insufficiency
follow s orthotopic heart transplantation,
the authors have evaluated protection
of the homograft provided by a cooling
and isolating bag during the operative
period of ischem ia and subsequently its
effect on cardiac function. In one group
of four d ogs hearts w ere transplanted
without using hypothermia. In
the second group, seven hearts were
excised, immediately cooled by
im m ersion in saline at 4 ° C and
orthotopically homotransplanted. In the
third group, six hearts were imm ersed
in saline and then isolated in a
cooling bag until transplantation had
been completed. Cardiac function
in all anim als w as evaluated at rest, 3,
24 and 48 hours after operation.
In group 1, lowering of the
temperature w as minimal and all
anim als died immediately after
operation. In group 2, the myocardial
temperature, which had been lowered
to 13°C by immersion, had risen to
25°C after 17 minutes. In group 3,
the myocardial temperature w as
maintained at 2 ?° C up to the time
the aortic clamp w as removed.
Three hours after operation, the cardiac
performance of group 3 w as much
better than that of group 2 as
dem onstrated by an increase of
cardiac output (39% ), stroke volum e
(4 4 % ), mean systolic ejection
rate (2 5 % ), maximum systolic flow
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(2 8 % ), peak velocity (2 6 % ), maximum
acceleration (2 0 % ), left ventricular
pow er (3 2 % ) and left ventricular w ork
(4 7 % ). In the following days, cardiac
function of groups 2 and 3 improved
and the disparity between them
decreased. These results demonstrate
that the cooling bag, while offering
technical advantages, maintains
profound hypothermia in the donor
heart and substantially improves
the performance of the homograft
in the immediate postoperative phase.
C om m e une insuffisance cardiaque
se ve re est observee suite a une greffe
cardiaque en position normale, les
auteurs ont evalue la protection allouee
a I’hom ogreffe par un sa c d'isolation
et de refroidissem ent durant la
periode operatoire d'ischemie, et so n
effet subsequent sur la fonction cardia
que. Chez un groupe de quatre chiens,
le coeur a ete greffe sa n s hypothermie.
D a n s un second groupe, sept coeurs
ont ete excises, refroidis immediatem ent par im m ersion d an s un solute
physiologique a 4 °C et hom ogreffes
en position normale. D a n s un troisiem e
groupe, six coeurs ont ete im m erges
d an s le solute physiologique, puis
iso le s dans un sac de refroidissem ent
jusqu'a ce que la greffe eut ete
completee. La fonction cardiaque de
to u s les animaux a ete evaluee au
repos, 3, 24 et 48 heures apres
I'operation. Dans le groupe 1, la b a isse
de temperature fut minim e et tous
les animaux sont decedes immediatem ent apres I'operation. Dans
le groupe 2, la temperature myocardique qui avait ete abaissee a 13°C
par im m ersion avait monte a 25°C
apres 17 minutes. Dans le troisieme
groupe, la temperature m yocardique
fut maintenue a 13°C jusqu'au retrait
du clamp aortique. Trois heures
apres I'operation, la performance
cardiaque des chiens du groupe 3 etait
tres superieure a celle du groupe 2,
tel que le demontrait (’augmentation
du debit cardiaque (3 9 % ), du
volum e systolique (4 4 % ), du taux
m oyen dejection systolique (2 5% ),
du debit systolique maximum (2 8 % ),
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de la velocite maximum (2 6 % ), de
I'acceleration maxim um (2 0 % ), de la
pu issan ce ventriculaire gauche
(3 2 % ) et du travail ventriculaire
gauche (4 7 % ). D a n s les jours suivants,
la fonction cardiaque des gro u p e s
2 et 3 s 'e s t amelioree et la d isp arite
entre les deux s ’est am enuisee. C e s
resultats dem ontrent que le s a c de
refroidissem ent, tout en offrant
certains avantages techniques,
maintient une hypothermie profonde
dans le coeur du donneur et am eliore
de facon m arquee la perform ance de
I'hom ogreffe d an s la periode postoperatoire immediate.

T o facilitate human cardiac trans
plantation and to improve selection
of homografts, much experimental
work has been devoted to techniques
for mid-term cardiac preservation.^
N o important contribution to the
short-term preservation of the homograft has been reported since the in
itial description by Lower and
Shumway8 of cardiac hypotherm ia by
cold immersion even though severe
postoperative cardiac failure has long
been known to be caused mainly by
peroperative ischemia.910
We have thus undertaken a series of
experiments aimed at developing dif
ferent techniques for perioperative
graft protection and at evaluating
their respective advantages.
This paper reports our attem pts to
develop a cooling and isolating bag
and to examine its protective effect on
the homograft during the ischemic
period by evaluating cardiac per
formance postoperatively.
A n im a ls and M e th o d s

Mongrel dogs (weight 16 to 22 kg)
were chosen according to our criteria
of normality.11 Following induction
with Nembutal and intubation, an
esthesia was maintained with halothane delivered through a constant
volume respirator (H arvard model
607; Harvard Apparatus, Millis,
Mass.). The minute volume was estab
lished according to the anim al’s weigh!
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and its efficacy was controlled con
stantly by blood gas analysis. Follow
ing left thoracotomy and dissection of
the left external jugular vein and right
inguinal vessel, the animal was linked
to the heart-lung machine. The tech
nique we used for extracorporeal cir
culation has been described previ
ously.12
Cardiac orthotopic homotransplant
ation was performed in the usual
fashion except that the superior vena
cava was cut 2 cm above the cavoauricular junction.1'1,14 The duration
of ischemia was 53.5 minutes in each
group. Once the anastomoses were
completed circulatory assistance was
maintained for an extra hour to allow
the transplant to recover function
During this period, an electromagnetic
probe was adapted around the root of
the aorta and no. 8 French catheters
were introduced into the aortic arch
through the left subclavian artery and
into the right atrium through the left
jugular vein.15 The flow probe cable
and catheters were exteriorized at the
base of the neck so that hemodynamic
studies could be done on the resting
subject. Following this the wounds
were sutured and assisted ventilation
was discontinued 1 to 2 hours later.
All dogs were thus subjected to iden
tical operative conditions save for the
modalities used to protect the donor
heart.
Donor dogs received heparin, 250
units/kg. Three different methods for
preparing the donor heart were in
vestigated.
Group 1
In four donors the heart was excised
and homotransplanted immediately
without myocardial protection.
Group 2
In seven dogs the donor heart was
prepared according to the method of
Lower and colleagues.13 After excision,
the heart was immersed in a basin of
cold saline (4°C) while the atrium
and great vessels were prepared for
implantation. The heart was then
removed from the cold saline and
sutured into position. When the atrial
anastomosis was complete, the hear!
was irrigated for 2 to 3 minutes with
cold saline through a catheter placed
into the left ventricle through the left
atrial appendage. No subsequent cool
ing was carried out up to the
time the aortic clamp was removed.
Myocardial temperature was recorded
periodically through a thermometric
electrode implanted in the left ventri
cular wall and connected to a tele
thermometer (model 41 TD; Yellow
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Springs Instruments
Springs, Ohio).

Co.,

Yellow

Group 3
In six dogs, the heart was excised
and immersed in cold saline (4°C) dur
ing the time of preparation. It was
then placed in a cooling bag developed
in our laboratory (Fig. 1). This bag is
made of two polyethylene membranes
between which a no. 8 French poly
vinyl tube 150 cm long is coiled. This
tube is continuously irrigated with
cold saline at 4°C at a flow rate of
80 ml/min. Drainage is by gravity
into a receptacle under the operating
table. The heart, thus isolated from
the surrounding structures, remained
in the bag for the total duration of the
implantation. Myocardial temperature
was monitored as in the other two
groups.
The preparation of these experi
mental models permitted serial hemo
dynamic studies to be carried out at
3, 24 and 48 hours after operation in
the animal at rest without medication.
Each study comprised: electrocardio
gram (ECG), and determination of
heart rate (HR), cardiac index (Cl),
stroke volume index (SVI), mean
systolic ejection rate index (MSERI),
maximum systolic flow index (M„SFI),
peak velocity index (PVI), maximum
acceleration index (TVLAccI), left ven
tricular stroke power index (SPI), left
ventricular stroke work index (SWI),
mean aortic pressure (MAP) and
mean peripheral resistance (MPR).
The techniques for recording, conver
sion, calculation, indexing and analysys have all been previously de
scribed.14 Results were then evaluated
by group for the three study periods.
The unpaired Student’s f-test was ap
plied for statistical analysis of the data
(Olivetti programma 101).

ture of 34°C dropped by 2°C within
6 minutes and remained between 30°C
and 31 °C until the end of the ischemic
period (Fig. 2).
In group 2, the temperature of the
graft immersed in cold saline dropped
to 13°C within 13 minutes. By the
time the atrial anastomosis was com
plete, the temperature had risen to
25 °C. With the temporary irrigation
of the left ventricle, the temperature
was lowered to 17°C within 3 to 4
minutes but then returned to 25°C
until the aortic clamp was removed
(Fig. 2).
In group 3, the initial cooling period
was identical to that of group 2. How
ever, the warming of the heart was
prevented by the isolation and cooling
bag which maintained hypothermia at
13°C constantly throughout the period
of implantation (Fig. 2).
Hemodynamic Status
At 3 hours (Table I).— Initially it
had been planned that subjects in
group 1 should serve as controls. How
ever, cardiac failure postoperatively
was so severe that all dogs died before
the first study could be carried out.
Thus, this group could not be in
cluded in the comparative hemody
namic results.
In group 2, all dogs survived. The
type of protection used in these anim
als was standard so this group served
as the control. Three hours after oper
ation, cardiac function in these anim
als was very limited and the data ob
tained were identical to those already
reported by our team /V "15
All animals in group 3 survived.
These dogs showed superior cardio
vascular function as demonstrated by

Results

Myocardial Temperature
The curves obtained during the
ischemic period differed between the
groups. In group 1, the initial tempera-

F IG . 1— T he cooling bag.

F IG . 2— M yocardial
tem perature.
D otted line = group 1 (no protection),
broken line = group 2 (cold immersion)
and solid line = group 3 (immersion and
use of cooling bag). Values are mean
± standard error of mean.
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the overall hemodynamic picture. In Discussion
tact, the mean data for all measure
ments are superior. The Cl was better
Orthotopic cardiac homotransplan
by 39%, the SV1 by 44%, the MSERI tation has been performed successfully
by 25%, the M*SFI by 28%, the for many years. However, a number
PVI by 26%, the MxAccI by 20%, the of pitfalls persist such as rejection and
SP1 by 32% and the SWI by 47%. the complications associated with
Also the MPR was 26% lower in these treatment, such as obtaining and pre
animals. The difference in the results serving the donor heart.
of most of these measurements is sta
For obvious reasons, for the pur
tistically significant (Table 1).
pose of expanding donor banks, much
A t 24 hours (Table II).—Cardiac- research has been done in the field of
performance improved in both groups mid-term cardiac preservation. With
and the disparity between the two had selective cardiac hypothermia the Stan
diminished by the end of the first day ford group has succeeded in stretch
after operation. The Cl of group 3 ing the tolerable ischemic period from
was superior by 13%, the SV1 hy
I hour to 13 hours in some animals.1,3
19%, the MSERI by 12% and the
In 1974, Reitz and associates7 ob
SWI hy 12%. The MPR remained in tained survival of 14 of 21 dogs for
ferior by 12% in this group. However, periods ranging from 8 hours to 5
these differences were not statistically days after initial coronary washout of
significant.
donor hearts followed by suspension
A t 48 hours (Table III).—'The
in an intracellular solution at 4°C
hemodynamic status of the animals for a period of 18 to 26 hours. Work
continued to improve. The per ing in the field of hypothermic per
formance index of the two groups re fusion, Proctor3-3 developed a system
mained stable as the SVI was superior by which the viability of hearts could
by 20% in group 3, the MSERI by be demonstrated after a period of
10% and the SWI by 10%. The MAP conservation of 72 hours and survival
was 15% inferior because MPR was of orthotopic transplant for 8 to 14
24%. lower.
hours could be obtained. In 1973,

Copeland and colleagues,2 using the
same system, reported consistent sur
vival of orthotopic transplants after a
preservation period of 24 to 28 hours.
Watson and associates,6 by intermit
tently perfusing the heart during 24
hours using Proctor's system and a
hypertonic intracellular solution, suc
ceeded in obtaining survival of cardiac
transplants for 24 hours. Thus much
of the work on mid-term cardiac pre
servation has been successful. In con
trast, since the work of Lower and
Shumway,8 there has been no im
portant contribution to the protec
tion of the homograft during trans
plantation itself. This is surprising
since severe post-transplantation car
diac failure has long been known.9"10
Because of this consistent failure of
function, and after demonstrating that
ischemia is the important factor in this
failure, we have undertaken a series
ot experiments aimed at evaluating
different techniques of graft protec
tion and at establishing their respect
ive benefits. In order to quantitate
these benefits with hard data, we
have carried out left ventricular per
formance tests during the postoper
ative period.

Table I - Hemodynamic Measurements 3 Hours after Operation
Group
2 - Mean
Standard deviation
3 - Mean
Standard deviation
P value

HR

Cl

SVI

MSERI

M .SFI

PVI

M .AccI

SPI

156.83
14.40
151.5
19.26

1484.2
399.22
2056.9
311.17

9.408
2.115
13.568
1.20

83.23
24.49
104.33
10.63

115.76
19.80
147.88
13.99

76.44
16.56
96.07
9.09

1535.4
319.04
1841.9
284.9

18179
5170
23 908
5 836

NS

<0.01

<0.005

< 0.1

<0.01

<0.025

< 0 .1

< 0 .1

SWI

MAP

MPR

1487.3
510.3
2187.6
488.3

98 33
12.04
103 12
12.92

89 7*5
10 92
fifi nn
11.09

<0.05

NS

<0.005

HR = heart rate (beats/m in), Cl = cardiac index (m l/m in • m2), SVI - stroke volume index (m l/m 2), MSERI = mean systolic ejection rate index
r ! w i > m \ Mcm
ma* lmum systolic flow index (m l/s m2), PVI = peak velocity index (cm /s • m 2), M .A ccI = maximum acceleration index
(cm /s- m d . SPI - stroke power index (1(P e rg s /m -), SWI = stroke work index (10:l gram -m etre-seconds/m 2), MAP = mean aortic pressure
(mm Hg), MPR = mean peripheral resistance (units), NS = not significant.
H

Table II
Group
2 - Mean
Standard deviation
3 Mean
Standard deviation
P value

HR

Cl

135.37
11.05
131.66
32.24

2723.3
407.27
3079.4
663.83

NS

NS

Table III
Group

Hemodynamic Measurements 24 Hours after Operation
SVI
20.347
4.117
24.135
5.090
NS

MSERI

M.SFI

PVI

M .AccI

SPI

SWI

MAP

MPR

143.29
22.92
161.10
24.46

216.17
31.84
223.40
30.09

143.66
33.38
145.12
19.55

3163.4
904.9
3163.5
340.7

37 655
7 741
36 747
5 855

3528 1
807.3
3947.3
764.0

98 71
12.44
104 04
15.1

50 83
6 34
44 70
6.84

NS

NS

NS

NS

NS

NS

NS

< 0 .1

Hemodynamic Measurements 48 Hours after Operation

HR

Cl

SVI

MSERI

M .SFI

PVI

M .A ccI

SPI

SWI

MAP

MPR

2 Mean
Standard deviation
3 Mean
Standard deviation

143.16
8.87
127.40
7.81

3596.5
319.61
3828.5
559.21

25.096
2.606
30.143
2.710

178.0
16.14
195.93
15.27

270.78
25.45
282.54
17.54

179.95
36.38
183.55
11.40

3888.4
1129.2
3983.2
455.3

55 312
6 483
52 184
6 279

5036.3
406.1
5553.3
636.4

123 91
19.51
104 75
6.82

45.81
6 99
35 04
4.51

P value

<0.1

NS

NS

NS

< 0.1

<0.05

< 0.0 2 5
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<0.01

<0.1

NS

THE CANADIAN JOURNAL OF SURGERY

NS

249

Our first method has been the util
ization of our cooling and isolating
bag. The purpose of such a device is
to maintain a constant, deep level of
hypothermia of the graft during trans
plantation. This bag has many ad
vantages: it is simple to make, the
cost is low and it is easy to place and
keep the graft in the bag. It does not
hinder the technique of anastomosis
and also prevents the operative field
from becoming obscured with fluid
during operation.
Following initial cooling by immer
sion, the grafts of group 3 maintained
the deep hypothermic level because of
the cooling device, whereas the initial
cooling of the grafts in group 2 by
simple cold immersion was followed
by rewarming within a few minutes
(Fig. 2). The rewarming is inevitable
for a number of reasons: the graft has
contact with the mediastinum and the
hands of the surgeon, the overhead
operating lamps radiate heat, the ambiant circulating air is warm, and
above all the bronchial flow returning
to the left side of the heart is warm
as shown by Rosenfeldt and Watson.16
These factors are also the ones re
sponsible for the minimal cooling of
grafts in group 1 (Fig. 2).
Three hours after operation, the
overall performance of the cooled
isolated hearts was clearly superior
to group 2 hearts used as controls
(Table I). Moreover, all mean values
in this group were higher and many
differences were statistically signif
icant.
Between the two groups, the only
difference in protection was the main
tenance of deep cardiac hypothermia
in group 3, so it may be concluded
that the cooling bag was responsible
for the better postoperative cardiac
function. Because heart failure is most
severe immediately following trans
plantation, it is interesting to note that
the benefits from the bag were most
marked in this period.
Twenty-four and 48 hours later car
diac function improved in both groups
and the margin of disparity between
the two groups decreased.
Conclusions

this cooling bag is thus a superior
method of cardiac protection partic
ularly in the first postoperative hours
when cardiac decompensation is at its
maximum.
We acknowledge the technical help of
Gaston Angrignon, Suzanne Chartrand,
Lise Langevin, Gaetan Lagace and the
secretarial help of Ginette Piteau and
Jocelyne Vachon.
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Multiprogrammable Pacemakers
G F rank O . T yers , m d , fr c s [c ], fa c s ,* E dward H . W il l ia m s , m d , fa c s . t A lb e r t o J. L arrieu , m d ,*
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Since 1962 it has been possible to
change, by noninvasive means, the
functions of implanted pacemakers.
This study reports a 3-year multicentre
experience, in 164 patients, with a
multiprogrammable pacemaker that
offers a wide range of choices
within five variables: mode, rate,
pulse width, sensitivity and telemetry
(over 3000 combinations). In a selected
series 83% of implanted pacemakers
w ere programmed for medical
indications and 100% for multi
param eter follow-up studies. The
advantages and disadvantages of three
leading multiprogrammable pacemakers
are compared. There is little doubt
that multiprogrammable pacemakers
can reduce the frequency of
reoperation in any large series.
Depuis 1962, il est devenu possible
de modifier le fonctionnement d'un
stimulateur cardiaque permanent par
des moyens non sanglants. Cette
etude decrit une experience de
3 annees, chez plus de 164 malades,
avec un stimulateur a programmation
m ultiple qui offre de vastes p o s sib ility
d'intervention sur cinq variables: le
mode, la frequence, la iargeur de
la pulsation, la sensibilite et la
telem etrie (plus de 3000 combinaisons
possibles). Dans une serie, 83%
des stimulateurs cardiaques ont ete
programmes pour des indications
medicates, et 100% I'ont ete pour
des etudes de controle de plusieurs
parametres. On compare les avantages
e t les desavantages de trois
stimulateurs cardiaques programmables
parmi les plus populaires. II y a peu
de doute que les stimulateurs a
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chambered fixed rate; refractory pe
riods, 200 to 500 ms; hysteresis, 0 to
600 ms and multiparameter telemetry.
The potential benefits of multi
parameter programming include the
In 1962, only 4 years after introduc following. Rate may be increased or
tion of the original “permanent” im decreased to optimize cardiac output
plantable rechargeable pacemaker,1 and control arrhythmias. It may also
be decreased to observe underlying
the first two-rate programmable unit
rhythms and to obtain an undistorted
activated by means of a reed switch,
was introduced.2 In 1963, Medtronic electrocardiogram for diagnostic pur
Inc. of Minneapolis introduced per poses. Output energy may be in
cutaneous needle adjustment of rate creased to assure capture or decreased
and output energy3 and in 1966, Tyers to conserve energy and to eliminate
and associates4 reported on experi stimulation of diaphragmatic or pec
mental results with the first truly mul toral muscles. Sensitivity may be
tiprogrammable pacemaker (six vari decreased to eliminate oversensing of,
ables, 120 combinations) which oper for example, T-waves and myopotentials and to minimize susceptibility to
ated on five spaced, biased, reed
switches.4 A rotating external magnetic electromagnetic interference or an im
technique was subsequently intro planted unit may be made more sen
duced by Medtronic for noninvasive sitive to eliminate undersensing of
adjustment of pulse width and, in premature ventricular contractions,
1972, Cordis Corp., Miami, Florida poor ventricular signals and P-waves
introduced the Omnicor with eight for demand atrial pacing. Mode may
be programmed to eliminate otherwise
rate and four output current options.
Interestingly, although never activated, insoluble sensing problems, to elimin
this unit also had the potential for ate muscle inhibition (VVT), to allow
programming sensitivity and four patients to work in difficult occupa
tional settings where there is severe
modes.
In 1977, Cardiac Pacemakers Inc. electromagnetic interference, to pro
of St. Paul, Minnesota introduced the vide for the safe use of electrocautery
Microlith with a major increase in during subsequent operations, for an
the number of rate (90) and pulse- alysis of sensing effectiveness and
width (19) options. Noninvasive pro timing particularly in atrial applica
gramming of multiple parameters tions and for energy conservation. The
became a reality clinically when Inter refractory interval may require
medics Inc., of Freeport, Texas intro lengthening if atrial demand pacing
duced the CyberLith (over 3000 com is complicated by recycling on the
binations) in February 1978. Subse trailing edge of the ventricular elec
quently Medtronic introduced the trical signal, although with careful
Spectrax SX in November 1978 (later design of the sensing circuit short re
temporarily withdrawn from the clinic fractory periods should infrequently
al program) and Pacesetter Systems cause clinical problems. The refrac
Inc. of Sylmar, California intro tory period may be shortened to allow
duced the Programalith commercially sensing of the occasional premature
in mid-1979. At least 10 multipro ventricular contraction not sensed
with a nominal refractory period.
grammable pacemakers are currently
being evaluated clinically. While no High-rate hysteresis pacing where the
unit contains all of the following, the pacemaker turns on at a more rapid
currently available choice and range rate than the nominal trigger rate of
of parameters are as follows: rates 0 70 may occasionally be beneficial to
to 150 pulses per minute (ppm); out patients with aortic insufficiency or
put energies, pulse widths 0.10 to 2.3 extremely poor ventricular function.
ms—voltage, 0.5 to 3 times cell Hysteresis, as more commonly used,
voltage; sensitivities, 0.6 to 8 mV; to allow the spontaneous rate to fall
modes, fixed rate, demand— R-wave below standard paced rates, is con
or P-wave triggered, demand—R-wave sidered by some to be more physiol
or P-wave suppressed, dual cham ogic because it allows the pulse rate
bered ventricular inhibited and dual to slow during sleep and rest without
programmation multiple peuvent
reduire la frequence des reinterventions
dans n’importe quelle grande serie
de patients.
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inducing pacing. Most of the so-called
physiologic indications for hysteresis
are, however, better served by atrial,
atrioventricular synchronous or atrio
ventricular sequential pacing, or pro
grammable ventricular pacing at rates
of less than 72 ppm.
The CyberLith, Spectrax and Programalith are the most frequently im
planted of the available multiprogrammable pacemakers with clinical im
plants in the range of 30 000, 20 000
and 10 000, respectively. We report
on our experience with 164 CyberLiths
and discuss our perception of the
relative merits of these three most
widely tested
multiprogrammable
pacemakers.
Features of the CyberLith
Variables

CyberLith programmable variables
include: 15 rates, 20 to 120 ppm; 15
pulse widths, 0.15 to 2.29 ms; 7 sen
sitivities, 0.6 to 2.8 mV; 6 modes,
ventricular or atrial fixed rate, de
mand or triggered in the various 253
models and 3 modes, ventricular de
mand or atrioventricular demand or
fixed rate in the 259 models; and mul
tiparameter telemetry.
Telemetry versus Rate Change
Pacemaker Follow-up Monitoring

CyberLith multiparameter telemetry
allows noninvasive follow-up of mul
tiple pacer and power-cell para
meters.5'6 Telemetry means simply the
transmission of information. Electro
cardiograms have long been trans
mitted both within institutions and
transtelephonically, but the CyberLith
includes a multifactorial tuned trans
mitter within the pacemaker which
noninvasively i transmits critical and
relevant pacemaker data to the phy
sician when the patient is in his office
(cell voltage and stimulation rate) or
transtelephonically from the patient’s
home (cell voltage, cell impedance,
electrode impedance and rate). Some
question the emphasis on follow-up
of cardiac pacemakers with improved
lithium power sources, but lithium
cells are more difficult to monitor
than previously available mercuryzinc batteries. This is particularly true
in multiprogrammable pacemakers in
which multiple pulse-width, rate, mode
and lead variables can easily give a
functional life for a single pacemaker
configuration ranging from only 2
years to more than 10 years.
Rate change monitoring by electro
cardiographic transmission has been
used for years and was excellent for
mercury-zinc battery powered pace
VOLUME 24, NO. 3, M A Y 1981
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makers in which, towards the end of
the life of the pacemaker, failure of a
single cell produced a variable but
usually marked drop in voltage and a
secondary rate change. However, an
ideal power cell for a pacemaker
would undergo a very gradual decline
in voltage, and this has been achieved
with some lithium cells. Lithiumiodine cells, which are most commonly
used today in standard and in all
multiprogrammable pacemakers with
extensive clinical application, undergo
only a very gradual decline in voltage
during discharge and will more likely
fail because internal resistance builds
up and limits current availability
rather than because of depletion of
the power cell’s chemical energy con
stituents with resultant decline in volt
age.7 We have recently removed two
Maxiliths because of loss of capture
and sensing while the demand and
magnet rates remained within normal
limits. Logically it would have been
assumed that loss of pacing was due
to lead failure, but at the time of re
moval long-term thresholds and Rwaves were satisfactory. However, the
output current from the units was as
low as less than 1 mA even though
voltage had not dropped enough to
result in any change of rate. Because
voltage drops are much less marked
in pacemakers having a lithium-iodine
power cell, rate changes are much
more difficult to follow. The CyberLith
telemetry system transmits a signal
that allows cell voltage to be followed
directly and accurately. However, an
other more important parameter for
monitoring the power cell is also in
cluded.6
In contrast to the very gradual dec
rease in voltage in lithium—iodine cells
during slow discharge, resistance rises
progressively within these cells as they
discharge due to a progressive build
up of a barrier layer of lithium iodide
as the lithium and iodine combine.7
This not only allows us to predict the
end of the power cell’s life but, when
compared to known beginning-of-life
and end-of-)ife impedances for the
particular cell, can be used in con
junction with lead impedance data and
current drains to estimate remaining
capacity.
Lead impedance can also be deter
mined noninvasively with the Cyber
Lith and also transmitted transtele
phonically; extensive clinical experi
ence confirms normal impedances in
the range of 200 to 3000 O in agree
ment with earlier experimental stu
dies.8’9 The major variable leading to
this wide range of “normal” impe
dances is electrode surface area.
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Programming Techniques

These may be broken down into
coupling, checking and information
transmission. The Cyberlith uses in
ductive coupling, redundant reci
procal transmission of 80 precisely
timed impulses organized in pairs and
multiple-bit binary coded data in
cluding special key codes for different
models. This system largely precludes
the potential for phantom program
ming that dogged earlier reed-switch
dithering techniques.10-11 Although not
used in the CyberLith, Spectrax or
Programalith, some pacemakers stillrely on similarly insufficiently selec
tive techniques.12'14
Results

The results of our study are sum
marized in Table I. Over 75% of
patients have undergone permanent
therapeutic programming and multiple
variables were programmed in several
units; 43% required multiple pro
gramming of a single parameter. Rate,
pulse width and mode were the most
frequently programmed therapeutic
parameters in 67%, 58% and 33%
of the cases respectively. Rate was
usually reduced to maximize the pa
tient’s time in sinus rhythm but was
sometimes increased to improve car
diac output, as documented by dye
dilution and thermodilution studies,
and to suppress arrhythmias. Pulse
width was usually decreased to extend
pacemaker cell life but in two cases
the primary indication for reducing
stimulus energy was diaphragmatic sti
mulation. Early in the study one pa
tient with a nonprogrammable pace
maker required a high output unit.
The cost of this unit and of hospital
ization and the risk to the patient
Table I—Experience with a Representative
Series of 164 Cyberlith Multiprogrammable
Pacemakers Monitored for up to 3 Years
(Figures are Percentages)*
Total reprogrammed for medical
indications
83
Therapeutic permanent
reprogramming
75
Rate 67 (33 multiple)
Pulse width 58 (10 multiple)
Mode 33
Sensitivity 2
Diagnostic temporary
reprogramming
8
Total reprogrammed only to
confirm functioning
17
’ Indications for multiprogrammable im
plant included: a history of arrhythmias
or angina and, at implant, high-threshold
energy requirements or borderline R-wave
amplitude, or both.
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could have been avoided by implant
ing a multiprogrammable pacemaker
initially. Mode programming was un
dertaken temporarily in the triggered
and fixed-rate modes so that an elec
trocautery could be used safely during
unrelated surgical procedures. One
patient, an industrial electrician, was
programmed to the fixed-rate mode
because of extremely severe electro
magnetic interference in his work.
Eight patients with arrhythmias or
congestive failure, or both, as the
primary indication were programmed
to the atrioventricular sequential
mode. Both atrial and ventricular
leads had been installed at the time
of implantation. Sensitivity program
ming was seldom required but early
in the series one patient exhibited
clear-cut myopotential inhibition. The
problem was solved by implanting a
CyberLith. Again reoperation could
have been avoided by implanting a
multiprogrammable unit in the first
place. Sensitivity programming has
been essential to maintain demand
function during long-term atrial pac
ing.
Indications for diagnostic or tem
porary reprogramming have included
programming to a slow rate (30 ppm)
to allow nonpaced assessment of a
patient with idiopathic hypertrophic
subaortic stenosis and (more com
monly) to allow observation of the un
derlying rhythm in evaluating the level
of digitalization or extent of myo
cardial ischemia, or both.
All 164 patients have been pro
grammed to the telemetry transmis
sion setting for multiparameter follow
up (Fig. 1). To date there have been
no cell failures or lead breaks and no
units have even begun to approach the
end of life. It is already apparent that
the increase in slope of the impedance
rise versus the voltage decline will
make cell impedance extremely useful
in predicting remaining capacity. In
itial telemetry transmissions have very
closely confirmed electrode impe
dance data collected at the time of
pacemaker implantation and known
new lithium-cell voltage and impe
dance patterns.9'15
D iscussion

In some community hospital series,
programming of implanted pace
makers has been accomplished much
less frequently than reported here.16
Therefore, we investigated a lessselected group of 420 patients with
CyberLith pacemakers followed up by
specialists not directly involved in
pacemaker research. Of these pace
makers, 54% have been repro
254

grammed. Most pacemakers and pre
sumably their recipients can poten
tially profit from reducing the pulse
width to prolong power-cell life.17 In
many cases a future adjustment of
one or another parameter can be pre
dicted. In the first author’s current
practice, approximately two thirds of
patients are expected to require a mul
tiprogrammable unit and one third
standard demand pacing although the
only justification for the latter is the
higher price of the multiprogrammable
units and the older age of the reci
pients. It has been demonstrated that
only a few reoperations would be re
quired in the group of patients re
ceiving standard nonprogrammable
pacemakers to eliminate the supposed
savings.18
The CyberLith was initially our mul
tiparameter programmable pacemaker
of choice because it was the first unit
of its type available and because of
the developmental work that one of
the authors had done on the telemetry

FIG . 1— Telem etry (dots) and non
telemetry (crosses) follow-up data from
early CyberLith im plant. N ote close cor
relation between electrode impedance de
termined at im plantation and that trans
mitted by pacem aker. Telem etry follow 
up functions available with CyberLith in
clude rate, cell voltage, cell impedance
and stim ulation or electrode impedance.
Refractory interval and hermeticity tele
metry are available with other Pennsyl
vania S tate/In term ed ics clinical trial
pacemakers b u t not with CyberLith. NA
= not applicable, R-R interval = R
wave to R wave interval on electro
cardiogram in milliseconds, BPM =
beats per minute.
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follow-up system.5,6,9,15 Considering the
introduction of alternative multipro
grammable units, our continued
primary, although not exclusive, selec
tion of the CyberLith should be ex
plained.
Advantages of the CyberLith
Pacemaker
Clinical experience with the Cyber
Lith is longer and larger. The Cyber
Lith is available in a choice of sizes with
the larger units having larger power
cells and therefore energy capacities
giving a potential longevity of up to
16 years at standard parameters versus
9.6 years for the Programalith and
8.5 years for the Unipolar Spectrax
SX. The CyperLith is the only system
available with transtelephonic mul
tiple parameter, all real value tele
metry. The Programalith transmits a
mix of real time and programmed
parameters. Thus, the real values of
pulse width, pulse rate and pulse
amplitude may vary up to 20% from
the values transmitted by the Programlith.19 The CyberLith is the only unit
that allows simple in-office read-out
of cell voltage and single-probe read
out of pulse width, interval and rate;
the Spectrax requires multiple peri
pheral lead attachments and the Pro
gramalith does not have this feature.
The several CyberLith models cur
rently offer the widest potential range
of applications including: multipro
grammable atrial or ventricular de
mand, triggered or fixed rate; multi
programmable atrioventricular de
mand or fixed rate and multiprogram
mable burst and train antitachycardiac
atrial or ventricular demand pacing.
The CyberLith has the highest potential
output energy for late capture prob
lems, with a maximum of 22 uC into
a 500-f) resistor versus 19.6 uC
for the Spectrax and 17 trC for the
Programalith. As long-term atrial
pacing may be associated with P-wave
potentials of less than 1 mV,20 satis
factory long-term atrial demand
pacing is more likely with the Cyber
Lith because it has the largest range of
low sensitivities with three values
below 1.2 mV, which is the lowest
available Spectrax setting. The lowest
sensitivity setting in the Programalith
using the American Association for
Medical Instrumentation standard test
signal is in the range of 2 mV.
The inductively coupled, 80-bit, re
dundant, reciprocal CyberLith pro
gramming method has already been
described. It is totally nonmechan
ical and markedly reduces the risk of
phantom or misprogramming. Both
of the other systems use a reed-switch
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mechanical coupling that, in addition
to introducing a known potential fail
ure mechanism,21'22 which has already
led to several problems,23,24 forces
these pacemakers into the fixed-rate
mode during programming. The
CyberLith remains in its preset mode
during programming. Finally, the
CyberLith offers the advantage of
simultaneous multiparameter program
ming which is simple enough that
instructions and codes can all be in
cluded on the face of the programmer.
The CyberLith has four end-of-life
indicators: cell voltage, cell impe
dance, decreased rate and increased
pulse width. The latter two are only
present in the magnetic mode. Both
the Spectrax and Programalith pace
makers have a gradually increasing
pulse width in the pacing mode which
is not only unnecessary in a multiprogrammable pacemaker25 but also is
imprecise and wastes energy. A pro
gressively changing pulse width with
time in a pacemaker with multiple
programmable pulse-width choices
may lead to confusion including false
diagnosis of phantom programming.
The Programalith includes three endof-life indicators— rate, pulse width
and cell impedance—whereas the
Spectrax depends entirely on the rate
change and pulse-width features de
veloped initially from pacemakers with
a mercury-zinc battery. The CyberLith
has no off mode and a maximum rate
of 120 ppm. There is a small poten
tial for failure of any mode in all
pacemakers and failure of the Spec
trax in either the off mode or at a rate
of 150 ppm, which necessitates bypass
of the rate-limiting circuit, may in
duce an unnecessary risk. The Cyber
Lith utilizes crystal-controlled timing
in its pacing circuits and all para
meters are within a decimal point of
those programmed at both room and
body temperatures. Thus, preimplant
testing will verify results actually
achieved at body temperature imme
diately after implantation and years
later. Many of the 10 other multiprogrammable pacemakers now available
are rate-accurate only to within a few
beats per minute, and rates at room
and body temperatures differ in most
of them. The crystal-controlled timing
circuit is so accurate that it cannot be
used as an end-of-life indicator, and
thus all CyberLiths include a redundant
pacing oscillator for the magnet rate
change and pulse-width tests. This re
dundant circuit automatically switches
on should the crystal-timing circuit
fail. The CyberLith and Programalith
also have redundant rate-limiting cir
cuitry so that multiple component fail
V O L U M E 24, NO. 3, M A Y 1981
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ures can occur without inducing run
away. fn spite of manufacturers’
claims to the contrary, runaway still
occurs.20'28 The CyberLith provides a
standard noncompetitive magnetic and
noise rate (approximately 90 at the
beginning of life) so that there is a
single rate-change end-of-life para
meter regardless of the programmed
rate.
Advantages and Disadvantages of
Other Multiprogrammable
Pacemakers

The Spectrax and Programalith
offer some features not available with
CyberLith pacemakers. Both have of
fice or clinic digital printers for mak
ing permanent records of programmed
parameters. This data must be re
corded manually with the CyberLiths.
As with the CyberLith, the Programa
lith transmits lead impedance and
power cell impedance, but current
drain is substituted for cell voltage.
The Programalith has the lowest
programmable sensitivity (8 mV) of
the units under discussion. However,
the Spectrax and CyberLith do not
need this because they have mode pro
grammability. The Programalith can
be permanently programmed only as
low as 45 ppm, with 30 ppm being
available only temporarily as a test
rate. Should lowest-rate failure modes
occur, this may be an advantage over
the permanent 30 ppm programming
available with the CyberLith and
Spectrax and would certainly be an
advantage over the test rate of 0 with
Spectrax. Pulse-amplitude program
ming, available in both the Spectrax
and Programalith, will help some
patients with diaphragmatic or phrenic
nerve stimulation not totally relieved
by pulse-width shortening alone. This
feature also allows a greater choice
of energy drain reducing combinations
and better calculation of energy safety
margins.29 Pulse amplitude can, how
ever, only be reduced from standard
settings, not increased in the Spectrax
and Programalith so that pulse-am
plitude programming with these units
is not of value for late high-threshold
problems that are potentially best
treated with the CyberLith which has
the highest maximum output energy.
However, pulse-width increases are
minimally effective over 2 milliseconds
because the strength duration curve is
fairly flat beyond this point. Some of
the newer programmable pacemakers
offer increased as well as decreased
output amplitude and presumably this
programmable range will be available
in the next generation of the three
pacemakers compared here. Refrac
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tory interval programming could po
tentially solve some nonsensing prob
lems using the Spectrax or Program
alith. Similarly, after-potential oversensing could be eliminated by pro
longing the refractory interval with
both the Programalith and Spectrax,
but this is unlikely to be a problem
with a rapid active discharge mechan
ism which largely precludes the after
potential and T-wave summation often
underlying so called T-wave sens
ing.30,31 Negative hysteresis is available
with both the Spectrax and Program
alith. In most of the settings where
this is recommended, even better phy
siologic results can be achieved with
atrial pacing, atrioventricular sequen
tial pacing or slow-rate ventricular
pacing in the range of 50 to 65 ppm.
Although not currently available, a
double hysteresis combination (pacer
turning on and off at lower spon
taneous rates than the paced rate) or
autoincremental hysteresis might offer
some advantages over slow-rate ventri
cular pacing in the 50 to 65 ppm
range.
Conclusions

Differences of varying significance
exist between the three leading multi
programmable pacemakers. However,
in terms of both scope and reli
ability, all represent great advances
over the early units activated by mul
tiple-biased reed switches4 and bipara
meter modification by reed-switch
dithering.,0,1’
In the future the range of pro
grammable options will obviously in
crease. New units will include both
local and transtelephonic digital tele
metry of multiple variables. Apart
from pacemaker diagnostics, such
nonpacemaker-related information as
blood sugar and blood pressure levels
are feasible. “Physiologic” pacing
modes will certainly be available in the
majority of units and apart from over
all sensitivity programming, slew rate
and unipolar to bipolar programming
and vice versa may also be expected,
particularly since this feature was
described as early as 1966.4 It can
even be predicted that in the future,
most standard pacemakers will record
detailed information on arrhythmias
for later transmission and analysis.
Future pacemakers will also have the
potential for automatic programming
to appropriate frequency and duration
settings for the treatment of most
troublesome arrhythmias.
Currently, the indications for se
lecting a multiprogrammable pace
maker are largely circumstantial.
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However, this was also true in 1975
when a wholesale switch was made
from mercury-zinc to lithium power
sources that were four times more
expensive. Five years later, only 10%
of the mercury—zinc units then im
planted were still functioning, whereas
80% of the lithium units were func
tioning.32 In this instance, a prospect
ive randomized trial would have signif
icantly delayed the achievement of a
major improvement in patient care.
The savings in rehospitalization, phy
sicians’ fees, patient risk and suffering
have many times offset the cost of
the more expensive lithium power
cell. However, at 5 years, 20% of
the lithium units have been removed
and by 6 years following implanta
tion, 40% of patients have required
reoperation.32 It is clear that many of
the problems leading to reoperation
were not related to power source fail
ure and even those that were related
to lithium power-source depletion
might have been delayed by reducing
pulse width.33 Many of the units
that continue to be implanted are as
sociated with an inferior clinical result
because of loss of sensing, compe
tition, failure to sense premature ven
tricular contractions, development of
arrhythmias, angina and low cardiac
output.
Finally, we do not know in how
many patients quality of life is inferior
because they receive standard demand
pacemakers without multiprogrammable, physiologic or multiparameter
telemetric monitoring capabilities.
There is little doubt that the majority
of patients receiving standard demand
pacemakers are at higher risk for re
operation than if they had received a
multiprogrammable pacemaker.18 Cer
tainly, the majority of physicians
knowledgeable in the field would now
choose a multiprogrammable unit for
themselves.
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Indications: Treatment of infected or potentially
infected burns, crush injuries, lacerations. Also vari
cose ulcers, bedsores and ulcerated wounds.
Contraindications: Known allergy to lanolin or fra
mycetin. Cross-sensitization may occur among the
group of streptomyces-derived antibiotics (neomycin,
paromomycin, kanamycin) of which framycetin is a
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Precautions: In most cases absorption of the anti
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of antibiotics may result in the overgrowth of nonsusceptible organisms, including fungi. Appropriate
measures should be taken if this occurs.
Dosage: A single layer to be applied directly to the
wound and covered with an appropriate dressing. If
exudative,dressings should be changed at least daily
In case of leg ulcers cut dressing accurately to size
of ulcer.
Supplied: A lightweight, paraffin gauze dressing
impregnated with 1% framycetin sulphate B.P.
Sofra-Tulle also contains anhydrous lanolin 9.95%.
Available in 2 sizes: 10 cm by 10 cm sterile single
units, cartons of 10 and 50; 10 cm by 30 cm sterile
single units, cartons of 10. Store at controlled room
' temperature.
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Sofra-Tulle is a quality surgical dressing
that goes on treating the wound long after
application. Bactericidal against Gram
positive and Gram negative infections,
Sofra-Tulle remains active in the presence of
blood, pus and serum .1

Sofra-Tulle is soft and pliable with minimal
adherence, easy to cut and contour to fit
the lesion. Sofra-Tulle avoids maceration,
helps drain exudate, and provides a sterile
healing environment.
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Upjohn
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available in a variety of sizes, shapes
and forms for most areas of
surgery where haemostasis is desired
ior nasal packing

packing for gynaecologic
and rectal surgery

packing cavities-obliterating
dead space

Sterile Pack, size 2 cm
40 x 2 cm
jar of one sponge

Sterile Pack, size 6 cm
40x6 cm
box of six sponges

Sterile Sponge, size 200
80x250x10 mm
box of six sponges

for general surgery

for general surgery

specially prepared for dry
application and emergency
haemostasis

Sterile Sponge, size 100
80x125x100 mm
box of six sponges

Sterile Sponge, size 50
80 x 62.5 x 10 mm
box of four sponges

Sterile Compressed Sponge
size 100
12.5x8 cm
box of six sponges

for general and neurological
surgery

for general and neurological
surgery

promote healing in chronic
leg ulcer

Sterile Sponge, size 12-3 mm
20 x 60 x 3 mm
box of four sponges

Sterile Sponge, size 12-7 mm
20 x 60 x 7 mm
box of four sponges
jar of four sponges

Sterile Powder
jar containing 1 g

non-haemostatic
for ocular surgery

Precautions
Gelfoam and Gelfilm are simple to use, and with conscientious observance of certain precau
tions satisfactory results may generally be expected where their use is indicated.
1. Gelfoam should be used discriminately in arterial bleeding because of the intra-arterial pres
sure. It is advisable to suture and reinforce where possible.
2. Although Gelfoam generally serves its purpose well in the presence of haemorrhagic blood
dyscrasias, it should not be relied upon as the sole method of haemostasis in such conditions.
3. Gelfoam should not be used to stop menstrual bleeding. In postpartum and menorrhagic
bleeding it serves only as a temporary vaginal tampon.

Ophthalmic Sterile Gelfilm
25 x 50 mm
box of 6

4. Gelfoam must be in snug contact with the bleeding surface in order to be effective.
5. Use Gelfoam as sparingly as possible in order to minimise the amount of implanted foreign
material.
6. Do not overfill cavities with Gelfoam.

Upjohn

7. Do not use Gelfoam in grossly contaminated wounds which are so deep that drainage is
interfered with. However, it may be used for temporary haemostasis in more superficial
contaminated wounds, provided it is removed after it has served its haemostatic purpose.
8. Avoid prolonged exposure to Gelfoam to contaminated air.
Detailed information available on request.

Myocardial Contracture: the Predominant Cause of
Impeded Reperfusion in Simulated Surgical Ischemia
C o l in E . B a y l iss ,

m d , f r c s [c ],

“Worst-case” surgical conditions
were simulated using the isolated
model of a parabiotically perfused
rabbit heart septum. Such conditions
occur clinically in regional myocardium
distal to stenosed coronary arteries
and are characterized by inadequate
or absent ionic influence on the
myocardium by chemical cardioplegia
and equilibration to room temperature.
This study tested the hypothesis
that ischemic contracture, rather than
intracellular or extracellular edema,
critical closing or delayed critical
opening, was the predominant cause
of impeded reperfusion that damages
myocardium.
In 20 reperfused ischemic septa,
conductance (flow per unit pressure)
decreased significantly (P < 0.05) as
ischemia at 24°C was prolonged from
15 to 90 minutes and as contracture
became more severe. Conductance
was not decreased significantly by
even large amounts of extracellular
edema. Intracellular edema did not
occur.
In 17 normal septa, the critical
closing pressure was 9.3 mm Hg.
Critical opening pressures following
5 to 90 minutes ischemia at 24°C
did not differ significantly. Although
early reflow was impeded progressively
with longer ischemic intervals, it
was not significant and was due to
contracture rather than critical
closing or delayed critical opening.
This study confirmed the hypothesis
that contracture is the predominant
cause of impeded reperfusion in
simulated surgical ischemia.
Les conditions chirurgicales des “ pires
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cas” ont ete simulees a i'aide du
modele du septum isole et perfuse
en parabiose du coeur de lapin.
Cliniquement, de telles conditions sont
observees dans la region du myocarde
distale a des arteres coronaires
stenosees. Elle sont caracterisees
par I’absence ou I'insuffisance de
I’influence ionique de la cardioplegie
chimique sur le myocarde et a un
equilibre avec la temperature ambiante.
Cette etude a verifie I’hypothese
voulant qu’une contracture ischemique,
plutot qu’un oedeme intracellulaire ou
extracellulaire, une fermeture critique
ou une ouverture critique retardee,
soit a I'origine du defaut de reperfusion
qui endommage le myocarde.
Dans 20 septa ischemiques, la
conductance (mesure du debit par
unite de pression) a diminue significativement (P < 0.05) lorsque
I'ischemie a 24°C a ete prolongee de
15 a 90 minutes et que la contracture
est devenue plus severe. La
conductance n'a pas diminue significativement meme avec un important
oedeme extracellulaire. II n’y a pas eu
d'oedeme intracellulaire.
Dans 17 septa normaux, la pression
critique de fermeture a ete de 9.3 mm
de Hg. Les pressions critiques
d'ouverture n’ont pas variees significativement apres 5 a 90 minutes
d’ischemie a 24°C. Bien que des
intervalles d'ischemie plus prolonges
aient progressivement entraver le
retour precoce de la circulation, cet
effet n'etait pas significatif et il
etait du a une contracture plutot
qu'a la fermeture critique ou a une
ouverture critique retardee.
Cette etude confirme I’hypothese
qu'une contracture est la cause
predominante de la reperfusion reduite
observee dans I'ischemie chirurgicale
simulee.

Coronary artery bypass grafting is a
low-risk method for treating patients
with atherosclerotic disease of the
coronary arteries. The major cardiac
causes of death and morbidity as
sociated with the operation are heart
failure, perioperative myocardial in
farction and arrhythmias.1 The in
troduction of cold potassium cardio
plegia to protect the ischemic,
VOLUME 24, NO. 3, M A Y 1981

/

F lo ra B. C r a w f o r d ,

rn

quiescent heart during operation has
minimized the occurrence of these
problems. Although the composition
of the ideal cardioplegie solution re
mains controversial,2 the principle of
infusing cold (4°C), hyperkalemic (20
to 30 mmol/1) fluid into the aortic
root to arrest and cool the heart is
widely accepted. In theory, cold car
dioplegia should markedly reduce or
eliminate damage to the heart during
the 30 to 90 minutes of ischemia
needed for the average grafting proce
dure. Why, then, does cardiac mor
bidity and mortality persist at a low
level?
In practice, the factors that defeat
ideal conditions are the presence of
critical coronary artery stenoses, non
coronary collateral blood flow and the
equilibration of specific regions of the
myocardium to room (24°C) or even
higher temperatures.2 There is now
ample evidence that the area distal to
a critical coronary artery stenosis may
be unprotected because it does not
receive sufficient cardioplegie solution
for ionic manipulation or cooling of
the myocardium.3’6 Noncoronary col
lateral flow may wash out otherwise
adequate doses of cardioplegie solu
tion. The right heart, including the
septal myocardium, may be warmed
by venous return blood that escapes
a single right atrial cannula. All por
tions of the exposed heart will even
tually equilibrate to room temperature
if cold cardioplegie solution is not re
peatedly perfused. There may be
regions of the heart, therefore, that
are at room temperature and unpro
tected by chemical cardioplegia. This
“worst-case” condition may be un
detected by the surgeon who observes
adequate global function postoperatively but fails to appreciate areas of
damaged myocardium that are fail
ing, infarcting or are foci of arrhyth
mias. These areas are likely to dete
riorate progressively because of the
impediment to reperfusion that ac
companies
significant
myocardial
ischemia.7 The pathogenesis of this socalled “no-reflow” phenomenon has
not been established.
This study tested the hypothesis
that, in worst-case surgical ischemia,
contracture is a major cause of im-
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peded reperfusion in damaged regions
of the myocardium. The effects of
intracellular and extracellular edema,
critical closing and opening were
assessed and compared with contrac
ture for their effects on reperfusion.
A new model of perfused rabbit heart
was developed to simulate unprotected
regional myocardial ischemia at room
temperature in the ditribution of the
septal artery and to allow controlled
assessment of myocardial function
and perfusability.
Methods

The Heart Model
The model (Fig. 1), its performance
norms and validation studies have
been reported in detail.8,8 A male New
Zealand white rabbit weighing 3 kg
was heparinized, then anesthetized
with thiopental sodium. The heart was
rapidly excised, the interventricular
septum dissected free and the septa!
artery cannulated within 2 to 4 min
utes. The perfusate was heated and he
parinized arterial blood recirculated
through a Holler pump at 32°C and
a flow rate of 1 m l/g-min through
another awake rabbit via cannulas in
an ear artery and vein inserted under
local anesthesia. The blood was diluted
from a normal hematocrit of 36.9 ±
3.0% (standard deviation) to 30.5 ±
3.2% by a combination of the circuit
priming solution (30 ml Normosol-R.
pH 7.4) and 10 ml of intravenous
“flow-promoting cocktail” (150 ml
Normosol-R, 10 g Dextran 40, 1.5 g
Pluronic F-68). This changed the plas
ma osmolality from the normal of
287.0 ± 6.2 to 300.4 ± 12.3 mOsm/1
water.
The triangular septal tissue was
mounted between opposing Harmon
forceps at the base and the apex was
connected to a Statham UC-4 tension
transducer
(Statham
Instruments,
Oxnard, Calif.) by a silk suture. The
septum was stimulated at a rate of 60

contractions/min using a 2-millisecond
stimulus. Contraction was isometric.
The perfusion pressure, septal tem
perature and acid-base status were
continuously monitored.
After 30 minutes of resuscitation
and stabilization, an arteriovenous
shunt in the circuit was opened, re 
moving the parabiotic rabbit from the
circulation. Thereafter arterial oxygen
pressure was maintained at 92 ± 7.0
mm Hg by the filming of blood on
the septal surface, and carbon dioxide
pressure was maintained at 37 ± 4.0
mm Hg by catching the drippings in a
funnel reservoir layered with carbon
dioxide. This nonparabiotic prepara
tion remained stable for 2 hours. The
following control measurements of
septal performance were made: maxi
mum active tension, resting tension,
maximum rate of relaxation and con
ductance. Each septum acted as its
own control. Maximum active tension
measured contractility, resting tension
and maximum rate of relaxation meas
ured contracture, and conductance
(the inverse of resistance and a meas
urement that decreased with impeded
perfusion) measured flow per unit
pressure.
Contracture and Edema
Twenty control septa were divided
into four groups of five. They were
subjected to 15, 30, 60 and 90 minutes
of ischemia respectively at room tem
perature (24°C). This was accom
plished by turning off the Holter pump
and stimulator and exposing the septa
to room air, which simulated quiescent
heart muscle, unaffected by cardioplegic solution, equilibrating with
operating room temperature.
All septa were paced and reper
fused at 32°C with 500 mg inulin
added to the perfusate as an extra
cellular tracer. The minimum reper
fusion interval was 30 minutes, the
time previously determined for inulin
equilibration in myocardium. Thus,

FIG. t — Parabiotic septum model for assessing myocardial function. Arterial
circuit, black; venous return circuit, stippled. Both circuits run through single capstan
of Holter pump. p C 02 = arterial carbon dioxide pressure, A-V = arteriovenous.
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groups subjected to 15 and 30 minutes
of ischemia were reperfused for 30
minutes while those subjected to 60
and 90 minutes of ischemia were re
perfused for 60 and 90 minutes re
spectively. These intervals maximized
the possibility of recovery while en
suring that inulin equilibrated in the tis
sue. The functional assessments made
during the control period were re
peated and expressed as a percentage
of control. Decreased conductance
signified impeded reperfusion; in
creased resting tension and decreased
maximum rate of relaxation signified
contracture.
Next, the septa were removed and
gently blotted on filter paper. The
net weight was recorded. The tissue
was then dried and defatted, and the
total water content in terms of fat-free
dry weight was determined by the
method of Flear and Florence.10
Plasma inulin concentration was deter
mined by the photometric method of
Roe and colleagues11 and muscle inulin
by the photometric method of Ross
and Mokotoff.12 The extracellular
water content was determined and in
tracellular water content was calcul
ated by subtraction. Reperfusion water
content (ml/kg of fat-free dry weight)
was expressed as a percentage of
control values previously determined
in 10 fresh septa from inulin-loaded
rabbits. Water content greater than
100% of control values indicated
edema.
Critical Closing and Opening
By a modification of the method of
Sherman and associates13 we deter
mined the perfusion pressure at which
flow ceased (critical closing pressure)
in 17 control septa at 24°C. The
stimulus was turned off and a Harvard
pump (Harvard Apparatus, Millis,
Mass.) was used to obtain pressureflow curves for the range 4000 to
0 ul/g»m. This represented a wide
range of flows above and below the
normal 1000 u.l/g »m. Pressures were
determined at 20 levels of flow. The
generation of a single closing curve
required about 5 minutes. A com
posite closing curve was constructed
for the 17 septa.
Total ischemia was maintained at
24°C for 5 minutes (10 septa), 30
minutes (2 septa), 60 minutes (3 sep
ta) and 90 minutes (2 septa). The
pressure at which flow began (critical
opening pressure) was determined
from pressure—flow curves for the
range 0 to 4000 |xl/g>min in each re
perfused, quiescent septum at 24°C.
The generation of a single opening
curve required about 3 minutes, the
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T a b le 1— C o n tro l M e a s u re m e n ts

M e a s u re m e n t

V a lu e ,
m e a n ± s ta n d a rd e rr o r

No. of
se p ta

16.0 ± 1.3
7.0 ± 0.3
85.0 ± 10.6

20
20
20

11.7 ± 0.8
4080 ± 63.0
1045 ± 73.7

20
10
10

M a x im u m a c tiv e te n s io n , g
R e s tin g te n s io n , g
M a x im u m r a te o f r e la x a tio n , g /s
C o n d u c ta n c e ( flo w p e r u n it m e a n p r e s s u r e ),
[ d / g • m in • m m Hg
T o t a l tis s u e w a te r c o n te n t, m l/k g FFD W
E x t r a c e llu la r w a te r c o n te n t, m l/k g F F D W
F F D W = f a t - f r e e d ry w e ig h t.

interval of “early reperfusion”. Com
posite opening curves were plotted for
each ischemic interval and their posi
tions compared with the composite
closing curve to determine whether
opening pressure was higher than
closing pressure (unpaired ?-test) and
whether pressure-flow relations dur
ing early reperfusion suggested that
reflow was impeded (right shift of the
opening curves).
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FIG. 2—Inverse relation between con
ductance and ischemia. Reperfusion was
significantly (*P < 0.05) decreased from
control after 60 minutes of ischemia. In
Figs. 2 to 5 control values are points
without standard error bars. For each
point with error bars n = 5. r = —0.939
(P < 0.01).

Results

Contracture and Edema
Control measurements for the func
tional performance of 20 septa and
the water content of 10 fresh septa
are summarized in Table I. All sub
sequent measurements from postischemic, reperfused septa were ex
pressed as a percentage of their own
controls.
Postischemic conductance (Fig. 2)
showed a significant negative correla
tion with the duration of ischemia.
Significant levels (P < 0.05) of im 
peded reperfusion occurred after 60
minutes of ischemia. These data in
dicate that the no-reflow phenomenon
in regional ischemia can be success
fully simulated using the septum
model.
Fig. 3 illustrates the significant posi
tive correlation (P < 0.01) between
conductance and active tension. The
conductance of 64.9% (after 90 min
utes of ischemia) corresponded to a
severely depressed active tension of
38.9%, the reason for not investi
gating levels of ischemia beyond 90
minutes.
The relation between conductance
and the two measures of contracture
is illustrated in Fig. 4. Resting tension
100
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showed a progressive increase with
decreasing conductance, indicating
that the myocardium was not relaxing
to control levels. Rate of relaxation
showed a positive correlation with
conductance. These data showed that
contracture correlated significantly
(P < 0.05) with impeded reperfusion.
The relation between edema and
conductance was determined for total
tissue water and extracellular water
contents (Fig. 5). While neither was
significant, the results were interest
ing. Both total and extracellular water
volume tended to increase with
decreasing conductance. Flowever,
only the extracellular compartment
showed significant edema (P < 0.05
vs control). This implied that the in
tracellular compartment did not be
come edematous, contrary to popular
belief. Furthermore, even massive
extracellular edema did not correlate
with impeded reperfusion.
Critical Closing and Opening
The critical closing and opening
pressures for the 17 septa are sum
marized in Table II. The differences
were not significant, indicating that
surgical ischemia did not retard critic
al opening in the coronary vasculature.
The composite closing and opening
curves are shown in Fig. 6. The close
grouping of critical closing and opening
pressures at zero flow can readily be
seen. The opening curves for the four
ischemic groups represented pressureflow relations only during the first
3 minutes of reperfusion. The opening
curves lay within the 95% confi
dence limits for individual values of
pressure at given flows during closing.
In this sense the displacements were
not significant. However, the trend
for progressive curve displacement to
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FIG. 3—Septal performance showing
progressive contractile deficit correspond
ing to decreasing conductance, r =
+ 0.940 (P < 0.01).
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resting tension (r = —0.903 [P < 0.05]) and rate of relaxation (r = +0.904
[P < 0.05]).
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Table II— Critical Closing and Opening Pressures
Critical closing
pressure, mm Hg
(mean ±SE)

Period of
ischemia,
min. at24°C

No. of
septa

Critical opening
pressure, mm Hg
(mean ±SE)

5
30

10
2

10.2 ± 1.34
7.8 ± 0.95

60
90

3
2

5.5 ± 1.42
8.G ± 1.35

9.3 ± 0.81

The difference between critical closing and opening pressures is not significant (P > 0.05).
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FIG . 5—Relation between tissue w ater and conductance. Only extracellular
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FIG . 6— Composite closing curve for 17 septa at 24°C. D otted lines indicate
± 2 standard deviations of pressure and are 95% confidence limits of pressure for
individual values of flow during closing. Composite opening curves for 5, 30, 60 and
90 minutes of ischemia are within these limits.
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the right with increasing ischemia was
unmistakable. From the contracture
and edema studies it was evident that,
even in these unpaced septa, con
tracture was likely responsible for the
displacement. In the paced septa,
measurements of resting tension at 3
minutes of reperfusion were 106.4% ,
112.4%, 139.3% and 257.4% of
control values for the ischemic in
tervals of 15, 30, 60 and 90 minutes
respectively. W hatever the explanation
for the displacement, the impediment
to reflow was not due to delayed
critical opening and probably was not
due to critical closing.
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It is impossible to determine how
closely this model of a worst-case con
dition parallels clinical surgical ische
mia. Nevertheless, the persistent low
mortality and morbidity from damaged
myocardium in the perioperative
period demands such closely con
trolled in vitro studies of pathogenesis.
One fact is certain— once a significant
impediment to reperfusion exists, sur
gically ischemic myocardium will
either die or be permanently damaged
It is not good enough for the surgeon
to rely on global function as an index
of regional performance. The value of
the septum model is that it points out
the deficits in regional perform ance
under surgical conditions that are now
known to be entirely realistic.2"8
It might be argued that the heart
model cannot reflect conditions in
the intact heart because it is isolated,
denervated and isometric. Extensive
validation studies9 have shown that the
model embodies all the important per
formance characteristics of intact
myocardium, particularly contraction,
relaxation, compliance and perfusability. Since the coronary vascular bed is
largely myogenically and metabolically
autoregulated in addition to being
dominated by intram yocardial pres
sure,14 denervation is of negligible
consequence in studies of perfusability.
In fact, isolation and denervation to 
gether ensure precise control of pre
load, afterload, heart rate and con
tractility, which determine cardiac
performance. Development of tension
is the important function of cardiac
muscle; the model focuses on isometric
contraction, the main tension-develop
ing phase of the cardiac cycle. The
development of tension cannot be
assessed adequately in isotonic con
tractions. Validation studies also show
that the model develops the same
impediment to flow regardless of
whether it functions isometrically or
263

isotonically. Isometric contraction is
the only simple way of eliminating
considerations of afterload
and
changing active state in assessments of
myocardial performance.
The high correlation between im
peded reperfusion and ischemic con
tracture does not establish a causal
relation, but circumstantial evidence
is abundant. The capacity of the
model to demonstrate no-reflow in re
sponse to ischemia is evident in Fig.
2. Contracture, a pathologic sustained
contraction due to calcium loading or
lack of ATP, is clearly demonstrated
by incomplete (increased resting ten
sion) and slower (decreased maximum
rate of relaxation) relaxation in the
model. Contracture must act in the
same way as contraction14 to com
press the microvasculature, impede
reperfusion and, because of its per
sistence, decrease performance (Fig.
3).
The nature of the relation between
edema and no-reflow is more specul
ative, There is certainly no direct rela
tion between tissue water content and
reduced conductance (Fig. 5). How
ever, edema could become important
in the presence of sufficiently dec
reased tissue compliance. Present
evidence suggests that the role of
edema in no>-reflow is negligible,
except possibly in extreme conditions
not normally encountered even at 90
minutes of surgical ischemia. Lee and
associates15 reached the same con
clusion in an elegant study of intact
dog hearts and an extensive review of
the literature.
Under conditions different from
surgical ischemia, hearts frequently
show morphologic evidence of cellular
edema following reperfusion.7,16 Our
inulin measurements did not demon
strate this in the heart model. An ex
planation was the model’s lack of non
coronary collateral flow during ische
mia; on the other hand cellular edema
accumulates mainly during reper
fusion and not during ischemia in dog
hearts with normal collateral circula
tion.16 A better explanation for the
lack of cellular edema was the high
levels of muscle tension, both con
traction and contracture, that charac
terized the reperfusion interval. Mus
cle tension of either type would be
expected to impede the accumulation
of intracellular water by a “wring
ing” effect. Because of the experi
mental design, this study did not test
the hypothesis that cellular edema
could produce no-reflow; it simply
showed that, because of its absence
in surgical ischemia, cellular edema
was eliminated as a possibility. The
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surgical implications of these data
are that a vigorously beating heart
during reperfusion is probably free of
contracture, cellular edema and im
peded reperfusion, but may have
considerable extracellular edema.
The use of inulin as an extracellular
tracer in ischemic tissue may lead to
an overestimate of extracellular water
content. The error is not in measuring
plasma or tissue inulin, where indices
of precision and accuracy are high
(less than 3.0%), but because the cal
culation assumes no intracellular pene
tration of the tracer. The known
ischemic damage to cell membranes
casts doubt on this assumption. In an
attempt to assess the magnitude of
the correction factor, a series of inulin
washout studies determined the equa
tion of the final exponential (intra
cellular phase) and found the factor
to be -2.3% to -4.6% . Furthermore,
the mean coefficient of variation for
extracellular water measurements in
this study was only 10.2%, reflecting
the small standard errors seen in Fig.
5. Although these considerations sug
gest that the overestimate of extra
cellular water was small, these data
are presently being confirmed mor
phometrically.
The only current evidence that
supports a cell-swelling hypothesis for
impeded reperfusion is the beneficial
effect of hypertonic mannitol in lower
ing the vascular resistance of reper
fused ischemic myocardium. Fixler
and associates17 have recently settled
the controversy by showing that the
mannitol effect is very short-lived and
reduces the resistance equally well in
reperfused and normal myocardium
by a direct effect on vascular smooth
muscle.
This study, in finding a critical
closing pressure of 9.3 mm Hg, con
firmed the pressure of 10.5 mm Hg
measured by Sherman and colleagues13
in vasodilated dog hearts. Sherman’s
surprisingly high critical opening pres
sure of 41.9 mm Hg is questionable
because of the problem of measuring
very low coronary flows in a right
heart bypass preparation. It is most
important to be able to measure flows
in the microlitre range when estim
ating the pressure intercept (Fig. 6). In
this study, critical closing and opening
pressures were found to be similar
and independent of ischemia. This
eliminates delayed critical opening as
an explanation for the no-reflow phe
nomenon.
We thank Drs. J. Grayson, I.A. Sher
man and G.J. Wilson for their helpful
comments and criticism.
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Does Pericardial Drainage Decrease
the Frequency of Postpericardiotomy Syndrome?
D enis D esaulniers,

md , facs, frcs [c],

The postpericardiotomy syndrome
occurs in 10% to 40% of patients
who undergo open-heart surgery.
Its frequency is reportedly decreased
when pericardial drainage is used.
To challenge this, 50 consecutive
patients (1 was disqualified) were
randomly assigned to two groups:
one in which only the anterior
mediastinum was drained (group 1)
and the other in which the
anterior mediastinum and posterior
pericardium were drained (group 2).
The surgical procedures performed
were: coronary artery bypass grafting
in 14 patients, valve surgery in 23
and repair of congenital defects in 12.
The two groups were similar with
respect to age and the volume of blood
drained. Significant differences were
found only for the duration of bypass
and volume of blood given.
At 7 to 10 days there were no
differences in the frequency of fever,
thoracic pain or presence of arthralgia.
Findings were similar in both
groups for leukocyte count,
sedimentation rate, serum lactic
dehydrogenase value and for the
frequency of positive blood, urine and
sputum cultures. Six patients (three
in each group) had a postpericardiotomy
syndrome that required steroid
treatment and prolonged hospitalization
for 10 more days. However, none
had postpericardiotomy syndrome
complicating coronary artery bypass
surgery. None of the patients had
cardiac tamponade.
This study demonstrates that
pericardial drainage has no effect
on the frequency of postpericardiotomy
syndrome and appears to be
unnecessary after open-heart surgery.

N icole G ervais,

rn and

J acques R ouleau ,

Le syndrome post-pericardiotomie
survient chez 10% a 40% des malades
qui subissent une operation a coeur
ouvert. On signale que sa frequence
est diminuee par I’emploi du
drainage pericardique.
Afin de contester cette derniere
assertion, 50 patients consecutifs
(dont 1 a ete elimine) ont ete
assignes au hasard a I’un ou I'autre
de deux groupes: un oil seulement
le mediastin anterieur a ete draine
(groupe 1) et I’autre ou le mediastin
anterieur et le pericarde posterieur
furent draines (groupe 2). Le pontage
aorto-coronarien a ete pratique chez
14 patients, la chirurgie valvulaire chez
23, et la reparation d'anomalies
congenitales dans 12 cas.
Les deux groupes etaient compa
rables pour I'age et le volume de sang
draine. Des differences significatives
n’ont ete enregistrees que pour la
duree de circulation extracorporelle
et du volume de sang administre.
Apres 7 et 10 jours, aucune difference
n’a ete observee pour la frequence
de la fievre, de la douleur thoracique
ou de la presence d'arthralgie. Dans les
deux groupes, des valeurs semblables
ont ete obtenues pour le compte
leucocytaire, la vitesse de sedimen
tation, la deshydrogenase lactique et la
frequence des cultures positives dans
le sang, I’urine et les expectorations.
Six malades (trois dans chaque
groupe) ont eu un syndrome postpericardiotomie traite avec des
steroides, ce qui a prolonge leur
hospitalisation de 10 jours.
Toutefois, aucun syndrome post-peri
cardiotomie n’est venu compliquer

md , facc

une operation de pontage aortocoronarien. Aucun patient n'a subi
de tamponnade cardiaque.
Cette etude demontre que le
drainage pericardique n'a aucun effe t
sur la frequence du syndrome postpericardiotomie et il ne semble pas
necessaire apres une operation
a coeur ouvert.

The postpericardiotomy syndrome is
characterized by fever with pericardia!
and pleural reaction, either persisting
or appearing beyond the first week
after intrapericardial surgery. The
etiology is unknown and the incidence
is reported to be between 10% and
40% .‘ Pericardial drainage reportedly
reduces this incidence to 2.8% or less2
(Rivera R, Ajuria M: Personal com
munication, 1979).
The objectives of our study were: to
challenge the value of pericardial
drainage in preventing the postpericar
diotomy syndrome; to evaluate the
need for pericardial drainage in pre
venting cardiac tamponade and to
evaluate the cost-effectiveness of me
diastinal sump drainage after openheart surgery.
Patients and M ethods

Between Dec. 12, 1979 and Mar.
31, 1980, 50 consecutive patients
scheduled for open-heart surgery were
studied prospectively. All were oper
ated on by the same surgeon whose
technique for each type of procedure
did not differ (Table I).
For extracorporeal circulation a
bubble oxygenator (Bentley BOS-5
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and BOS-10 Spiraflo, Bentley Labo
ratories, Irvine, Calif.) was used with
hemodilution and a blood flow rate of
3 1/m in-m 2. Cardioplegia was used
when aortic clamping lasted more
than 15 minutes. The solution used
consisted of Ringer’s lactate 1000 ml,
potassium chloride 25 mmol, dextrose
10 g, insulin 20 units, methylprednisolone 1 g and sodium bicarbonate 1.7
ml at a pH of 7.6 and osmolarity of
350 mOsm/1.
The pericardium was opened from
the aortic reflection to the diaphragm,
tacked with Mersilene 2-0 sutures to
the soft tissues anterior to the sternum
and approximated at the end of the
procedure by interrupted sutures
placed 2 to 3 cm apart (Fig. 1).
Patients were then randomized into
one of two groups. In group 1, 24
patients had the anterior mediastinum
drained by two thoracic tubes (Argyle
thoracic catheter nos. 32 and 20F; dis
tributed by Ingram & Bell Ltd., Don
Mills, Ont.), the smaller tube being
used as a sump and its air inlet pro
tected by an air filter (PF-302 biologic
gas line filter; Bentley Laboratories)
recovered from the extracorporeal sys
tem (Fig. 2). Negative pressure was
provided by a wall suction system and
set at 20 cm H 2 O, with an underwaterseal bottle (Fig. 2).
In group 2 were 26 patients who
had the same drainage as group 1
patients plus drainage of the post
erior pericardial cavity by a Portovac
system (Fig. 3). Vacuum was restored
manually in the Portovac system
whenever necessary.
Packed red cells were used for
blood replacement (250 to 300 ml/
unit) and the amount given was regis
tered for the period of the patient’s
hospitalization. One unit of plasma
was given for every 3 units of packed
red cells.
Between 7 and 10 days after oper
ation, all patients were assessed for
the presence of fever, thoracic pain
and arthralgia and the amount of
weight gain. Blood samples were taken
to measure the hemoglobin value,
hematocrit, leukocyte count, serum
lactic dehydrogenase value and
erythrocyte sedimentation rate. Chest
roentgenography
and
echocardio
graphy were done.
All patients were followed up for
at least 2 months after operation.
Finally, the records of 1000 pa
tients operated on between January
1978 and December 1979 were re
viewed to determine the incidence of
postpericardiotomy syndrome, cardiac
tamponade and hemostasis. Post
pericardiotomy syndrome was diag
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nosed if the echocardiogram was posi
tive for pericardial effusion and if two
of the following symptoms were
present: fever, thoracic pain or ar
thralgia.
One patient was excluded from
group 1 because the pericardium
could not be closed; this patient had
had an aortic valvulotomy in child
hood and the pericardium was not
closed at that time. This left 23 pa
tients in group 1.
Statistical Analysis
The results were analysed using the
two-tailed Student’s f-test for the dif
ference between two means with a
critical P value of < 0.05 and by the
X2 test using Yates’ correction for con
tinuity at a critical level of P < 0.05.

groups in the number of units of
packed cells given during the patients’
hospital stay (P = 0.001) and in the
time taken for cardiopulmonary by
pass (P = 0.002) (Table II). Four
group 1 patients received more than
10 units of blood: the two who un
derwent the Bentall coronary bypass
procedure required 14 and 12 units,
one who had aortic valve replacement
received 16 units and one patient who
had four grafts placed during an aor
tocoronary bypass procedure received
11 units. In group 2 no patient re
ceived more than 10 units. The num
ber of units of blood given and cardio
pulmonary bypass time had no bearing
on the frequency of postpericardio
tomy syndrome.

Results

The two groups of patients were
similar with respect to age, body sur
face area, leukocyte count, erythrocyte
sedimentation rate and duration of
hospital stay postoperatively (Table
II), and also the serum lactic dehy
drogenase value, the frequency of
fever, the volume of drainage post
operatively (Fig. 4) and the incidence
of postpericardiotomy syndrome.
However, statistically significant dif
ferences were seen between the two

FIG. 1— Drainage system for group 1
patients. Pericardium is approximated
every 2 to 3 cm. Two thoracic tubes are
positioned in anterior mediastinum.
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FIG. 2— Group 1 drainage. Perme
ability check list. 1— suction “hiss” at
air filter inlet, 2— liquid-free sump drain
and 3— continuous air bubbles in under
water-seal bottle indicate that negative
pressure is being maintained.

FIG. 3— Drainage system for group 2
patients. In addition to anterior media
stinal drainage, tube is placed in posterior
pericardial cavity.

THE CANADIAN JOURNAL OF SURGERY

Complications
Group l.—One patient with hemo
stasis underwent reoperation, four pa
tients had urinary tract infections and
one had a pleural effusion drained 6
days after operation.
Group 2.—One patient had a tran
sitory neurologic deficit after a mitral
valve replacement for calcified mitral
stenosis and three patients had urinary
tract infections.
Postpericardiotomy Syndrome
The postpericardiotomy syndrome
occurred in three group 1 and in three
group 2 patients. One patient in each
group was rehospitalized 1 week after
discharge. Only one patient had a re
currence after treatment consisting of
prednisone (2 mg/kg daily in divided
doses for 1 week, with tapering during
the following 3 weeks). Acetylsalicylic

acid (600 mg q4h for 3 to 4 days) was
given without success in each case
before steroid therapy. In none of
these patients was pericardial drainage
needed. One patient had a pericardial
tap for diagnostic purposes 3 weeks
postoperatively.
If the patients with coronary by
pass are excluded from our study
the incidence of postpericardiotomy
syndrome after procedures for valve
and congenital defects would increase
from 12% to 17%. It is interesting
that only two cases of postpericardio
tomy syndrome have been docu
mented in the last 500 patients who
underwent coronary artery bypass
surgery at our institution.

continuous appearance of air bubbles
in the underwater-seal bottle.
If necessary, permeability of the
system was easily restored by a 15- to
30-second aspiration at a negative
pressure of 200 cm H20 .
Compared with the commercially
available sump drain, this “home
made” system was more permeable,
less noisy (the Saratoga sump drain
requires a negative pressure of 200
cm H20 ) and less expensive (Table
III). Furthermore the air filter was
recovered from the extracorporeal sys
tem at the end of the surgical proce
dure.

Cardiac Tamponade

Prevention of Postpericardiotomy
Syndrome

None of our patients had cardiac
tamponade and during the last 2 years,
only 2 out of 1000 patients were re
operated on because of cardiac tam
ponade: both had drainage of more
than 300 m l/h before they were re
turned to the operating room. The
cause was slippage of a ligature on a
collateral branch of a saphenous vein
bypass graft in one and left ventri
cular rupture after mitral valve repla
cement in the other.
Cost-Effectiveness

FIG. 4— Postoperative drainage. White
bars = group I. cross-hatched bars =
group 2.

Permeability of the drainage system
was easily checked by noting the fol
lowing: the presence of the suction
hiss at the air filter inlet, the absence
of liquid in the sump drain and the

Table II— Characteristics of the Population Studied*
Group 1

Feature

42
1.54
9.74
63
15.7
155
6.6

Age, yr
Body surface area, m2
Leukocyte count, X 109/ l
Erythrocyte sedimentation rate, mm/h
Hospitalization postoperatively, d
Cardiopulmonary bypass time, min
Blood given (packed cells), units

dr
dr
zb
dz
dr
zb
dt

5
0.09
0.68
5

1
11
0.7

Group 2

P value

44
± 5
1.47 dr 0.09
8.6 dz 0.42
65
db 5
13.6 dz 1.2
100
dr 9
4.2 dr 0.4

NS
NS
NS
NS
NS

0.001
0.02

‘ Figures are mean ± standard error of the mean.

Table III —Comparative Cost of Drainage Systems

Drainage system
Argyle thoracic catheters 20 F
24 F
32 F
Argyle Saratoga sumpdrain 24 F
Portovac 6147-0
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U nit price, $
5.30 (2 per case)
12.75 (2 per case)
12.95 (1 per case)

/

Cost/500 caseload
annually, $
5300.00
12750.00
6475.00
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Discussion

First described following wounds of
the heart as “polyserositis”,3 then fol
lowing mitral commissurotomy as
“postcommissurotomy
syndrome”,4
this unusual syndrome is character
ized by fever, pericardial pain, pleural
pain, pulmonary infiltrates, arthralgia,
dyspnea, pericardial effusion, pleural
effusion, pericardial friction rub, or
any combination of these signs and
symptoms.5
The entity has also been described
after myocardial infarction (postmyocardial infarction syndrome),8 pericar
diotomy
(postpericardiotomy
syn
drome),7 and after penetrating8 or
blunt chest trauma.9
The cause of postpericardiotomy
syndrome is still unknown. While a
heart-reactive antibody was described
by Engle and colleagues,10 a later re
port showed that antiviral antibody
was frequently associated with anti
heart antibody.1'11 Viral infection was
proposed as the trigger for the im
mune response. The presence of ma
ternal antibody may explain why in
fants are spared. Similarly some
patients who manifest postpericar
diotomy syndrome are spared the
complication if they have to undergo
a second intrapericardial operation.1
Cunningham and associates,2 in a
prospective study of 100 patients,
proposed that pericardial drainage
played a role in preventing post
pericardiotomy syndrome. While half
of the patients underwent a coronary
artery bypass procedure, the authors
do not state after which procedures
the postpericardiotomy syndrome oc
curred. In fact, the only difference
described between the two groups was
whether or not pleural tubes were
inserted.
Postpericardiotomy
syn
drome occurred in 11% of patients
267

with and 3% of patients without
pleural tubes. All had drains placed in
the anterior mediastinum and dia
phragmatic surface of the pericar
dium. In our study, only two patients
had tubes placed in the right pleural
cavity in group 1, one peroperatively
because the right pleura was opened
during the sternotomy, the other 12
hours after operation because a right
pneumothorax developed. Neither pa
tient had postopericardiotomy syn
drome. Thus, the decreased incidence
of postpericardiotomy syndrome re
ported by Cunningham and as
sociates could be because their study
population comprised more patients
who underwent coronary artery by
pass.
Cardiac Tamponade
Classically cardiac tamponade is
prevented either by leaving the peri
cardium open in communication with
one pleural cavity,12 or by closing the
pericardium and draining it with a
separate tube.5
A closed pericardium suggests that
most of the bleeding originates from
extrapericardial rather than intrapericardial sources.2 At reoperation for
hemostasis; blood clots were seldom
found around the heart when the
pericardium was closed, but when it
was left open clotting was common.13
When the pericardium is approximated
at 2-cm intervals, there is still com
munication with the anterior media
stinum and if the mediastinal tube is
permeable, any liquid accumulating in
the pericardial cavity will be drained.
The only reason for using a pericardial
tube would be to differentiate between
an intrapericardial and an extraperi
cardial source of bleeding.
We have shown that there is sa
tisfactory communication between the
pericardial and the anterior media
stinal cavities when the pericardium is
approximated at every 2 cm. We have
used the mediastinal drainage system
since 1976. Cardiac tamponade in the
postoperative course has been rare
(0 .2 %).

Cost-Effectiveness
The effectiveness of the system is
satisfactory, as shown by our results.
This leaves the nurses with more time
to devote to the patient and less to
the drainage system. The cost of any
such system must be examined in
these days of inflation and “restrained
budgets”. Our “home-made” system
affords all the advantage of the sump
drain at far less cost.
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Conclusions

From the results of our study we
conclude that intrapericardial drainage
does not affect the frequency of post
pericardiotomy syndrome or of car
diac tamponade.
Continuous permeability, minimal
nursing care and low cost are the
advantages of the mediastinal “home
made” sump drainage system.
Mediastinal drainage, with the peri
cardium approximated at every 2 to
3 cm, is suggested for effective drain
age after open-heart surgery.
We thank Drs. Jean-Paul Despres,
Michel Lemieux, Jacques Metras and
Gilles Raymond who participated in the
development of the drainage system. We
also thank Ms. Cecile Bilodeau for
preparing the illustrations and Ms.
Francyne Dolbec for typing the manu
script.
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Evolution of Ileostomy Surgery
N ils G. K o c k , m d , ph d , h on frcs

Ileostomy in association with
proctocolectomy in one or two stages
is the accepted treatment for ulcerative
colitis. There are many difficulties in
managing the permanent ileostomy in
spite of improvements in design and
construction, in availability of
stomal appliances and in better skin
protection and adhesive materials.
The collection and storage of excrement
in a bag outside the body imposes
severe difficulties.
To eliminate these problems an
alternative ileostomy method, the
continent ileostomy, was devised and
the clinical results achieved in 314
patients are reported. There was a
2.2% overall operative mortality but
no operative deaths in the last
consecutive series of 152 patients. The
nonfatal complication rate has
decreased from 24% to 7% and
revision because of a malfunctioning
outlet valve has decreased from
54% to 6% . At follow-up, 94% of the
patients were continent. Except for a
slightly increased loss of bile salts
and a potential risk of decreased
vitamin B,2 absorption no harmful
effects of the reservoir procedure
have been found after observation
times up to 12 years.
L'ileostomie en association avec une
proctocolectomie en un ou deux
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temps est le traitement reconnu de la
colite ulcereuse. L'entretien d’une
ileostomie permanente presente de
nombreuses difficultes malgre les
ameliorations apportees a son concept
et sa construction, la disponibilite
de dispositifs d’abouchement, de
meilleurs moyens de protection pour
la peau et de meilleures substances
adhesives. L'accumulation et le
stockage des excrements dans un sac
place hors du corps sont a I'origine
de difficultes graves.
Afin d'eliminer ces problemes, une
methode d'ileostomie differente,
l'ileostomie continente, a ete mise
au point. On decrit les resultats
cliniques obtenus chez 314 patients.
Pour I’ensemble, le taux de mortality
operatoire a ete de 2.2% mais aucun
deces operatoire n’a ete observe
dans la derniere serie de 152 malades.
Le taux de complications non fatales
a baisse de 24% a 7% et les revisions
pour mauvais fonctionnement de la
valve d'evacuation a diminue de 54%
a 6%. Aux examens de controle,
94% des patients etaient continents.
Sauf pour une legere augmentation
de ('elimination des sets biliaires et un
risque possible d’une absorption
reduite de la vitamine Bl2, aucun effet
nocif attribuable au reservoir n'a ete
observe apres une periode d'observation
allant jusqu'a 12 ans.

to be improved by this measure. How
ever, it was soon realized that the
colitis tended to recur as soon as the
bowel was reunited and that for per
manent cure the diseased bowel must
be removed. In the 1930s cxcisional
surgery for ulcerative colitis was per
formed as a multiple-stage procedure
starting with the creation of an ile
ostomy. This method was used for
about 20 years before ileostomy and
proctocolectomy in one or two stages
became accepted as treatment for
ulcerative colitis.
The reluctance of surgeons to adopt
the permanent ileostomy was mainly
due to the difficulties in managing the
ileostomy. The ileum was simply
brought out through the lower end of
the laparotomy incision or through a
separate stab incision, projecting about
2.5 cm beyond the skin level and a
rubber tube or a Paul glass tube was
tied into it (Fig. 1). After about 7

Methods o f colostomy evolved slowly
but ileostomy, introduced late in this
evolutionary process, benefited from
experiences gained with colostomy.
Technical improvements in ileostomy
came quickly. The first ileostomy
created for
ulcerative colitis
is
ascribed to John Young Brown of St.
Louis who, in 1913,' reported on 10
ileostomies, only 1 of which was for
ulcerative colitis. It was originally in
tended that the ileostomy should be
temporary since the disease seemed
V O L U M E 24, N O . 3, M A Y 1981
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days, the tube separated and over the
next week the exposed ileal surface
was gradually covered by granulation
tissue and was ultimately converted
into fibrous tissue. By the process of
“maturation” the ileal mucosa subse
quently was everted and drawn down
to the skin.
In the early phase of this procedure,
the lumen of the ileostomy was often
partly obstructed by the edematous
wall or later by contracting scar tissue
of the serosa, giving rise to irregular
ileostomy action. Symptoms of ob
struction with abdominal pain, disten
sion and vomiting, often associated
with a profuse ileostomy discharge,
occurred in nearly half of the pa
tients, beginning about 1 week after
operation.
In an attempt to reduce the healing
time and to minimize the skin prob
lems associated with the simple ile
ostomy technique, Dragstedt and
associates2 wrapped a split-thickness
skin graft around the exteriorized
ileum. Crile and Turnbull3 abandoned
this method when partial obstruction
due to subdermal fibrosis and con
traction developed in more than half
of their patients. In 1951, Warren and
McKittrick4 explained the patho
physiologic mechanisms behind the
disturbances in ileostomy function and
introduced the term dysfunction of
ileostomy.
Brooke5 of Birmingham solved
many of these problems. He everted
the end of the ileum and sutured
mucosa to skin (Fig. 2). His method
gained widespread acceptance and
although many modifications and im
provements in technique were added
the construction of a conventional
ileostomy still is based on his tech
nique.

Stoma Appliances

Theoretic Considerations

In the early days no stoma appli
ances existed. The patient arrived
home to find he had to work out his
own salvation—the surgeon had done
his job and subsequent management
was the patient’s concern. The lack of
a reliable appliance was of the greatest
importance to the patient as a human
being. Although a few attempts were
made by surgeons or patients to pro
duce a collecting appliance, none was
satisfactory and patients had to rely
on pads, absorbent dressings and
binders.
The introduction of the KoenigRutzen bag in 1944® was an im
portant step, but it took another 20
years before disposable plastic ap
pliances, effective skin protection and
adhesive materials became available.
It is no exaggeration that access to
a variety of modern stoma appliances
and to specialized stoma therapists
has revolutionized the life of the
patient who has an ileal stoma.

The small bowel responds to me
chanical and chemical stimuli within
its lumen with increased motor ac
tivity, resulting in raised intraluminal
pressure and aboral transport of its
contents. If transport is prevented, the
coordinated contractions of the in
testinal smooth muscle will increase
the intraluminal pressure in order to
overcome this resistance. If this is
not achieved, obstructive ileus with its
consequences will develop. Because of
these characteristics of the small in
testine and since the ultimate aim of
ileostomy is to produce a complete
obstruction at the end of the small
bowel, some primary demands had to
be fulfilled to achieve successful con
struction of a continent ileostomy— an
intestinal reservoir and an outlet
provided with a closing mechanism.
Intestinal reservoir.— For the col
lection and storage of the intestinal
discharge, an intestinal reservoir had
to be constructed proximal to the ob
structed outlet of the bowel. As the
amount of discharge expelled from
the ileostomy is approximately 600
ml/24 h plus varying amounts of gas,
the volume in the reservoir had to be
approximately 400 ml to keep the
number of reservoir evacuations to
about three per day. To reduce the
pressure at the obstructed outlet and
to prevent reflux of reservoir contents
into the proximal small bowel, there
should be no pressure waves in the
reservoir either at rest or during
filling.
Different types of intestinal reser
voir have been widely used as urinary
bladder replacements after subtotal
cystectomy. Most of these substitutes
have failed functionally in that the
patients have become incontinent, at
least at night, because the intestinal
smooth muscle at filling tends to pro
duce pressure elevations that over
come the resistance of the urethral
sphincters.
After studying the functional bebehaviour of different types of in
testinal bladder substitutes and anal
ysing the pressure records obtained,
we constructed a new type of intes
tinal reservoir, designed to eliminate
all intraluminal pressure increases at
filling. By splitting an intestinal seg
ment at its antimesenteric border and
folding the split segment twice (Fig.
3) the motor activity in different parts
of the created pouch was counter
acted and no increase in intraluminal
pressure occurred at filling despite
vigorous motor activity. The reservoir
rapidly dilated to take a volume of

Physical and Emotional Problems

No matter how skilful the stoma
construction or how well fitted and
convenient the ostomy appliance, the
patient is still faced with many prob
lems. The cutaneous stoma implies
that excrement must be collected and
stored in a bag outside the body. The
emotional impact of soiling oneself
is considerable and fear of leakage
may influence behaviour. While the
quality of appliances has improved
greatly, leakage and skin problems are
to a degree inherent in the use of an
appliance. Odour and disturbing noise
may occur. Care of the stoma is de
manding, skin problems occur easily
and may be disabling and difficult
to manage. Even if the patient accepts
the situation or at least adjusts to it
in an apparently satisfactory way,
attitudes of healthy people exposed to
the patient may be more responsible
for creating an emotional problem
than the attitudes of the patient him
self. Although most ileostomy patients
today enjoy perfect physical health
and live a near-normal life, there are
still problems directly or indirectly
associated with the ileostomy that en
croach on the quality of life.710
The Continent Ileostomy

FIG. 2—Construction of subcutaneous
Brooke ileostomy.
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To eliminate the problems related to
the conventional ileostomy, the conti
nent ileostomy was devised for clinic
al use at Sahlgren’s Hospital in
Goteborg, Sweden.
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FIG. 5— Construction of ileostomy re
servoir and isoperistaltic outlet.

400 to 600 ml, thus providing an ap
propriate intestinal reservoir for con
structing a continent ileostomy. In
1967, the reservoir procedure was used
in a few patients with ileostomy, and
a preliminary report on the method
was published.11 The original proce
dure has since been modified but the
basic principle for construction of
the reservoir is the same.
Outlet.— In the original procedure,
one corner of the reservoir was left
open (Fig. 3) and was drawn to a
small opening in the anterior ab
dominal wall for direct suture to the
skin. Although the five patients
provided with this type of ileostomy
could manage for long periods with
out carrying external ileostomy ap
pliances, occasionally they experienced
leakage of gas and feces through the

FIG. 6—Construction of ileostomy reservoir and isoperistaltic outlet provided
with nipple valve.
272
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ileostomy. Moreover, it became ob
vious that the outlet had to be im
proved in order to prevent leakage
through it evoked by increased intra
abdominal pressure from such ac
tivities as abdominal straining and
coughing. For this purpose, three
basically different types of outlet have
been tried.12
• Anti peristaltic outlet. In 35 pa
tients the reservoir was connected to
the skin with an antiperistaltic intes
tinal segment, which was drawn obli
quely through the rectus muscle (Fig.
4).
• Isoperistaltic outlet. In 31 pa
tients, the reservoir was connected to
the skin with an isoperistaltic intes
tinal segment (Fig. 5), emerging be
tween two crossed bundles of rectus
muscle. Although the antiperistaltic
and isoperistaltic procedures provided
complete continence in many patients,
a considerable number experienced
leakage through the outlet, for un
known reasons.
__
• Outlet with nipple valve. To
eliminate completely the partial fail
ures, a nipple valve was constructed
at the outlet from the reservoir by intussuscepting a part of the terminal
segment into the reservoir (Fig. 6).
The intussuscepted intestine was an
chored by placing 8 to 10 isolated silk
sutures transversely through both in
testinal walls. The nipple valve con
structed in this way proved effective
in preventing leakage through the out
let, but the intussusception tended to
slip out partially or completely after
some time, thereby causing difficulties
of intubation and also some incon
tinence. Because of the tendency to
spontaneous sliding, the nipple-valve
construction has undergone modifica
tion and several steps have been
added to th,e procedure to prevent
sliding.
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Clinical A pplication
In principle, three different modifi
cations for construction of the nipple
valve have been used in our depart
ment. The original procedure for
maintaining the position of the nipple
valve employed through and through
sutures with or without scarification
of the serosa.12 Later, this procedure
was modified. The mesenteric peri
toneum and fat were excised and the
two intestinal segments forming the
nipple valve were rotated with respect
to each other (Kock NG, Myrvold
H, Nilsson LO, Ahren C: Unpublished
data). In this way mesenteric bulk
was diminished and separated into
two parts. Since January 1978 a tech
nique using staples and a strip of
Marlex mesh around the base of the
nipple valve has been used (Kock
NG, Myrvold H, Nilsson LO, Ahren
C: Unpublished data).
Selection of patients for the proce
dure, preoperative preparation, details
of the operative method and postoper
ative management have been published
previously.13
Patients
During the period 1967 to 1979,
314 patients have been provided with
a continent ileostomy in our depart
ment. The diagnoses (Table I),
based on the microscopic examination
of the removed intestine, were
not always in agreement with the pre
operative diagnoses, especially in pa
tients with Crohn’s disease. The re
servoir procedure was performed in
connection with proctocolectomy in
142 patients, with rectal excision in
12 patients with ileorectal an
astomosis, with excision of remaining
colon in 12 patients with colostomy
and for various diseases of the colon
(primary procedure) and as a con
version of a conventional ileostomy
to a continent ileostomy at a second
operation in 148 patients.
Complications
Early.—Seven (2.2%) of the 314
patients died of complications follow
ing the operation. All operative deaths
occurred before 1975 (4.3% of 162
Table 1— Diagnoses in 314
Patients Provided w ith
Continent Ileostomy
Diagnosis
U lcerative colitis
Crohn’s disease
Familial polyposis
Other

No. of patients
241
51
17
5
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After introduction of the present tech
nique for construction of the valve
no internal fistulas have been seen.
• Revision. Because of late com
plications causing malfunction of the
ileostomy, revision of the ileostomy
was necessary in 54% of patients in
the early series of 246 patients (Table
II). After modification of the tech
nique for construction of the nipple
valve one third of patients still needed
revision. With the present procedure
sliding of the nipple valve and inter
nal fistula have been eliminated and
the need for revision has decreased
to 6% . Two out of 32 patients in
this series underwent revision because
the ileostomy malfunctioned. In one
patient the fascia transplant around
the base of the nipple valve disap
peared and partial eversion of the nip
ple valve occurred intermittently. An
other patient suddenly was unable to
intubate the pouch and an angulation
of the outlet was observed at endo
scopy but could be passed by the
small-sized rectoscope. At laparotomy
it was found that the lateral aspect of
the reservoir had come loose from the
inner stomal opening causing angula
tion of the outlet and consequent dif
ficulty of intubation.
• Inflammatory changes. Nonspe
cific inflammatory changes in the
reservoir (ileitis) cause diarrhea with
liquid feces sometimes containing
blood. If the valve is involved the
patient may become temporarily in
continent. If the ileitis is severe and
long-lasting, the patient may become
dehydrated and depleted of sodium.
Endoscopy reveals an inflamed mu
cous membrane with contact bleeding
and sometimes discrete ulcers. Non
specific ileitis always responds to
treatment with either sulfasalazine,
metronidazole or various antibiotics
given orally. In severe cases conti
nuous drainage of the reservoir may
be necessary as well as parenteral
administration of sodium and water.

patients); none of the 152 patients
operated on since then have died.
Early complications requiring some
kind of surgical intervention occurred
in 23.8% of patients operated on
between 1967 and 1974 and in 7.2%
of patients operated on since then.
Late.—Late complications occur
ring at varying times after the oper
ation included sliding of the nipple
valve, formation of fistulas, stricture
of the stoma (skin stricture) and in
flammatory changes in the reservoir
(Table II).'
• Sliding of nipple valve. This
complication leads to incontinence
and difficulty in inserting the catheter.
When the different procedures used
for constructing the valve were com
pared it was found that the frequency
of sliding had decreased consecutively
from 44% when the original method
was employed to 19% with the rota
tion procedure and 0% in 32 patients
operated upon with the present tech
nique.
• Prolapse of nipple valve. In
seven patients eversion of the nipple
valve occurred, with prolapse of the
nipple through the ileostomy. Al
though extrusion of the nipple valve
in general is easily corrected manually
it is a recurrent disturbance. It has
therefore been treated surgically by
narrowing the inner opening of the
channel through the abdominal wall or
by applying a cylinder of Marlex
mesh around the base of the outlet.
With the present technique for con
struction of the valve, partial eversion
has occurred in only one patient in
whom the fascia sling did not sur
vive the transposition.
• Internal fistula. A fistula oc
curred in 23 cases through the base
of the nipple valve causing incon
tinence because the contents of the
reservoir bypass the nipple valve. All
fistulas have been repaired either by
local excision and closure of the fis
tula or by reconstruction of the valve.

Table II— Late Complications Related to the N ipple Valve in 246 Patients w ith
Continent Ileostom y
Com plication, %
Technique for
constructing
nipple valve
Original procedure
(through and through
su tu re s+ serosal
excoriation)
Modified procedure
(rotation procedure)
Present procedure
(staples-)- fascia
or M arlex mesh)

Sliding

Prolapse

Internal
fistula

44.1

0

9.7

18.5

5

10.7

0

1

0
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Miscellaneous

Revision
needed, %

53.8
33
2

6.3
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Before we knew how to treat this
complication the reservoir was re
moved in two patients with severe
ileitis but our current experience in
dicates that excision of the pouch
should not be necessary. In our total
series of patients, excluding those with
Crohn’s disease, ileitis occurred in 23
(approximately 10%). An account of
our patients with Crohn’s disease and
continent ileostomy will be presented
in a separate paper.
Functional Results
At follow-up in May 1980 the total
series of 314 patients was analysed.
The observation time ranged from 5
months to 12 years. Of the 314
patients 7 had died as a result of the
operation, 1 because of a late com
plication of Crohn’s disease and an
other 6 had died of causes unrelated
to their intestinal disease. Tn 14 pa
tients the reservoir had been removed.
Thus, 286 patients could be evaluated.
Of 62 patients in the early series
with an iso- or antiperistaltic outlet
35 subsequently were provided with
a nipple valve leaving 27 for evalua
tion of the function of the original re
servoir. Of these 27 patients, 22 never
used ileostomy appliances. Of 259
patients with a nipple valve 96%
never used bags (Table III).
Quality o f Life
After successful construction of a
continent ileostomy, the intestinal dis
charge is accumulated in the intra
abdominal pouch and involuntary
escape of gas or feces from the re
servoir through the ileostomy is im
possible. The ileostomy is covered by
a small pad for absorption of mucus
excreted by the stoma and patients
empty the reservoir three times a
day, spending approximately 5 min
utes each time for the intubation, in
cluding irrigation if necessary and ap
plication of the pad. Emptying of the
reservoir is performed when it is
convenient for the patient, generally
in the morning, before breakfast, in
the afternoon after returning home
from work and in the evening before
going to bed.

As the flat stoma in these patients
is placed just above the pubic hair
line, it is cosmetically acceptable and
is, in general, concealed by the under
wear. When dressing, the patients do
not have to pay attention to their
ileostomy.
Patients are instructed to avoid
eating such food as vegetables, onions,
mushrooms and peanuts, in the first
few weeks after operation, as these
foods can easily block the catheter
openings, making emptying difficult.
Later, when the patients are used to
intubating the reservoir and have
gained confidence, there is no need
for dietary restrictions. If the catheter
gets blocked, the patient can wash it
and repeat the intubation. Very few
of our patients are on any special diet
for more than a few weeks after the
operation.
It seems that resuming a full profes
sional and social life after proctocol
ectomy is greatly facilitated by a con
tinent ileostomy.9 The complete con
fidence in the ileostomy was the most
important gain of conversion from
conventional ileostomy reported by
our patients and this confidence cer
tainly will appreciably influence the
patients’ activities, including sexual
life. So far, we have recorded 14 preg
nancies, with normal deliveries in 13
and by cesarean section in 1. In a
recent study, ileostomists retrospect
ively evaluated the influence of an
ileostomy on sexual life before and
after conversion to a continent ile
ostomy.1* They found that the con
ventional ileostomy in many patients
interfered to a considerable extent
with sexual activity and quality of
sexual life and that conversion to con
tinent ileostomy resulted in an im
proved quality of sexual life in 85%
of patients. Since most patients need
ing an ileostomy are at an age when
family planning and sexual life are
important, this drawback of the con
ventional ileostomy has to be serious
ly considered when discussing the two
ileostomy alternatives. It is the re
sponsibility of the surgeon not only
to cure but also to minimize side ef
fects of curative surgery.

Table Ill-F u n c tio n a l Results in 286 Patients with
Continent Ileostomy
Use of ileostomy
appliances
Always
Occasionally
N ever
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Patients w ithout
nipple valve ( n = 27)

Patients with
nipple valve (n = 259)

1
4
22 (81.5% )

5
6
248 (95.8% )
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Biological Changes in the Reservoir
Theoretically, the ileal reservoir can
be considered as a "blind loop”. The
stagnation of intestinal contents for
many hours might favour bacterial
growth, alter mucosal morphology and
interfere with normal absorption. For
that reason, postoperative follow-up
studies have been carried out at in
tervals after the creation of the re
servoir.
Bacteriology.—The long storage
periods of the reservoir contents, a
rich culture medium, the recurrent
contamination by the nonsterile emp
tying catheter and the ideal tempera
ture must favour bacterial growth.
Construction of a conventional ile
ostomy leads to alteration of the flora
from that found in normal terminal
ileum. After a reservoir is created, the
quantity and quality of the microbiologic population changes even
more. The increased number of micro
organisms and the preponderance of
“colonic” anaerobes places the reser
voir, from the bacteriologic viewpoint,
in an intermediate position between
the terminal ileum and the rectum.
Repeated cultures taken from the
same group of patients at intervals
showed that although variations occur
in both the numbers and proportions
of bacteria, the intermediate position
is relatively stable.15'16
Morphology.—Biopsy
specimens
taken from ileostomy reservoirs have
been studied during a period of 6 to
10 years.16,17 When these specimens
were evaluated under the dissecting
microscope, it was noted that shortly
after construction of the reservoir the
tall fingerlike villi of normal ileal
mucosa changed into shorter, cluband leaf-shaped villi and remained so
during the first year. Later the villi
reassumed a fingerlike appearance.
When studied under the light micro
scope the reduction in villus height
was striking and, in addition, the
crypts were elongated (Fig. 7). An
inflammatory reaction was noted in
the lamina propria early after con
struction, although this resolved after
the third postoperative month. By
light as well as electron microscopy
the microvillus layer appeared normal
in all instances. Quantitative studies
have been carried out in which villus
height and number of crypt cells and
mitoses have been recorded. The villus
height in biopsy specimens taken 1,
2 and 6 to 10 years after operation
was measured. Compared with values
from control specimens the villus
height was notably reduced at all in
tervals; however, values obtained after
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6 to 10 years were appreciably higher
than in specimens taken after 1 year.
The number of crypt cells was in
creased in all reservoir samples after
operation. The number of mitoses
gives an indication of the cellular turn
over: during the first postoperative
year there was a substantial increase
compared with control samples; in
samples obtained after 2 and 6 to 10
years the values had returned to nor
mal. No changes of dysplasia, fibrosis
or progressive atrophy have been seen
in the reservoir mucosa. Histochemical
investigations have also shown largely
unchanged strong enzymatic activity
in the epithelial cells.
Absorption .—The presence of a
large number of bacteria in proximal
areas of the intestine may result in de
conjugation of bile salts and conse
quent malabsorption of fat and vita
min Bis, Contamination of the proxi
mal bowel from the reservoir could
theoretically interfere directly with
normal absorption. In studies per
formed during the first 2 postoper
ative years the absorption of D-xylose,
L-phenylalanine and fat in a group of
patients with a reservoir ileostomy
equalled that of a group of patients
with a conventional ileostomy.18 In a
follow-up study 6 to 10 years after
construction of the reservoir, special
interest was focused on vitamin B,2,
fat and cholic acid.19’21 In spite of
borderline values of the Schilling test
in 6 out of 14 patients all had a nor
mal vitamin BJ2 level in plasma.
Excretion of fecal fat was studied
after a standardized oral intake of
150 g fat, an unusually large intake
which should make defective absorp
tion more obvious. Ten patients had
an excretion of less than 10 g/d which

was considered normal. Two patients
had increased excretion but not to
the level of clinical steatorrhea.
The loss of cholic acid was studied
by means of fecal excretion of intra
venously administered 14C-cholic acid
in patients with a reservoir and in
patients with a conventional ileostomy.
The results showed an increased loss
of bile salts in patients with an ile
ostomy reservoir. Neither correlation
between the fecal loss of cholic acid
and the fecal fat excretion nor be
tween cholic acid and vitamin B,2 ab
sorption could be found. The fecal
loss of cholic acid in the patients with
a reservoir ileostomy was equal to the
loss in patients with a conventional
ileostomy who had undergone resec
tion of 50 cm of ileum (Fig. 8).
The construction of an ileostomy
reservoir leads to an altered bacteriologic milieu in the pouch. M or
phologic changes occur rapidly in the
pouch mucosa. However, long-term
follow-up studies show a trend towards
normalization of the mucosal m or
phology, a view which was also sup
ported by enzyme histochemistry.
Apart from malabsorption of cholic
acid in the majority of patients our
studies have demonstrated little dif
ference between patients with an ile
ostomy reservoir and patients with a
conventional ileostomy.

biologic consequences of an intestinal
pouch at the terminal ileum may be
harmful to the patient in the long run.
With growing experience, improved
surgical technique and introduction
of technical modifications, the early
and late complication rates have been
markedly reduced. The excellent
health of the majority of patients with
this type of ileostomy, some followed
up for 12 years, and the studies con
cerned with the biologic consequences
of the ileostomy reservoir indicate that
unfavourable effects need not be ex
pected in patients correctly selected
for this procedure. I believe that the
continent ileostomy now has a definite
place in ileostomy surgery.
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sim ila r to n aturally-occurring ch ylom icro n s. The total caloric value of
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LIPOSYN* 10% (Intravenous Fat Emulsion 10%) provides the patient requiring
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calories for patients requiring parenteral nutrition. This includes pre- and post
operative nutritional disorders and nutritive disorders resulting from decreased
or inhibited intestinal absorption, as with tumours of the digestive tract, or in
ulcerative colitis and terminal ileitis.
LIPOSYN* 10% Injection is also indicated in burn cases, where nitrogen loss
can be excessive, in prolonged states of unconciousness if tube feeding is
inadvisable and in cachexia due to serious diseases other than of the alimenta
ry tract.
Where such nutrition is required for extended periods of time (more than five
days), LIPOSYN* 10% Injection is also indicated as a source of essential fatty
acids to prevent biochemical changes in fatty acid composition of plasma lipids
(elevated triene/tetraene ratio) and the clinical manifestations of EFAD.
CONTRAINDICATIONS
Intravenous fat administration is contraindicated when normal fat metabolism is
disturbed, such as in certain forms of liver disease, metabolic disturbance, or
uncompensated diabetes. Since intravenously administered fat is removed
from the bloodstream by the liver, patients with severe liver disease should not
be given fat infusions until further experience has shown this to be without risk.
Caution is required when LIPO SYN* 10% is administered to patients with
moderately severe liver disease.
Infusion of fat emulsion is contraindicated in patients demonstrating distur
bances in normal fat metabolism, such as hyperlipidemia, lipoid nephrosis, or
acute pancreatitis if accompanied by hyperlipidemia. The use of fat emulsion
with heparin is contraindicated in patients with coronary artery disease.
Because of the risk of acidosis, fat emulsion should not be used in diabetics
who are not receiving insulin. The safety of fat infusions in diabetics treated with
oral hypoglycemic agents is not known.
WARNINGS
Caution should be exercised in administering Intravenous Fat Emulsion 10% to
patients with severe liver damage, pulm onary disease, anemia or blood dis
orders or when there is danger of fat embolism.
In very low-birth weight infants, the adverse effects of fat emulsion infusion on
pulmonary function and bacterial defences may outweigh the benefits (Fischer,
et al. 1980; Leven, et al. 1980). See special precautions for use in premature
and small-for-gestational age infants under DOSAGE AND ADMINISTRATION
- pediatric patients.
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the welfare of the patient.
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During fat emulsion therapy, the patient's hemogram, blood coagulation, liver
function, platelet count and plasma lipid profile must be closely monitored.
Lipemia (as determined from observation of a centrifuged sample of plasma)
must clear daily between infusions. LIPO SYN* 10% Injection should be dis
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Use in Renal Disease:
Lipid infusion should be used with caution in patients with acute renal disorders
and in those with coagulation disturbances or blood dyscrasias. The serum of
such patients should be examined regularly for the presence of lipids.
Extreme care should be used in administering fat infusions to diabetics control
led with insulin and to patients with liver disease (See CONTRAINDICA
TIONS).
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ADVERSE REACTIONS
Adverse reactions reported to occur during or following infusion of fat emul
sions include: fever, chills, nausea, vomiting, headache, anemia, fatty throm
bus, thrombophlebitis, “ colloid reaction", which is characterized by back or
chest pain with dyspnea and cyanosis and "overloading syndrome", which is
generally characterized by fever, headache and/or hyperirritability, often in the
presence of persisting hyperlipidemia.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Overdosage of LIP O S YN * 10% Injection is most likely to result in the
"overloading syndrome" (See under ADVERSE REACTIONS). The infusion
should be stopped immediately and sodium chloride 0.9%. or balanced salt
solution given. When symptoms have abated, the plasma is clear and other
blood lipid measurements have returned to normal, LIPOSYN* 10% Injection
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DOSAGE AND ADMINISTRATION
LIPOSYN* 10% Injection (Intravenous Fat Emulsion) should be administered
as part of an intravenous total nutrition program via peripheral vein or central
venous catheter.
LIPOSYN* 10% Injection should not be mixed with electrolytes, nutrients or
other additive solutions. However, Heparin has been shown to be stable when
added to the emulsion at a concentration o f 1-2 Units/mL. Filters should not be
used for administration of the emulsion.
LIPO SYN* 10% Injection is supplied in 100 mL and 500 mL single-dose
containers. Partially used bottles must be discarded and should not be stored
or re-sterilized for later use. Do not administer the contents of any container in
which the emulsion appears to be oiling out.
LIPOSYN* 10% Injection can be infused into the same central or peripheral
vein as the carbohydrate/amino acid solutions by means of a short, Yconnector near the infusion site. This allows for mixing of the solutions imme
diately before entering the vein or for alternation of each solution. Flow rates of
each solution should be controlled separately by infusion pumps if these are
used. Fat emulsion may also be infused through a separate peripheral site. If
desired, Heparin may be added to LIPO SYN* 10% Injection at a concentration
of 1-2 Units/mL prior to administration.
LIPO SYN* containing fluids have a propensity to extract phthalates from
phthalate-plasticized polyvinyl chloride (PVC). Although the amount is very
small and no adverse clinical effects have been reported from administration of
such amounts of phthalate. it may be advisable to consider administration of
LIPOSYN* 10% Injection through a non-phthalate infusion set.

The amount of intravenously administered fat normally should not exceed 2 g of
fat (corresponding to 20 mL of L IP O S Y N * 10%) per kg body weight.
LIPOSYN* 10% Injection has a caloric value of 1.1 kcal/mL. Of this total, 0.7
kcal/mL is supplied by linoleic acid.
Adult Patients:
LIPOSYN * 10% Injection can provide up to 2 g fat/kg body weight per day. The
remaining calories should be provided by carbohydrate and amino acids.
For the prevention of essential fatty acid deficiency, the recommended daily
requirement is approximately 4% of the caloric intake as linoleate. In most adult
patients, this can be supplied as 500 mL of LIPO SYN* 10% Injection adminis
tered twice weekly.
The infusion should be started at a rate of 1 mL/minute for the first 15 minutes.
If no adverse effects are observed during this initial infusion, the rate can be
increased to allow no more than 500 mL to be given over a period of four to six
hours.
Pediatric Patients:
LIPOSYN* 10% Injection can provide up to 60% of daily calories at a dose not
to exceed 4 g/kg of body weight per day. The other 40% should be provided by
carbohydrate and amino acids. For the prevention of essential fatty acid defi
ciency, the recommended daily requirement is approximately 4% of the caloric
intake as linoleate. The daily dosage ranges from 5 mL to 10 mL per kg,
depending on the size and maturity of the patient.
The infusion should be started at a rate of 0.1 m L/minute for the first 15 min
utes. If no adverse effects are observed during this initial infusion, the rate can
be increased to allow no more than 100 mL per hour.
Premature and Small-for-Gestational-Age Infants:
Sick infants, premature and small-for-gestational-age infants are at greater risk
of developing hyperlipidemia. Lipidemia has the potential for lowering oxygen
tension, especially in infants with pulmonary insufficiency. Small babies tolerate
fat infusion better if it is given by continuous infusion at a rate of 0.2 g fat/kg
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AVAILABILITY
LIPOSYN* 10% Injection (No. 4335; DIN 503401) is supplied in 100 mL and
500 mL single-dose containers.
Product monograph available on request.
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Reference: 1. Rapp RP et at: Safety of a New Safflower Oil Emulsion (Liposyn 10%) in Total
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Symposium on the Management of Early Breast Cancer
(Stages I and II).
Part I: Rationale for Treatment Methods
1. Introduction
The aim of this symposium on breast
carcinoma is to provide the partici
pants with enough updated knowledge
to help them in the daily management
of their patients with breast cancer.
It is hard to change habits that have
come through training and experience
and it is dangerous to change pre
maturely without sufficient data and
evidence that the new techniques are
yielding better results.

This symposium will help every
participant to judge for himself. In
breast carcinoma it is imperative that
changes be made—if one realizes how
little gain has been achieved by con
ventional therapy, one also realizes
that the time has come for new thera
peutic methods. Once the principles
of these new methods are under
stood, the next phase is to try them on
humans to explore their curative pos

sibilities. “Adjuvant therapy” is avail
able today—the mechanics are well
understood and its feasibility is pro
ven. This is the tool with which breast
cancer patients should be managed.
Louis J. D io n n e ,

m d , frcs [c ], facs

Department of surgery,
Hotel-Dieu de Quebec,
Quebec, PQ

2. Cancer du sein: dilemme 1980
Louis D ion n e ,

m d , frcs [c ],*

M ichel P lante ,

Le cancer du sein demeure le sujet
le plus controversy en oncologie.
Ce n’est pas sans raison, puisque,
apres plusieurs annees, la plupart
des questions litigieuses concernant
le diagnostic et la conduite
therapeutique des cancers du sein
n'ont pas trouve de solution
satisfaisante. Le systeme TNM ouvre
la porte a plus d'une interpretation et
I'indice d'erreur dans 1'evaluation de
I'aisselle reste eleve meme entre
des mains expertes.

*Service de chirurgie generate,
Hotel-Dieu de Quebec, Quebec, Que.
\Pathologiste, Hotel-Dieu de Quebec
tAncien resident, service de chirurgie
generate, Hotel-Dieu de Quebec
SPhysicien, Hotel-Dieu de Quebec
Presente an 49e congres annuel du
College royal des medecins et chirurgiens
du Canada par le College royal en
collaboration avec le Societe canadien
d’oncologie, Ottawa, Ont., le 5 juin, 1980
Accepte pour publication le 14 octobre,
1980
Les demandes de tires d part doivent
etre adressees au Dr L. Dionne,
Service de chirurgie generate,
Hotel-Dieu de Quebec, 11, Cote du
Palais, Quebec, Que G1R 2J6
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La therapeutique pose egalement
des problemes. Les modes de
traitements sont a ce point varies
et controverses que ('interpretation
des resultats ne permet pas de
comparaisons valabies. Seuls des
essais cliniques pourront apporter
reponses aux questions fondamentales.
For many reasons, breast cancer is
still the most controversial topic in
oncology. Questions raised many years
ago in relation to diagnosis and
treatment have not yet been answered.
Clinical classification, such as the
TNM system, is open to many pitfalls
and the degree of error in axillary
staging is still high, even in
expert hands.
The situation with regard to
management is similar. The types of
treatment are numerous and contro
versial, so that interpretation of
results is unreliable. The fundamental
questions will be answered only by
clinical trials.

A l’epoque de Halsted (1890), on ne
disposait que de la chirurgie pour
trailer le cancer du sein; l’excision
chirurgicale visait l’extirpation de
VOLUME 24, NO. 3, M A Y 1981
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toutes les lesions visibles macroscopiquement. Les lesions localement invasives etaient courantes et le traitement, habituellement tardif.
Puis, des ameliorations diagnostiques et therapeutiques naquit la controverse. De telle sorte, qu’il serait
sans doute aujourd’hui plus facile de
parler des “points d’entente” que de
relever les divergences d’opinion au
sujet du cancer du sein. En effet, a
premiere vue, il semble y avoir beaucoup plus de disaccords que de con
sensus. Comment pourrait-il en etre
autrement? II existe, en effet, plus
d’un point de friction entre les chi
rurgiens eux-memes ainsi qu’entre les
chirurgiens et leurs collegues oncologues, radiotherapeutes et pathologistes. II suffit d’assister a quelques
“Cliniques des tumeurs” pour en
etre convaincus. La medecine d’aujourd’hui est un “art reposant sur
I’incertitude et une science des probabilites”, et la cancerologie une me
decine de confrontation.
Meme avant Halsted, en l’annee
1700, dans la ville de Quebec, le
chirurgien Michel Sarrazain traitait
chirurgicalement les cancers du sein.
Les historiens rapportent que le doc-
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teur Sarrazin pratiqua une mastectomie chez quatre religieuses, dont l’une,
soeur Marie Barbier de FAssomption,
survecut 19 ans apres l’ablation de
son sein cancereux. Elle etait porteuse d’un cancer mammaire, depuis
plus de 2 ans, localement avance avec
ulceration de la peau.
Pour illustrer ces commentaires sur
les controverses entourant le cancer
du sein, nous nous proposons d’utiliser comme point de comparaison
l’experience accumulee par Fun d’entre-nous en 15 ans de pratique. Cet
exercice permettra de mettre en lumiere les controverses importantes,
celles que la majorite des therapeutes ont rencontrees au cours de leur
carriere, les obligeant parfois a reconsiderer les habitudes prises en cours
de formation.
Controverses cliniques

Les multiples classifications utilisees pour grouper les cancers du sein
sont a Forigine de certaines contro
verses therapeutiques parce qu’elles
sont difficiles d’application et peu
sures.
Pour notre part, nous avons utilise
le systeme TNM propose par FUnion
internationale
contre
le cancer
(UICC).1 Cette classification repose
principalement sur l’examen physique
et elle en comporte toutes les imper
fections.
En effet, les lacunes du systeme
TNM decoulent de Fevaluation sub
jective de criteres qui se veulent objectifs, tels que le diametre de la
tumeur (T), la presence et la qualite
des ganglions axillaires (N) et Fabsence ou la presence de metastases
(M).
Cependant, comment peut-on com
parer deux tumeurs de merne dimen
sion chez des patientes dont les seins
sont de volumes differents? Aucune
classification ne tient compte du rap
port volume du sein/volume de la tu
meur. Ce rapport nous semble toutefois important puisqu’il rend compte
du degre de penetration de la tumeur:
l’envahissement des tissus lymphatiques et sous-cutanes voisins est d’autant plus rapide que le rapport volume
du sein/volume de la tumeur diminue.
Que dire egalement de Fevaluation
clinique du contenu axillaire et de
la qualite de l’examen qui se veut
discriminant; malgre l’experience de
l’examinateur, Fappreciation des ade
nopathies axillaires reste souvent en
dega des limites acceptables et les
variations peuvent atteindre 25% a
50%.
Aussi, n’est-ce pas sans raison que
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plusieurs groupes, dont le National
Surgical Adjuvant Breast Project
(NSABP), preferent la classification
pathologique et s’en servent comme
critere de selection du traitement ad
juvant postoperatoire.
Malheureusement, Fexamen anatomo-pathologique manque souvent de
rigueur et de fiabilite. S’il doit servir
de guide therapeutique, il doit etre
complet et inclure Fexamen detaille
de toute la glande mammaire et du
contenu axillaire. II nous parait illusoire de classifier les cancers du sein
selon un rapport pathologique limite
a Fexamen du foyer tumoral ou de
trois a quatre ganglions axillaires.
Ainsi, au NSABP, une revue histopathologique minutieuse des cancers
de stade I a revele la presence de
ganglions envahis microscopiquement
dans 25% des cas juges negatifs au
premier examen pathologique.
Si on additionnait le pourcentage
d’erreur de Fexamen clinique a celui
de Fexamen histopathologique, il se
pourrait que la classification des
cancers du sein soit inutilisable pour
l’interpretation des resultats therapeu
tiques.
Il semble paradoxal pour un anatomiste et pour les tenants de la dis
semination par voie lymphatique,
qu’on puisse avec certitude classer
comme stade I, un cancer du sein de
siege interne (quadrant infero-interne
par exemple) chez une patiente dont
les ganglions axillaires ne sont enva
his ni cliniquement ni pathologiquement. Comment, sur ce critere. peuton s’abstenir de therapie complementaire si le traitement a visee curative
sera limite a une mastectomie segmentaire. Fort heureusement, la lympho-scintigraphie de la chaine mam
maire interne pourra trancher le
dilemme et completer ia c la s s ific a tio n
du stade clinique des cancers mammaires de siege interne.
Ces controverses cliniques ouvrent
grande la porte a toute une serie de
questions dont nous parlerons plus
loin et qui touchent Fevaluation des
resultats de divers traitements utilises
dans le cancer du sein. En effet, I n 
terpretation des resultats devient
souvent une dialectique de sourds,
“politique et vaniteuse” pour reprendre l’expression de Rider,2 ou l’on
compare des patientes souvent fort
differentes.
Quelle serait la valeur d’une com
paraison de deux methodes de de
gustation si, a l’insu des degustateurs,
on utilisait des fruits differents. De
meme pour evaluer les resultats d’une
therapeutique et les comparer a ceux
des autres traitements, il faudrait, au
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depart, s’assurer d’une certaine homogeneite et pouvoir classer, sans
erreur, les cancers du sein selon des
criteres fixes, reproductibles et faciles
d’interpretation.
Controverses therapeutiques

Entourant la technique chirurgicale
Au temps de Halsted3 le traitement
n’etait que chirurgical et la portee
qu’anatomique. On excisait les tissus
atteints aussi largement que possible
pour eviter la recidive locale et ses
consequences. On parlerait aujourd’hui de mastectomie de “proprete”
(toilet mastectomy).
Les traitements conventionnels des
cancers mammaires, tels que la chirurgie et la radiotherapie, reposent
sur le concept de la propagation par
voie lymphatique. Maladie locale, le
cancer envahit de proche en proche,
et les cellules se disseminent d’abord
par voie lymphatique, aux ganglions
regionaux, axillaire, supra-claviculaire
et mammaire interne, avant de se
propager a distance. C’est ainsi que
nous avons connu l’epoque de la
chirurgie radicale et supra-radicale,
et de la radiotherapie complementaire de principe. Plus agressif etait
le traitement, meilleurs seraient les
resultats, croyait-on. On employait la
chirurgie radicale dans tous les cas,
quels que soient le foyer, le stade et
le grade histologique de la lesion
primaire. Et souvent, la radiotherapie
radicale completait Fextirpation chi
rurgicale en irradiant les zones ganglionnaires limitrophes et la cage
thoracique.
Puis, en 1948, McWhirter,4 radiotherapeute d’Edimbourg, publia les
resultats d’un traitement conservateur
asscciar.t la mastectomie simple et
la radiotherapie. Ceux-ci se comparaient tres bien avec les pourcentages
de guerison obtenus par les methodes
plus radicales. On assista alors a une
levee de houcliers et plusieurs auteurs
dont Ackerman,5 Watson6 et Haagensen7 voulurent demontrer que la
technique McWhirter n’avait pas la
valeur que semblait lui attribuer son
auteur. Et qui plus est, lorsque Bruce
et Tough,8 deux chirurgiens de l’equipe d’Edimbourg, se joignirent aux
opposants, il sembla que e’en etait
fait de cette technique dite conservatrice.
Cependant, le mouvement etait
lance. La mastectomie simple en as
sociation avec la radiotherapie se
repandit un peu partout, y compris
en Amerique. Quant a nous, depuis
1965, c’est la methode que nous avons
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utilisee pour les cancers de siege
interne (quadrant supero-interne et
quadrant infero-interne), preferant la
chirurgie radicale, avec ou sans ra
diotherapie, pour les cancers de siege
externe et central (fig. 1). Ces deux
methodes sont radicales dans leur
approche et les principes physiopathologiques sur lesquels elles s’appuient sont les memes: le cancer du
sein est d’abord une maladie locale
et le traitement vise l’eradication
totale des cellules cancereuses, soit
par la chirurgie, soit par la radiotherapie, au niveau du sein et des zones de
drainage lymphatique et ganglionnaire. C’est le principe de la chirurgie
“en bloc” avec resection en continuite
du sein et des chaines lymphatiques.9'12
II semble que ce soit Crile13 qui, le
premier en Amerique, preconisa l’approche conservatrice du cancer du
sein avec preservation d’une partie
importante de la grande mammaire.
Plusieurs auteurs par la suite, dont
Peters14 au Canada, ont publie les
resultats d’un traitement associant
mastectomie partielle et radiotherapie.
Sujet de controverse, la technique
chirurgicale est souvent laissee pour
compte et n’entre que tres peu dans
les regies d’un protocole. Que Ton
parle de mastectomie totale, radicale
modifiee ou segmentaire, il semble
exister autant de techniques que de
chirurgiens.
E n to urant les choix therapeutiques

On peut diviser arbitrairement la
maladie cancereuse du sein en deux
composantes: il y a d’une part la
maladie locale, la tumeur du sein, et
d’autre part, la maladie generale qui
fera mourir 85% des cancereuses du
sein dont la lesion primaire aura
cependant ete sterilisee (guerison
locale). Cette distinction permettra
de mettre en lumiere les diverses possibilites therapeutiques.

Dans un esprit de synthese, Baum15
a regroupe hypothetiquement les can
cers du sein et mis en evidence les
implications therapeutiques (tableau
I). Dans cette optique, la composante
“locale” de la maladie cancereuse
pourrait etre traitee localement avec
conservation de la glande mammaire.
Quant a la composante “generale”
ou “systemique”, le traitement doit
etre par voie generale et n’implique
pas necessairement la perte du sein.
Il semble toutefois tres difficile de
reconnaitre dans quelle categorie
une patiente peut etre classee. Comme
l'ecrivait Devitt: “In a patient with
breast cancer, it is difficult to de
termine if, when and where she will
develop metastases.”16
La multicentricite decrite par Gallager et Martin17 et Contesso et collegues18 se rencontre dans plus de la
moitie des cancers du sein. Le devenir
de tels foyers microscopiques reste
inconnu, mais il est logique de croire
que tout traitement efficace contre la
maladie generale pourrait les extirper.
Cette hypothese laisse perplexes les
tenants de l’extirpation totale du sein
qui craignent, de bon droit, la conse
quence souvent letale d’une recidive
locale. Pour Gallager et Martin:
“Once invasion has occurred behavior
is always the same for all tumors.”17
Quant a la composante “systemi
que” de la malade cancereuse, elle a
fait l’objet d’etudes fort interessantes
qui sont en train de revolutionner la
therapeutique du cancer du sein et
de permettre un optimisme raisonnable pour ceux qui preconisent la con
servation du sein. Le concept de la
micro-metastase tel que decrit par
Schabel,19 l’equation “hote/tumeur”,
1’hvpothese des cellules “dormantes”,
sont aujourd’hui des theories appliquees a la therapie adjuvante.
Elies prennent une importance certaine puisque, quel que soit le traite
ment conventionnel utilise, le taux
de guerison demeure a peu pres in
change depuis pres de 30 ans. Com
ment peut-on accepter de maintenir

une politique d’attente et esperer que
la nature fera le reste, surtout quand
le pathologiste met en evidence les
signes d’un mauvais pronostic, lors
de l’examen du specimen. La disse
mination des cellules par voie veineuse peut et doit etre traitee au
moment du traitement primaire.
Il semble, par ailleurs, que la majo
rity des cancers du sein, au moment
ou ils se presentent, soient deja en
phase avancee.4 Plusieurs auteurs pensent que le cancer du sein est une
maladie systemique.
En 1958, le National Adjuvant
Breast Group20 mettait sur pied aux
Etats-Unis un programme de traite
ment adjuvant du cancer du sein,
faisant appel a une chimiotherapie a
base de thiotepa pour detruire les
cellules cancereuses delogees et disseminees par voie veineuse, lors de
I’operation. Apres plus de 10 ans
de recul, les resultats positifs de cet
essai viennent confirmer l’hypothese
de Schabel19 et Fisher.20
En ce qui concerne la radiothera
pie, il fut un temps ou elle etait un
complement essentiel de la radiothe
rapie. Apres l’etude de Paterson,21
elle fut releguer au cancer de stade
II. A l’heure actuelle, il semble qu’on
veuille en faire une therapeutique
preponderante et exclusive.
Pour un chirurgien, il semble para
doxal qu’alors que la chirurgie du
cancer du sein a tendance a devenir
conservatrice, la radiotherapie sem
ble vouloir prendre la direction opposee. En effet, la radiotherapie utilisee
il y a 10 ans a peine, semble consideree aujourd’hui comme inadequate.
On applique maintenant des surdosages au niveau du sein, soit par super
voltage, soit par implantation interstitielle dans la glande mammaire, on
agrandit les champs d’irradiation et
on propose meme une technique
comparable a celle utilisee dans le
traitement des lymphomes.
Quant a la castration prophylactique, chirurgicale ou radiologique,
popularisee par Nissen-Meyer,22 sa

T a b le a u 1— R e p a rtitio n th e o riq u e d e s c a n c e rs du s e in

Stade
1
a
b

FIG. 1— Protocole therapeutique 1965.
QSE = quadrant supero-externe, QSI =
quadrant superio-interne, QIE = qua
drant infero-externe et QII = quadrant
infero-interne.
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N a tu re b io lo giq u e
S a n s m e ta sta se (ra re )
A fo y e r u n iq u e
M u ltifo c a l

II

A v e c m e ta sta se s a u x
g a n g lio n s ly p h a tiq u e s
r e g io n a u x

III

A v e c m e ta sta se s d is se m in e e s
par la circ u la tio n
s a n g u in e
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Im p lic a tio n s th e ra p e u tiq u e s

G u e r is sa b le p a r tum orecto m ie
G u e r is sa b le p a r m a stectom ie
sim p le
G u e r is sa b le p a r m a stectom ie
ra d ica l ou p a r m astectom ie
sim p le a v e c ra d io th e ra p ie
re g io n a le
In c u ra b le p a r tra ite m e n t local
se u l; re q u ie rt un traite m e nt
a d ju v a n t p a r v o ie g e n e ra le
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place a ete mise en doute puisqu’elle
ne semblait que retarder l’apparition
des metastases; cependant, avec le
dosage des recepteurs hormonaux, il
semble que nous assisterons bientot
a une reprise de la castration chez
les patientes en pre-menopause, ayant
un cancer hormono-dependant.
Nous avons connu depuis notre
entree en pratique plusieurs de ces
changements, face auxquels nous
avons adopte une attitude d’adaptation. Nous avons tente de promouvoir
un meilleur traitement du cancer du
sein en participant aux programmes
nationaux. Voici comment cela s’est
traduit:
• Nous avons cesse de faire des
mastectomies radicales de type Halsted a partir de 1970.
• Nous avons exclu la radiotherapie postoperatoire dans les cancers
du siege externe ou central, quand
les ganglions n’etaient pas envahis
(stade I pathologique).
• En 1972, nous nous sommes
joints au groupe NSABP et avons
prescrit, lorsque cela etait possible,
des traitements par voie generate pour
les cancers de stade II pathologique.
• Progressivement, nous avons
augmente le nombre de mastectomies
segmentaires dans le cadre du proto
cole B-06 du NSABP.
Pour cette periode s’etalant de

1965 a 1979 (inclusivement), nous
avons retenu 402 dossiers rencontrant les criteres de traitement a
visee curative (tableau II). De ce
groupe, 258 cancers (65.6%) etaient
de siege externe (217 [55.2%] au
quadrant superieur et 41 [10.4%] au
quadrant inferieur), 49 (12.5%) de
siege central et 86 (21.9%) de siege
interne (62 [15.8%] au quadrant su
perieur et 24 [6.1%] au quadrant
inferieur). Pres de 65% des patientes
etaient agees de plus de 50 ans (fig.
2) et 84% etaient de stade I et II,
soit T1 a T2, NO a N + (tableau III);
86% des cancers etaient de type canaliculaire et 4% de type lobulaire.
Bien que notre pratique chirurgicale
se soit modifiee, 63% des operations
ont ete des mastectomies radicales,
27 % des mastectomies simples et
10% des mastectomies partielles
(tableau II).
Pour illustrer les changements de
technique operatoire nous avons calcule les courbes de survies pour les
patientes operees avant 1970 et pour
celles qui 1’ont ete entre 1970 et
1975.
Des 64 malades operees avant
1970, 43 (67.2%) ont survecu, exemptes de maladie, pendant 5 ans et
33 (51.6%) ont survecu pendant
plus de 10 ans. Des 223 malades
operees entre 1970 et 1975, 143

(64.4%) ont survecu sans recidive
pendant 5 ans; 1 des 223 patientes
n’a pas ete revue aux examens de
controle.
On constate done que, independamment de la methode utilisee et malgre
une tendance vers des interventions
plus conservatrices, notre taux de
survie a 5 ans s’est maintenu aux
environs de 63% (fig. 3).
Controverses des resultats

Ces resultats ne peuvent, a notre
avis, servir qu’a notre auto-critique.
II n’est pas dans notre intention de
vouloir utiliser notre propre expe
rience pour comparer, critiquer ou
inciter a un choix therapeutique, car
ce serait la tomber dans d’autres polemiques. En effet, trop souvent les
revues de litterature consistent a
mettre en parallele des choses fort
differentes qui n’aboutissent qu’a
alimenter les diversites d’opinions.
D'autre part, la consideration exageree que certains accordent a leurs
resultats personnels devient un ob
stacle majeur au travail de groupe.
La longue et penible experience du
Breast Cancer Working Group de

Tableau 11- Traitement chirurgical du cancer du sein
Periode
1965-1970
Type de
mastectomie

No.

Segmentaire
avec dissection
axillaire
sans dissection
axillaire
Simple
Radicale modifiee
type Madden
type Patey
Radicale (type
Halsted)
Total

3

1970-1980
No.

%
3.1

37

%
12.2

—

—

—

—

—

—

—

—

30
24

30.3
24.2

79
180

26.1
59.4

Total
No.

%

40

10

(16)

(4)

(24)
109
204
(85)
(119)

(6)
27.1
50.1
(21.1)
(29.6)

—

—

—

—

—

—

—

—

42

42.4

7

2.3

49

12.2

99

100.0

303

100.0

402

100.0

Age, ans

FIG. 2— Repartition en fonction de
Page des patientes ayant un cancer du

Tableau III—Classification TNM des cancers du sein (402 malades*)
Tumeur (T)

Ganglions (N + )

Classification

No.

%

T1
T2
T3
T4

135
201
51
13

33.7
50.3
12.7
3.3

Total

400

100.0

No.

%

52
110

38.5
54.2

—

—

_

_

*2, classification non precisee.
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FIG. 3— Courbe de survie chez 402
patientes ayant un cancer du sein.

/

THE CANADIAN JOURNAL OF SURGERY

281

l’lnstitut canadien du cancer est un
temoignage non equivoque de cette
attitude controversee. Apres 5 ans de
rencontres, il n’a pas ete possible de
conclure un essai therapeutique cana
dien pour le cancer du sein, chacun
des paticipants croyant posseder la
“recette” ideale.
Par ailleurs, la multitude des methodes devaluation scientifique des
resultats dans le cancer du sein porte
egalement a confusion. Comment
comparer des etudes oil Ton a utilise
la methode directe, la methode actuarielle, le taux de recidive/mortalite,
le taux brut ou le taux corrige. Aussi,
Ariel23 pouvait-il ecrire: “One can go
through the literature and find re
ports for practically anything one
wants to substantiate.”
Autre obstacle aux comparaisons
de resultats, les premisses sont souvent differentes et les sujets non com
parables. Ainsi, la plupart des statistiques de survie prennent comme
point d’entree dans l’etude, la date
du diagnostic ou celle du debut du
traitement a visee curative de la
tumeur primaire. Cependant, la date
a laquelle la patiente est regue en

Tableau IV— Etude retrospective des
problemes rencontres chez 252 patientes
mastectomisees
Probleme

No.

%

Aucun
Physique
Sexuel
Emotif
Social

44
194
34 1
79
27 1

17.5

Sans reponse

V

4

80.9

1.6

consultation ne coincide pas avec le
debut de la maladie; de plus, le temps
de dedoublement d’une tumeur et la
phase preclinique varient d’une malade a l’autre. MacKay et Sellers,24 par
exemple, ont montre que chez 145
patientes qui n’avaient regu aucun
traitement, le taux de survie a 5
ans, a compter du premier symptome
etait de 35.2%. Cependant, dans les
cas de tumeurs de stade I, ce taux
passait a 68.8%.
Controverses sur la qualite de la vie

Pendant des annees et encore aujourd’hui, nos discussions se sont
adressees a l’aspect “quantitatif” de
la survie et l’aspect “qualitatif” fut
laisse pour compte. Nous avons parle
trop souvent de taux de mortalite,
taux de recidive, taux de survie, tout
en negligeant d’evaluer la qualite de
survie ou la qualite de la vie.
Comme consequence, la profession
medicale doit faire face actuellement
a une controverse des plus importantes qui a ete etalee sur la place
publique par les femmes elles-memes.
Pour la patiente, l’experience d’une
mastectomie est un evenement catastrophique dont les consequences,
queique difficiles a evaluer, sont profondes, intimes et permanentes. La
balafre physique n’est que le temoin
de consequences beaucoup plus penibles que la patiente gardera pour
elle-meme. Dans une analyse retro
spective, nous avons pu realiser la
profondeur de la balafre chirurgicale.
Dans la periode postoperatoire im
mediate, un tiers des patientes ne
manifestent aucune reaction, quelques-unes avouant meme ne rien ressentir a la suite de la perte d’un sein.

Tableau V —Comparatif du comportement selon le degre de readaptation periode comprise
entre 0 et 1 an apres la mastectomie
Comportement
Considere que I’operation a porte
a tte in te a sa fem inite
C ra in t de ne plus plaire physiquement
a son conjoint
Ressent de la gene se montrer nue
Accepte que son conjoint caresse son
sein
D im inution des marques d’affection
de la part du conjoint
C ra in t que son conjoint repousse
ses avances
Changements dans la pratique des
relations sexuelles
P la isir ressenti etait different
In te re t pour les relations sexuelles
D im inution de la frequence des
relations sexuelles
Ressent de I’anxiete face a ses
futures relations sexuelles
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Inadaptee, %

Readaptee, %

Mesadaptee, %

74.4

77.8

87.5

73.6
60.5

82.4
88.2

93.8
93.8

75.0

62.5

34.2

64.7

87.5

40.5

58.8

62.5

48.6
2.7
94.6

70.6
29.4
82.4

100
50.0
62.5

56.8

82.4

100

56.8

82.4

100
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Cependant, des le retour a la maison,
la situation change radicalement. Une
fois seule avec sa cicatrice, la pa
tiente ressent profondement l’importance du geste ablatif (tableau IV).
Si le couple est stable et fort, l’epreuve peut approfondir l’amour conjugal
et la qualite des relations sexuelles,
Cependant, tel n’est pas le cas pour
un tiers des patientes qui voient leurs
relations amoureuses changees, sinon
abolies de fagon permanente (tableau
V). Et que dire de la celibataire qui
voit disparaitre 1’espoir d’une vie
sexuelle ou maritale.
Devant les sequelles psychologiques
permanentes et profondes de la mas
tectomie, nombreux sont ceux qui
pronent maintenant la preservation
du sein de fagon quasi inconditionnelle. Meme si plusieurs d’entre nous
sommes hesitants devant cette ten
dance au conservatisme, nous devons
nous demander quel serait le mini
mum therapeutique qui pourrait garantir une survie equivalente.
Cette controverse ne fait que commencer et forcera, nous en sommes
convaincus, les specialistes a repenser le traitement du cancer du sein.
Que dire maintenant des traitements adjuvants preconises aujourd’hui et qui sont loins d’etre sans
consequence sur la qualite de la vie.
Pourtant, peu d’etudes ont ete conduites a ce jour afin d’approfondir
cette question.
Enfin, mentionnons la polemique
qui s’est elevee autour du “consentement averti”. Celui-ci affirme le droit
legitime d’une patiente a etre pleinement informee et a consentir de plein
gre a recevoir le traitement qui lui
est propose. En ce domaine, le legis
la te s est en voie de trancher le
debat medical. En effet, depuis novembre 1979, l’Etat du Massachusetts
a statue, suite aux pressions des groupes feministes, que les malades souffrant d’un cancer du sein ont le droit
a une information complete sur tous
les choix therapeutiques qui sont medicalement acceptables. (The Montreal
Gazette, le 10 avril, 1980, p 75).
Conclusions

L’ensemble du debat se situe au
niveau de la glande mammaire et du
traitement de la tumeur primaire que
Ton voudrait, a juste titre, conservateur. Et pourtant c’est au niveau des
resultats sur “la vie” elle-meme de la
patiente que se jouera la partie. Qu’un
traitement efficace et curatif permettant de preserver la glande mammaire
survienne eventuellement, et toutes ces
discussions n’auront plus leur raison
THE CANADIAN JOURNAL OF SURGERY

d’etre. II faudra cependant que ce
traitement ne soit pas entache d’une
morbidite excessive et qu’il puisse offrir a la patiente une qualite de vie
respectable. D’ici la, il ne faudrait pas
que par humanisme on mette en peril
la vie d’une majorite de patientes qui,
par des methodes conventionnelles
quoique multilatrices, auraient pu esperer une guerison. C’est la le dilemme : pour sauver les seins, il ne fau
drait pas perdre trop de patientes.
A la lumiere de nos connaissances
actuelles, voici comment, a notre avis,
on devrait aborder le traitement du
cancer du sein :
1. Si la tumeur du sein est vrairnent localisee (stade I), le traitement
conservateur local, avec preservation
de la glande mammaire, parait logique. Cependant, nous savons que c’est
rarement le cas, qu’il existe la plupart
du temps des foyers multiples ailleurs
dans le sein et que l’examen clinique
de l’aisselle est inadequat. Avant de
limiter le traitement a l’excision tumorale, il faudra atteindre un degre de
certitude plus grand dans l’etablissement du stade de la maladie, utiliser
par exemple la lymphoscintigraphie de
la chaine mammaire interne, l’examen
anatomo-pathologique des adenopa
thies et, si possible, des marqueurs
biologiques.
2. A l’oppose, si la tumeur a depasse le stade de la guerison (stade IV),
il faut conserver le sein, en excisant
la tumeur, a moins qu’une mastectomie de proprete ne soit necessaire. Le
traitement doit etre par voie generale
et on doit eviter a la patiente le traumatisme psychologique de la perte
d’un sein.
3. Si la tumeur n’a pas depasse les
limites regionales (stade II), le traite
ment local doit etre complete d’un
traitement par voie generale parce que
les chances de guerison sont faibles.
Que la chirurgie ou la radiotherapie
soit utilisee comme traitement, il nous
semble superflu, cependant, que les
deux methodes soient employees de
fafon complementaire; quant au trai
tement par voie generale, le dosage des
recepteurs hormonaux devrait orienter
le choix entre l’hormonotherapie et la
chimiotherapie.
Il y a place pour la conservation du
sein dans le stade II, mais a la condi
tion que le stade soit bien etabli, que
la mammographie exclut la possibilite
de foyers secondaires, que la tumeur
primaire soit peripherique et de petit
volume, et que le sein soit d’un cali
bre suffisant pour permettre une re
construction valable apres une exci
sion assez large.
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Nous ne croyons pas qu’un therapeute puisse prendre de telles deci
sions seul; l'enjeu est trop grand pour
la patiente. La decision doit etre prise
en groupe lors d’une clinique des tumeurs.
Nous croyons par ailleurs que les
patientes ainsi traitees devraient etre
inscrites dans un protocole therapeutique national sans lequel une reponse
valable et rapide aux questions qui
ont ete soulevees ici ne pourra etre
obtenue.
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NOTICES
Clinical Application of
Hyperbaric Oxygen
The sixth annual conference on the
clinical application of hyperbaric
oxygen is scheduled for June 10-12,
1981 at the Memorial Hospital Medi
cal Center of Long Beach, University
of California, Irvine Center for Health
Education. This clinically oriented
conference will discuss the currently
accepted uses of hyperbaric oxygen
in plenary sessions, and will also in
clude original papers, workshops,
sound slides and scientific and com
mercial exhibits.
For further information, contact
Dr. G.B. Hart, Director, baromedical
department, Memorial Hospital Medi
cal Center, 2801 Atlantic Ave., Long
Beach, CA 90801.

Association of Surgeons
of South East Asia
The Association of Surgeons of South
East Asia is presenting its third bien
nial general scientific meeting June
18 to 20, 1981 at the Hotel Sari Pa
cific in Jakarta. This will be a 2 Vi-day
meeting which will include scientific
sessions dealing with surgical problems
of regional interest in South East
Asia.
The registration fee is US $30.00
for members and US $50.00 for non
members.
For further information please
contact Professor Raden Sjamsuhidajat, 6 Salemba Raya, PO Box 487,
Jakarta, Indonesia.
*

(continued on page 310)

283

•

r y y - . / f ....

Because “biphasic infection”
threatens to complicate surgery
of the large bowel...

control sepsis with
an antibiotic to arrest primary
gram-negative aerobic infection
in combination with

Product Monograph available on request.

DalacinC

Phosphate S.S.

(Clindamycin Phosphate Injection N.F.)

to treat or prevent
secondary abscess formation
, Rupture of the large bowel can result in contami
nation of surrounding tissues with gram-negative
pathogens initiating primary aerobic infection. While
' the primary infection often responds to a gram-negative
T antibiotic, e.g. gentamicin, secondary anaerobic
y vinvaders may persist and produce abscess formation,
r This“biphasic infection” process increases morbidity
, and delays recovery.
►

Dalacin C Phosphate IV during and following surgery to
control anaerobes such as Bacteroides fragilis, along with
' appropriate antibiotic therapy to control gram-negative
* aerobic pathogens, can prevent abscess formation,
reduce morbidity and speed recovery.
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Indications: Dalacin C Phosphate (clindam ycin phosphate in je c tio n N.F.) Dalacin C Phosphate Sterile Solution is indicated for the trea t
m ent of in fe c tio n s where the oral route is not indicated or feasible
C lindam ycin phosphate is in dicated in the treatm ent of serious in fe c tio n s due to sensitive anaerobic bacteria, such as Bacteroides
species, peptostre pto coccus, anaerobic streptococci, C lostridium species and m icro-aero philic streptococci.
C lind am ycin phosphate is also in dica te d in serious in fectio ns due to sensitive G ram -positive organism s staphylococci (includin g p e n ic il
linase-producing staphylococci), stre p to c o c c i and pneum ococci when the patient is intolerant of, or the organism resistant to, other
appropriate a n tib io tic s .
Contraindications: The use of Dalacin C Phosphate is contraindicated in patients previously found to be hypersensitive to this com pound,
the parent com pound, c lindam ycin , or clindam ycin palm itate. A lth ough cross-se nsitizatio n w ith Lincocin (lincom ycin) has not been
dem onstrated, it is recom m ended that Dalacin C Phosphate not be used in patie nts who have dem onstrated lincom ycin sensitivity. Until
further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn (infants below 30 days of age), or in pregnant women.
Warnings: Some cases of severe and persistent diarrhoea have been reported durin g or after therapy w ith Dalacin C Phosphate. This
diarrhoea has been occasionally associated w ith blood and m ucus in the s tools and has at tim es resulted in acute colitis . When endoscopy
has been perform ed, som e of these cases have shown pseudom em brane form ation.
If s ig n ifica n t diarrhoea occurs du rin g therapy, this drug should be disco n tin u e d or, if necessary, continued only w ith close observation.
S ign ifica n t diarrhoea occurring up to several weeks post-therapy should be managed as if antibiotic-associated.
If c o litis is suspected, ^ndoscop y is recommended. M ild cases show ing m inim al m ucosal changes may respond to sim ple drug dis 
continuance. Moderate to severe cases, including those show ing ulceration or pseudom em brane form ation, should be managed w ith fluid,
electrolyte, and protein supp lem entation as indicated. C o rticoid rete ntion enemas and system ic c orticoid s may be of help in persistent
cases. A n tic h o lin e rg ic s and a n tip e ris ta ltic agents may worsen the c ond ition. O ther causes of c o litis should be considered
Precautions: Dalacin C Phosphate, lik e any drug, should be prescribed w ith cautio n in ato p ic individuals.
The use of a n tib io tic s occasionally re s u lts in over-growth of non susceptible organism s - particularly yeasts. Should superinfections occur,
appropriate measures should be taken as dictated by the c linica l situation.
Since abnorm alities o f liver fu n c tio n te s ts have been noted occasionally in anim als and man, periodic liver function tests should be per
form ed during prolonged therapy. Blood coun ts should also be m onitored during extended therapy.
As w ith all a n tib io tic s , perform cu ltu re and sensitivity studies in c o n ju n c tio n w ith drug therapy.
C lindam ycin phosphate may be used in anuretic patie nts and patie nts w ith im paired liver function. The serum half-life c f clindam ycin
phosphate in patie nts w ith m arkedly reduced renal fu n c tio n is greater than that of the half-life of the com pound in normal patients. The
dose of clindam ycin phosphate should, therefore, be appropriately decreased. Haem odialysis and peritoneal dialysis are not effective
means of removing the com pound from the blood. Periodic serum levels o f clindam ycin should be determ ined in patients w ith severe renal
insufficiency.
Adverse Reactions: Local.
(a) Intram uscular In je c tio n s : Of 404 p atie nts treated w ith clindam ycin phosphate in tram uscula rly (with a solution containing 150 m g/m l),
six (1.5%) dem onstrated local reactions as follows: Two com plained of pain at the in je c tio n site, tw o dem onstrated induration at the in je c
tio n site and tw o developed sterile abscesses.
(b) Intravenous Infusion: Of 192 p a tie n ts treated w ith clindam ycin phosphate by intravenous in fusion, 14 (7.3%) dem onstrated local
reactions. Eleven patie nts developed s upe rficial thro m bo phleb itis and one patient developed both superficial and deep throm bophlebitis.
The m ajority o f these cases developed in conjunction w ith the use of in d w e llin g IV catheters and it is d iffic u lt to know how m uch the drug
contributed to the irrita tio n . Two p a tie n ts developed localized erythem a, sw e llin g and pain at the site o f the infusion.
Systemic Side Effects: Tw enty-eight p a tie n ts of 596 treated w ith clindam ycin phosphate by either the intram uscular or intravenous routes
developed system ic side e ffe c ts as fo llo w s:
Number o f Patients
Num ber o f Patients
H yp ote nsion...............................................................................................1
R a s h .............................................................................................................7
H y p e rte n s io n .............................................................................................1
U rtica ria ....................................................................................................... 1
Shortness o f B re a th ................................................................................. 1
P ru ritis ......................................................................................................... 1
S u p e rin fe c tio n *.........................................................................................4
Fever, L e u c o c y to s is ..................................................................................1
C ardiac a r r e s t* * .......................................................................................1
Nausea, w ith or w ith o u t v o m itin g .......................................................... 1
Bad or bitte r taste in m o u th ................................................................... 5
Diarrhoea (See also under “ W arnings’' ) .............................................. 4
'S uperinfection is a com p lic a tio n of a n tib io tic therapy in general and is not necessarily a true side effect of clindam ycin phosphate.
Due to underlying m yocarditis in this patient.
Clinical and Laboratory Findings: Patients treated during clin ic a l tria ls of clindam ycin phosphate were followed w ith c linica l laboratory
tests, including com ple te haematology, urinalysis and liver and kidney fu n c tio n tests. Some o f these tests were abnormal in itia lly and
returned to norm al during therapy w ith clindam ycin phosphate, w h ile others were norm al in itia lly and became abnormal during therapy.
Overall evaluation of c lin ic a l laboratory values in these patie nts does not in dicate that c lindam ycin phosphate therapy has a to xic effect on
the haem atopoietic, hepatic or renal system s. Transient elevations of serum transam inases have occurred in some patients, but other liver
function tests (alkaline phosphatase, serum bilirubin) have not show n any tendency to increase and there have been no clinica l signs of
drug-induced hepatic toxicity.
Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No s p e c ific antid ote is known. Doses as high as
1200 mg every six hours (4800 mg/day) by in fusion for five days have been given w ith o u t adverse effect.
DOSAGE AND ADMINISTRATION
Adults
Intram uscular Injectio n: 600 m g /d a y in tw o equal doses.
M oderately severe in fe c tio n s : 600 to 1200 m cj/day in tw o or three equal doses.
Severe in fe c tio n s : 1200 to 2400 m g /d a y in two, three or four equal doses. Intram uscular in je c tio n s o f more than 600 mg into a single site
are not recom mended.
Intravenous A d m in is tra tio n : Dalacin C Phosphate m ust be diluted prior to IV a d m in istratio n to a d ilu tio n of 300 mg in 50 ml of diluent
(6 m g /m l) or more, and in fuse d in not less than 10 minutes. A d m inistra tion of m ore than 1200 mg in a single one-hour infusion is not recom 
mended. Dalacin C Phosphate should not be in jected intravenously und ilu ted as a bolus.
M oderately severe in fe c tio n s : 900 to 1800 m g /d a y by contin uous drip or in tw o or three equal doses, each infused over 20 m inutes or longer.
Severe in fe c tio n s : 1800 to 2700 m g /d a y by continuous drip or in three or four equal doses, each infused over 20 m inutes or longer. In lifethreatening in fectio ns, doses o f 2700 to 4800 m g/day by contin uous drip or in three or fo u r equal doses each infused over 20 m inutes or
longer may be given.
Children: (Over one m onth o f age)
Intram uscular Injectio n: 10 to 15 m g /k g /d a y in two. three or four equal doses.
Moderately severe in fe c tio n s : 15 to 20 m g /k g /d a y in three or four equal doses.
Severe in fe c tio n s : 20 to 30 m g /k g /d a y in three or four equal doses.
Intravenous Administration:
M oderately severe in fe c tio n s : 15 to 25 m g /k g /d a y by contin uous drip or in three or four equal doses, each infused over 20 m inutes or
longer. In severe in fe c tio n s , it is recom m ended that children be given not less than 300 m g /d a y regardless of body weight. (Dilute Dalacin C
Phosphate Sterile S o lution in the same m anner as for adults.)
AVAILABILITY:
Dalacin C Phosphate Sterile Solution - Each ml contains clindam ycin phosphate equivalent to clindam ycin base 150 mg in 2 ml ampoules.
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Successful closure...
but the bleed won’t stop

AMICAR
(AMINOCAPROIC ACID]

The Clot Stabilizer
Inhibits excessive activity of plasmin
and plasminogen activators
Prevents excessive breakdown of
fibrin and fibrinogen
Stops bleeding because clots are
stabilized
Infusion of whole blood, fibrinogen,
and other measures may be used
concomitantly
Available in 3 form sIntravenous (5 gnt/20 mi);
Tablets (500 mg); Syrup (250 mg/ml)

AM ICAR
Aminocaproic Acid

Th e ra p e u tic C la s s ific a tio n — Antifibrinolytic
Agent.

Indications— Treatment of excessive bleeding
resulting from systemic hyperfibrinolysis and uri
nary fibrinolysis.
Contraindications-Active intravascular clotting.
The effects on foetal development are unknown. Do
not use during the first and second trimester of
pregnancy unless potential benefits outweigh
possible hazards.
Precautions— The drug should not be adminis
tered without a definite diagnosis and/or laboratory
findings indicative of hyperfibrinolysis. Rapid I.V.

administration should be avoided as it may induce
hypotension, bradycardia and/or arrhythm ia.
Caution should be used treating patients with car
diac, hepatic or renal diseases.
A d v e r s e R e a c tio n s — O ccasionally nausea,
cramps, diarrhea, dizziness, tinnitus, malaise,
conjunctival suffusion, nasal stuffiness, headache,
skin rash have been reported, but rarely has it been
necessary to reduce or discontinue medication be
cause of one or more of these side effects. As with
all I.V. medication, thrombophlebitis should be
guarded against.
D o sa g e - Oral tablets, syrup, I.V.— Initial dose S gms
followed by 1 -1 % gms hourly until bleeding Is con
trolled. Administration of more than 30 gms in any

24 hour period is not recommended, intravenous
administration should be by infusion over one hour.
Rapid I.V. injection of undiluted A M IC A R is not
recommended.
A v a ila b ility — Intravenous— 20 ml vial, Sgm s/
20 cc. R aspbe rry flavour s y ru p — 500 ml bottle,
250 mg/ml. Oral tabs, 500 mg.

Pull p re s c rib in g In fo rm a tio n a v a ila b le on
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3. Surgical Approaches to the Treatment of
Early Breast Cancer
J.L . H a y w a r d , f r c s *

Various methods have been explored
for treating early breast cancer
with conservation of the breast.
Although local recurrence increased,
early trials indicated that in patients
with clinical stage I disease (T1 or
T2 NO or N1a), wide excision and
radiotherapy of the breast and gland
fields resulted in the same distant
recurrence and survival rates as
the radical operation. It was suggested
that local control of the disease was
not important in the ultimate prognosis,
that minimal surgery incurred no
penalty and that breast cancer would
soon be treated by radiotherapy
alone.
Four recent developments affected
this forecast.
1. Assays of hormone receptors in
primary tumours give important
information on prognosis in early
cancer.
2. in clinical stage II disease (T1
or T2 N1b), limited surgery exacts
a penalty in terms of distant recurrence
and survival.
3. The number of involved axillary
lymph nodes must be known to
evaluate prognosis.
4. Adjuvant chemo- or endocrine
therapy is effective in patients with
extensive involvement of axillary nodes.
Currently, only modified radical
mastectomy effectively fulfils the
requirements resulting from these
developments.
Differentes methodes ont ete
explorees afin de traiter le cancer
au sein au stade precoce tout en
* D irector, Guy’s Hospital breast unit
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Fund, breast cancer unit,
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conservant la glande mammaire. Bien
qu'il y ait eu une augmentation du
nombre des recidives locales, les
premiers essais indiquent que, chez
les patientes ayant un cancer de
stade I (T1 ou T2 NO ou N1a), une
excision large et I'irradiation des
champs mammaire et ganglionnaire
ont permis les memes resultats que
I'operation radicale en ce qui a
trait aux recidives a distance et aux
taux de survie. II a ete suggere que
le controle local de la maladie n’avait
pas d’effet important sur le pronostic
ultime, qu’une intervention chirurgicale
retreinte n'entrainait aucun prejudice
et que le cancer du sein serait bientot
traite par radiotherapie seule.
Quatre decouvertes recentes ont
modifie cette prevision.
1. Le dosage des recepteurs
hormonaux dans la tumeur primaire
offre une importante information sur
le pronostic du cancer precoce.
2. Dans le cancer de stade II
(T1 ou T2 N1b), une chirurgie limitee
cause un prejudice en termes de
recidive a distance et de survie.
3. Le nombre des ganglions
lymphatiques axillaires doit etre
connu pour 1'evaluation du pronostic.
4. La chimiotherapie ou I'hormonotherapie adjuvante est efficace chez
les patientes ayant une atteinte
etendue des ganglions axillaires.
A I’heure actuelle, seule la
mastectomie radicale modifiee ren
contre efficacement les exigences qui
decoulent de ces constatations.
The modern history of surgery for
early breast cancer dates from 1894
when
Halsted*
described
radical
mastectomy. The principles of this
operation, in which the tumour, the
organ in which it lies, the draining
lymph nodes and the intervening tis
sues are removed en bloc, formed the
basis of cancer surgery for the sub
sequent half century. Until the early
1950s early breast cancer was man
aged almost exclusively by radical
mastectomy.
In the late 1940s the need for such
a radical operation was questioned.
Concern was based on two develop
ments. First, patients were presenting
V O L U M E 24, NO. 3, M A Y 1981
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with tumours at a much earlier stage.
Indeed, the patients described in
Halsted's original series' would now
be considered to have inoperable tu
mours. Second, effective radiotherapy
became available. Radiotherapy had
been available previously but in a
relatively primitive state and the use
of high doses had meant destruction of
large amounts o f normal tissue. After
World War II the development of
high-voltage machines made it pos
sible to treat tumours with a higher
dose o f radiation and largely to spare
the suirounding normal tissues.
Starting with McWhirter's series2 in
1948, a number o f reports suggested
that simple mastectomy with radical
radiotherapy to the axillary nodes gave
survival and recurrence rates similar
to those obtained with the radical oper
ation. Subsequently, clinical trials*1
compared these more conservative
procedures with radical mastectomy
and in each case it was apparent that
no gain accrued from the more exten
sive operation. The trend towards con
servatism continued and one trial5 sug
gested that, at least in clinical stage I
tumours (T l or T2 NO or N la ) wide
excision o f the tumour alone with
conservation o f the breast, followed
by radiotherapy, resulted in length of
survival and distant recurrence rates
similar to those of radical mastecto
my. Moreover in France and the
United States, series were reported6*7
in which radiotherapy alone was used
with only minimal excision of the
tumour and again the results were
similar to those obtained from more
radical procedures. About 10 years
ago it was generally forecast was the
days of the radical operation, if not
mastectomy itself, were numbered.
But since then four developments
have changed our approach to the
management o f early breast cancer.
1. It was demonstrated that assays
of hormone receptor sites, when car
ried out on the primary tumour, give
important information on prognosis in
early disease.8 This means that suf
ficient tumour must be removed at
the primary operation to carry out
this assay.
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2. In clinical stage II (T1 or T2
Nib) disease, wide excision with ina
dequate radiotherapy to the axilla
resulted in a higher frequency of
distant recurrence and shorter sur
vival than radical mastectomy.5 This
means that the efficiency of primary
treatment for patients with early
disease affects prognosis and local
control is essential. This was empha
sized by Host and Brennhovd9 who
found that patients with medial
tumours and involved axillary nodes
had a significantly diminished recur
rence rate and longer survival if the
internal mammary nodes were irra
diated. Again, this indicates that local
control is important.
3. Fisher and colleagues'0 showed
that not only is it important to know
whether the axillary lymph nodes con
tain malignant cells but also how
many nodes are affected. The more
lymph nodes that contain tumour, the
worse is the prognosis. When four or
more lymph nodes are involved, 50%
of tumours recur in 18 months and
80% in 5 years. This means that to
get full information on prognosis,
total axillary dissection is essential.
4. Bonadonna and colleagues" in
Milan and Meakin and associates'2 in
Toronto have demonstrated that, in
premenopausal patients, adjuvant che
motherapy or endocrine therapy can
significantly decrease recurrence and
probably improve survival. But, for
patients to be selected for these treat
ments, full information on axillary
node status is essential.
The primary operation must there
fore achieve the following. First, suf
ficient tumour must be removed to
allow a proper histologic and bio

chemical analysis; second, the opera
tion must provide effective local con
trol of disease; third, the operation
must be an effective staging proce
dure. To date, there is no firm evi
dence that local control can be
achieved by any treatment other than
mastectomy. Moreover, for the tumour
to be staged effectively, a full axillary
node dissection must be carried out.
Radical mastectomy is the only proce
dure that serves the dual purpose of
providing the information necessary
for the use of ancillary therapy and
effectively treating axillary metastases.
Thus, the management of early
breast cancer has turned full circle in
the past decade. To obtain proper
staging with control of local disease,
some form of radical mastectomy
seems essential. But no longer does
radical surgery entail the removal of
all of the pectoralis major muscle as
in Halsted's day. In the modern oper
ation, either the muscle is left intact
or only the portion of it that lies
behind the tumour is removed, giving
a cosmetic result very similar to that
obtained by simple mastectomy.
In the future, similar control and
staging information may be obtained
from lesser procedures. Trials are now
under way to test whether radiother
apy, using both internal and external
irradiation of the breast, achieves
local control of disease that is as good
as mastectomy. This therapy could be
combined with an axillary dissection
so that full staging information would
be obtained. Until the results of these
and other trials are known, a modified
radical procedure seems essential for
the effective management of most
patients with early breast cancer.
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SESAP III Question
514 . A 29-year-old woman has had a tender mass in the upper outer quadrant of the right breast for six weeks.
The mass became somewhat smaller during her last menstrual period but then increased in size again. The mass is
now 3 cm in diameter, smooth in contour, and slightly tender. The most appropriate next step would be

(A)
(B)
(C)
(D)
(E)

a mammogram
an excisional biopsy
an incisional biopsy
a needle aspiration
reexamination in four weeks

For the incomplete statement above select the one answer that is best of the five given.
For the critique of Item 514 see page 325 of this issue.
(Reproduced by permission from SE SA P III Syllabus : Surgical Education and Self-assessment Program N o. 3.
For enrolment in the Surgical Education and Self-assessment Program No. 3, please apply to the American Colledge of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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4. Steroid Receptors in Adjuvant Hormonal
Therapy for Breast Cancer
J.H . G oldie , md , fr c p [c ], N. B ruchovsky , md , ph d , fr c p [c ],
A .J. COLDMAN, MA AND G.A. GUDAUSKAS, PHARM D

Using a computerized mathematical
model the authors found that either
a small (5%) or large (50%) hormonedependent reduction in tumour cell
population at the beginning of adjuvant
chemotherapy for breast cancer
greatly increases the probability of
achieving a cure. The fact that even
a minor response to hormonal therapy
early in the treatment of the tumour
is effective underlines the importance
of using estrogen receptors to select
potential responders in whom a cure is
at least a strong theoretical
possibility.
A I'aide d'un modele mathematique
programmable, les auteurs ont montre
qu'une diminution hormono-dependante
legere (5%), ou bien importante
(50%), de la population cellulaire
tumorale coincidente avec un
traitement chimiotherapique adjuvant,
augmente considerablement les
probabilites de guerison. Le fait
qu’une reponse, meme faible detectee
lors d’une therapie hormonale
entreprise sans delais dans I'histoire
de la tumeur, s'avere aussi effective,
souligne I'importance de mesurer
les recepteurs pour oestrogenes.
En effet, cela permettrait de
selectionner les patients pour lesquels
la guerison est, pour le moins
theoriquement, probable.

Oophorectomy is effective in tempo
rarily arresting the advance of breast
cancer in many premenopausal women
with advanced disease.1 Not infre
quently, inoperable breast cancer in
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postmenopausal women is mitigated by
removing other endocrine glands or by
giving hormonal agents, the most use
ful being compounds with estrogenic
or antiestrogenic activity.1 Whether
the withdrawal or replacement of hor
mones at a much earlier stage of
disease can delay recurrence or in
crease longevity has been examined in
several clinical trials carried out dur
ing the past two decades; in none of
these was a role for adjuvant hormonal
therapy clearly defined.2-3 It can be
argued persuasively that the impact of
prophylaxis needs to be reassessed in
patients whose tumours are positive
for the estrogen-receptor phenotype.
On the other hand, there is only a
small chance that such a study could
now be completed owing to the strong
appeal of alternative therapy with
combinations of hormones and drugs.
In this paper we consider the degree
to which new strategies will be in
fluenced by the measurement of
steroid-hormone receptors.

Adjuvant Hormonal Therapy

Adjuvant hormonal therapy has
been limited almost entirely to the
ablation of ovarian function either by
irradiation or surgery, immediately
after mastectomy. Cole19 reported that
ovarian irradiation definitely delayed
the onset of the first sign of reac
tivated disease but did not significantly
prolong survival. Similarly NissenMeyer20 found that surgical oophorec
tomy or ovarian irradiation increased
the symptom-free period as well as
the duration of survival, but the im
provements were slight. Using ovarian
irradiation prophylactically, Meakin
and colleagues21 demonstrated an ap
parent delay in recurrence and in
creased longevity that were not statisti
cally significant. However, small doses
of prednisone given at the time of
ovarian irradiation significantly de
layed recurrence and prolonged sur
vival in premenopausal women over
45 years of age. Contrary findings
have been presented by Nevinny and
Clinical Use of Steroid-Hormone
associates22 and Ravdin and col
Receptors
leagues;23 neither randomized study
At the start of hormonal therapy for found evidence that prophylactic
breast cancer, the physician should oophorectomy lengthened the time
bear in mind that the probability of from mastectomy to recurrence or de
achieving a response increases with the layed death. In a related investigation
amount of estrogen receptor present4"6 Kennedy and associates24 noted that
and that patients with receptor-positive the total duration of survival from ini
tumours remain disease free for longer tial breast cancer therapy to death
than do patients with receptor-negative was not significantly affected by the
tumours.5-7"12 The prolonged disease- timing of the oophorectomy.
That no consistent promising trends
free interval appears to be explained
by the smaller growth fraction asso have resulted from prophylactic
ciated with tumours that are receptor- oophorectomy has justifiably discour
positive.13"15 Not only do these findings aged its use in premenopausal women
imply that the tumour burden in with early breast cancer. Nevertheless
creases more slowly in patients with the concept remains valid and is at
receptor-positive disease, but they also tracting renewed interest because of
suggest that adjuvant chemotherapy two recent developments— the meas
would be more effective against urement of estrogen receptors as a test
tumours that contain estrogen recep of hormonal sensitivity and the introd
tors. Results obtained by Kiang and uction of antiestrogenic compounds.25
associates16 are consistent with the For patients with tumours that are
latter thesis while those of Lippman positive for estrogen receptors, im
proved therapies can be designed to
and associates17 are not.
No relation has been found be take advantage of the associated
tween the presence or absence of pro higher response rate and longer dis
gesterone, androgen or glucocorticoid ease-free interval. With the introduc
receptors and the disease-free inter tion of the estrogen antagonist, tamox
ifen, adjuvant hormonal therapy can
val.18
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now be contemplated for postmeno
pausal women with hormone-sensi
tive disease. Since the incidence of
major side effects associated with the
use of tamoxifen is low,26 this agent
may be applicable to the preoperative
management of both premenopausal
and postmenopausal patients in whom
very early control of tumour growth
would be desirable.
Although prospects for more effec
tive adjuvant hormonal therapy have
clearly improved, still there is no evid
ence to support the idea that this ther
apy alone will cure patients with
breast cancer.
Combinations of Drugs and Hormones

The cautious use of single agents to
treat advanced breast cancer touched
off a succession of therapeutic inno
vations designed to maximize the clin
ical effectiveness of cytotoxic chemi
cals.
• Whereas single agents induce re
gression of tumours in 20% to 35%
of patients, drug combinations can
double this response rate and induce
a complete remission in 4% to 31%
of cases.2
• Chemotherapy is no longer un
dertaken as a last resort to control
advanced malignant tumours. As a

FIG. 1—Hypothetical treatment sched
ule. Chemotherapy alone.

Hormone (+)

FIG. 2— Hypothetical treatment sched
ule. Initial cycle of hormonal therapy
followed by chemotherapy.
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result of mounting awareness of the tions. We also assumed that the hor
serious consequences of micrometas- monal treatment is effective against
tases, the potential value of chemo both drug-sensitive and resistant cells,
therapy started before gross metastatic but that the quantitative effect of the
disease develops is being empha hormone is limited to a specific total
sized.2,3,27
fractional cell kill of the tumour popu
• The need to prevent or delay lation (i.e., 0.5 log, 0.1 log etc.).
the emergence of drug-resistant tu
In this model, cure is defined as the
mour cells has been met in part by eradication of the entire tumour with
the use of two or more non-cross-re out the production of a mutant cell
sistant treatments administered in al that is resistant to both drug treat
ternating sequence, usually at monthly ments. For example, eradication of the
intervals.28,29
tumour with 18% probability means
• Methods are being sought to ex that in 18% of cases no doubly re
ploit the different ways that hormones sistant (to both drugs) cells will have
and drugs cause cell death. The lethal formed. In the other 82% of cases,
effects of hormonal therapy are prod a doubly resistant cell will have devel
uced by autophagic lysis of cells30 and oped and cure will be impossible.
those of chemotherapy chiefly by in
For the analysis of the hypothetical
terrupting DNA replication.28 Being treatment schedules the following
independently active and not cross-re measurements were used: (a) tumour
sistant, hormones and drugs should be mass is 106 cells; (b) doubling time
more destructive when given together is 30 days; (c) chemotherapy is given
than alone. Recommendations con as an alternating sequence of two dif
cerning the best combinations hinge ferent treatments administered every
upon the outcome of several ongoing 21 days for 15 cycles; (d) fractional
trials,28 and logically such treatment cell kill is 10"1 per cycle; (e) rate of
may be especially applicable to pa resistance to first treatment is 10"4;
tients who have early breast cancer (f) rate of resistance to the second
and whose tumours contain estrogen treatment is 10'3; (g) all cells are
sensitive to hormonal therapy.
receptors.
We found that chemotherapy alone
Computer Simulation of the Effects of will eradicate the hypothetical tumour
Combined Drug-Hormone Therapy
after 13 treatments with an 18%
Using a computerized version of the probability of cure (Fig. 1).
The first schedule consisted of an
mathematical model formulated by
Goldie and Coldman31 for relating the initial cycle of hormone therapy fol
drug sensitivity of tumours to their lowed by several drug treatments. In
spontaneous mutation rate, we anal the event that the hormone reduced
ysed three different schedules of drug the tumour burden by 5% , the com
and hormone administration to learn bination of hormone and drugs de
whether any one would prove superior stroyed the tumour after 14 cycles of
to the others.
therapy with a 12% probability of
We made two basic assumptions in cure (Fig. 2). The probability of cure
applying the model: that we have two rose to 18% if the initial response
drug-resistant subpopulations of tu to hormonal therapy reduced the tu
mour cells and that we have available mour burden by 50%. In this exam
two non-cross-resistant drug treat ple, the outlook is compromised by
ments. Each treatment is effective the delay in starting chemotherapy.
against the drug-sensitive tumour cells
The second schedule provided for
and one of the resistant subpopula- an interruption of chemotherapy at
the ninth treatment when hormonal
therapy was interposed. If a 5% re
duction in tumour burden occurred at
that time, the total number of treat
ments required for the tumour to be
eliminated was 14 and the probability
of cure 10% (Fig. 3). If hormonal
therapy reduced the malignant cell
population by 50%, the number of
cycles for successful completion of
therapy did not change, but the prob
ability of achieving a cure increased
to 18%.
In the third schedule, combined
hormonal
and chemotherapy were
FIG. 3—Hypothetical treatment sched
ule. Interruption of chemotherapy by given at the start. If the tumour cell
population was decreased 5% by horhormonal therapy at ninth treatment.
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monal therapy, the tumour would be
eradicated after 13 treatments with a
64% probability of cure (Fig. 4).
Should the hormonal therapy produce
a 50% reduction in tumour burden,
the tumour would be eradicated after
only 11 treatments with a 79% prob
ability of cure.
From this analysis we infer that a
combination of drug-hormone ther
apy is likely to be most effective
when both modalities are started
simultaneously as early as possible,
perhaps in conjunction with, or even
before, primary treatment. The reason
why the early simultaneous addition
of hormonal treatment has such a
marked effect on the probability of
cure is related to the effect of the
treatment on the two drug-resistant
subpopulations. The probability of a
doubly resistant cell developing is
critically dependent on the size of the
single drug-resistant cell compart
ments. Even a relatively small frac
tional reduction in the size of these
compartments when they are at their
maximum size (i.e., at the start of
treatment) will greatly reduce the
probability of a doubly resistant
mutant appearing subsequently.
It should be emphasized that these
marked effects of additive hormonal
therapy become apparent only when
the chemotherapy itself is effective
and capable of producing cure in at
least a small percentage of cases. The
model predicts (results not shown)
that if the hormonal therapy is used
concurrently with an ineffective drug
regimen, then the effect of hormonal
treatment becomes minimal producing
only relatively small increases in per
centage and duration of response. Thus
we infer that additive hormonal ther
apy should be most effective in the
adjuvant
chemotherapy
situation,
where treatment has a definite prob
ability of cure.

Hormone ©

FIG. 4—Hypothetical treatment sched
ule. Combined hormonal and chemother
apy given at onset.
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Clinical Experience with Combination
Drug-H orm one Therapy

The increasing tendency to treat all
premenopausal patients with chemo
therapy when metastatic disease first
becomes manifest has provided op
portunities to evaluate the combined
effects of oophorectomy and chemo
therapy. Data obtained from several
such studies suggest that the response
rate and duration increase when with
drawal of estrogen coincides with drug
administration.32'36 Better results have
been obtained when chemotherapy has
been started early after oophorectomy
rather than late;34 moreover, little
seems to be gained if chemotherapy
is withheld until there is a clear-cut
response to hormonal therapy.37 The
fact that all clinical studies using a
combined approach have been carried
out in premenopausal women with
widely disseminated disease may ex
plain why the results of therapy have
been inconsistent.2'3 Since it is impos
sible to compensate for extreme varia
tions in the size and distribution of
the tumour burden, the likelihood of
uniformly observing a significant re
sponse in such patients is indeed re
mote; on the other hand, since meas
urable differences are regularly
observed, there is good reason to be
optimistic about the success of future
therapies. As suggested by our mathe
matical analysis, an amendment to
current protocols that might prove
beneficial is to start systemic treatment
with drugs and hormones early, when
the tumour burden is smallest and
most amenable to complete eradica
tion.
Summary and Conclusions
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5. Adjuvant Therapy for Breast Cancer
R .G . M a r g o l e s e ,

After several decades in which the
scope and intensity of regional
therapies increased, without a
corresponding increase in cure rates,
attention has turned to systemic
treatments. Adjuvant therapy for
carcinoma is used in an attempt to
destroy micrometastases thus
preventing the development of clinical
metastases. Initial results have been
encouraging and an understanding of
tumour cell kinetics has led to the
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use of better schedules and
combinations of drugs that have
substantially decreased the probability
of treatment failure and prolonged
survival compared with the results of
operation alone.
Apres plusieurs decennies ou I'etendue
et I'intensite des traitements
regionaux se sont accrues sans qu'on
constate une augmentation correspondante des taux de guerison,
I'attention s'est tournee vers les
traitements par voie generate. Le
traitement adjuvant du cancer par voie
generate est utilise dans I'espoir
de detruire les micrometastases et
de prevenir, de la sorte, I'apparition
des metastases cliniques. Les premiers
resultats sont encourageant et une
connaissance de la cinetique des
cellules tumorales a permis I'utilisation
de meilleurs schemas de prescription
et de meilleures associations
mecamenteuses qui ont diminue la
probability d'un echec de traitement
et produit une prolongation marquee
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de la survie comparativement aux
resultats de I'operation seule.

Patients in whom clinically apparent
metastases develop after primary sur
gical treatment for breast cancer are
rarely cured. One aim of treat
ment for primary breast cancer
must be concerned with salvaging
those patients not cured by initial
surgery. Historally, operations more
extensive than the Halsted mastectomy
were devised in an attempt to improve
cure rates by removing more of the
potentially involved lymphatic tissue.
The reasons why these operations were
unsuccessful was for a long time not
fully understood or examined. Later,
radiotherapy was added postoperatively as an adjuvant to radical sur
gery in an effort to extinguish any
small residual foci of cancer cells in
the lymph nodes that the surgeon
might have missed. Several large trials
have shown that adjuvant radiother
apy is similarly futile and the im 
portance of the regional lymphatics
293

has become increasingly controversial.
In a prospective trial designed to
evaluate the role of the regional lym
phatics in breast cancer, the National
Surgical Adjuvant Breast Project
(NSABP), protocol B-04, showed that
outcome is not altered by any treat
ment of axillary lymph nodes.1 In this
protocol patients were treated by
radical mastectomy, total mastectomy
with axillary irradiation, or total
mastectomy alone with removal of
axillary lymph nodes subsequently if
they became affected by the disease.
All three groups had the same 5-year
recurrence and survival rates.
These results are, in a sense, com
plementary and reveal that local
control of the cancer is but one aspect
of treatment and must be differen
tiated from the problem of controlling
distant disease. Enlarging the scope of
local treatment by more aggressive
surgery or by adding adjuvant radio
therapy does not increase the cure
rate and conversely, leaving axillary
nodes untreated does not decrease the
cure rate. Patients whose axillary
nodes are involved by tumour have a
much poorer prognosis than those with
negative nodes regardless of the type
of operation performed. Thus, in
volved lymph nodes are an indication
of metastatic disease but not the
source of it. Because local treatment
of these nodes does not decrease the
frequency of metastatic disease it
cannot increase cure rates. But the
finding of tumour in axillary nodes
does identify those patients likely to
harbour occult systemic disease. This
can help select patients for adjuvant
treatment.
To determine relative risk, pathol
ogical staging is far more accurate
than clinical staging. It gives a better
indication of the true gravity of the
problem. Patients whose nodes are
disease-free (stage I) have a favour
able recurrence rate, but the failure
rate in patients with involved nodes
(stage II) is 76% at 10 years. The
latter group can be subdivided into
patients with only one to three nodes
involved who have a 64% recurrence
rate and patients with four or more
nodes involved who have an 86%
recurrence rate at 10 years. Clearly,
patients with positive nodes deserve
ancillary treatment. A comprehensive
treatment plan should involve local
therapy for control of local tumour
and systemic therapy for patients at
risk for metastatic disease.
Much of the rationale for the use
of chemotherapy in this setting has
been demonstrated by Schabel.2
The smallest clinically palpable
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tumour is approximately 1 cm in
diameter. (Nonpalpable tumours of a
slightly smaller size can be found by
mammography, but the majority of
these are carcinoma in situ, and me
tastatic disease is very rare in such
cases.) Although a 1-cm tumour seems
small, cell doubling times in breast
cancer show that such a tumour may
be from 3 to 10 years old, certainly
not an early tumour in a biologic
sense. A tumour will go through 30 or
35 doublings to reach this clinically
detectable size. If, at any lime in its
history, metastatic foci were seeded,
such metastases may also be small,
but not early, at the time the
primary tumour is diagnosed and
treatment instituted. A tumour 1 mm
in diameter may contain a million
cells and as such probably constitutes
a lethal load of disease if untreated. It
is fair to assume that such foci are
indeed the cause of later failures in
patients whose initial operation was
apparently successful. Obviously pa
tients who demonstrate visceral or
bony metastases several years after
the primary operation had these or
other metastases before the procedure,
but they were undetected due to their
small size. It is postulated that early
treatment might eliminate these micrometastases and thus result in cure of
the patient who would otherwise have
recurrent tumour and a fatal outcome
at some future date.
The results of experiments per
formed by Schabel2 confirmed that
hypothesis. Mice or hamsters were
injected with a 25-mg fragment of
transplantable tumour and divided
into four
groups: (a) control
animals, (b) those who underwent sur
gical removal of the tumour at 14
days, (c) those who received chemo
therapy at 14 days and (d) animals
treated by both surgery and chemo
therapy at 14 days. While surgical
removal or chemotherapy alone failed
to prolong life significantly when com
pared with control animals, surgery
and chemotherapy combined resulted
in a substantial number of cures.
Thus, the surgery that failed to cure
because of metastatic disease and the
chemotherapy that failed to control
the total load of metastatic and
primary tumour, could together con
trol the primary tumour and the min
imal microscopic metastases.
This experiment can be applied to
human patients by combining tradi
tional surgery with postoperative
chemotherapy. The first such study,
initiated in 1958 by the NSABP,3 used
thiotepa during the course of the sur
gery and for 3 days postoperatively.
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Although this treatment was designed
to minimize metastases resulting from
surgical manipulation and dislodgement of cells into the circulation, it
was soon recognized that this was a
minor, if not negligible cause of me
tastatic disease and that most me
tastases were already present long
before the surgery took place. The
thiotepa study did show a small im
provement in survival among one sub
set of patients: premenopausal women
with four or more axillary nodes
containing malignant cells, but other
groups of patients were not helped by
the drug. We now know that the
choice and schedule of drug were
wrong. However, if minimally positive
results could be obtained on this basis,
further improvement should result
from a more specific program.
A more modern study, begun in
1971,4 incorporated ideas derived
from better understanding of the for
mation of metastases and the kinetics
of tumour cell growth. Based on the
understanding of prolonged cell-cycle
times, a program of continued, cyclic,
high-dose therapy with an alkylating
agent was used. Patients were chosen
at random to be treated by placebo
or L-phenylalanine mustard (l -PAM)
in 6-week cycles of intensive therapy.
This study showed a remarkable im
provement in disease-free survival for
premenopausal women compared with
controls treated by surgery alone.4
Since the study demonstrated an ad
vantage of treatment, the placebo arm
has been dropped. The study has been
continued to compare results in pa
tients receiving l-PAM with those in
patients receiving l-PAM plus 5fluorouracil (5-FU) to determine
whether two drugs are better than one,
and if toxicity is any greater with two
drugs.
With the use of the two-drug re
gimen, it appears that postmenopausal
patients are also deriving some bene
fit; they have shown a decreased rate
of treatment failure and an increased
survival rate, compared with l -PAM
alone, and with the original control
group.5 Further studies comparing
three drugs, l -PAM, 5-FU and metho
trexate to the original two drugs have
resulted in similar findings.5 The most
recent studies are using three-drug
combinations of l -PAM, 5-FU and
tamoxifen, or l-PAM, 5-FU and
Corynebacterium parvum. These stu
dies are too recent to provide any
evaluable results and more time will
be needed before they can be reported.
It is hoped that with better combina
tions of drugs, the initial improve
ment seen with l-PAM alone will be
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extended, and that the prolonged dis
ease-free survival currently being de
monstrated will, in the final analysis,
be a true increase in overall survival.
If so, it would be the first demonstra
tion of enhanced survival with ad
juvant therapy in primary breast can
cer. In this case, more patients will
have survived owing to the addition
of chemotherapy to standard surgery
than would have survived following
the standard surgical procedure alone.
Thus, a modern treatment strategy
for breast cancer involves: (a) control
of the local tumour, and (b) systemic
treatment to control all distant meta
static disease.
Involvement of lymph nodes by
tumour is a marker for the probable

existence of metastatic disease. More
specific markers would be useful apd
would help ensure that adjuvant ther
apy would be given to those patients
who most needed it, whether they
had clinical stage I or stage II breast
cancer. It is hoped that better iden
tification of patients at risk and better
drugs or drug combinations will fur
ther improve these preliminary results.
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6. Panel Discussion: Part I
Panelists:

Chairmen: L.J. D i o n n e and J.W. M e a k i n *
D.M. B o w m a n ,! N. B r u c h o v s k y , J.L. H a y w a r d , R.G. M a r g o l e s e

Dr. Meakin: Mr. Hayward, I would

like to start the discussion with a ques
tion on surgical principles in the man
agement of breast disease, before the
diagnosis of classic cancer of the
breast has been made. What is your
view on the role of prophylactic sub
cutaneous mastectomy in the manage
ment of a person who presents with a
family history of breast cancer or who
has had repeated episodes of benign
breast disease in which biopsy speci
mens have shown some degree of
atypia?
Mr. Hayward: It is, of course, a situa

tion in which you have to weigh two
things, one against the other. One is
the risk of breast cancer developing,
which, in the situations that you de
scribe, is probably greater but not ma-

terially greater than normal. You have
to measure that against the apprehen
sion and anticipation of the patient,
the considerable morbidity associated
with the operation and, on many occa
sions, the relatively poor cosmetic
result of subcutaneous mastectomy
and prosthetic replacement. I don’t
think there is any general rule. There
are patients at high risk whose lives
are dominated by the worry of breast
cancer for whom, although consider
able morbidity may be anticipated,
this procedure is quite right—and it
will transform their lives. On the other
hand, I think this operation is being
done for rather trivial reasons. Yes,
there is a place for it, but for selected
patients and all these features should
be taken into account.
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Question from the audience: I wish to
address two questions to Mr.
Hayward. What would be your com
ment on the proposition that, if one
removes the lower axillary nodes in
continuity (that is those below the
lower border of the minor pectoral
muscle), one has enough tissue for
staging and, if these nodes are normal,
what is the incidence of positive nodes
higher up? My second question is, do
you recommend that to clear the axilla
properly, one must follow David
Patey’s operation detaching the minor
pectoral muscle from the coracoid
process?
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Mr. Hayward: 1 think that a biopsy of
the lower axillary nodes gives you the
worst of both fields. First, it has been
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shown to be inaccurate. You will miss
positive nodes in the axilla in 10%
of patients by doing this. Second, if
you do this and find positive nodes,
you then have to irradiate the axilla.
If you do not find positive nodes, you
will still worry about the 10% that
might be there. The advantage of axil
lary clearance is that not only does it
give you absolutely accurate staging
information but it also treats the axilla
so radiotherapy is not needed later.
As far as the minor pectoral muscle
is concerned, personally, I can’t do a
proper axillary dissection if I leave
the minor pectoral muscle behind.
Dr. Dionne: I think, in general, for a
surgeon who does few mastectomies,
the Patey operation is difficult and the
clearance of the axilla when you re
move the minor pectoral muscle is
much easier but it is still much more
difficult than to clear the axilla when
you do a Halsted operation. So, I firm
ly believe that you should remove all
the nodes. The treatment will differ if
the nodes are not invaded and, if you
want to know the exact answer for
all cases, I believe you have to do a
complete dissection.
Dr. Margolese: I’d like to add a little

of the opposite point of view. Dr.
Edwin Fisher who is the project
pathologist for the National Surgical
Adjuvant Breast Project (NSABP)
has done a careful review of the
errors in staging and it does not
seem to matter whether 5 or 35 nodes
are in the specimen. The errors and
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the accuracy seem to be the same.
That does not mean that one should
do a sloppy biopsy of those few nodes
near the tail of the breast but it seems
to me, from interpreting these data,
that one could do a successful staging
operation without necessarily re
moving the minor pectoral muscle.
Our technique is to leave this muscle
and carefully to expose the other
structures in the axilla, namely the
two main nerves, as well as the axil
lary vein, and to clean off everything
inside those boundaries. That does not
get the so-called apical node but, of
course, this node is nothing more than
the highest one we can reach. I think
the figures show that our accuracy is
sufficient for determining who should
receive chemotherapy.
Mr. Hayward: We may as well have
a decent argument here. As you say,
you probably leave a few nodes
behind, some of which may be posi
tive. Now, on the assumption that one
of our aims is to prevent local recur
rence of disease, do you give radio
therapy?
Dr. Margolese: No.
Mr. Hayward: So you leave active
disease in the axilla in a number of
cases knowingly?
Dr. Margolese: Well, not knowingly.
We leave some lymph nodes at the
apex but, when you take out the
minor pectoral muscle, you also
leave some nodes—those that are
just behind the clavicle or the costo
clavicular junction. If you look at the
anatomy books, you’ll see that the
clavicle is a surgical anatomical limit
but not the end of the lymphatic
chain. I think if you do the kind of
dissection I talked about and you
recover 15 to 30 nodes, you should
consider that as good as 31 to 40
nodes.
Question from the audience: I’d like
to address myself to Mr. Hayward
and Dr. Margolese. Mr. Hayward,
I think that in your study the patients
who did not have radical dissection
of the axilla had more local recur
rences because irradiation was not
sufficient. What do you do when the
patient has a local recurrence? Dr.
Margolese, will the survival be af
fected if nodes left behind are treated
adequately later?
Mr. Hayward: Well, one can only
report what one finds. If we get a
recurrence in the axilla, the patient
either undergoes a straight direct
axillary clearance or a radical mastec
tomy. There is no question of leaving
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disease behind and not treating it and
I can only say that, not only did it
happen in that first series, but in a
second series with a completely new
set of patients precisely the same re
sults were obtained; the patients who
were inadequately treated locally, died
earlier.
Dr. Margolese: Can I amplify? The
question of local recurrence is vexing
because some local recurrences are
probably local residual disease and
many others are probably circulating
disease in which the local recurrence
is just a part of the overall picture. In
the NSABP study which I showed,
about 400 patients were treated
by simple mastectomy alone with
out dissection of the axilla unless
axillary involvement by tumour de
veloped subsequently. The incidence
of axillary recurrence in these patients
was higher but the survival did not
differ from patients who had radical
mastectomy. In the study that Mr.
Hayward showed, there was, of
course, a difference in survival, al
though it was not statistically signif
icant. It struck me, however, that the
5- to 10-year survival rates for radical
mastectomy were far better than those
we see in this country. Now admit
tedly Mr. Hayward's patients had
clinical stage II disease and ours had
pathological stage II but, beyond that,
I wonder if Mr. Hayward has any
explanation for what seems to be a
better survival in the radical mastec
tomy group than we see in stage II
disease.
Mr. Hayward: No. These were totally
unselected patients; any patient who
had what we termed operable disease,
that is, patients with or without
palpably involved axillary nodes were
entered into the first part of this trial
when we compared stage I and stage
II disease. I have no reason what
soever for saying, if this is so, that our
total group of patients who had radical
mastectomy did better than they would
be expected to do here in America.
Dr. Margolese: The two radical
mastectomy groups cannot be com
pared because ours are pathologically
staged.
Mr. Hayward: Yes, not all our pa
tients could be pathologically staged.
Those who had. radical mastectomy
could but those who had wide excision
couldn’t be because the axilla was
never touched. But there really was no
patient selection at all. These were
straight sequential patients coming to
one unit’s breast clinic over a number
of years.
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Dr. Margolese, I would like to
comment on your statement that the
survival figures for patients whose
axilla was untouched but who were
treated for recurrence did not differ
from those for patients who had
radical mastectomy. Our patients have
been followed up for nearly 20 years
whereas the follow-up of the NSABP
study is, I think, only 5 years.
Dr. Bowman: Just to prolong the
axillary dissection debate a moment
longer, Dr. Margolese pointed out that
the error in clinical staging was not
related to the number of nodes that
the pathologist examined, from 1 to
30 or so; furthermore, when I asked
Dr. Edwin Fisher about the local re
currence rates in each of those groups,
the local recurrence rates in the
NSABP experience were the same. I
would like to ask two simple ques
tions of each of my three surgical col
leagues. First, are there currently any
patients for whom you believe Halsted
radical mastectomy should be per
formed? Second, in those patients
who are not eligible, for whatever
reasons, for ongoing clinical trials,
what is the procedure that each of you
recommends?
Mr. Hayward: Do you really mean the
Halsted operation? If you mean with
total removal of the pectoral muscles,
I don’t think anybody does it. I don’t
do this operation at all now. For other
than in-situ carcinoma, of either
lobular or intraductal type, I know of
no patient in whom I can, with ab
solute confidence, do anything less
than a total mastectomy with axillary
clearance. In patients who are not en
gaged in clinical trials my standard
procedure is the same.
Dr. Margolese: The question reminds
me of a story about three baseball
umpires of different ages who are
comparing their approach. The young
one says “The pitcher throws in the
ball and those that are strikes, I call
strikes and those that are balls, I call
balls.’’ The slightly more experienced
fellow says, “You’ve got it wrong—
those that look like strikes you call
strikes and those that look like balls,
you call balls.” The wise old veteran
stops them both and says, “Look, the
pitcher throws them in, the catcher
catches them and they ain’t nothing
until I call them.” Really, we’re look
ing at the opposite side of that story
because you are asking us for our
opinions, but they are only opinions
and it’s really the facts that count. I
do not know of anyone who does a
radical mastectomy and, if I did,
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I would argue with him. On
the other hand, 25 000 radical
mastectomies were done in North
America last year, which is about
25% of the primary breast cancers
treated, so clearly, it is being done,
even though what we’ve discussed
shows that there is no really good sup
port for it. I do not think we should
ridicule people who are doing what is
standard but I will point out that,
although the majority of surgeons
have shifted from radical to modified
radical, they have done this without
any demonstration that the two oper
ations are equivalent in terms of
length of survival. There has never
been a comparative trial between these
two operations. It has just been a slow
evolution over the last two decades
and it really takes the form of a
fashion. That is not entirely to the
credit of the surgical and scientific
attitudes of our community but it's
probably correct. It would be far
better to complete the clinical trials
we are engaged in. The clinical trial
Mr. Hayward reported on was a his
torical trial. It was conceived without
the best radiotherapy techniques and
such a trial would not be done
today. He, himself, in his conclusion,
showed you he was doing a new trial
to test a breast-conserving operation
because it is still worth testing. The
question of what operation is best will
only be answered by the results of
clinical trials. Therefore, people
should be participating in such trials.
Dr. Dionne: In a recent Canadian
survey responses from 27 surgeons
showed that 22 Halsted operations
were performed among 800 mastec
tomies in 1979. I did one 2 weeks ago.
I’ve done seven since 1970. Those
patients who cannot be entered in a
protocol for any reason are treated
with the same mode of treatment.
Question from the audience: My ques
tion for Dr. Bruchovsky is on estro
gen receptors. In Australia we are
participating in the Ludwig adjuvant
trial. We do not use the estrogen-re
ceptor assay in that trial, although it is
done. The reason for this is that
Gordon Safferty circulated the sample
to all Australian laboratories; the
variation in the value ranged from
about fourfold to sixfold and last
week at the American Society for
Clinical Oncology meeting in San
Diego a similar study in the United
States was reported. However, the im
portant thing is that within one labo
ratory your estrogen-receptor assay is
valid if you use the same laboratory
assay as the standard at all times. My
VOLUME 24, NO. 3, M A Y 1981
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question to you is, has this been done to follow the second suggestion at
in Canada? If a national study is con present. I think that, if we look at
templated, I think it is mandatory that trends towards earlier use of adjuvant
this sort of study be done because the therapy with drugs and hormones, we
correction factor has been advocated might even find ourselves giving hor
to standardize the assay across the mones (and possibly drugs) preoperboard.
atively before we even know the re
sult
of the estrogen-receptor test; so
Dr. Bruchovsky: I’m glad you brought
up the subject. I have had the experi that would negate the value of the test
in the early management of breast
ence of chairing an ad hoc committee
that was asked to recommend a stand cancer.
ard assay for measuring estrogen re Dr. Pilleron: Les dosages hormonaux
ceptors; unfortunately, in 2 years we ont ete faits par forage biopsique et
have not convinced the National Can maintenant a la Fondation Curie on
cer Institute of Canada or any pro essaie de faire des dosages hormonaux
vincial body of the pressing need for meme apres ponction cytologique. A
this. The answer to your question then propos de 1’excision locale suivie d ’un
is— no: there is no reference labora traitement par irridium plus une irra
tory in Canada against which provin diation—j'ai fait ce genre de therapie,
cial centres can standardize their tests.
et il y a un gros ennui, c’est celui de
I think that this has delayed the intro la sclerose post-therapeutique et la sur
duction of clinical trials on breast veillance. C’est un des gros problemes
cancer. There has been no published de pouvoir dire a quel moment il
correlation between biochemical re s’agit d'une sequelle radiotherapique
sults and clinical results. We really ou au contraire d’une recidive. Pour
do not know whether the estrogen-re M. Bruchovsky, je voudrais lui dire
ceptor test as performed in Canadian qu'a la Fondation Curie nous attachons
laboratories predicts the things that I beaucoup d’importance a l’association des recepteurs des progestamentioned (response rates, recurrence
rates); consequently one can be jus tifs et que nous avons trouve uniquetifiably hesitant to use the estrogen- ment a peu pres un cas sur quatre
et
receptor test as a guideline to hor d’hormono-dependance (25%);
monal therapy. I think we have to souvent les cas qui sont hormonowork quickly in order to bring the dependants sont les formes organoi'des
application of this test in this country
relativement de meilleur pronostic.
up to the level of its use in other Pour le probleme des envahissements
countries, like the US and Europe.
ganglionnaires, je pense en particulier
Commendably, the Ontario govern dans les lesions des quadrants exment has just agreed to fund a study ternes, on peut proceder a un examen
involving several centres with a re histologique extemporane des gan
ference laboratory. Perhaps Dr. glions. Si les ganglions inferieurs et
Meakin would like to comment on centraux de l’aisselle, sont indemnes,
what has happened in Ontario. I
il est a ce moment la inutile de faire
think he is more familiar with the un evidement au-dessus; il n’y a
recent developments than I am.
pratiquement pas d’envahissement
ganglionnaire. Quant au type d’operaDr. Meakin: Very briefly, it is as you
tion, je fais maintenant l’operation
said. Dr. Bruchovsky. The Ontario
Halsted modifiee qui n’est pas tout a
provincial government is now fund fait l’operation de Patey qui enleve
ing in cooperation with the Ontario
le petit pectoral. Mais je pense qu’en
Cancer Foundation and the steroid- particulier lorsque les patients ont eu
receptor tests are available in a num une irradiation importante a titre
ber of centres throughout Ontario.
pre-operatoire, le resultat cosmetique
Question from the audience: I wish est meilleur, mais parfois il existe une
to ask Dr. Bruchovsky, and perhaps myosite postradique de grand pectoral
the others on the panel, one question. qui gene les mouvements d’abduction.
Do you think the estrogen-receptor Dr. Dionne: We will now hear from
assays are sufficiently reliable that
Dr. Eve Shulman* who has asked to
you would use them to design a cli
speak of a national survey currently
nical trial? In other words, do you
being done by her department and of
think clinical trials now should in
interest
to you all.
clude this assay when considering
hormone manipulations or do you
think we should just take this inform
ation into consideration and not
stratify patients on that information? *Epidemiologist, health services and
Dr. Bruchovsky: I would be inclined
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promotion branch, Health and
Welfare Canada, Ottawa, Ont.
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Dr. Shulman: Our survey is in the

very early stage and there are as yet
no results. Rather, I would like to
show a few slides on information that
1 collected in our department from
the provincial medical care plans.
These show the number of surgical
procedures for breast cancer that are
done in Canada. You will notice that
during the 1970s there was a slight
decrease in the number of simple
mastectomies. We were not able to
separate all the procedures for cancer
patients from those for benign disease,
for example breast biopsies. However,
we were able to do that for some pro
cedures for most of the provinces. In
the 1970s there was a slight drop in
the rates as well as the numbers for
simple mastectomy and an increase in
radical mastectomy, but that has
stabilized. With respect to the burden
of breast cancer in Canada in the
1970s there was a very slight increase
but the number of hospital patientdays has remained fairly constant. Of
particular interest, I think, to this
meeting, is the death rate. Using ageadjusted death rates, we have found
no real improvement although there
are annual variations. This brings up
a point that is of interest to our de
partment. I think that mortality data
are a bit too insensitive to reflect
small changes that might come from
either improved survival data or as
benefits from clinical trials. What we
must try to do is to look at and collect
survival data rather than mortality
data, so that, if there are improve
ments associated with modes of treat
ment, particularly advances in treat
ment, it will be easier for us and for
you to detect them. Our department
is interested in efforts from the prov
inces or surgical groups to collect
survival data.
BOOKS RECEIVED
(continued from page 256)
Le traitenient des fractures du bassin et
de leurs complications immediates.

Rapport presente au 82e congres francais de chirurgie, Paris, 22 au 25 septembre 1980. H. Dejour, J.-M. Cor
mier et M. Le Guillou. 128 pp. lllust.
Masson, Paris, 1980. Prix non mentionne, broche. ISBN 2-225-67518-X.
Vagotomy and Pyloroplasty Advances

1975-1980. The Non-Resective Method
(Adequate Selective Proximal Vago
tomy — “A-SPV” — Combined with
Pyloroplasty Appropriate to Form and
Function —■ “FF-PYPL” —) as a
Means of Operative Treatment of
Peptic Ulcer Disease and Other Benign
Disorders of the Stomach. Edited by
F. Holle and G.E. Holle. 143 pp.
lllust. Springer-Verlag New York Inc.,
New York, 1980. $58, paperbound.
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"Zinacef
CEFUROXIME SODIUM INJECTION
Prescribing Information:
Indications and Clinical uses: ZINACEF may be indicated for the
treatment of the following infections when caused by susceptible
organisms: lower respiratory tract, urinary tract and soft tissue
infections.
Appropriate culture and susceptibility studies should be performed
to determ ine the s u s c e p tib ility of the ca u sa tive organism to
ZINACEF. Therapy may be started while awaiting the results of these
tests, however, modification of the treatment may be required once
these results become available.
Clinical studies have shown ZINACEF to be effective against infec
tions caused by sensitive strains of
Gram positive cocci Staphylococcus aureus
Streptococci (excluding S. faecalis)
Gram negative rods - Hemophilus influenzae
Escherichia coli
Proteus mirabilis
Klebsiella spp.
Contraindications: Hypersensitivity to cephalosporins.
Warnings: Before therapy with ZINACEF is instituted, careful inquiry
should be made concerning previous hypersensitivity reactions to
cephalosporins, penicillins or other drugs. ZINACEF should be given
only with caution to penicillin-sensitive patients.
There is some clin ical and laboratory evidence of partial cross
allergenicity of the cephalosporins and penicillins. Patients have
been reported to have had severe reactions (including anaphylaxis)
to both types of drugs.
Any patient who has demonstrated some form of allergy, particularly
to drugs, should receive antibiotics, including ZINACEF, with cau
tion. If an allergic reaction to ZINACEF occurs, administration of the
drug should be discontinued. Serious acute hypersensitivity reac
tions may require treatment with epinephrine and other emergency
measures.
Precautions: The safety of ZINACEF in the treatment of infections
during pregnancy has not been established. If the administration of
ZINACEF is considered to be necessary, its use requires that the po
tential benefits be weighed against possible hazards to the patient
and to the fetus. Animal studies have shown ZINACEF to affect bone
calcification in the fetus and to show maternal toxicity in the rabbit.
The safety of ZINACEF for the treatm ent of infections in infants,
children and nursing mothers, has not been established.
Prolonged use of ZINACEF may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is there
fore essential, and if superinfection should occur during therapy,
appropriate measures should be taken. Should an organism become
resistant during antibiotic therapy, another antibiotic should be
substituted.
Patients w ith renal or hepatic im pairm ent should be carefully
monitored during therapy w ith ZINACEF. Patients with impaired
renal function should be placed on the special dosage recom
mended under DOSAGE AND ADMINISTRATION, because normal
doses in these individuals are likely to produce excessive serum
concentrations.
Studies suggest that the concurrent use of potent diuretics, such as
furosemide and ethacrymc acid, may increase the risk of renal tox
icity with cephalosporins.
ZINACEF may interfere w ith Benedict's and Fehling’s tests for
glycosuria. It may cause false negative reactions in the ferricyamde
test, and possibly, may cause an erroneously high reading in the
alkaline picrate test for creatinine.
Adverse reactions: The following reactions have been observed
during treatment with ZINACEF.
Hypersensitivity: rash and eosinophilia. Anaphylaxis, pruritus and
drug fever have also been observed w ith cephalosporin therapy.
Local reactions: thrombophlebitis, stiffness at the site of injection
and inflammatory reactions at the site of injection. Some degree of
pain, after intram uscular injections when using water as the d i
luent, has been observed.
Blood: increased erythrocyte sedimentation rate and decreased
hemoglobin. Some patients developed a positive direct Coombs test.
Renal: increases in BUN and serum creatinine.
Hepatic, transient increases in serum bilirubin, transaminases and
alkaline phosphatase.
Others: drowsiness, loose stools, faint feeling, sweating, palpita
tions and Candida intertrigo.
Symptoms and treatment of overdose: Other than general suppor
tive treatm ent, no specific antidote is known. Excessive serum
levels of cefuroxime can be reduced by dialysis. For treatment of
hypersensitivity reactions, see WARNINGS.
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Dosage and administration: Adults: the intramuscular dose is 750
mg three times daily and the intravenous dose is 750 mg or 1.5 g
three times daily.
For most infections the usual recommended dosage is 750 mg every
8 hours (2.25 g/day) and may be administered either l/M or l/V.
For severe or life-threatening infections, the higher dose is sug
gested. For infections of the lower respiratory tract, caused by gram
negative organisms, the higher dose may also be required. A nti
biotic therapy for infections caused by B-hemolytic streptococci
should be continued for at least 10 days.
There is insufficient evidence for recommending the use of ZINACEF
in children or in nursing mothers.
Dosage in adults with impaired renal function: ZINACEF may be
used for patients with impaired renal function but a reduced dosage
must be employed and serum levels of cefuroxime may need to be
monitored. The following Table shows the dosage recommendations.
Serum creatinine
(mg/mL)
2.0 - 3.5
3 .5 -6 .0
> 6 .0

Glomerular filtration rate
(m L/m in)*
2 0 -5 0
1 0 -2 0
< 10

Dose of ZINACEF
(mg)
500 t.i.d
500 b id
500 q.d

*For more precise calculations, whenever possible, the glomerular
filtration rate should be used
Patients on dialysis should receive an additional dose of 500 mg at
the end of dialysis.
Preparation of solutions: For intram uscular use Add 3.2 mL of
Water for Injection to a vial containing 750 mg of ZINACEF and
shake gently to produce an opaque suspension. The total volume
obtained is approximately 3.7 mL.
For intravenous use: When a single bolus injection is prepared, 750
mg of ZINACEF is dissolved in 7 mL of Water for Injection, which pro
vides a volume of approximately 7.5 mL. Reconstitution of 1.5 g of
ZINACEF is done by adding 19 mL of Water for Injection, thereby ob
taining an approximate volume of 20 mL.
For short intravenous infusion, 1.5 g of ZINACEF is dissolved in
49 mL of Water for Injection, resulting in an approximate volume of
50 mL
Administration: Intramuscular: ZINACEF should be injected into a
large muscle mass to m inim ize pain. As the preparation is in
suspension form, a 21 gauge needle should be used.
Intravenous: ZINACEF may be administered intravenously either by
a bolus injection or by a short intravenous infusion over a period of
approximately 30 minutes.
For continuous intravenous infusions, a solution of ZINACEF (1.5 g
dissolved in 19 mL of Water for Injection) may be added to a suitable
bottle containing an appropriate intravenous infusion fluid mthe
amount calculated to give the desired antibiotic dose.
Compatibility: Reconstituted primary solutions of ZINACEF may be
further diluted with Sodium Chloride Injection B.P. 0.9% w/v. 5%
w /v Dextrose Injection B.P. or Compound Sodium Lactate Injection
B.P. (Hartmann's Solution).
NOTE: The pH of 2.74% w/v Sodium Bicarbonate Injection B.P. con
siderably affects the colour of the solution, therefore, this solution is
not recommended for the dilution of ZINACEF. However, if required,
for patients receiving Sodium Bicarbonate Injection by infusion, the
ZINACEF may be introduced into the tube of the set.
NOTE: ZINACEF should not be mixed w ith aminoglycoside antibiotics
(e g gentamicin sulfate, tobramycin sulfate, amikacin sulfate) be
cause of potential interaction.
Stability: The dry powder in vials should be stored below 25°C and
protected from light.
Suspensions of ZINACEF for intramuscular injection and aqueous
solutions for intravenous injection retain their potency for 6 hours if
kept below 25°C, and for 48 hours if refrigerated More dilute solu
tions. i.e. 1.5 g in 50 mL Water for Injection, retain their potency for
at least 12 hours if kept below 25°C, and for 36 hours when re
frigerated. Some increase in the intensity of colour may occur on
storage
Dosage forms: ZINACEF is available for intramuscular or direct in
travenous injection in 18 mL vials containing cefuroxime sodium
powder equivalent to 750 mg of cefuroxime, in packs of five
For intravenous injection, 30 mL vials contain cefuroxime sodium
powder equivalent to 1.5 g of cefuroxime, in individual packs.
For intravenous infusion. ZINACEF is available in 75 mL vials con
taining cefuroxime sodium powder equivalent to 1.5 g of cefuroxime.
in individual packs.
Product Monograph available on request.
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CCPP
References:
1) Product Monograph
2) Adapted from Proc. Roy. Soc. Med. (1977) 70, Suppl. 9, p.7 and
Product Monograph
3) Proc. Roy. Soc. Med. (1977) 70. Suppl. 9. p.26
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Anewchoicein
firstchoicehospitalantibiotics.
Zinacef is a new third generation injectable
cephalosporin with advantages that
make it an excellent first choice antibiotic.
T

Unlike most penicillins and cephalosporins which
are inactivated by 5-lactamase producing pathogens,
Zinacef has a novel structure (the addition of an
<» methoximino group)' which helps protect the betalactam ring against destruction.

• Lower individual dosage (750 mg) and longer half-life
(70 minutes)1thanotherthird generation cephalosporins.
• Convenient eight-hour dosage interval for a low
usual daily dose of 2.25 g.1
• Therapeutically effective levels throughout body
tissues.1
1
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Zinacef has a broad range of activity
and excellent pharmacokinetics.• Rapidly absorbed and not meta
bolised, yielding high levels
(91-96% ) of active unchanged
antibiotic in the urine.1
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Zinacef hasa high intrinsicactivityagainstthe
range of Gram-positive and Gram
negative pathogens responsible for
the vast majority of hospital
infections.1 Up to 9 2 % of isolated
pathogens were effectively treated
by Zinacef.3

From Glaxo Laboratories We started cephalosporin research. And we’ve never stopped.
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Use of Hypertension and Electroencephalographic
Monitoring during Carotid Endarterectomy
R obert R. H ansebout, md , m sc, facs, frcs [c ],
G ustav B lomquist Jr ., md , Pierre G loor, md , ph d, frcp [c ],
C hristopher T hompson , m sc and D avy T rop, md , faca , frcp [c]

Intraoperative hypertension and
continuous electroencephalographic
(EEG) monitoring were used during
42 carotid endarterectomies performed
on 37 patients from 1970 to 1978.
Computer spectral analysis of a
majority of the electroencephalograms
was also performed. Linder
supplemented nitrous oxide general
anesthesia, elevation of the mean
arterial blood pressure to 20% above
the individual's preoperative mean
blood pressure resulted in reversal
to normal of an ischemic EEG pattern
in 19% of the patients. The authors
discuss the benefit of this technique.
They present guidelines for patient
selection and analyse the data to help
the surgeon decide whether to use
a shunt during carotid endarterectomy.
Entre 1970 et 1978, I'hypertension
peroperatoire avec surveillance electroencephalographique (EEG) continue
a ete employee dans 42 endarterec
tomies carotidiennes pratiquees sur
37 patients. On a aussi effectue sur
ordinateur une analyse spectrale de
la majorite des electroencephalogrammes. Sous anesthesie generate
su p p lem en ts d'oxyde nitreux, une
elevation de 20% de la tension
arterielie moyenne au dessus de la
tension preoperatoire mesuree chez
le sujet a ramene a la normale un
trace EEG ischemique chez 19% des
patients. Les auteurs commentent les
avantages de cette technique.
From the Montreal Neurological
Hospital and Institute, M cG ill University,
Montreal, PQ
Accepted for publication Sept. 30, 1980
Reprint requests to: Dr. Robert
R. Hansebout, Department of
surgery, St. Joseph’s Hospital,
50 Charlton Ave. E, Hamilton, Ont.
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lls proposent des directives sur le
choix des malades et I'analyse des
donnees afin d'aider le chirurgien
a decider de I’emploi d’une derivation
durant I'endarterectomie carotidienne.
Although atheromatous disease o f the
carotid artery has been described for
m ore than 60 years,1 the surgical treat
ment o f this condition has been as
sociated with high morbidity and mor
tality.2-7 T h e recent eclectic approach
has resulted in an increasing aware
ness o f cerebral ischemia that occurs
during clamping o f the carotid ar
teries.8 Continuous electroencephalo
graphic (E E G ) monitoring is an excel
lent method o f measuring the brain’s
functional
state intraoperatively,9"12
and the criteria fo r placing a shunt
during carotid endarterectomy have in
part been based upon the E E G find
ings.13'16
W e describe a series o f 42 carotid
endarterectomies performed in 37
patients in 40% o f whom slow-wave
E E G patterns developed upon clamp
ing
either
the
common
carotid
artery or both the common and inter
nal carotid arteries. In about half
these patients (1 9 % o f the total), an
increase in the intraoperative mean
blood pressure by about 20% reversed
the E E G abnormality to normal.

Patients
The series comprised 29 men and
8 women ranging in age from 45 to
70 years (65% were over 60 years).
Angiographic assessment indicated no
bruit in 14 patients, unilateral carotid
bruit on the side o f the operable
lesion in 11, bilateral carotid bruits in
11 others and bruit on the side op
posite the operable lesion in 1 other
patient. Hypertension was present
preoperatively in 17 patients; 14
V O L U M E 24, NO. 3, M A Y 1981
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smoked cigarettes; 4 had diabetes and
3 were obese.
Patient selection for operation was
strict. Indications included recurrent
transient ischemic attacks while the
patient was receiving adequate m ed
ical therapy, amaurosis fugax or a
minor completed stroke with subse
quent recovery. Patients presenting
with a stroke in progress underwent
carotid endarterectomy only if an
operation could be done within the
first few hours follow ing the initial
event.
Contraindications included obstruc
tion o f the internal carotid artery high
up in an inaccessible area (e.g., the
carotid siphon), complete occlusion
o f a vessel fo r 24 hours and medical
complications precluding angiography
and operation.
The preoperative assessment in
cluded general physical and neurologic
examinations with evaluation o f pulses
and search fo r bruits. Ophthalmody
namometry was o f great value in
assessing carotid stenosis, since re
duced values usually indicated dec
reased blood flow in the ipsilateral
carotid system.
Blood studies included measure
ment o f serum triglycerides, blood
sugar and electrolytes, and lipid and
coagulation profiles. A n electrocardio
gram was obtained in all patients.
Carotid circulation studies, using
radioisotopes,
were
performed
in
most cases; they may indicate reduced
carotid blood flow on the ipsilateral
side when the stenosis is particularly
severe. W e have recently incorporated
positron emission tomography (P E T )
into the preoperative protocol to aid
in assessing ischemic areas o f the
brain. Preoperatively, a 16-channel
E E G recording was obtained to pro
vide a baseline for comparison during
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intraoperative monitoring. An aortic
arch angiogram including the circle of
Willis provided a radiologic evalua
tion of the complete length of the
carotid vessels bilaterally as well as
the vertebral arteries. Computerized
axial tomography was performed in
the majority of patients from 1973
onwards.
Operative Technique

The operative team consists of sur
geon, anesthetist and electroencephalographer.
In addition to the neck, the inguinal
area and thigh on one side are pre
pared in the event that a saphenous
vein patch graft is used or a femoral
to carotid artery bypass shunt is
necessary.
Sodium pentothal is used for in
duction of anesthesia,17 which consists
of nitrous oxide supplemented by
fentanyl citrate, droperidol and cur
are.18’19 Normal arterial carbon di
oxide pressure and increased oxygen
concentration (50% to 60%) are
maintained throughout the operation.
Blood pressure is monitored using an
arterial line in a peripheral vessel.
During the entire procedure, the
anesthetist does not allow the blood
pressure to fall below the patient’s

mean normal pressure. Phenylephrine
is used to increase the pressure, when
necessary, to as much as 20% above
the patient’s mean preoperative pres
sure. In this group of patients the
mean diastolic pressure ranged be
tween 110 and 120 mm Hg and in
some, this was raised to about 140
mm Hg. The systolic range was be
tween 160 and 210 mm Hg.
An eight-channel EEG recording is
obtained from the scalp. Symmetrical
channels are submitted to on-line spec
tral analysis by a PDP 12 computer
(Digital Equipment Corp., Maynard,
Mass.) and displayed in the operating
room on the screen of a Tektronix ter
minal (Tektronix Inc., Beaverton,
Ore.) in the form of compressed spec
tral arrays.20 The electroencephalo
gram is digitized at 200 samples per
second and stored permanently on
magnetic tape. At the same time, four
consecutive samples are averaged (to
prevent aliasing errors from electro
myographic activity) and the fast
fourier transform is performed to
extract frequency components up to
25 Hz on 5-second epochs. The com
pressed spectral array is displayed on
a storage screen which is updated
every 5 seconds. The spectra are pre
sented with frequencies from 1 to 12
Hz on one horizontal scale and 13 to

FIG. 1—Baseline compressed spectral array before clamping of carotid artery
shows relative frequencies of delta, theta, alpha and beta waves over frontocentral
brain regions. Columns from left to right represent left frontocentral, left centroparietal, right centroparietal and right frontocentral regions. Horizontal bars indicate
ratio of slow to fast activity.

35 Hz at one quarter scale to em
phasize the frequencies of interest
(Figs. 1 and 2).
General heparinization is used to
prevent thromboembolic phenomena;21
the usual dosage is between 5000 and
8000 units given intravenously. The
carotid vessels are then clamped for
1 minute at the patient’s “normal”
blood pressure. If EEG slow-wave
activity in the delta range is going to
occur, it will do so within 20 seconds
after clamping of either the common
or both common and internal carotid
arteries (Figs. 3 and 4). Should slow
waves appear, indicating inadequate
collateral circulation and probable
ischemia, the carotid vessels are un
damped to allow resumption of blood
flow and the patient’s blood pressure
is raised by about 20%. The carotid
vessels are then clamped again and
when no slow waves are seen, the
endarterectomy is carried out. If the
“raw” electroencephalogram or its
spectral analysis indicates probable
ischemia (Figs. 2 and 4), bypass caro
tid shunting is carried out. Usually,
the shunts used are those designed by
the National Research Council of
Canada to provide low turbulence. If
the blood pressure fluctuates greatly
during carotid dissection, the carotid
sinus nerves are cut. Periarterial sym
pathectomy is included as part of the
dissection. When the common and in
ternal carotid vessels have been open
ed, meticulous care is taken to ensure
that internal carotid artery back-flow
is obtained whenever possible22,23 and
that the vessels are flushed during the
unclamping procedure. A Fogarty
arterial balloon catheter is usually
passed up the internal carotid artery
3 or 4 cm to free and pull back any
thrombus or plaque that might be
present and to re-establish the normal
calibre of the vessel. This must be
done carefully so as not to cause em
bolization of distal plaque fragments
which could be a source of embolic
ischemia.24
The time of carotid artery occlu
sion, endarterectomy and resuturing
of the internal carotid vessels averages
less than 12 minutes. The EEG moni
toring continues until carotid closure
is complete.
Results

FIG. 2— Compressed spectral array after clamping of right carotid vessels
showing increased slow-wave activity over right frontal region compared with left.

VOLUME 24, NO. 3, M A Y 1981

/

THE CANADIAN JOURNAL OF SURGERY

Of those patients showing slow-wave
abnormalities when the carotid vessels
were clamped for 1 minute, 19%
had a normal electroencephalogram
after raising the intraoperative mean
blood pressure by 20% and reclamp
ing the carotid vessels. In nine (21%)
patients the slow-wave pattern reap305

peared on clamping the carotid vessels endarterectomy and only an occa neurologic status reverted to normal.
despite an increase in the systolic sional slow wave was noted. However,
after suturing the vessel and removing Discussion
blood pressure of 30 to 40 mm Hg.
The electroencephalogram provides
Shunting was carried out during en the shunt, the electroencephalogram
showed generalized slow waves over a simple means of monitoring cerebral
darterectomy in all of them. In 79%
of the patients in whom a normal both hemispheres. Postoperatively the activity during carotid artery surgery.
EEG pattern was obtained either at patient was aphasic and had a right It is a sensitive indicator of brain
normal blood pressure or following hemiparesis, both of which persisted. ischemia25"28 and it has been demon
A 44-year-old woman with high strated that hypoxic distress can be
the 20% increase, a shunt was not
serum triglyceride levels, diabetes and identified in the patient under general
required.
The computer analysis of the elec severe atherosclerosis underwent right anesthesia as it happens.
Carotid endarterectomy performed
troencephalogram offered no addi carotid endarterectomy. She was
tional advantage over the conventional found to have a left hemiparesis post under local anesthesia30 allows imme
eight-channel recording. The EEG operatively which was shown angio- diate monitoring of subtle changes in
graphically to be due to recent occlu the level of consciousness during
changes were impressive when they
sion of the right internal carotid artery clamping. However, we believe that
occurred and were characteristically
noted on the ipsilateral side. In all but at the operative site. The electroen a carotid endarterectomy can be per
two cases the postoperative EEG find cephalogram showed slow waves on formed with less stress on the patient
the right side that disappeared follow using general anesthesia; a more com
ings compared favourably with those
ing reoperation and re-establishment plete endarterectomy can be done
of the preoperative record.
The compressed spectral array of flow in the right carotid system. without a shunt, particularly if a vein
derived from the electroencephalo Following the second procedure, her graft or other modification is needed.31
gram demonstrated the changes that
were due both to the pathologic slow
waves and the anesthesia. In general,
the effects of anesthesia on the spec
tral array were more pronounced than
C4-P 4
those of cerebral ischemia. This made
a comparison of the spectral array
derived from the preoperative electro
encephalogram and the one derived
from the electroencephalogram re
corded during operation of limited
value. A comparison of the spectral
rf
array recorded before with that re
corded during operation is valid but
seems of no more value than the elec
troencephalogram.
Following carotid endarterectomy,
72% of the patients improved and
l_s__ ! 5fyv
had no transient ischemic attacks or
showed improved neurologic status.
There was no change in 11%. Neu
FIG . 3— Patient under general anesthesia at norm al blood pressure before
rologic complications were present in
clamping of left carotid system. L etter and number com binations indicate bipolar
7% postoperatively.
electrode placements according to standard 10-20 international system.
Fatal complications occurred in six
patients within the first week after
V \A /w vv\A V 1A/^/v^/v ^v'A*'\/V/vv'W \/VA/sfu^i/vW W
endarterectomy. Two patients died 4
days after operation, one of a massive
stroke due to carotid occlusion at the
site of endarterectomy and the second
of a massive intracerebral hematoma
j
while taking anticoagulants. A third
patient died of basilar artery occlu
P 2 _ (3 3
--N/Wv>A/vv\/'4AA''W‘'V'-'AVNW'^/WVAA''-~'A>/VVrJ\ V V ^
sion in the postoperative period. A
fourth patient died of complications
following angiography. Two patients
had fatal cardiac arrhythmias within
the first few days after operation.
One 68-year-old man had complete
occlusion of the right internal carotid
artery and 80% stenosis of the left
internal carotid artery preoperatively.
I s __ j 50|iv
Clamping of the left carotid system
for 1 minute induced delta waves that
persisted for 10 minutes. Using hyper
FIG . 4— Same patient under general anesthesia 20 seconds after clamping left
tension and a femoral to carotid artery
carotid system showing slow waves in frontal regions with left side affected more
than right.
shunt, we were able to perform the

F4-C4

P4-02
F3-C3

C3-P3
P3-0 1
T4-Cz

Cz-T3

P4-02 A,Vi
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Moreover, vital signs are better con
trolled when the patient is under
general anesthesia.
The problem is to decide which
patients might benefit from having
a shunt in place during the endarterec
tomy. Raising the mean blood pres
sure with increase of cerebral per
fusion through collateral channels may
reduce the need for a bypass shunt
during the procedure.32 The data from
this series indicate that EEG changes,
if they occur, do so quickly, often
within 20 seconds of clamping the
carotid vessels. If slow waves persist
when the carotid vessels are again
clamped following a 20% increase
in mean arterial pressure the neces
sity for a shunt is established.
In our clinical series, two patients
had EEG slow waves during or im
mediately after the surgical proce
dure. This correlated with a worsening
of their neurologic status postoperatively; it shows that the ischemia
heralded by EEG slow-wave activity
does have clinical importance. When
no EEG slow waves occurred, there
was no worsening of neurologic status
postoperatively. Thus our series has
demonstrated that continuous EEG
monitoring is useful during general
anesthesia for carotid endarterectomy
and is clinically important.
Although these patients often have
compromised cardiovascular systems
usually with severe atherosclerotic
changes,33 there was no adverse reac
tion from the phenylephrine infusion.
The careful technique used for anes
thesia with increased oxygen concen
tration (50% to 60%) may be an im
portant factor, particularly in reducing
myocardial stress.
It is probable that by raising the
mean blood pressure 20%, the cere
bral blood flow per minute is main
tained at the necessary 16 to 22 ml/
100 g.34 Postoperative hemorrhage due
to increasing blood pressure in the
presence of advanced atherosclerotic
lesions must be infrequent. This
modification is useful combined with
continuous EEG monitoring and care
fully used nitrous oxide anesthesia sup
plemented by fentanyl citrate, droperidol and curare.

alysis of the electroencephalogram35 is
no better than conventional EEG
monitoring alone. If EEG slow-wave
activity is going to develop because of
ischemia, it will occur within 20 sec
onds of clamping the vessel in the
majority of cases. The technique of
raising mean blood pressure by
20% is of immediate benefit in re
versing the EEG changes usually
heralding ischemia. Continuous EEG
monitoring and elevation of mean
blood pressure under general anes
thesia can, in some patients, safely
eliminate the need for a shunt. The
use of this technique can aid the sur
geon in his decision of whether shunt
ing is necessary.
We gratefully acknowledge the tech
nical assistance and advice of Dr. David
Dubuisson.
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(methylprednisolone sodium succinate)
Action:

Solu-Medrol, like other corticosteroids, exerts its action
by its anti-inflammatory effect.
Indications and Clinical Uses:

Intravenous administration of Solu-Medrol is indicated
in situations in which a rapid and intense hormonal
effect is required.
Shock:

In severe shock adjunctive use of intravenous methyl
prednisolone sodium succinate (Solu-Medrol) may aid
in achieving hemodynamic restoration. Corticoid
therapy should not replace standard methods of
combating shock, but present evidence indicates that
concurrent use of large doses of corticoids with other
measures may improve survival rates. In particular,
large pharmacological doses of Solu-Medrol have been
proven useful in bacteremic or endotoxin shock,
hemorrhagic shock, traumatic shock, and cardiogenic
shock.
Contraindications:

Except when used for short-term or emergency therapy
as in acute sensitivity reactions, Solu-Medrol is
contraindicated in patients with arrested tuberculosis,
herpes simplex keratitis, acute psychoses, Cushing’s
syndrome, peptic ulcer, vaccinia and varicella.
Precautions:

Existence of diabetes, osteoporosis, chronic psychoses,
active tuberculosis, renal insufficiency or predisposition
to thrombophlebitis requires that Solu-Medrol be
administered with extreme caution. In the presence of
infection, the causative organism must be brought
under control with appropriate anti-bacterials, or
therapy with Solu-Medrol should be discontinued.
While therapy with corticoids does not appear to be
contraindicated in pregnancy, caution is recommended,
particularly during the first trimester. Also, newborn
infants of mothers who received such therapy during
pregnancy should be observed for signs of hypoadrenalism and appropriate measures instituted if such
signs are present. Since Medrol, like prednisolone, sup
presses endogenous adrenocortical activity, it is highly
important that the patient receiving Solu-Medrol be
under careful observation, not only during the course
of treatment but for some time after treatment is
terminated. Adequate adrenocortical supportive
therapy including ACTH, must be employed promptly
if the patient is subjected to any unusual stress such as
surgery, trauma, or severe infection. Patients should be
advised to inform subsequent physicians of the prior
use of Solu-Medrol.
There have been a few reports of cardiovascular
collapse associated with the rapid intravenous admini
stration of large doses of Solu-Medrol (greater than
0.5 grams) in organ transplant recipients. The cause
and relation to other medications (i.e., diuretics) is not
known at this time, but physicians should be alert to
this possibility.
Adverse Reactions:

Adverse reactions are not likely to result from short
term intravenous administration of Solu-Medrol, but
may be anticipated if continued therapy with oral or
intra-muscular corticosteroid preparations is to follow.
Medrol has less tendency than prednisolone to induce
retention of sodium and water, and in some cases has
been observed to produce diuresis and an increased
excretion of sodium. Likewise, therapy with Medrol
appears to produce less nervousness and psychic
stimulation than that produced by prednisolone. While
epigastric distress has not been totally lacking in
patients receiving Medrol, the incidence and severity of
this side reaction to date suggest that although Medrol
has an enhanced anti-inflammatory potency when com
pared with prednisolone on a weight basis, the socalled ulcerogenic potential of this corticosteroid is no
greater, and may even be less, than that of
prednisolone.
With the exception of the differences noted in the
preceding paragraph, Medrol is similar to hydro-

310

cortisone and prednisolone in regard to the kinds of
adverse reactions and metabolic alterations to be
anticipated when treatment is intensive or prolonged.
Negative nitrogen balance is usually counteracted by a
high protein intake. In patients with diabetes mellitus,
Solu-Medrol may increase insulin requirements during
the period of administration. Ecchymotic manifesta
tions, while noted only rarely during the clinical
evaluation of Medrol, may occur. Excessive loss of
potassium is not likely to be induced by effective
maintenance doses of Medrol. If such reactions are
serious or distressing to the patient, reduction in
dosage or discontinuance of corticoid therapy may be
indicated. While a retardant effect on wound healing is
seldom encountered, except in high doses, it should be
a matter of consideration when Solu-Medrol is admin
istered in conjunction with surgery.
Symptoms and Treatment of Overdosage:

Single large doses of Solu-Medrol do not have any
apparent toxic effect and require no specific therapy.
Continuous overdosage would require careful gradual
reduction of dosage in order to prevent the occurrence
of acute adrenal insufficiency.
Dosage and Administration:

In treating severe shock there is a tendency in current
medical practice to use massive (pharmacological)
doses of corticosteroids. The following are Solu-Medrol
doses suggested by various authors:
Author

Dose

Repeat

Oaks
Weil
Melby
Cavanagh
Dietzman

100 mg
200 mg
250 mg
15 mg/kg
30 mg/kg

Every 2-6 hours
100 mg. every 4-6 hours
Every 4-6 hours
Every 24 hours
In 4 hours if needed

Therapy is initiated by administering Solu-Medrol
intravenously over a period of at least 10 minutes. In
general high dose corticosteroid therapy should be
continued only until the patient’s condition has
stabilized; usually not beyond 48 to 72 hours.
Although adverse effects associated with high dose
short term corticoid therapy are uncommon, peptic
ulceration may occur.
In other indications initial dosage will vary from 10 to
500 mg depending on the clinical problem being
treated. The larger doses may be required for short
term management of severe, acute conditions. The
initial dose usually should be given intravenously over
a period of at least 10 minutes. Subsequent doses may
be given intravenously or intramuscularly at intervals
dictated by the patient’s response and clinical
condition.
Availability:

As Solu-Medrol (methylprednisolone sodium succinate)
in 40 mg and 125 mg Mix-O-Vial; 500 mg and 1 g vials
with water for injection.
Product monograph is available on request.
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A 2-day symposium on the esophagus
will be presented Sept. 10 and 11,
1981 by the Department of surgery
of the University of Montreal.
For information and registration
please contact the Division of con
tinuing medical education, Faculty of
medicine, University of Montreal, PO
[ Box 6207, Station A, Montreal, PQ
H3C 3T7 or call (514) 343-6367.
Meeting of Canadian
Lung Association

| The 81st annual meeting of the Can
adian Lung Association and its divi
sions (Canadian Thoracic Society,
Canadian Nurses’ Respiratory Society
J and Physiotherapy) will be held June
21 to 24, 1981 at the Bessborough
Hotel, Saskatoon, Sask. During the
free communications sessions such
j topics as clinical care, community and
| governmental education, occupational
health and research will be discussed.
A variety of topics during the struc
tured communications session will be
covered, such as acid rain, indoor
air pollution, oxygen therapy, respi
ratory health in farming and industry
and tuberculosis. There will also be
seminars on fund raising, health edu
cation and public relations.
For more information please write
the Canadian Lung Association, 75
Albert St., Ste. 908, Ottawa, Ont. KIP
5E7 or telephone (613) 237-1208.
Symposium on Vascular Disease

An international symposium on vas
cular disease will be held in London,
England. Sept. 10 to 17, 1981.
The aim of this symposium is to
stimulate discussion on controversial
aspects of vascular disease. There will
be invited papers from the interna
tional advisory committee, plenary
lectures and free communications,
including poster sessions. In addition,
there will be an optional postgraduate
course for surgeons-in-training and
technician’s workshops. There will be
a supporting social program and a
trade exhibition forming an integral
part of the meeting.
The symposium has been planned to
bring together surgeons, physicians
and scientists who treat vascular dis
ease. It will give them a unique chance
to reach firm decisions concerning
management of their patients.
For information contact, Secreta
riat, Conference Associates IVS, 34
Stanford Rd., London, England
W8 5PZ.
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Role of Needle Aspiration in Reducing the
Number of Unnecessary Breast Biopsies
D .R . Sa l t e r , m d * and A.A. B assett , m d , f r c s [ c ], fa c s I

The accuracy of the results obtained
from 2334 open breast biopsies
performed during a 9-year period at
Mount Sinai Hospital in Toronto are
reviewed. With meticulous follow-up and
the liberal use of needle aspiration, the
senior author (A.A.B.) noted a
progressive increase in his malignant
to benign ratio, from 18% in 1970
to as high as 56% near the end of the
study. In contrast, the overall hospital
ratio of malignant to benign breast
biopsies obtained over the same
decade remained stationary at 25%.
A low ratio implies unnecessary
hospital admissions and biopsies, all
adding to the patient's anxiety.
The authors conclude that a
currently acceptable malignant to
benign ratio is 1 to 3 and that with
the use of fine-needle aspiration
the number of surgical biopsies can be
reduced, minimizing patient anxiety
and morbidity, and increasing the
efficiency of hospital bed use.
On a etudie la precision des resultats
obtenus dans 2334 biopsies sanglantes
du sein pratiquees au Mount Sinai
Hospital de Toronto au cours d'une
periode de 9 annees. Avec des
examens de controle meticuleux et
(’utilisation liberate de la ponctionbiopsie a I'aiguille, le principal auteur
(A.A.B.) a note une augmentation
progressive de son index tumeurs
malignes/tumeurs benignes, de
18% en 1970 jusqu'a presque 56% vers
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la fin de I'etude. En comparaison,
I'index biopsies malignes/biopsies
benignes obtenu pour I’ensemble de
I'hopital au cours de la meme decennie
est reste stationnaire a 25%. Un
faible index signifie des hospitalisations
et des biopsies inutiles, ajoutant
davantage a I'anxiete de la patiente.
Les auteurs concluent qu’un index
des biopsies malignes par rapport
aux biopsies benignes de 1 a 3 est
actuellement acceptable et qu'avec
I’emploi de la ponction biopsie a
I'aiguille, on peut reduire le nombre
des biopsies chirurgicales inutiles,
minimisant ainsi I'anxiete et la
morbidity pour la patiente, et
augmentant I’efficacite d’emploi
des lits d’hopitaux.

Early detection and treatment of
breast cancer remains a challenge. In
spite of diagnostic and therapeutic
advances, breast cancer is the leading
cause of death in women aged 35 to
55 years and eventually affects 1 in
12 women. Unfortunately, the cure
rate has remained unchanged for 30
years.1
For nearly 50 years aspiration cyto
logy has been used to help decide
whether a biopsy should be performed
on a palpable breast lump.“ In
centres with skilled cytologists the
correlation between cytologic findings
and subsequent histologic findings is
very high (89% to 91%). In such
circumstances a confident assessment
can be made preoperatively on the
basis of examination and cytology
alone, resulting in few surprises for
either patient or surgeon. A positive
mammogram further reinforces the
preoperative diagnosis.
Basically, our approach has been
careful clinical examination and the
use of aspiration cytology in all cases
in which an abnormality is palpable,
whether or not it is a dominant lesion.
The decision to perform an open
breast biopsy in a patient with a pal
pable breast lesion is at present
mainly a clinical one and every sur
geon should strive to achieve a con
sistently high malignant to benign
biopsy ratio.
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The technique of open breast biop
sy, although simple, frequently re
quires a hospital bed, creates a scar
which makes subsequent clinical
assessment more difficult, can be
esthetically displeasing and causes
considerable anxiety for the patient.
Not all palpable breast lesions re
quire an open biopsy for diagnosis
and the decision as to whether biopsy
is necessary is frequently resolved in
the office with simple needle aspira
tion and cytologic examination. At
Mount Sinai Hospital, fluid as well as
solid aspirates are examined. In a
series6 of 834 cystic lesions, carcinoma
or atypia was found in 10 instances;
the atypical lesions subsequently were
found to contain malignant cells on
biopsy, giving a positive yield of ap
proximately 1.2%. Out of a total
series of 3724 cases in which needle
aspiration was carried out, 890 open
biopsies were subsequently performed.
The incidence of cytologic false-neg
ative and false-positive results due to
misinterpretation was 1.6% and 2% ,
respectively."
Close follow-up is necessary to
avoid serious errors in management.
While the value of open breast biopsy
is indisputable and it is of paramount
importance not to miss an early malig
nant tumour it is equally important
not to perform an unnecessary sur
gical biopsy.
The senior author has practised
fine-needle aspiration of the breast
since 1969. This paper is an attempt
to define further the role of aspiration
in the management of breast lesions
and its use in reducing the number of
unnecessary biopsies,7,8 and to assess
the accuracy of open breast biopsies at
the Mount Sinai Hospital to deter
mine whether this has changed over
the past decade. The results are com
pared to those of others to determine
an acceptable or “ideal” biopsy ratio.
M aterials an d M ethods

The pathologic features of 2334
open breast biopsies performed at the
Mount Sinai Hospital during a 9-year
period (1970 to 1979) were reviewed.
The ratio of malignant to benign
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biopsy findings was determined for
the entire series and the results of
individual surgeons, including the
senior author (A.A.B.) were compared.
Each patient in whom the biopsy
specimen was positive for malignant
cells and who subsequently underwent
mastectomy was further classified as
having either axillary node-negative
(stage I) or node-positive (stage II)
disease.
During the later years of the study,
an increasing number of biopsies were
performed on nonpalpable, mammographically suspicious lesions. With
these patients, needle localization and
specimen radiography were used in an
effort to detect carcinoma at an ear
lier stage. In this group of patients,
the decision to perform an open
breast biopsy was not strictly clinical,
for mammographically suspicious,
nonpalpable breast lesions were con
sidered to represent a radiologic
assessment. Our results in surgery for
occult (mammographically suspicious)
lesions will be reported subsequently.
All nonpalpable lesions identified as
suspicious on the basis of two-view
mammography showing clusters or
streaks of fine calcification were ex
cised with the assistance of preoper
ative needle localization and specimen
radiography. One third of such lesions
was malignant. When small, nonpal
pable, nonstellate nodules seen on
mammography were the basis for sur
gery, needle localization was also used
but not specimen radiography, as it
did not contribute to the accuracy of
the procedure. In this group, mammo
grams were obtained postoperatively;
in all instances the lesions sought had
been excised, but in this group the
rate of malignant tumours was very
low. In the senior author’s series this
group was large and resulted in a
fall in malignant to benign ratio in
1978 to 30% from 56% in 1977
(Fig. 1).
Breast examination was thorough
and systematic, and fine-needle aspira
tion was used freely. Although mam
mography was also used extensively,
and its value is unquestioned, espe
cially in nonpalpable lesions, we
found that fine-needle aspiration
allowed us to reject for biopsy many
patients who would have undergone
open biopsy before we began using
needle aspiration. This is only pos
sible when the department of pathol
ogy is keenly interested in cytologic
interpretation. Of great concern was
the fear that we might miss cancers
by adopting a conservative approach.
Patients were therefore followed up
closely, and with a follow-up of
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almost 100% in the senior author’s of patient selection was a reflection
series, there was no delay in carrying of the personal philosophy of each
out necessary biopsy.
surgeon.
There appeared to be a trend
Results
towards earlier detection of carcino
During the past decade, the overall mas near the end of the study in the
ratio of malignant to benign biopsies senior author’s 635 cases; however, a
at Mount Sinai Hospital (excluding the large number of final pathology re
senior author’s personal series) was ports could not be located for the
23% with an annual hospital range earlier years to make this observation
of 19% to 29%. In contrast, the statistically significant (Fig. 3).
senior author’s series showed a pro Discussion
gressive increase over the same decade
from 18% to a high of 56% near the
A low ratio of malignant to benign
end of the study reflecting a greater biopsies not only implies unnecessary
concentration in the area of breast admissions and unnecessary biopsies
cancer and greater use of aspiration but adds unduly to the anxiety of
cytology. The cumulative average of patients in whom an abnormality has
this subgroup of patients was 34% been detected.
(Fig. 1).
Our malignant to benign biopsy
The study included both biopsies ratio of 34% compares favourably
performed on inpatients and out with recent data from other large
patients; however, most biopsies were studies (Table I9"11); however, the
performed in the hospital and required overall hospital ratio of 23% is
a stay of 1 or more days.
somewhat below that expected as an
The biopsy ratios of individual sur ‘‘ideal” biopsy ratio. During the past
geons varied widely. The lowest an
nual biopsy ratio was 8% and highest
56% with four surgeons having a
ratio below 16%. As seen in Fig. 2,
the number of biopsies performed an
nually by individual surgeons did not
influence their ratio. Several surgeons
who performed relatively few biop
sies obtained a high ratio, yet others
who performed a large number of
biopsies had a low ratio.
FIG. 2— Average annual malignant to
It is interesting that each surgeon benign
biopsy ratio for 11 surgeons at
consistently produced predictable an Mount Sinai Hospital. Dotted line repre
nual ratios suggesting that the pattern sents average for senior author.

FIG. 1— Malignant to benign ratio for
open breast biopsies performed bv senior
author (A.A.B.) from 1970 to 1978.
Dotted lines represent corresponding
ratios for Mount Sinai Hospital series.

FIG. 3— Staging of carcinoma at time
of diagnosis. Stage I = no involvement
of axillary nodes, stage II = axillary
nodes contain cancer cells, cross-hatched
= stage undetermined.

Table I— Malignant to Benign Ratio of Open
Breast Biopsies from Various Studies

Series
Mt. Sinai Hospital,
Toronto
DevitO
Degenshein and associates10
Mahoney and associates11

No. of
biopsies

No. malignant

Ratio (range), %

2334
2004
1208
480

606
509
401
126

26 (8 56)
25 (4 - 55)
33 26
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decade the acceptable malignant to
benign biopsy ratio has been reduced
by 50% from 1 in 612 to a currently
accepted 1 in 4 to 1 in 3911 reflecting
greater selectivity in biopsy practices.
Defining an acceptable biopsy ratio
should, as with appendectomy rates,
provide an excellent form of peer re
view of surgical procedures and
stimulate efforts to achieve a con
sistently high quality of surgical care.
By adopting a conservative ap
proach to biopsy, is there a danger of
missing a malignant tumour? We re
commend close follow-up examination
if any suspicious area persists, and to
our knowledge, no patient has subse
quently returned with breast cancer.
When necessary, open breast biop
sies can be performed either as an
inpatient or outpatient procedure.
Once the final diagnosis is available
the surgeon is able to discuss, in an
unhurried way, further options with
his patient. This routine also spares
the patient the uncertainty and
anxiety of not knowing whether she
will still have her breast when she
awakens from surgery.
Our initial impression on reviewing
the stage at which disease is first
being seen (Fig. 3) is that we are
seeing earlier carcinomas; however,
this question has yet to be answered
and is being further studied.
Conclusions
A currently acceptable malignant to
benign ratio appears to be 1 in 3 or
33% . With discrimination, a high
ratio should be maintained and an
alysis of hospital practices can act as
an excellent form of peer review. A
high ratio is also valuable in ensuring
efficient use of surgical beds during
these years of continuing escalation
of costs for in-hospital care.
We acknowledge the efforts of Morag
M. Simpson of the department of sur
gery.

References
1. W i zen berg M J, B r i ck n er TJ j r : C arcinom a
of the breast. Surg G ynecol O bsret 1979;
149: 321-5
2. M artin H E , E l l is E B : B iopsy by n eed le
p u n c tu re a n d a s p ira tio n . A n n Surg 1930; 92:
169-81
3. R im s t e n A, St en k v is t B, J o h a n s o n H,
L ind gren A : The diagnostic accuracy of

palpation and fine-needle biopsy and an
evaluation o f their combined use in the
diagnosis o f breast lesions. R eport on a
prospective study in 1244 w omen with
sym ptom s. A n n Surg 1975; 182: 1-8

VOLUME 24, NO. J, M AY 1981

/

4. R o s e n P, H a jd u SI, R o b b in s G, F o o te F W
j r : Diagnosis of carcinom a o f the b reast by
aspiration biopsy. Surg G ynecol O bstet
1972; 134: 837-8

8. Idem : C ytodiagnosis in the clinical m an
agem ent of m am m ary carcinom a (ab str).
A n n R Coll Physicians Surg C an 1973; 6:
34-5

5. R u ss JE ,

9. D e v itt

W in c h es te r D P, Sca n lo n EP,
C h r ist M A : Cytologic findings of a sp ira 
tion o f tum ors of breast. Surg G ynecol
O bstet 1978; 146: 407-11

6. S traw bridge H TG , B a s sett A A , F oldes I:

Role o f cytology in m anagem ent of lesions
o f the breast. Surg G ynecol Obstet 1981;
152: 1-7

b re a s t

JE :

U nnecessary m orbidity
Can M ed A sso c J

su rg ery .

from
1972;

106: 37-9
10. D e g e n s h e in G A , C ecca relli F , B l o o m N ,
D aluv oy R V : B reast biopsies: ra tio of
m alignant to benign. N Y State J M e d 1976;
76: 1538-9
L J , B ird B L , C o o k e G M , B all
D G : Early diagnosis of breast can c e r:
experience in a c onsultant breast clinic.
Can M ed A ssoc J 1977; 116: 1129-31

11. M a h o n e y

7. B a ssett AA, S traw bridge H TG , F oldes I:
C ytodiagnosis in the clinical m anagem ent
o f m am m ary carcinom a (abstr). In M al t o n i C , C r e spi M, B u r ch P R J (eds): In ter
national Sym posium on C ancer D etection and
Prevention, 2d, Bologna, Italy, A pril 1973.
A bstracts o f papers presented (International
Congress Scries, no. 275), Excerpta M edica,
A m sterdam , 1973, p 76

12. M o o r e FD , W o o d r o w SI, A l ia p o u l io s
MA, W il s o n R E: C arcin o m a of the breast.
A decade of new results w ith old concepts.
N Engl J M e d 1967; 277: 293-6

1981 DAVIS & GECK SURGICAL ESSAY AWARD
FOR RESIDENTS
Davis & Geek annually awards $1000.00 to the surgical resident submitting
the best paper on a surgical topic to the Canadian Journal of Surgery. This
award is intended to promote scientific and literary excellence among
Canadian surgeons in training. In the event that there is no paper of
sufficiently high calibre, the award will not be made.
The conditions of entry for the 1981 award are the following:—
1. Candidates shall currently be engaged in a recognized surgical residency
program leading to eligibility for Fellowship of the Royal College
of Physicians and Surgeons of Canada in one of the surgical specialties
(cardiovascular and thoracic surgery, general surgery, neurosurgery,
obstetrics and gynecology, ophthamology, otolaryngology, orthopedic
surgery, plastic surgery and urology).
2. The material to be submitted shall be in the form of a manuscript
relating to work in which a surgical resident is or has been the prime
or major investigator. Prior oral presentation at a Royal College meeting
or a surgical forum meeting will not be a disqualification, but prior
publication as a formal paper in a journal will. The paper should relate
to any field of surgical interest. The manuscript must conform to the
style requirements of the Journal and must not exceed 3000 words of
text and six tables and/or six figures. Coauthors are permitted on the
understanding that the candidate shall be the first author and that only
the first author shall be eligible for the award.
3. Entries must be received in the office of the Journal no later than
June 30. 1981. Each entry must be submitted to the editorial office of
the Canadian Journal of Surgery, PO Box 8650, Ottawa, Ont. K1G 0G8
with a letter stating that the paper is being submitted as an entry for
the Davis & Geek Surgical Essay Award.
4. All papers submitted shall be the property of the Canadian Journal of
Surgery unless returned to the author without publication.
All papers submitted will be judged by an independent committee com
prising at least one member of the editorial advisory board of the Journal,
one fellow of the Royal College of Physicians and Surgeons of Canada and
one representative of the Canadian Medical Association, together with other
fellows invited to serve at the discretion of the three permanent members
of the committee. For the purpose of judging, the candidates will be
anonymous. The judges’ decision shall be final.
The name of the successful candidate and the title of the paper will be
announced in the November 1981 issue of the Journal.
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To Treat M any M ixed Infections
W ithout M ultiple A

ntibiotics

In intra- abdominal and pelvic infections, MEFOXIN*
— an effective single agent — provides bactericidal activity against
many mixed aerobic/anaerobic organisms including B. fragilis.
In many cases MEFOXIN* may eliminate the need for combination
antibiotic therapy which could include potentially more toxic agents.
MEFOXIN* is generally w ell tolerated... Data from
108 studies conducted world-wide on 2277 patients with infections at
various sites, 1924 of whom received MEFOXIN* revealed the drug to be
well tolerated by more than 90% of patients.1

The First C ephamycin D erivative

rtVIefoxin

(CEFOXITIN SO DIUM FOR INJECTION)

For S ingle-Antibiotic Therapy
O f M any M ixed Infections
MEFOXIN* is not active against Pseudomonas spp.,
most strains of enterococci, many strains of
Enterobacter cloacae, and methicillin-resistant
staphylococci.
1. van Winzum, C.: Clinical safety and tolerance of cefoxitin sodium: an overview,
J Antimicrob Chemother 4 (Suppl B): 91-104. 1978.

3koMt

ADVERSE REACTIONS

ANTIBIOTIC
ACTION
In vitro studies demonstrate that the bactericidal action of MEFOXIN*, a cephamycin
derived from cephamycin C, results from the inhibition of bacterial cell wall synthesis.
Evidence suggests that the methoxy group in the 7Ot position is responsible for the
resistance of MEFOXIN* to degradation by bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
The treatment of the following infections when due to susceptible organisms:
1 — Intra-abdominal infections such as peritonitis and intra-abdominal abscess.
2 — Gynecological infections such as endometritis and pelvic cellulitis.
3 — Septicemia.
4 — Urinary tract infections.
5 — Lower respiratory tract infections.
6 — Bone and joint infections caused by Staphylococcus aureus.
7 — Soft tissue infections such as cellulitis, abscesses and wound infections.
Appropriate culture and susceptibility studies should be performed to determine the
susceptibility of the causative organism(s) to MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however, modification of the treatment may be
required once these results become available.
Organisms particularly appropriate for therapy with MEFOXIN* are:
Gram positive
Staphylococci, penicillinase producing and non-producing.
Streptococci excluding enterococci.
Gram nagativa: (bata-lactamasa producing and non-producing strains)
E. Coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Hemophilus influenzae
Providencia species
Anaarobas
Bacteroides fragilis
MEFOXIN* may also be appropriate for the treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that MEFOXIN* can be administered to patients
who are also receiving carbenicillin, gentamicin, tobramycin, or amikacin (see PRECAU
TIONS and ADMINISTRATION).
Intravenous Administration
The intravenous route is preferable for patients with bacteremia, bacterial septicemia, or
other severe or life-threatening infections, or for patients who may be poor risks because
of lowered resistance resulting from such debilitating conditions as malnutrition, trau
ma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or
impending.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who have shown hypersensitivity to cefoxitin or
to the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted, careful inquiry should be made to determine
whether the patient has had previous hypersensitivity reactions to MEFOXIN*, cephalo
sporins, penicillins or other drugs. MEFOXIN* should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence of partial cross-allergenicity between
cephamycins and the other beta-lactam antibiotics, penicillins and cephalosporins.
Severe reactions (including anaphylaxis) have been reported with most beta-lactam
antibiotics.
Any patient who has demonstrated some form of allergy, particularly to drugs, should
receive antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs, administration of the drug should be
discontinued. Serious hypersensitivity reactions may require treatment with epinephrine
and other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced when MEFOXIN* is administered to patients
with transient or persistent reduction of urinary output due to renal insufficiency (see
DOSAGE and ADMINISTRATION) because high and prolonged serum antibiotic concen
trations can occur from usual doses.
In patients treated with MEFOXIN* a false-positive reaction to glucose in the urine may
occur with Benedict's or Fehling's solutions but not with the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine values in serum may occur if serum
concentrations of cefoxitin exceed 100 mcg/mL. Serum samples from patients treated
with MEFOXIN* should not be analyzed for creatinine if withdrawn within two hours of
drug administration.
Increased nephrotoxicity has been reported following concomitant administration of
cephalosporins and aminoglycoside antibiotics.
The safety of MEFOXIN* in the treatment of infections during pregnancy has not been
established. If the administration of MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated benefits be weighed against possible
hazards to the fetus. Reproductive and teratogenic studies have been performed in mice
and rats and have revealed no evidence of impaired fertility or harm to the fetus due to
MEFOXIN*.
Cefoxitin has been observed in the milk of nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition is essential and if super-infection occurs
during therapy, appropriate measures should be taken. Should an organism become
resistant during an antibiotic therapy, another antibiotic should be substituted.
The safety and efficacy of MEFOXIN* for the treatment of infections in infants and
children have not yet been established.

MEFOXIN* is generally well tolerated. Adverse reactions rarely required cessation of
treatment and usually have been mild and transient.
Local Reactions
Thrombophlebitis has occurred with intravenous administration. Some degree of pain
and tenderness is usually experienced after intramuscular injections using water. Indu
ration has occasionally been reported.
Allergic
Maculopapular rash, urticaria, pruritus, eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal
Diarrhea has been reported rarely.
Blood
Transient leukopenia and neutropenia have been reported Some individuals may develop
positive direct Coombs tests during therapy with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum LDH, and serum alkaline phosphatase have
been reported.
Kidney
Elevations in serum creatinine and/or blood urea nitrogen levels have been observed. The
role of MEFOXIN* in changes in renal function tests is difficult to assess, since factors
predisposing to prerenal azotemia or to impaired renal function have often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no specific antidote is known. MEFOXIN* can
be eliminated by dialysis in patients with renal insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN* may be administered intravenously or intramuscularly when required. (See
monograph for reconstitution directions for each route.)
Adult Dotage
The usual adult dosage is 1 g or 2 g of MEFOXIN* every 6 to 8 hours. Dosage and route of
administration should be determined by severity of infection, susceptibility of the
causative organisms, and condition of the patient. The usual adult dosages are shown in
the table below.
•i

Usual Adult Dosage
Type uf Infection
Uncomplicated forms* of
infections such as
pneumonia, urinary tract
infection, soft tissue infection
Moderately severe or
severe infections

Daily Dosage
3-4 grams

6-8 grams

Frequency and Route
1 gram every 6-8 hours
IV or IM
1 gram every 4 hours
or
2 grams every 6-8 hours IV
2 grams every 4 hours
or
3 grams every 6 hours IV

Infections commonly
12 grams
needing antibiotics in
higher dosage (e.g.
gas gangrene)
•Including patients in whom bacteremia is absent or unlikely.

Therapy may be started while awaiting the results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic streptococcal infections should be main
tained for at least 10 days to guard against the risk of rheumatic fever or glomerulo
nephritis. In staphylococcal and other infections involving a collection of pus, surgical
drainage should be carried out where indicated.
Dosage in Adult Patients with Impaired Renal Function
MEFOXIN* may be used in patients with reduced renal function but a reduced dosage
should be employed and it is advisable to monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial loading dose of 1 g to 2 g should be given.
After a loading dose, the following recommendations for maintenance dosage may be
used as a guide:
RENAL
CREATININE
FUNCTION
CLEARANCE
OOSE
FREQUENCY
mL/min
Mild impairment
1-2 g
every 8-12 hrs
5 0 -3 0
Moderate impairment
every 12-24 hrs
2 9 -1 0
1 -2 fl
every 12-24 hrs
Severe Impairment
9 -5
0 .5 -1 g
every 24-48 hrs
Essentially no function
<5
0 .5 -1 g
In the patient undergoing hemodialysis, the loading dose of 1-2 g should be given after
each hemodialysis, and the maintenance dose should be given as indicated in the table
above.

DOSAGE FORMS
Sterile MEFOXIN* is a dry white to off-white powder supplied in vials and infusion bottles
containing cefoxitin sodium as follows:
1 g cefoiitin equivalent
2 g cefoiitin equivalent
No. 3356 in vials
No. 3357 in vials
No. 3368 in infusion bottles
No. 3369 in infusion bottles
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Surgical Reconstruction of the Quadriplegic Hand
I ain G. D omisse,

mb , ch b , frcs [c],* W. R obert H arris , md , frcs [c ]* and
E. P eter McDougali., md, FRCs[c]t

Fifty-four quadriplegic patients had
reconstructive surgery to improve hand
function. The most useful procedure
was transfer of the extensor carpi
radialis longus to the flexor digitorum
profundus. This provided major
improvement in finger flexion and
significantly improved activities of
daily living. The most useful procedure
to improve thumb pinch was a
modification of the Royle-Thompson
procedure, in which the insertion of
flexor digitorum sublimis to fourth
finger was transferred to the thumb,
and the brachioradialis was used as
its motor. Interphalangeal fusion of
thumb to provide increased stability
for pinch was not considered
worthwhile.
Cinquante-quatre quadriplegiques
ont subi une chirurgie reconstructive
destinee a ameliorer le fonctionnement
des mains, (.'intervention la plus
utile a consiste a transfere le muscle
premier radial externe a la place
du muscle flechisseur commun profond
des doigts. Ceci a permis une
amelioration majeure de la flexion
des doigts et a ameliore sensiblement
les activites de la vie courante.
L’intervention la plus utile pour
ameliorer la prehension du pouce a ete
une modification de I'operation de
Royle-Thompson alors que I'insertion
du muscle flechisseur commun
superficiel du quatrieme doigt est
transfere au pouce et que le muscle
humerostylo-radial est utilise comme
muscle moteur. La fusion interphalangienne du pouce destinee a assurer
une meilleure stability pour la
prehension n'a pas ete consideree
valable.

sity of Toronto with 54 quadriplegic
patients in whom we performed 76
operations (22 bilateral) on the hand.
The follow-up was 1 to 27 years.

medial epicondyle of the humerus so
that it would be isometric and prevent
simultaneous elbow flexion when the
fingers were flexed (Fig. 1).

Patients

Flexor Tenodesis

The 54 patients, ranging in age
from 18 to 56 years fell into two
groups: those in whom the fifth cerv
ical root still functioned (group 1) and
those in whom the sixth cervical root
was functional (group 2). Group 1 pa
tients had active elbow flexion and
some activity in the brachioradialis
and pronator teres muscles. Group 2
patients had normal power of elbow
flexion, normal brachioradialis ac
tivity and good (but not normal) power
in the pronator teres and both extensor
carpi radialis longus muscles.
In group 1 the biceps was used as a
motor to improve finger flexion. In
group 2, the extensor carpi radialis
longus was used to improve finger
flexion and the brachioradialis to im
prove thumb pinch or opposition. An
alternative method of improving
finger flexion was tenodesis of the
flexor digitorum profundus tendons
to the radius.

The flexor digitorum profundus
tendons were severed at their mus
culotendinous junction and passed
en masse through a drill hole in the
radius and sutured to themselves with
sufficient tension to hold the fingers
semiflexed with the wrist in a neutral
position (Fig. 2). When the wrist was
actively dorsiflexed, passive flexion of
the fingers occurred.

Surgical Techniques
Biceps to Flexor Digitorum
Profundus

The insertion of the biceps tendon
was severed from the bicipital tuber
osity and attached by a free tendon
graft (palmaris longus or toe extensor)
to the musculotendinous junction of
the flexor digitorum profundus. The
extension was routed behind the

Extensor Carpi Radialis Longus
to Flexor Digitorum Profundus

In this procedure it is important to
make certain that both extensor carpi
radialis longus and brevis are function
ing, because sometimes the brevis re
ceives most of its innervation from
the seventh cervical root and would
be weak or paralysed when the sixth
cervical root had survived. In most
cases the activity of each muscle can
readily be determined by clinical
examination alone. If any doubt
existed, the tendons of extensor carpi
radialis longus and brevis were first
exposed at their insertions through
a small incision under local anesthesia.
The patient was then asked to dorsiflex his wrist. If this verified that
both extensors were active, the patient
was given a general anesthetic and the
main procedure was carried out.
The long extensor was detached
from its insertion in the second meta
carpal, withdrawn through a second

To provide some guidelines as to how
hand function in quadriplegic patients
may best be improved we have re
viewed our experience at the UniverFrom the *division of orthopedic
surgery, Toronto General Hospital,
and t division of plastic surgery,
St. Michael’s Hospital, Toronto, Ont.
Accepted for publication Sept. 8, 1980
Reprint requests to: Dr. W. Robert
Harris, Rm. ENI-234, Toronto
General Hospital, 101 College St.,
Toronto, Ont. M5G 1L7
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New Addition to the PNh-UP T-amily

Now PRE-OP sponges with
chlorhexidine gluconate:
The most popular antiseptic and the most popular
sponges com binedjnto a complete system.

PRE-OP* sponges with
chlorhexidine... the advantages of
the com plete system:

\

■PRE-OP and PRE-OP II.. .choice of sponge or
sponge/brush formats.
■Excellent antiseptic.. .chlorhexidine has a
broad antibacterial spectrum, is bacteric/da/ind
fungicidal, has a rapid bacterial kill rate, M
persistent effect, and is safe and virtually }
non-irritating.
• Maximum convenience.. complete system
eliminates need for a separate brush.
• Economical, controlled antiseptic dose.
eliminates the frequent overuse of liquid soaps
from dispensers.
• Sterile, single-use sponges or sponge/
brushes.. .can’t harbor pathogenic organisms
as soap dispensers11z3> and reusable
brushes can.
• Always ready to use... no dispenser refilling, no
clogging, no mechanical problems, and no
:
maintenance.
• Fast, pleasant lather.. .and special
emollient-containing formula is easy on the
hands.
• Minimal possibility of reactions.. .dilution during
use avoids high antiseptic concentration on .
skin.
• Superior removal of resident as well as transient
micro-organisms.. .sponge or sponge/brush
format more likely to dislodge resistant bacteria.

And, most importantly, proven
chlorhexidine effectiveness:
Improved log kill.. .the recommended scrub
time of PRE-OP and PRE-OP II sponges with
chlorhexidine provides a significantly improved
log kill when compared to that achieved with
the chlorhexidine soap recommended scrub
time.
Standard "Glove Juice" Antiseptic test proves
that the highly recommended 5-minute scrub
effectively utilizes the full potential of |1 ||
chlorhexidine and yields a significantly greater
log kill ...a valuable extra margin of safety.
References
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Atria North, 2255 Sheppard Ave. E., Suite E440
Willowdale, Ontario M2J 4Y5

A tradition of innovation.

•

H L j jlm ch

Hospital

Infections,"ed byJV Bennett
and PS Bradm an Little. Brown & Co.. • •. v & j V :
fa y a p l
Boston (1979)
2 A.C. SteereandG.F. Mallison, “ Handwashing Practices for the Prevention ol
Nosocomial Infections," Annals of Internal Med 83:683-690 ( 1975)
3 D.W. Burdon and J.L. Whitby, "Contamination of Hospital Disinfectants with
Pseudomonas Species." Brit Med J o u r2 153-156(1967)
PRE-OP is a registered trademark of Cyanamid Canada Inc.

incision higher in the forearm, then
passed subcutaneously around the
radial side of the forearm to a third
incision over the flexor tendons. It
was then passed through a slit in each
flexor digitorum profundus tendon
and sutured to each tendon in turn
(Fig. 3). It was important to obtain the
right amount of tension in each finger
flexor. To do this it was helpful to
bandage the fingers over a roll (Fig. 4)
and to attach the transferred tendon
to each profundus tendon with suf
ficient tension that this position was
maintained.
In most of the patients treated by
one of us (E.P.M.), the extensor
longus tendon was attached to the
flexor pollicis longus tendon in addi
tion to the flexor digitorum profundus
mass.
Transfers to Improve Thumb
Function
To improve side-to-side or “key”
pinch the brachioradialis tendon was
transferred directly to the flexor pol
licis longus. The former was detached
from its insertion on the styloid
process of the radius and passed sub
cutaneously into the volar wound
used for the transfer of the extensor
carpi radialis longus. The flexor polli
cis longus tendon was then divided
proximal to the carpal tunnel and
the brachioradialis sutured to its distal
end with sufficient tension to hold the
thumb against the side of the index
finger with the wrist in a neutral
position (Fig. 5).
To improve opposition of the
thumb, two techniques were used. The
first was a modification of the Royle-

Thompson flexor digitorum sublimis
transfer from the fourth finger.1 The
distal end of that tendon was trans
ferred to the thumb in the usual way.
The tendon was then divided proximal
to the carpal tunnel and attached to
the brachioradialis which had been
separated from the radial styloid (Fig.
6).

In the second method, the brachio
radialis was detached from the radius
and then, by an extension of the palmaris longus tendon, passed subcu-

taneously across the dorsum of the
wrist, around the ulna and sub
cutaneously across the palm to the in
sertion of the abductor pollicis brevis
(Fig. 7).
Results

Transfer of biceps to flexor digi
torum profundus, done in four pa
tients, functioned successfully for the

FIG. 4— Bandaging fingers over roil
helps to obtain proper tension in each
slip of flexor digitorum profundus.

FIG. 3—Suture of rerouted extensor
carpi radialis longus to tendons of flexor
digitorum profundus.

FTG. 5—Transfer of brachioradialis
(BR) to flexor pollicis longus (FPL) to
improve side-to-side thumb pinch.
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first year but then failed because of
attrition of the tendon where it
passed behind the epicondyle.
Tenodesis of the flexor digitorum
profundus tendon to the radius was
done in one patient. It failed after a
year because of wear on the tendons
where they passed through the radius.
Transfer of extensor carpi radialis
longus was done in 58 hands of 46
patients (12 bilateral). Review of 40
patients showed that 33 had excellent
results with strong finger flexion in
any position of the wrist (Fig. 8). All
were pleased with improved hand
function which substantially increased
their activities of daily living. Results
in six were rated as fair because the
transplant was too weak initially. One
patient had a good result at first but
the transfer failed after 1 year because
of an unexplained ascending myelo
pathy. A significant problem in this
group was insufficient power in the
index finger. This emphasizes the im
portance of obtaining equal tension in
each profundus tendon.
Direct transfer of brachioradialis
to the flexor pollicis longus was done
in four patients. Three of these were
reviewed. While some improvement in
side-to-side pinch was obtained (Fig.
10), its active power was weak and
improvement seemed mainly to be the
result of a tenodesis effect.
The modified Royle-Thompson pro
cedure was done on 12 thumbs in
nine patients (in three bilaterally).
While an opposed position of the
thumb was maintained in all, active
power was weak but the increase in
function was better than in the pre
ceding group.
Transfer of the brachioradialis via
a tendon extension to the first meta
carpal was done in nine thumbs of
seven patients (two bilaterally). Six of
these were reviewed. The transfer was
functioning solely as a tenodesis and
the improvement in function was less
than in the preceding two groups.
Interphalangeal fusion of the thumb
to provide greater stability was done
in five of the patients who had tendon
transfers to the thumb. It contributed
little to thumb function.

had been recorded, any improvement
that occurred took place within 6
months. Thus, we believe tendon
transfers should be done early at
about the time the patient starts to
use a wheelchair. Wrist fusion, which
seems logical to free motors to im
prove finger function is not recom
mended. In a few patients seen earlier
and not included in this series, the
fixed position of the wrist resulted in
pressure sores on the ulnar side of the
hand from propelling a wheelchair.
The general principles of tendon
transfer apply. The joints to be ac
tivated must be free of contractures.
Several of our patients required pre
liminary splinting or myotomy to re
lieve flexion deformities of the fingers.
Some form of protective sensation is
desirable, though anesthesia did not
necessarily preclude a satisfactory
result.
Biceps transfer to the finger flexors
provided appreciable initial improve
ment. In those patients with biceps
function only, the principle is worth
pursuing but tendon fraying behind
the medial epicondyle must be pre
vented. One ingenious suggestion
(Dewar FP: Unpublished data, 1978)
makes use of a compound graft of one
of the peroneal tendons and a portion
of the fibular malleolus to preserve
an intact fibro-osseous tunnel for the
rerouted tendon. We have not at
tempted this.
By far the most satisfactory proce
dure was transfer of the extensor carpi

radialis longus to the flexor digitorum
profundus. This provided strong, use
ful finger flexion. It requires attention
to detail to obtain equal tension on
each finger.
When the flexor pollicis longus was
included in the transfer, there was
useful improvement of thumb flexion.
Of the three procedures used to im
prove thumb pinch, the modification
of the Royle-Thompson method was
most useful. Transfer of the brachio
radialis to flexor pollicis longus was
disappointing and did not, contrary to
Moberg’s3 belief, enhance side-to-side
pinch. The principal problem with
the brachioradialis as a motor is its
short excursion and the fact that it is
not in phase with the flexor pollicis
longus and thus requires careful train-

F IG . 7— T ransfer of brachioradialis
via tendon graft around ulnar side of
wrist to im prove thum b opposition. PI.
= palm aris longus.

D iscu ssion

We found, as have others,2 that the
radiologic level of the injury in the
neck did not always correspond with
the clinical findings. Moreover, asym
metry of neurologic change in each
upper extremity was not uncommon.
The timing of the procedures varied
in our group from a few months to
several years after the accident. How
ever, where accurate muscle grading
320

FIG . 6— T ransfer of brachioradialis
via flexor digitorum sublimis (FDS) to
improve thum b opposition. APB = ab
ductor pollicis brevis.
V O L U M E 24, NO.
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F IG . 8— Successful transfer of exten
sor carpi radialis longus to flexor digi
torum profundus. Exam iner’s hands are
at top.

T H E C A N A D IA N JO U R N A L O F SU RG ERY

ing to be of any use. Interphalangeal
fusion of the thumb to improve thumb
stability did not appreciably improve
function.
Conclusions

Tendon transfers to improve func
tion in the quadriplegic hand are
worthwhile.
Active flexion can be restored to
the finger in high cord lesions by
transfer of the biceps to the flexor
digitorum profundus. While all of
these ultimately failed in our series,
the initial improvement was so suc
cessful we believe the principle is
worth pursuing.
When the extensor carpi radialis
longus is functioning, it provides the
best improvement in finger flexion
when transferred to the flexor digi
torum profundus.
The most useful transfer to im
prove thumb function is a modifica
tion of the Royle-Thompson transfer
of the flexor digitorum sublimis.
Flexor tenodesis and wrist fusion
are not recommended. Interphalan
geal fusion of the thumb to improve
its stability does not seem necessary.
■: . i

We are indebted to Drs. W.A. Brown
of Toronto and F.P. Dewar of Collingwood for access to their files of many of
the patients reviewed. We also thank
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assistance in locating patients.
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July 1981 issue
In this issue will appear five
presentations and a panel discus
sion which make up the second
part of the Royal College—
Canadian Oncology Society sym
posium on breast cancer. Also
included will be four papers pre
sented at the 12th annual meeting
of the Canadian Association of
Pediatric Surgeons in June 1980.
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To lower
blood pressure
during
anesthesia

reduces excessive
blood loss

Precautions

for controlled hypotension during anesthesia
Rx Summary
‘Nipride' is only to be used as an infusion with sterile 5% dextrose
in water without preservatives. Not for direct injection.
Indications
‘Nipride’ is indicated for producing controlled hypotension during
anesthesia to reduce bleeding in surgical procedures where deemed
appropriate. Benefit-risk ratio should be carefully considered on an
individual basis.
Contraindications
In the treatment of compensatory hypertension, e.g. arteriovenous
shunt or coarctation of the aorta. It is also contraindicated in physically
poor-risk patients (A.S.A. Risk 5), in patients with uncorrected anemia
or hypovolemia or in those with known inadequate cerebral circulation.
In patients with liver disease, severe renal disease, Leber's optic
atrophy and disease states associated with vitamin B 12 deficiency.
Warnings
‘Nipride’ is only to be used as an infusion with sterile 5% dextrose
in water without preservatives. Not for direct injection. Infusion rates
greater than 8 jug/kg/minute are virtually never required. If at this
rate an adequate reduction in blood pressure is not obtained within
10 minutes, administration of ‘Nipride’ should be stopped.
Fatalities due to cyanide poisoning have occurred following sodium
nitroprusside administration. One factor is common to all known
cases, namely that large amounts of nitroprusside were infused at
high rates. Since detoxification relies upon enzymatic action, the
rare possibility of deficient or atypical enzymes occurring in humans
should always be considered. Patients most apt to run into difficul
ties are those who are resistant to the hypotensive effect or those
in whom maintenance at the selected blood pressure level is difficult
or impossible.
Constant attention to the patient's dose-response characteristics
is mandatory. If infusion rates are in excess of 8 ^ig/kg/minute deter
mine the nature of the response (effective constant response at
higher dose; tachyphylactic; resistant - none or less than expected).
As soon as either tachyphylaxis or resistance is determined the infu
sion of ‘Nipride’ should be discontinued immediately. In abnormal
responders it has been noted that metabolic acidosis may occur
at higher doses.
Caution should be exercised in using 'Nipride' in patients with hypo
thyroidism or severe renal impairment.
Blood levels of thiocyanate should be determined if treatment is to
be extended especially in patients with severe renal dysfunction.
As long as blood thiocyanate levels do not exceed 10 m g /100 ml, it is
probably safe to continue with the infusion. Peritoneal dialysis can
be helpful if too high levels of thiocyanate are found.
Hypertensive patients are more sensitive to the intravenous effect
of sodium nitroprusside than are normotensive subjects. Patients
receiving concomitant antihypertensive medications (especially
hydralazine or hexamethonium) are more sensitive to the hypotensive
effect of sodium nitroprusside and the dosage of 'Nipride' should
be adjusted downward accordingly.
The following Warnings apply to the use of 'Nipride' for controlled
hypotension during anesthesia:
1. Extreme caution should be exercised in patients who are especially
poor surgical risks (A.S.A. class 4 and 4E).
2. Tolerance to blood loss, anemia and hypovolemia may be dimin
ished. If possible, preexisting anemia and hypovolemia should be
corrected prior to employing controlled hypotension.
3. Hypotensive anesthetic techniques may alter pulmonary ventilation
perfusion ratio. Patients intolerant of additional dead air space
at ordinary oxygen partial pressure may benefit from higher oxygen
partial pressure.
4. Resistance and tachyphylaxis occur more frequently in normoten
sive patients infused with sodium nitroprusside. Induction of delib
erate hypotension in healthy young individuals may prove to be
more difficult than in other segments of the population.
5. Upon discontinuance of the sodium nitroprusside infusion for the
purpose of controlled hypotension during anesthesia a rebound
hypertension has been observed on rare occasions.

Adequate facilities, equipment and personnel should be available
for frequent and vigilant monitoring of blood pressure. When the infu
sion is slowed or stopped, blood pressure usually begins to rise imme
diately and returns to pretreatment levels within one to ten minutes.
It should be used with caution and initially in low doses in elderly
patients, since they may be more sensitive to the hypotensive effects
of the drug.
If, in the clinical situation, stress induced by pain or m anipulation
is reduced or eliminated during ‘Nipride’ infusion, the patient could
experience a greater than expected reduction in blood pressure
unless the rate of infusion is adjusted downward as required.
'Nipride' tends to deteriorate in the presence of light. Therefore, the
infusion bottle should be wrapped with aluminum foil or other opaque
material. Solutions o f ‘Nipride’ should not be kept or used longer
than four hours. 'Nipride' in aqueous solution yields the nitroprusside
ion, which reacts with even minute quantities of a wide variety of
organic and inorganic substances to form usually highly coloured
reaction products (blue, green or dark red). If this occurs, the infusion
should be replaced as quickly as possible.
Adverse reactions
Nausea, retching, emesis, diaphoresis, apprehension, headache,
restlessness, agitation, muscle twitching, retrosternal discom fort and
chest pain, palpitations, dizziness, faintness, weakness, rash, abdo
minal pain, confusion and somnolence have been noted with too
rapid reduction in blood pressure. These symptoms rapidly disap
peared with slowing of the rate of infusion or temporary discontinua
tion of infusion and did not reappear with continued slower rate
of administration.
Irritation of the injection site may occur. Methemoglobinemia and
one case of hypothyroidism following prolonged therapy have been
reported.
Dosage and administration (for controlled hypotension)
Use of ‘Nipride’ in anesthetized normotensive patients undergoing
deliberate hypotensive surgery must be restricted to carefully
selected cases. There is a possibility of an abnormal response
occurring in normotensive patients. In this event, the infusion of
‘Nipride’ should be discontinued immediately. (See Warnings).
The contents of a 50 mg 'Nipride' vial should be dissolved in 3 ml
of sterile dextrose in water without preservatives. No other diluent
should be used. Depending on the desired concentration, all of the
prepared stock solution should be diluted in 500 or 1000 ml of 5 per
cent sterile dextrose in water and promptly wrapped in aluminum
foil or other opaque material. Both stock solution and infusion solu
tion should be freshly prepared and any unused portion discarded.
The freshly prepared solution for infusion has a very faint brownish
tint. If it is highly coloured, it should be discarded. (See Precautions).
The solution should not be kept or used longer than four hours from
initial reconstitution. The infusion fluid used for the administration
of 'Nipride' should not be employed as a vehicle for simultaneous
administration of any other drug.
'Nipride' dosage varies considerably from patient to patient, hence
the need for individual titration. The infusion should be started at
the lower dosage range, 0.5 jug/kg/minute and increased by
0.2 /ig/kg/m inute every 5 minutes until the desired reduction in
blood pressure is obtained. The blood pressure usually starts to drop
immediately or at least within a few minutes. Continuous monitoring
of the blood pressure is necessary. Blood pressure should not be
allowed to drop at too rapid a rate and systolic pressure should not
be lowered below 60 mm Hg.
Infusion rates greater than 8 fig/kg/m inute should rarely be used.
The maximum recommended dose is 800 jig/m inute.
'Nipride' should be administered by an infusion pump, micro-drip
regulator or any similar device that will allow precise measurement
of the flow rate. Avoid extravasation. The rate should be adjusted
to maintain the desired hypotensive effect, as determined by frequent
blood pressure determinations.
For the use of 'Nipride' in the treatment of hypertensive crises please
refer to the Product Monograph.
Supply
'Nipride' is supplied in 5 ml amber-coloured vials containing the
equivalent of 50 mg sodium nitroprusside for dilution with 5 percent
sterile dextrose in water (available in packages of 10).
Product Monograph available on request.
* Reg. Trade Mark for sodium nitroprusside ‘Roche’
®Reg. Trade Mark

Can. 8042

(sodium nitroprusside)

Usage in pregnancy
The safety of 'Nipride' in women who are or who may become preg
nant has not been established; hence, it should be given only when
the potential benefits have been weighed against possible hazard
to mother and fetus.
Usage in children
The safety of 'Nipride' in children has not been established. Clinical
experience is limited.

Hoffm ann-La Roche Limited
Vaudreuil, Quebec
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BOOK REVIEWS

ANESTHESIA FOR ORTHOPAEDIC
SURGERY. Edited by Howard I..
Zauder. 229 pp. Illust. F.A. Davis
Company, Philadelphia, 1980. $36.
(Can.); $30 (US). ISBN 0-8036-9771-6.

The explosion in orthopedic operative
technology in the last two decades com
pletes the emergence of that specialty
from the “strap-and-buckle” era into
the world of independent surgical dis
ciplines. Pari passu, the increasing de
mands for more varied, flexible and safer
techniques of anesthesia have been ad
mirably met.
Compiled by Dr. Zauder with the help
of distinguished contributors from both
fields, this excellent volume will serve
as a valuable reference for those in
volved in the widening spectrum of
orthopedic operations. Appropriately,
parallel subjects such as evaluation of
the patient with multiple injuries, post
operative respiratory support, transfu
sion and its complications, and preven
tion and treatment of fat embohsm are
covered. I am not sure that hemophilia
deserves a chapter of its own, but that
section is concise and informative.
Throughout, bibliographies are ample
and complete. The section on regional
anesthesia is well illustrated, although
illustrations in the rest of the volume
generally are sparse. A discussion of
hypotensive anesthetic technique in the
section on total hip replacement details
an advance that I have found most
valuable.
While this volume is directed prin
cipally towards anesthesiologists, ortho
pedists at all stages of training and prac
tice will find that it adds another dimen
sion to their appreciation of immediate
problems in clinical management.
M ark G . L azansky ,

m d , facs

60 East End Ave.,
New York, NY
FIRST CLINICAL CONFERENCE ON
CONGENITAL HEART DISEASE.
Based Upon Proceedings of a Con
ference Held in Los Angeles, Cali
fornia, January 12 and 13, 1979.
Edited by Bernard L. Tucker and
George G. Lindesmith. 346 pp. Illust.
Grune & Stratton, Inc., New York;
Academic Press Canada Limited, Don
Mills, Ont., 1979. $22.50. ISBN 08089-1199-6.

Contained in this monograph are papers
presented at the first clinical conference
324

on congenital heart disease held in Los
Angeles in January 1979. That the book
was released during that same calendar
year is a very impressive accomplish
ment, testifying to the organization of
Drs. Tucker and Lindesmith and to the
commitment and technologic expertise
of the publishers. The book certainly
does not reflect this rapid preparation;
the printing and illustrations are all
good.
The subject matter consists primarily
of conditions first treated surgically,
beginning 40 years ago: patent ductus
arteriosus, vascular rings, coarctation of
the aorta and cyanotic heart disease
(treated by systemic to pulmonary
shunts). The operations used to treat
these conditions constituted for many
years the basic repertoire of John C.
Jones to whose memory the book is
dedicated and who initiated heart sur
gery on the west coast by performing
ligation of a patent ductus arteriosus in
March 1939.
Each of the four major sections is
comprised of three to five papers by
recognized authorities focusing on cur
rent controversies and advances in our
knowledge. Thus, in the section on co
arctation, Castaneda and Norwood dis
cuss their surgical experience with re
sidual coarctation. In the chapters on
cyanotic heart disease, Edmunds and
associates discuss total correction versus
staged repair for tetralogy of Fallot. The
section on vascular compression of the
trachea and esophagus includes a
thorough, beautifully illustrated, author
itative presentation by Jesse Edwards,
documenting the anatomy and embry
ology of this group of anomalies. The
section on patent ductus arteriosus in
cludes presentations on surgical ligation
in the premature newborn, others on
pharmacologic manipulation in the
neonate who is cyanotic or acyanotic
and the current state of surgery for
patent ductus arteriosus.
Several sections conclude with worth
while discussion between the participants
and the book concludes with a delightful
dialogue between Drs. Helen Taussig
and Louis E. Martin reminiscing over
a combined professional experience ex
ceeding a century.
The book will be of great interest to
pediatric cardiologists and cardiac sur
geons and to those training in these
fields. It is a first-class effort and it is
hoped that volumes will be forthcoming
to document subsequent conferences or
VOLUME 24, NO. 3, M AY 1981
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ganized by the Children’s Hospital of
Los Angeles.
A nthony R.C. D obell , md , facs,
FRCS[C]

Director,
Division of cardiovascular and
thoracic surgery,
Montreal Children's Hospital,
Montreal, PQ
A HANDBOOK OF SURGICAL DIA
THERMY. 2nd ed. J.P. Mitchell, G.N.
Lumb and A.K. Dobbie. 127 pp. Illust.
John Wright & Sons Ltd., Bristol.
1978. Price not stated. ISBN 0-72360449-5.

This small handbook presents the basic
principles and hazards of surgical dia
thermy. Accident prevention based on
thorough knowledge of these principles
is the main theme of this text. All links
involving the electrical circuit including
the patient through whom the electricity
passes are discussed in detail. The tech
nologic aspects with regard to power
units, power outputs and wave-forms of
electrical energy are clearly described.
Chapters on the specific use of surgical
diathermy in urology, neurology and
gynecology and others on medicolegal
problems and maintenance of equip
ment round out this useful guide and
reference book. I recommend this text
for residents in training, surgeons and
operating room personnel.
M ax B. K adziora, md , frcs [c],
FACOG

Ste. 202,
1105 Carling Ave.,
Ottawa, Ont.
POSTGASTRECTOMY AND POST
VAGOTOMY SYNDROMES. H.D.
Becker and W.F. Caspary. 188 pp.
Illust. Springer-Verlag New York, Inc.,
New York, 1980. $78. ISBN 0-38709445-8.

This monograph, written in flawless,
flowing English, presents the results of
collaboration between an experienced
gastroduodenal surgeon and a gastroen
terologist. The subject matter is well
organized and succinctly presented, lead
ing from early gastrectomy through all
the developments of gastroduodenal sur
gery to the present surgical methods.
Detailed comparisons of various proce
dures are presented in numerous tables.
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These tables are the results of random tomy bone disease and special aspects of
ized prospective studies carried out in total gastrectomy are all presented with
Europe, England and the United States. notes on the pathophysiology and man
Obvious conclusions based on these agement.
results are drawn and discussed.
The postvagotomy syndromes are not
The syndromes following gastrectomy
as frequent, less severe and generally
and vagotomy are presented separately
more easily managed. They are dis
and discussed in detail. The pathophy cussed under the headings: physiology,
siology is especially well done and is symptomatology and management.
particularly helpful when applied to the
At the end of each section is a useful
investigative and treatment techniques. reference list that would be invaluable
Considerable space is devoted to the to the postgraduate student. The prac
methods available for function testing tising gastroenterologist or surgeon would
in the presence of ulcer disease, dumping find this book interesting, at times en
syndrome, loop syndromes and diarrhea. tertaining and always helpful. It is con
The drawbacks and advantages of the cise, presenting easily assimilated facts
various techniques are presented and without any padding. For such a small
book a large and complex subject is
compared and valid conclusions drawn.
remarkably reduced and presented in
The syndromes are then considered and
analysed and the different forms of readily digestible form.
management for each syndrome are out
T.P. L eadman , md , c m , frcs, fr cs [c ]
lined and compared and conclusions are
reached.
Department of surgery,
The postgastrectomy problems are pre
Grace General Hospital,
sented first and constitute the bulk of
Ottawa, Ont.
the book. Many of the problems are
common and occur in up to 50% of
patients in some series. Early and late
dumping syndromes are distinguished, PRE- AND POSTOPERATIVE EVALU
both in clinical presentation and man
ATION OF SURGICAL PATIENTS.
agement. Acute and chronic afferentTeruo Matsumoto. 397 pp. Illust. Med
and efferent-loop syndromes are dis
ical Examination Publishing Co., Inc.,
cussed. Postoperative reflux gastritis is
Garden City, New York, 1979. $13.50,
thoroughly covered as is recurrent peptic
paperbound. ISBN 0-87488-735-6.
ulceration and gastric remnant carci
noma. Postgastrectomy malabsorption, The concept of this multiauthored pocketpostgastrectomy anemia and postgastrec sized book is long overdue. The book

whenever a laxative is required
consider the timely action of
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Mammograms are not a helpful test for young women
because of the dense fibrous stroma of the breast.
Also, this patient has a palpable mass that must be
defined. Reexamination in four weeks is a possible
approach although the woman has already been
through one menstrual period without disappearance
of the lesion, and therefore the likelihood of spon
taneous resolution is quite small. A needle aspira
tion will establish the nature of this abnormality.
Confirmation of a breast cyst by the needle aspira
tion technique is a safe and accurate diagnostic
method. The criteria for diagnosis of a cyst include:
I) the aspirate must be bloody, 2) the mass must
disappear totally with aspiration, and 3) the mass
must not recur. Cytologic examination of the fluid
is not performed because of the constant lack of
cellular elements.
If biopsy is required, an excisional biopsy
should be performed to remove the entire abnormal
area. An excisional biopsy is not warranted at this
stage until diagnostic needle aspiration is first
undertaken.
®
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will be invaluable for the surgical stu
dent, intern and resident because it cor
relates the whole gamut of investigations
and assessment of the surgical patient
preoperatively and postoperatively. It
also helps in the interpretation and an
alysis of this information. In a precise
way it focuses on how to obtain the
data required to reach the preoperative
diagnosis expeditiously and with the
least effort. For example, it includes
chapters on the use and interpretation
of clinical laboratory tests which are so
often needed. Exfoliative cytology of the
gastrointestinal tract, female genital tract
and respiratory tract, radiology of the
chest and abdomen, and angiography in
the surgical patient are also covered.
There is also a most useful section on the
preoperative assessment and preparation
for surgery of the patient with chronic
lung disease. Other chapters deal with
endocrine disorders, antimicrobial agents
in infection, and radio- and chemothera
py in cancer patients. Unfortunately it
does not deal with postoperative renal
problems.
Other salient features of this book
are the good clear roentgenograms, which
depict the problem being discussed, and
the other drawings, graphs and figures
used to demonstrate the point at hand.
Each chapter contains a comprehensive
up-to-date bibliography.
This is not a “controversy in surgery”
book, but one that provides basic infor
mation which is well established.
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Narcotic
analgesia
can be
shadowed by
respiratory
depression

nuBRin
Nalbuphine HC1 Injection

Casts new light
on narcotic analgesia
Provides the same analgesic efficacy as
meperidine or morphine
Nubain, a new injectable analgesic, has an onset, a
peak of action, and analgesic effectiveness similar to
those of meperidine or morphine. Nubain generally
provides longer analgesia (3-6 hours) than
meperidine (2-4 hours), helping to reduce the
amount of narcotic required.

As an adjunct, to supplement surgical
anesthesia, Nubain provides
hemodynamic stability, good
postoperative analgesia and limits
postoperative respiratory depression
A recent study showed that nalbuphine is an effective
supplement to balanced anesthesia. Post-operative
recovery time may be reduced due to limited
respiratory depression and good post-operative
analgesia4’5.
In 27 single or cross-over clinical studies (2,038 drug
evaluations) these side effects were observed:

Unlike morphine, Nubain has a
limited respiratory depressant
effect:

Dose response curve
for respiratory depression1

Morphine 10 mg/h
— Nubain 10 mg/h
Nubain 10mg/45min.

} j Cumulative dose mg/70 kg
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I NUBAIN (1,066 patients)
I MEPERIDINE (234 patients)
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I___ I MORPHINE (486 patients)
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I PENTAZOCINE(252patients)

With a greater margin of safety

Significantly fewer side effects

Unlike other narcotics which can cause undesirable
respiratory depression even at moderate doses1, the
respiratory depressant effect of Nubain is limited and
does not increase appreciably beyond a peak effect
equivalent to that produced by 20 mg/70 kg of
morphine1. Therapeutic doses of nalbuphine have
been associated with hemodynamic stability, and
clinical studies of the hemodynamic effects of
Nubain in patients with coronary artery disease and
acute myocardial infarction demonstrated that
nalbuphine HC1 produced no major untoward clinical
or cardiocirculatory effects2’3.

Nubain has a lower incidence of reported side effects
than other narcotics or pentazocine6, causing
significantly less nausea and vomiting than
meperidine or morphine7. Psychotomimetic effects
have rarely been reported1. The incidence of
constipation is less than 1%6.
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nuBnin
NUBAIN INJECTION
(Nalbuphine Hydrochloride) Analgesic
ACTION
Nubain (nalbuphine hydrochloride) is a synthetic narcotic
agonist-antagonist analgesic for parenteral use, related
chemically to the narcotic oxymorphone and to the
narcotic antagonist naloxone. Nabulphine has an
analgesic (agonist action) potency equivalent to that of
morphine on a milligram basis, and an antagonist activity
(reversal of major effects of opioid drugs) about
one-fourth that of nalorphine and ten times that of
pentazocine. The analgesic effect of 10 mg of nalbuphine
is about equal to that of 10 mg o f morphine sulfate. The
onset of action begins within 2 to 3 minutes after
intravenous administration, and within 15 minutes
following subcutaneous or intramuscular injection. The
plasma half life of nalbuphine is five hours and the
duration o f action has ranged from three to six hours.
At the usual dose of 10 mg, nalbuphine produces
respiratory depression equivalent to that of equianalgesic
doses of morphine. At much higher doses, above 30 mg
i. v. (which produces a respiratory depressant activity
equivalent to 20 mg o f morphine i. v.), the respiratory
depressant effect of nalbuphine does not appear to
increase appreciably. Nalbuphine may precipitate
abstinence, when administered to individuals taking
narcotics chronically or produce withdrawal symptoms
when.discontinued abruptly after prolonged use. It is
reported to have an abuse potential comparable to that of
pentazocine. The mechanism o f action of nalbuphine has
not yet been established.
INDICATIONS AND CLINICAL USE
NUBAIN (nalbuphine hydrochloride) is indicated for the
relief of moderate to severe pain.
Clinical studies indicate that it can also be used for
preoperative analgesia, as a supplement to surgical
anesthesia, and for obstetrical analgesia during labor.
CONTRAINDICATIONS
NUBAIN (nalbuphine hydrochloride) should not be
administered to patients who are hypersensitive to the
drug or to its inactive ingredients (see section on
‘AVAILABILITY’).
WARNINGS
In patients physically dependent on opiate drugs,
NUBAIN (nalbuphine hydrochloride) should not be given
prior to detoxication since withdrawal symptoms are
likely to be produced.
Drug Dependence:
On the basis o f behavioural, substitution and direct
addiction studies in humans. NUBAIN has been shown to
have low abuse potential which approximates that of
pentazocine. Psychological and physical dependence and
tolerance may follow the abuse or misuse o f nalbuphine.
Therefore, caution should be observed in prescribing it
for emotionally unstable patients or for individuals with a
history o f narcotic abuse. Such patients should be closely
supervised, since increases in dosage or frequency of
administration in susceptible individuals might result in
physical dependence.
Abrupt discontinuation of NUBAIN following prolonged
use has been followed by symptoms of narcotic
withdrawal, such as abdominal cramps, nausea and
vomiting, rhinorrhea, lacrimation, restlessness, anxiety,
elevated temperature and piloerection.
Use in Ambulatory Patients:
NUBAIN may impair the mental or physical abilities
required for the performance o f potentially dangerous
tasks such as driving a car or operating machinery.
Therefore, NUBAIN should be administered with caution
to ambulatory patients, who should be warned to avoid
such hazards until recovered from the effects o f the drug.

Interaction With Other Central Nervous System
Depressants:
Although NUBAIN possesses narcotic antagonist
activity, there is evidence that in non-dependent patients
it may not antagonize the analgesic effect of narcotic
analgesics. Patients receiving narcotic analgesic, general
anesthetics, phenothiazines or other tranquilizers,
sedatives, hypnotics, or other CNS depressants (including
alcohol) concomitantly with NUBAIN may exhibit an
additive effect. When such combined therapy is
contemplated, the dose o f one or both agents should
be reduced.
Use in Children:
Because clinical experience in children under the age of
12 years is limited, the administration of NUBAIN in this
age group is not recommended.
Use in Pregnancy:
Safe use of NUBAIN in pregnancy (other than labor) has
not been established. Although animal reproductive
studies have not revealed teratogenic or embryotoxic
effects, NUBAIN should only be administered to
pregnant women when, in the judgement of the
physician, the potential benefits outweigh the possible
hazards.
Use in Labor and Delivery:
Since NUBAIN can produce respiratory depression in the
neonate, it should be administered with caution to women
delivering premature infants.
Head Injury and Increased Intracranial Pressure:
The possible respiratory depressant effects and the
potential of potent analgesics to elevate cerebrospinal
fluid pressure (resulting from vasodilation following CO 2
retention) may be markedly exaggerated in the presence
o f head injury, intracranial lesions, or a pre-existing
increase in intracranial pressure. Furthermore, potent
analgesics can produce effects which may obscure the
clinical course o f patients with head injuries. Therefore
NUBAIN should be administered in these circumstances
only when essential, and with extreme caution.
PRECAUTIONS
Impaired Respiration:
Caution should be observed when administering
NUBAIN (nalbuphine hydrochloride) to patients with
impaired respiration, or who are receiving other
medications which produce respiratory depression. In the
presence of bronchial asthma, uremia, severe infection,
cyanosis, or respiratory obstruction, NUBAIN should be
administered only with great caution and in reduced
doses. Respiratory depression induced by NUBAIN can
be reversed by the administration o f naloxone
hydrochloride.
Impaired Renal or Hepatic Function:
Because NUBAIN is metabolized in the liver and
excreted by the kidneys, patients with renal or liver
dysfunction may show an exaggerated response to
customary doses. Therefore, in these individuals
NUBAIN should be used with caution and administered
in reduced amounts.
Myocardial Infarction:
As with all potent analgesics, NUBAIN should be used
with caution in patients with myocardial infarction who
have nausea or vomiting. Hemodynamic studies in
patients with severe arteriosclerotic heart changes reveal
that NUBAIN has circulatory effects similar to those of
morphine, i.e ., a minimal decrease in oxygen
consumption, cardiac index, left ventricular end-diastolic
pressure and cardiac work.
Management o f Narcotic Withdrawal Symptoms:
If NUBAIN is inadvertently administered to a patient
physically dependent on narcotics and unduly
troublesome narcotic withdrawal symptoms develop,
these symptoms may be controlled by the slow
intravenous administration of small increments of
morphine, until relief occurs.

ADVERSE REACTIONS
In clinical trials with NUBAIN (nalbuphine
hydrochloride) the most frequently reported side effects
were: sedation (36%) of 1066 patients treated), sweating
or clamminess (9%), nausea or vomiting (6%), dizziness
or vertigo (5%), dry mouth (4%) and headache (3%).
Other adverse reactions which may occur:
Central Nervous System: nervousness, crying,
depression, restlessness, euphoria, hostility, confusion,
faintness, floating, unusual dreams, numbness, feeling of
heaviness, and psychotomimetic effects such as
hallucinations, feeling of unreality and dysphoria.
Cardiovascular: Hypertension, hypotension,
bradycardia, tachycardia.
Gastrointestinal: Cramps, dyspepsia, bitter taste.
Respiration: Depression, dyspnea, asthma.
Dermatological: Itching, burning, urticaria.
Miscellaneous: Speech difficulty, urinary urgency,
blurred vision, flushing and warmth.
SYMPTOMS AND TREATMENT
OF OVERDOSAGE
Symptoms:
These are expected to be similar to those of other drugs of
this class. (TTie administration of single I.M. doses of
72 mg of NUBAIN to eight normal subjects has been
reported to have resulted primarily in symptoms of
sleepiness and mild dysphoria.)
Treatment:
NARCAN (naloxone hydrochloride) administered
intravenously is a specific antidote for NUBAIN. Since
the duration of action of NUBAIN may exceed that of
NARCAN, the patient should be kept under continued
surveillance and repeated doses of NARCAN should be
administered as necessary. Oxygen, intravenous fluids,
vasopressors and other supportive measures should be
employed as indicated.
DOSAGE AND ADMINISTRATION
The usual recommended dose of NUBAIN (nalbuphine
hydrochloride) is 10 mg for a 70 kg individual
administered subcutaneously, intramuscularly or
intravenously. This dose may be repeated every 3 to 6
hours as required. The recommended dosage range is 10
mg to 20 mg, with a maximum single dose of 20 mg and a
maximum total daily dose of 160 mg. Dosage should be
adjusted according to the severity o f the pain, physical
status of the patient, and other medications which the
patient may be receiving. (See Interaction with Other
Central Nervous System Depressants under
WARNINGS .)
Patients who have been taking narcotics chronically for
pain under medical supervision may experience
withdrawal symptoms upon the administration of
NUBAIN. If NUBAIN is administered to these patients
as an analgesic, it should be introduced gradually.
NUBAIN should not be used as a substitute for other
narcotics or for withdrawal purposes in individuals
dependent on these drugs.
AVAILABILITY
NUBAIN (nalbuphine hydrochloride) is supplied in glass
ampoules of 1 ml and 2 ml, and in multiple-dose vials of
10 ml containg 10 mg of nalbuphine hydrochloride per
ml. Each ml also contains 0.1% sodium chloride, 0.94%
sodium citrate, 1.26% citric acid anhydrous, 0.1%
sodium metabisulfite and 0.2% of a 9/1 mixture of
methylparaben and propylparaben as preservatives.
STORE AT CONTROLLED ROOM TEMPERATURE
(15° TO 30°C). PROTECT FROM EXCESSIVE LIGHT.
NUBAIN (nalbuphine hydrochloride) is a Schedule G
(Controlled) drug.
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The principle advantage of this book is
that it correlates and illuminates topics
that are otherwise scattered throughout
many other radiologic, clinical pathologic
and surgical texts.
In general, this is a lucid, concise and
cohesive account of preoperative and
postoperative evaluation and management
of the surgical patient. I believe that a
copy of this book should be in the white
coat pocket of every surgical apprentice
because it will find its greatest use in
the investigation of new patients and in
the early hours of the morning when no
other advice is readily available.
Alfred J. Stedman,

md , frcs(i ), frcs[c]

Ste. 603,
1081 Carling Ave.,
Ottawa, Ont.
PROGRESS IN RADIO-ONCOLOGY.
International Symposium, Baden (Aus
tria). Edited by K.-H. Kitrcher, H.D.
Kogelnik and H.-J. Meyer, 168 pp.
Illust. Georg Thieme Verlag, Stuttgart.
1980. Price not stated, paperbound.
ISBN 3-13-5817-01-6.

This book outlines the proceedings of a
conference held in Baden, Austria in
1978 to review the progress in radiation
oncology. Subjects covered include high
LET radiation, combination immuno
therapy and radiotherapy, radiosensi
tizers, hyperthermia, hypoxyradiotherapy
and hyperbaric oxygen with irradiation.
Other subjects introduced at the meet
ing but not detailed are combination
chemotherapy and radiotherapy in treat
ing tumours, and developments in hor
mone therapy. The central theme of this
conference was the use of newer methods
to improve the “therapeutic ratio” (dam
age to malignant versus healthy cells)
in radiation oncology, largely by im
proving the response of hypoxic tumour
cells which are believed to be a factor
limiting the local control of a number of
cancers. Several papers describe the use
of neutrons (known to have a greater
effect on hypoxic cells of a tumour than
conventional radiation methods) in anim
al experiments and clinical situations. Al
though neutrons and other high LET
radiation are known to be more effect
ive on hypoxic cells, the actual gain may
be small, since with a fractionated radia
tion regimen many of the hypoxic cells
within the tumour oxygenate during the
course of the therapy. Other factors in
neutron and high LET radiation may
well be more effective than the effect on
hypoxic tumour cells. These factors in
clude the proportion of cells in a rela
tively resistant phase of the cell cycle
which are more sensitive to high LET
radiation than standard radiation, and
also the different intrinsic radiosensi
tivity of the cells which may lead to a
varying relative biologic effect of high
LET radiation compared with standard
radiation therapy. From clinical experi
ence neutron beams, particularly a mix
ture of neutron and photon beams, show
VOLUME 24, NO. 3, M A Y 1981
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promise in advanced cancers of the head
and neck, in some prostatic and gyne
cologic tumours and in soft tissue sar
comas and thyroid carcinomas. Late
damage from the high LET radiation is
more pronounced than with conventional
forms of radiotherapy. Most of the pre
sented papers plead for a controlled
clinical trial comparing neutron therapy
or high LET radiation, either alone or
with a photon beam, with conventional
radiotherapy.
Several papers in the section on im
munotherapy and radiotherapy reflect
the complex relation of the effect of
radiotherapy on the immune system. In
the discussion, the authors do not reach
a clear consensus. It was obvious that a
well conducted clinical trial would be
necessary to clarify this interrelationship.
Moreover, more specific and appropriate
immunologic tests would be required.
A section on radiosensitizers reviewing
the drugs presently available, their phar
macologic properties and cytotoxicity is
also included. Animal experiments are
reviewed and clinical experience with
misonidazole in combination with radio
therapy is presented. Pilot studies
showed some enhancement of the radia
tion effect using these radiosensitizers.
Again, a plea is made for controlled
clinical trials of radiosensitizers and
radiotherapy.
Hyperthermia, which has cell killing
effects, was also discussed at this con
ference. It was shown that neoplastic
cells may be more sensive than normal
cells to hyperthermia. Tumours that
are hypoxic or at a low pH are at least
as sensitive to heat and perhaps more
sensitive than normal cells. Nutritionally
deprived cells are in the same category.
Cells in the S phase of the reproductive
cycle are also more sensitive to heat than
to x-rays in this context. Combination of
the two modalities, discussed at some
length, is believed to have definite ther
apeutic advantages. Difficulties in del
ivering heat to deep tissues are out
lined. The advantage of combining hy
perthermia and radiotherapy (an addi
tive effect rather than a potentiating one)
is discussed. Again a plea for clinical
trials is made.
Finally, hypoxyradiotherapy is briefly
discussed and a clinical trial described
in which advanced head and neck tu
mours treated in a relatively hypoxic
situation seemed to respond more than
would be expected. Once again, the need
for clinical trials is emphasized.
Hyperbaric oxygen radiation is reviewed
and although this topic is considered
passe, the results of recent trials have
pointed out a possibly advantageous use
in advanced carcinomas of the head and
neck, and also in the cervix. This
evidence will have to be compared with
trials now in progress using radiosen
sitizers to see if the same effect may be
accomplished with this method.
In summary, various methods of ra 
diation used to increase the therapeutic
ratio are reviewed and further clinical
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trials to elucidate and confirm the
process advocated. This book should be
read by all those currently involved with
radiation oncology in the clinical context.
J.J. H azel, md , dabr, frcp [c]
Division of therapeutic radiology,
Royal Victoria Hospital,
Montreal, PQ
TO MEND THE HEART. Lael Wertenbaker. 344 pp. The Viking Press, New
York, 1980. $14.95. ISBN 0-67047092-9.

The heart, as an organ, has certain mythologic, religious and emotional conno
tations that often distort an objective
view. Surgery on the heart, “the last
great frontier” of modern surgical history,
was initially condemned and later looked
upon with pessimism and despair. Heart
surgery has dominated the professional
and lay literature because of the tre
mendous achievements of the past three
decades. This book, as a history of heart
surgery, is of considerable interest and
is well worth reading, although it suffers
from the somewhat breathless admira
tion that was so common in the press
during the initial era of transplantation.
The author set out to write a bio
graphy of a dynamic and thoughtful
cardiac surgical pioneer, Dwight E.
Harken of Boston, Massachusetts. The
forward by Dr. Harken suggests that his
modesty prevailed and that the author
was coerced into creating a historical
anthology of heart surgery. In fact, this
is a biography, set against the tableau
of the development of heart surgery, with
personal glimpses and references to many
of the colourful and controversial figures
involved in the growth of this exciting
field. The structure of the book has been
taken directly from the 2nd Henry Ford
Hospital symposium held in Detroit in
1975, which collected together the
founders and the pioneers of heart sur
gery and acknowledged the accomplish
ments of the 22 years following the
original 1953 gathering.
In this biography we are given
Harken’s recollections, opinions, attitudes
and perspectives on a variety of subjects,
including transplantation, medical mal
practice, device legislation, patient care,
ethics and morality. In the last two
chapters, particularly, Harken’s attitudes
on the surgeon’s responsibility to the
patient become almost paternalistic. We
are also subjected to Harken as judge,
arbiter and commentator or. the past and
the future in a dialogue with his col
leagues. Their thoughts on coronary
units, transluminal dilatation, heart watch
programs and so on, become too per
sonal and almost tedious.
The book generally reads well and
contains fascinating material. The evolu
tion of cardiac surgery, and in particular
Harken’s monumental contribution dur
ing World War II (removing foreign
bodies from the heart without causing
death), are a pleasure to read. The
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should be forwarded
immediately to:

The D ivision of General Surgery of the
Toronto General Hospital w ill present a
C lin ica l Day for general surgeons at the
Toronto General Hospital on June 5, 1981.
Contact: Ms. Karen Lambert, D ivision of
General Surgery, 8 Eaton C-315, Toronto
General HosDital, 101 College Street, Toronto
Ontario M5G 1L7-or-telephone: (416) 595-3556.
— S81-014

Interested candidates should direct their
enquiries and curriculum vitae to:

P. L. Heilpern, MD, FRCP(C)
Director of Professional Services
SIR MORTIMER B. DAVIS
JEWISH GENERAL
3755 Cote Ste. Catherine Road
Montreal, Quebec H3T 1E2

— S81-004

— S81-007
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W ill) V K K Yl
{Polygiacdn910)suture
p

SNUGS D O W N
AND HOLDS
First coated synthetic absorbable
Coated for smoothness
Allows adjustable knot
tension for precise knot
placement
Produces less suture drag
than uncoated synthetic
absorbables

Low tissue reaction
Soft—on the surgeon’s
hands
Complete absorption
before 90 days
High in vivo tensile
strength

innovators in wound closure

I

>

Ethicon Sutures Ltd., Peterborough, Ontario

Trademark

TI-CRON

... and where it counts at
the heart of the matter.
Ti-cron, a braided polyester suture
with a unique silicone treatment.
The silicone coating is exclusive to
Davis & Geek and results in a smooth
ness and suppleness unexcelled by
other polyester sutures.

DAVIS+GECK
where progress is born

Cyanamid Canada Inc.
2255 Sheppard Ave. East,
W illowdale, Ont. M2J 4Y5

